Metal Ions and Neurodegenerative
Editor
Paolo Zatta
-,t
r
Picture on cover Metallothionein-l-ll positive astrocytes in mouse cerebral cortex (Photo: Dr. Pamela Zambenedetti, Brain Bank, General Hospital, Dolo-Venice, Italy)
Metal Ions and Neurodegenerative Disorders
This page is intentionally left blank
Metal Ions and Neurodegenerative Disorders
Editor
Paolo Zatta CNR - National Research Council, Italy
'~world Scientific NEW JERSEY· LONDON· SINGAPORE· SHANGHAI· HONG KONG· TAIPEI· BANGALORE
Published by World Scientific Publishing Co. Pte. Ltd. 5 Toh Tuck Link, Singapore 596224 USA office: Suite 202, 1060 Main Street, River Edge, NJ 07661 UK office: 57 Shelton Street, Covent Garden, London WC2H 9HE
British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library.
METAL IONS AND NEURODEGENERATIVE DISORDERS Copyright © 2003 by World Scientific Publishing Co. Pte. Ltd. All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the Publisher.
For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.
ISBN 981-238-398-0
Printed in Singapore by Mainland Press
Preface Many metal ions are as essential to life (Williams and Fausto da Silva, 1996) as other constitutive elements within living matter, such as fats, carbohydrates, and proteins. Today, research into the role of metal ions is of particular interest to nutritional sciences, which have discovered that a wide range of common pathologies are caused by a lack of metalloions. Physiologists maintain that the constitutive and functional roles of some metal ions (such as Na, K, Ca, Mg, Fe, Co, Mn, Cu, and Zn) are vital to the smooth functioning of cells, as well as various organs and tissues. Toxicologists have performed indepth research into the harmful properties of some metal ions (such as Al, Cd, Hg, and Pb), and environmental disasters, such as Camelot and Minamata, have enabled them to be studied on a vast scale. However, until recently, little attention had been paid to the role of metal ions as etiopathogenic agents for some neurodegenerative diseases such as Alzheimer's, Parkinson's, and Lateral Amyotrophic Sclerosis, to name but three. Today, a new field, metalloneurochemistry, is breaking fresh ground on account of the burgeoning number of studies which show the importance of metal ions as etiopathogenic factors or co-factors (Bush, 2000; Zatta, 2001). From this point of view, the concept of metallochaperones is comparatively new in that molecules that could be used for this function were only discovered in the mid-1990s (Halloran and Culotta, 2000). Theories that suggest metal ions are vital etiological agents in neurodegenerative diseases are finding it hard to break into mainstream thought not only on account of the technical and conceptual difficulties, but also of the financial complexities of investing in both basic and applied research in order to discover more about the molecular mechanisms that account for the physiopathological action of metalloions. Chelation therapy is still in the early days of its research into new products that could revolutionize treatment. Two international conferences, Metals and the Brain: From Neurochemistry to Neurodegeneration (University of Padova, Italy, 2000 and University of Fez, Morocco, 2002;
V
VI
Preface
see also Zatta, 2001), were held on metals and their role in physiopathology as a sign of their importance. This book follows the same train of thought as these conferences in order to highlight the unquestionable importance of metal ions to research into the neurochemistry of neurodegenerative diseases. The excellent reputation of the scientists who have contributed to this project bears testimony to the quality of these studies, which we hope can be developed further with a whole host of new research within this field; one which is still in its infancy. PAOLO ZATTA
REFERENCES Bush AI. Metals and neuroscience. Curr Op Chem Biol 2000; 4:184-191. Halloran TV, Culotta VC. Metallochaperones: An intracellular shuttle service for metal ions. J Biol Chem 2000; 275:25047-25060. William RJP, Frausto da Silva JJR. The Natural Selection of the Chemical Elements. Oxford: Clarendon Press, 1996. Zatta P, editor. Metals and the brain. A special issue. Brain Res Bull 2001; 55:123-325.
Contents Preface
v
List of Contributors
xi
Chapter 1. Metal-Catalyzed Redox Activity in Neurodegenerative Disease Marta A Taddeo, Mark A Smith, Quart Liu, Craigh S Atwood, Lawrence M Say re, George Perry Chapter 2. Metals Distribution and Regionalization in the Brain Margherita Speziali, Edoardo Orvini
1
15
Chapter 3. The Olfactory Pathway as a Route of Entry of Metals into the Brain Hans Tjalve, Jonas Tallkvist
67
Chapter 4. Aluminum in Neurological Disorders and Systemic Chelation Therapy Theo P Kruck, Walter J Lukiw
99
Chapter 5. Alumium and Central Nervous System Morphology in Hemodialysis Erich Reusche
117
Chapter 6. Zinc, Brain, and Aging Eugenio Mocchegiani, Mario Muzzioli, Robertina Giacconi, Tiziana Casoli, Giuseppina DiStefano, Patrizia Fattoretti
139
Chapter 7. Transition Metals, Oxidation, Lipoproteins, and Amyloid-3: Major Players in Alzheimer's Disease Anatol Kontush
183
Chapter 8. Molecular Basis of Copper Transport: Cellular and Physiological Functions of Menkes and Wilson Disease Proteins (ATP7A and ATP7B). David R Kramer, Roxana M Llanos, Julian F B Mercer
207
Vll
Contents
Vlll
Chapter 9.
Importance of Copper and Zinc in Alzheimer's Disease and the Biology of Amyloid-(3 Protein and Amyloid-(3 Protein Precursor Avi L Friedlich, Xudong Huang, Seiichi Nagano, Jack T Rogers, Lee E Goldstein, Ashley I Bush, Gerd Multhaup, Konrad Beyreuther, Wolfgang Stremmel, Thomas Bayer
Chapter 10. Copper-Zinc Superoxide Dismutase and Familial Amyotrophic Lateral Sclerosis Moon B Yim, P Boon Chock, Earl R Stadtman
245
263
Chapter 11. Copper and Prion Disease Judyth Sasson, David R Brown
279
Chapter 12. Metallothioneins in Neurodegeneration Michael Aschner, William F Silverman, Israel Sekler, Paolo Zatta
307
Chapter 13. Iron and Neurodegeneration Stacey L Grab, James R Connor
323
Chapter 14. Iron, Neuromelanin, and a-Synuclein in Neuropathogenesis of Parkinson's Disease Kay L Double, Kurt Jellinger, Luigi Zecca, Moussa B H Youdim, Peter Riederer, Manfred Gerlach
343
Chapter 15. Iron and Epilepsy Wie-Yi Ong, Benjamin Kian-Chung Ong, Akhlaq A Farooqui, Chuang-Chin Chiueh, James R Connor
365
Chapter 16. Role of Iron Metabolism in Multiple Sclerosis Maritha J Kotze, J Nico P De Villiers, Monique G Zaahl, Kathryn J H Robson
399
Chapter 17. Manganese Toxicity: A Critical Reappraisal Patrizia Vernole, Maria Morello, Giuseppe Sancesario, Alessandro Martorana, Giorgio Bernardi, Antonella Canini, Palma Mattioli
415
Contents
Chapter 18. Cupric and Mercuric Ions Affect the Structure and Functions of Cell Membranes Mario Suwalsky, Fernando Villena, Hernan Cardenas,Beryl Norris, Carlos Patricio Sotomayor, Paolo Zatta
IX
427
Chapter 19. Influence of Lead Exposure on Brainstem Functions Ombretta Mameli, Marcello Alessandro Caria
441
Chapter 20. Neuroprotective Effects of Lithium Sophie Ermidiou-Pollet, Serge Pollet
467
Chapter 21. Histopathological Changes in Brain of Uremic Patients on Chronic Hemodialysis Pamela Zambenedetti, Mario Andriani, Maurizio Nordio, Paolo Zatta
483
Chapter 22. Clinical Neurotoxicity of Metals and Neurodegenerative Disorders Marcello Lotti
495
Index
509
This page is intentionally left blank
List of Contributors Michael ASCHNER Departments of Physiology and Pharmacology Wake Forest University School of Medicine Winston-Salem, NC, USA Email:
[email protected] Craigh S ATWOOD Institute of Pathology Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Thomas BAYER Department of Psychiatry University of Bonn Medical Center Bonn, Germany Giorgio BERNARDI Department of Neuroscience University of Rome Tor Vergata and IRCCS S Lucia 00100 Rome, Italy Konrad BEYREUTHER ZMBH-Center for Molecular Biology University of Heidelberg Heidelberg, Germany David BROWN Department of Biology and Biochemistry University of Bath Bath BA2 7AY, UK Email:
[email protected] XI
Xll
Ashley I BUSH Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA Email:
[email protected] Antonella CANINI Department of Biology University of Rome Tor Vergata 00100 Rome, Italy Hernan CARDENAS Faculty of Biological Sciences University of Concepcion Casilla 160-C Concepcion, Chile Marcello Alessandro CARIA Department of Biomedical Sciences Human Physiology Division University of Sassari Viale San Pietro 43/B 07100 Sassari, Italy Email:
[email protected] Tiziana CASOLI Neurobiology Center Research Department Italian National Research Center on Aging (INRCA) Via Birarelli 89 60121 Ancona, Italy Email:
[email protected] Chuang-Chin CHIUEH National Institute of Mental Health LCS, NIH 10/3D-41 Bethesda, MD 20892-1264, USA
List of Contributors
List of Contributors
P Boon CHOCK Laboratory of Biochemistry National Heart, Lung and Blood Institute National Institutes of Health Building 50, Room 2152 50 South Drive, MSC-8012 Bethesda, MD 20892-8012, USA James R CONNOR Department of Neuroscience and Anatomy Pennsylvania State University Hershey, PA 17033-0850, USA Email:
[email protected] J Nico P DE VILLIERS Division of Human Genetics Faculty of Health Sciences University of Stellenbosch Tygerberg 7500, South Africa Giuseppina DiSTEFANO Neurobiology Center Research Department Italian National Research Centers on Aging (INRCA) Via Birarelli 89 60121 Ancona, Italy Kay L DOUBLE Prince of Wales Medical Research Institute Sydney, Australia Email:
[email protected] Sophie ERMIDIOU-POLLET Department of Biochemistry Medical School, University of Athens Athens, Greece Email:
[email protected]
XIV
List of Contributors
Akhlaq A FAROOQUI Department of Molecular and Cellular Biochemistry The Ohio State University Columbus, Ohio OH 43210, USA Patrizia FATTORETTI Neurobiology Center Research Department Italian National Research Centers on Aging (INCRA) Via Birarelli 89 60121 Ancona, Italy Email:
[email protected] Avi L FRIEDLICH Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA Manfred GERLACH Clinical Neurochemistry Department of Child and Youth Psychiatry and Psychotherapy University of Wurzburg Wiirzburg, Germany Robertina GIACCONI Immunology Center Section Nutrition, Immunity and Aging Research Department Italian National Research Center on Aging (INRCA) Via Birarelli 8 60121 Ancona, Italy Lee E GOLDSTEIN Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA
List of Contributors
Stacy L GRAB Department of Neuroscience Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center Hershey, PA 17033, USA Email:
[email protected] Xudong HUANG Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA Kurt JELLINGER Institute of Clinical Neurobiology Vienna, Austria Email:
[email protected] Anatol KONTUSH INSERM Unite 551 Papillon Benjamin Delessert Hospital de la Pitie, 83 Boulevard de l'Hopital 75651 Paris Cedex 13, France Email:
[email protected] Maritha J KOTZE Division of Human Genetics Faculty of Health Sciences University of Stellenbosch Tygerberg 7500, South Africa Email:
[email protected] David K KRAMER Center for Cellular and Molecular Biology School of Biological and Chemical Sciences Deakin University, 221 Burwood Hwy Melbourne 3125, Australia Email:
[email protected]
XVI
List of Contributors
Theo P KRUCK Surrey Place Center and Department of Physiology University of Toronto Ontario M5S 2C2, Canada Email:
[email protected] Quan LIU Institute of Pathology Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Roxana M LLANOS Center for Cellular and Molecular Biology School of Biological and Chemical Sciences Deakin University 221 Burwood Hwy Melbourne 3125, Australia Email:
[email protected] Marcello LOTTI Dipartimento di Medicina Ambientale e Sanita Pubblica Universita di Padova, Azienda Ospedaliera di Padova Via Giustiniani 2 25128 Padova, Italy Email:
[email protected] Walter J LUKIW LSU Neuroscience Center and Department of Ophthalmology Louisiana State University Health Science Center New Orleans, LA 70112, USA Email:
[email protected] Ombretta MAMELI Department of Biomedical Sciences, Human Physiology Division University of Sassari Viale San Pietro 43/B 07100 Sassari, Italy Email:
[email protected]
List of Contributors
Alessandro MARTORANA Department of Neuroscience University of Rome Tor Vergata and IRCCS S Lucia 00100 Rome, Italy Palma MATTIOLI Department of Biology University of Rome Tor Vergata 00100 Rome, Italy Julian F B MERCER Center for Cellular and Molecular Biology School of Biological and Chemical Sciences Deakin University 221 Burwood Hwy Melbourne 3125, Australia Email:
[email protected] Eugenio MOCCHEGIANI Immunology Center Section Nutrition, Immunity and Aging Research Department Italian National Research Center on Aging (INRCA) Via Birarelli 8 60121 Ancona, Italy Email:
[email protected] Maria MORELLO Department of Neuroscience University of Rome Tor Vergata 00100 Rome, Italy Gerd MULTHAUP Institut fuer Chemie/Biochemie Freie Universitat Berlin Universitat Berlin Thielallee 63 14195 Berlin, Germany Email: multhaup @ chemie.fu-berlin.de
xvn
xvm
List of Contributors
Mario MUZZIOLI Immunology Center Section Nutrition, Immunity and Aging Research Department Italian National Research Center on Aging (INRCA) Via Birarelli 8 60121 Ancona, Italy Seiichi NAGANO Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA Maurizio NORDIO Nephrology Division General Hospital Venice, Italy Email:
[email protected] Beryl NORRIS Faculty of Biological Sciences University of Concepcion Casilla 160-C Concepcion, Chile Benjamin Kian-Chung ONG Department of Medicine National University of Singapore Lower Kent Ridge Road Singapore 119260 Wei-Yi ONG Department of Anatomy National University of Singapore Lower Kent Ridge Road, Singapore 119260 Email:
[email protected]
List of Contributors
Edoardo ORVINI Department of General Chemistry University of Pavia, Viale Taramelli 12 27100 Padova, Italy Email:
[email protected] George PERRY Institute of Pathology Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Email:
[email protected] Serge POLLET Department of Biochemistry Medical School, University of Athens Athens, Greece Email:
[email protected] Erich REUSCHE Institute of Pathology and Neuropathology University of Lubeck Ratzeburgerallee 160 23538 Lubeck, Germany Email:
[email protected] Peter RIEDERER Clinical Neurochemistry Department of Psychiatry and Psychotherapy University of Wurzburg 97080 Wurzburg, Germany Email:
[email protected] Kathryn J H ROBSON MRC Unit of Molecular Hematology Weatherall Institute of Molecular Medicine John Radcliffe Hospital, Headington Oxford OX3 9DS, UK
XX
Jack T ROGERS Laboratory of Oxidation Biology Genetics and Aging Research Unit Massachusetts General Hospital Building 114, 16th Street Charlestown, MA 02129, USA Giuseppe SANCESARIO Department of Neuroscience University of Rome Tor Vergata 00100 Rome, Italy Email:
[email protected] Judyth SASSOON Department of Biology and Biochemistry University of Bath Bath BA2 7AY, UK. Email:
[email protected] Lawrence M SAYRE Department of Chemistry Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Israel SEKLER Zlotowski Center for Neuroscience Faculty of Health Science Ben-Gurion University Beer Sheva, Israel William F SILVERMAN Zlotowski Center for Neuroscience Faculty of Health Science Ben-Gurion University Beer Sheva, Israel
List of Contributors
List of Contributors
Mark A SMITH Institute of Pathology Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Carlos Patricio SOTOMAYOR Faculty of Basic Sciences Catholic University of Valparaiso Casilla 4059 Valparaiso, Chile Margherita SPEZIALI CNR-Institute for Energetics and Interphases Department of General Chemistry, University of Pavia Via Taramelli 12 27100 Pavia, Italy Email:
[email protected] Earl R STADTMAN Laboratory of Biochemistry National Heart, Lung and Blood Institute National Institutes of Health Building 50, Room 2152 50 South Drive, MSC-8012 Bethesda, MD 20892-8012, USA Wolfgang STREMMEL Department of Medicine Division of Gastroenterology University of Heidelberg, Germany Heidelberg, Germany Mario SUWALSKY Faculty of Chemical Sciences University of Concepcion Casilla 160-C, Concepcion, Chile Email:
[email protected]
XX11
Marta A TADDEO Institute of Pathology Case Western Reserve University 2085 Adelbert Road Cleveland, OH 44106, USA Jonas TALLKVIST Department of Pharmacology and Toxicology Faculty of Veterinary Medicine Swedish University of Agricultural Sciences Biomedicum, Box 573 Uppsala 751 23, Sweden Hans TJALVE Department of Pharmacology and Toxicology Faculty of Veterinary Medicine Swedish University of Agricultural Sciences Biomedicum, Box 573 Uppsala 751 23, Sweden Email: Hans .Tj alve @ farmatoxslu. se Patrizia VERNOLE Department of Public Health University of Rome Tor Vergata 00100 Rome, Italy Fernando VILLENA Faculty of Biological Sciences University of Concepcion Casilla 160-C Concepcion, Chile Moon B YIM Laboratory of Biochemistry National Heart, Lung, and Blood Institute National Institutes of Health Building 50, Room 2152, 50 South Drive, MSC-8012 Bethesda, MD 20892-8012, USA Email:
[email protected]
List of Contributors
List of
Contributors
Moussa B H YOUDIM Department of Pharmacology B Rappaport Faculty of Medicine Eve Topf Neurodegenerative and National Parkinson Foundation Centers Technicon, Haifa, Israel Email:
[email protected] Monique G ZAAHL MRC Unit of Molecular Hematology Weatherall Institute of Molecular Medicine John Radcliffe Hospital, Headington Oxford 0X3 9DS, UK Pamela ZAMBENEDETTI Anatomopathology Division and Brain Bank Dolo General Hospital Dolo-Venice, Italy Email:
[email protected] Paolo ZATTA CNR-Institute for Biomedical Biotechnologies Padova Unit "Metalloproteins" Department of Biology, University of Padova Viale G. Colombo 3 35121 Padova, Italy Email:
[email protected] Luigi ZECCA CNR-Institute for Biomedical Technologies Via Fratelli Cervi 93 20090 Segrate, Italy Email:
[email protected]
xxm
CHAPTER 1
Metal-Catalyzed Redox Activity in Neurodegenerative Disease Marta A Taddeo, Mark A Smith, Quan Liu, Craigh S Atwood, Lawrence M Sayre, George Perry
ABSTRACT Oxidative damage and response are major features of Alzheimer's disease and other neurodegenerative diseases. Metal-catalyzed oxidative events are at the center of radical formation and abnormalities in iron and copper have been noted. In this review, we consider the evidence implicating the central role of metals. Keywords: Amyloid-(3; copper; iron; metal-binding protein; oxidative stress; tau.
1. INTRODUCTION There has been considerable investigation into the roles of redox-active transition metals in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and prion diseases. Iron, copper, manganese, and other such metals are usually found in essential normal biological processes, and are also involved in enzymatic activities such as those related to respiration. In these functions, deficiency of these metals can be hazardous to normal organ function, including central nervous system activities. However, inappropriate accumulation of excessive metal deposits can also be cytotoxic. In short, disruption of the normal homeostatic metal balance in either direction can result in cellular disturbance. In the latter case, these changes are characterized by oxidative 1
2
Taddeo MA et al.
stress and increased production of free radicals. Oxidative stress results from excessive levels of reactive oxygen species (ROS) generated through imbalance of normal biochemical processes. These oxygen radicals can then damage all types of macromolecules, disrupting normal cellular functions and, ultimately, causing cell death. ROS can normally be found at some level in all aerobic organisms, usually arising from the secondary production of superoxide by mitochondrial reduction of molecular oxygen. Increased levels of ROS during oxidative stress point to increased oxygen processing by mitochondria as a possible source. In addition, greater oxidative stress susceptibility can be caused by production of H 2 0 2 by oxidases such as monoamine oxidase. Examination of nitric oxide (NO) has also gained recognition through the term "nitrosative stress", a form of oxidative stress characterized by the reaction of superoxide with NO to yield peroxynitrite, which is further capable of both oxidation chemistry and nitration reactions. The primary ROS implicated in oxidative stress is the hydroxyl radical, whose damage is dependent upon its diffusion capacity over nanometer distances from its generation site. Although peroxynitrite also appears capable of hydroxyl-like activity, most hydroxyl radicals reflect the Fenton reaction between reduced transition metals (usually iron[II] or copper[I]) and H 2 0 2 . Re-reduction of iron[III] and copper[II] can be performed by superoxide or other cellular reductants such as ascorbate. In addition to their role in redox processes, transition metals may contribute to neurodegeneration, along with redox-inactive metal ions, through their deleterious effects on protein and peptide structure, such as a pathological aggregation phenomenon. In such cases, transition metals can sometimes exert dual neurotoxic effects. In contrast, there are also a number of normal antioxidant defenses to combat the effects of ROS through both enzymatic and nonenzymatic pathways in mammalian cells. Cytosolic copper-zinc superoxide dismutase (CuZnSOD) and mitochondrial manganese superoxide dismutase (MnSOD) are two such important players in antioxidant defenses. These enzymes convert reactive superoxide to harmless 0 2 and H 2 0 2 . The latter is then removed by catalase and peroxidases, which are abundant throughout tissues. In addition, there are a number of proteins closely tied to metalinduced redox activity. These include proteins involved in metal transport
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
3
and those which do not normally have a metal-binding function, but are able to bind metals for neuroprotection. This review explores the interplay between these various factors and evaluates recent work concerning the role of redox-active metals in neurodegenerative diseases.
1.1. Redox-Active Transition Metals in AD AD is pathologically diagnosed by the presence of neurofibrillary tangles (NFTs), senile plaques, neuropil threads, amyloid-beta (A(3) deposits, and selective loss of neurons (Perry and Smith, 1999). Though a number of hypotheses have been presented describing the origins of AD, the one receiving the most recent attention involves a role for oxidative stress (reviewed in Markesbery, 1999; Smith et al., 2000a; Perry et al., 2001). Past studies have already implicated a number of trace metals whose imbalances can contribute to AD, including aluminum, silicon, lead, mercury, zinc, copper, and iron (Lovell et al., 1998). Disruptions in iron and copper levels, in particular, have quite a substantial effect on levels of oxidative stress markers such as lipid peroxidation, as well as on damage related to NFT, senile plaque deposition, and nucleic acid oxidation (Smith et al., 2000a). It was recently found through microparticle-induced X-ray emission that Zn(II), Fe(III), and Cu(II) are significantly elevated in the AD neuropil, and that these metals are further concentrated in the core and periphery of senile plaques (Lovell et al., 1998). These results build on earlier studies reporting increased levels of iron, transferrin receptors and ferritin in AD. Using an in situ iron detection method, we found a marked association of redox-active iron with both NFT and senile plaques in AD (Smith et al., 1997). The association with NFT may partly involve iron binding to the primary NFT protein component, tau (Perez et al., 1998). At the same time, iron regulatory protein (IRP)-2 was found to co-localize with redox-active iron in NFT, senile plaque neurites, and neuropil threads (Smith et al., 1998). IRP-1, in contrast, was found to be present at similar levels in both AD and control brain tissues. These latter results suggest that alterations in IRP-2 may be linked to impaired iron homeostasis in AD (Smith et al., 1998). We have found that redox activity in AD lesions can be directly detected in tissue sections and homogenates using cytochemical methods
4
Taddeo MA et al.
(Smith et al., 1997; Sayre et al., 2000). This activity is inhibited by preexposure to copper- and iron-selective chelators, with incubation in metal solutions post-chelation restoring activity. These studies indicating the presence of iron, and probably also copper related to AD pathology, suggest that accumulations of these metals are major generators of ROS. This production is responsible for the numerous oxidative stress markers apparent in NFT and senile plaques, as well as the more global markers observed in AD (Sayre et al., 2001).
1.2. Aggregation of Amyloid-p and Amyloid |3 Protein Precursor/Amyloid-p-Linked ROS Production Evidence for a disruption of trace metal homeostasis in AD has sparked off efforts to identify possible associations between metal ions and A3 aggregation. Under neutral conditions, it was found that aluminum, iron, and zinc accelerated Ap aggregation, while calcium, cobalt, manganese, copper, magnesium, sodium, and potassium did not (Mantyh et al., 1993). More recent studies, however, suggest that this aggregation due to metals depends more critically on pH. For example, it was found that Cu(II) was able to induce A p ^ o aggregation when the pH was lowered from 7.4 to 6.8, and that this result was unique to this particular metal (Atwood et al., 1998). A mildly acidic environment, as well as increased levels of Zn(II) and Cu(II), is a common feature of inflammation associated with increased oxidative damage due to microglial-derived peroxynitrite. The association of Cu(II), Zn(II), and Fe(II) with amyloid-pi seen in vitro could explain the deposition of these metals in senile plaques in AD. It is interesting to note in these studies on A|3 aggregation that the effect of the transition metal does not involve a redox role. This contrasts with results which suggest a synergistic action of A(3 and copper or iron in mediating ROS production (Bondy et al., 1998). Also, Cu(II) binds to amyloid-|3 protein precursor (ApPP) and appears to be reduced to Cu(I) accompanied by production of a disulfide linkage (Multhaup et al., 1998). Subsequent exposure to H 2 0 2 results in reoxidation of Cu(I) along with site-specific cleavage of ApSPP. Redox chemistry associated with Ap- or ApPP-bound metals could, therefore, contribute to a perturbation of free radical homeostasis.
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
5
Recent genetic studies have revealed a number of mutations in the genes encoding the A(3PP and the presenilin proteins (Perry and Smith, 1999). Alterations in these genes lead to overproduction and/or altered proteolytic processing of A(3PP, in both cases leading to increased levels of A(3. Transgenic mouse models expressing these mutations can develop senile plaques and some neurotoxicity, but the model is not complete for familial AD, and the mechanism of this demonstrated neurotoxicity may be unrelated to the neuronal loss present in AD (Perry et al., 2000; Smith et al., 2000b). Furthermore, even though genetic mutations in these genes account for the majority of familial AD cases, they only comprise a small percentage of total AD cases since the predominance of AD is sporadic.
1.3. Iron in Neurodegenerative Disease Free iron has long been implicated in neurodegenerative disease through its redox transitions in vivo. The consequential generation of oxygen free radicals can further induce oxidative stress in tissues. Abnormally high levels of iron and oxidative stress have been found in neurodegenerative disorders such as AD, PD, multiple system atrophy, and progressive supranuclear palsy (Smith et al., 1997; Sayre et al., 2000). Oxidative stress, under these conditions, has been associated with levels of free iron. An increased level of total iron does not necessarily signify increased oxidative stress if it is accompanied by a concomitant increase in iron storage proteins, which keep iron in a redox-inert state. One such iron storage protein, ferritin, contains a core of insoluble and unreactive ferrihydrate. The binding and release of iron to and from ferritin, however, occurs through the ferrous iron state, which is quite active in the generation of hydoxyl radicals by Fenton reactions. Microglia are the main locations of ferritin-bound iron and are thought to be somewhat responsible for oxidative damage in PD and other neurodegenerative diseases (Smith et al., 1994; Premkumar et al., 1995; Kakimura et al., 2002; Castellani et al., 1995; Schipper et al., 1995; Ham and Schipper, 2000). Microglia stimulated in vivo using phorbol ester demonstrate increased lipid peroxidation due to superoxide-dependent release of iron from ferritin (Yoshida et al., 1998). This release can also be induced by 6-hydroxydopamine, a neurotoxin already implicated in PD, and other easily oxidized catechols (Double et al., 1998).
6
Taddeo MA et al.
These studies support the hypothesis that release of iron from ferritin contributes to free radical-induced cellular damage in vivo by Fenton production of hydroxyl radicals. The interplay between oxidative stress and iron metabolism in the brain is further demonstrated by the finding of abnormal iron deposition accompanied by lipid peroxidation in a transgenic mouse model of progressive neurodegeneration (Castelnau et al., 1998). In addition to primary management by the transferrin receptor and ferritin, it has been shown more recently that the handling of iron at the cellular level can be regulated by the lactotransferrin receptor, melanotransferrin, ceruloplasmin (Castellani et al., 1999), and divalent cation transporter 1. Disruptions in the expression of these latter proteins in brain tissues probably contribute to altered iron metabolism in disorders such as AD and PD (Qian and Wang, 1998). Overall, regulation of cellular iron metabolism relies on the actions of two known iron regulatory proteins, IRP-1 and IRP-2. IRPs undergo significant alterations in AD patients, supporting a role for redox-active iron in this disease (Smith et al., 1998). Levels of extracellular H 2 0 2 rapidly activate IRP-1, suggesting a regulatory connection between iron regulation and oxidative stress. This activation has been recapitulated in vitro and shown to require a cellular membrane-associated component which is sensitive to temperature and alkaline phosphatase (Pantopoulos and Hentze, 1998). Future work in this area should result in a clearer understanding of the causative link between iron-induced oxidative stress and neuronal death.
1.4. Iron-Mediated Oxidative Stress in Parkinson's Disease Even though the etiology of PD remains undefined, several biochemical abnormalities in PD brain tissue have been identified, including a mitochondrial complex I deficiency, oxidative stress, and excess iron (Jenner and Olanow, 1996). In addition, the somewhat recent identification of a mutation in the a-synuclein gene in cases of familial Parkinsonism may ultimately lead to an understanding of the biochemical mechanisms of selective dopaminergic cell death in these cases. Iron accumulations have been found in astrocytes in the substantia nigra of old rats (Schipper, 1996; Schipper et al, 1998), along with an increase in
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
7
the Fe(III), to Fe(II) ratio and a decrease in reduced glutathione (Riederer et al., 1989). One interpretation is that mitochondrial sequestration of redoxactive iron in aging nigral astroglia may predispose the senescent nervous system to Parkinsonism and other neurodegenerative disorders. In fact, a persistent condition of elevated oxidative stress associated with greatly perturbed intracellular redox equilibria is widely recognized as a pathogenic factor underlying neurodegeneration. Moreover, there is circumstantial evidence that the intracellular redox imbalance results in aberrant oxidation of dopamine to 6-hydroxydopamine, which in turn can undergo autoxidation to the corresponding quinone accompanied by the generation of superoxide. This reaction cascade, either by itself or amplified by redox cycling of the quinone, which leads to further generation of ROS while depleting cellular reductants, can serve to explain the ultimate demise of these neurons. Studies to clarify the mechanism of dopamine oxidation in vitro have demonstrated conversion to 6-hydroxydopamine in the presence of Fe(II) and either H 2 0 2 or alkyl peroxides (Pezzella et al., 1997).
1.5. Manganese and Parkinson's Disease Chronic exposure to manganese results in extrapyrimidal syndromes resembling PD. Manganese has, therefore, been labeled as an environmentally toxic factor that induces brain dysfunction. One hypothesis to explain these results suggests that manganese acts as a dopaminergic neurotoxin, in the same manner as iron, by promoting the generation of ROS and the subsequent nonenzymatic autoxidation of dopamine to the neurotoxin 6-hydroxydopamine. There is, however, no convincing in vivo evidence for a pro-oxidant role of manganese in the brain. Also, the clinical picture of manganese-induced Parkinsonism is unclear because there is conflicting evidence regarding whether it is selectively toxic to dopaminergic neurons (Calne et al., 1994). In addition, more recent findings suggest that manganese actually may act as an antioxidant rather than as a pro-oxidant (Sziraki et al., 1998). In this study using rats given Fe(II) intranigrally, Mn(II) was found to protect against the toxicity of Fe(II) in a dose-dependent fashion. This protection could result from the fact that Mn(II), while itself inactive in Fenton chemistry, competes with Fe(II) in oxidative cascades. Thus, it appears that the Parkinsonian-like condition induced by chronic
8
Taddeo MA et al.
manganese exposure has little connection to nigrostriatal damage occurring in idiopathic PD.
1.6. Antioxidant and Transition Metal Homeostasis Many studies of oxidative stress in AD have focused on the inducible mitochondrial MnSOD and the constitutive cytoplasmic CuZnSOD enzymes as possible targets for therapy. The CuZnSOD gene has been associated with AD neuropathology, and levels of both MnSOD mRNA and CuZnSOD were found to be increased in AD, whereas the total antioxidant status was decreased. However, since superoxide dismutase (SOD) enzymes are key cellular antioxidant components, any pro-oxidant mechanism linked to SOD must derive from the balance in the local concentrations of superoxide and H 2 0 2 , which together can produce hydroxyl radicals by the Haber-Weiss process. The development of transgenic mouse "knockout" and overexpression models have allowed a range of studies to critically evaluate the extent to which selected biological processes affect cell viability. For example, if one of the SOD enzymes serves a crucial antioxidant function, then knockout animals may exhibit increased oxidative stress parameters, either on a global level or localized to the specific cellular compartment normally protected by that SOD enzyme. In support of this notion, MnSOD knockout mice, which suffer a 50% drop in mitochondrial SOD activity with no reduction in CuZnSOD or glutathione peroxidase activity, were found to exhibit increased oxidative damage to mitochondria. This was shown by increased mitochondrial protein carbonyls and 8-hydroxydeoxyguanosine in mitochondrial DNA (Williams et al., 1998). In contrast, no damage to cytosolic proteins or to nuclear DNA was observed. Analysis of homozygote knockouts showed mitochondrial degeneration throughout the two weeks that the mice lived (Melov et al., 1998). These in vivo results suggest that decreases in MnSOD activity can account for increased oxidative damage in mitochondria and alterations in essential mitochondrial function. In other studies, a tenfold higher expression level of human CuZnSOD in both myocytes and endothelial cells of mice was able to quench a burst of superoxide (in electron paramagnetic resonance detection) and reduce functional damage following 30-minute global ischemia (Wang et al., 1998).
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
9
These results suggest that superoxide is an important factor in protecting against post-ischemic injury, and it is apparent that decreases in CuZnSOD activity can lead to a perturbation of cellular antioxidant defense mechanisms, thereby promoting a pro-oxidant condition. It is surprising, however, that CuZnSOD knockout mice show little, if any, significant neurodegenerative phenotype (Bruijn et al., 1998). Hence, while absences of CuZnSOD have little effect, enzyme inactivation by metal-catalyzed oxidation can promote oxidative damage (Kwon et al., 1998). These differences, while seemingly paradoxical, may be particularly relevant to human diseases. Ceruloplasmin (CP) is an important copper storage protein, the major Fe(II)-oxidizing enzyme in the central nervous system, and one of the key proteins that responds to oxidative stress. A related inherited metabolic disorder, aceruloplasminemia, is associated with impairment in iron homeostasis and consequent neurodegeneration (Harris et al., 1998). Studies directed at clarifying the relationship between oxidative stress and tissue metal-ion levels indicate that both the ratio of copper to zinc and the levels of CP are significantly higher with increasing age, and higher yet in cases with neurodegeneration. Interestingly, while CP is increased in brain tissue and cerebrospinal fluid in AD, PD and Huntington's disease patients (Loeffler et al., 1996), neuronal levels of CP remain unchanged (Castellani et al., 1999). Therefore, while increased CP may indicate a compensatory response to increased oxidative stress in AD, its lack of increase in neurons may play an important role in metal-catalyzed damage. Since the copper to zinc ratio is significantly correlated with systemic oxidative stress (that is, lipid peroxidation), it is probable that an increased oxidative stress burden in aging and neurodegeneration may reflect, in large part, copper-mediated ROS production. In this case, redox-inert zinc may serve as an antioxidant by preventing binding of pro-oxidant copper at tissue sites. A novel glycolipid-anchored membrane-bound form of CP expressed by astrocytes in the mammalian CNS has been identified, and any possible role for this CP in the neurodegenerative process will be investigated. The escalating interest in prion diseases (such as Creutzfeldt-Jakob disease), characterized by infection with an altered prion protein conformation that is transmissible through endogenous protein, continues to question the role of this cell-surface glycoprotein in healthy individuals. Thus far,
10
Taddeo MA et al.
several lines of evidence indicate that the prion protein binds Cu(II) and, thus, as with CP, may serve a cytoprotective role (Brown et al., 1997, 1998). One possibility, consistent with the finding in cell cultures that copper stimulates endocytosis of prion protein from the cell surface, is that prion protein controls copper metabolism by serving as a recycling receptor for uptake of extracellular copper (Pauly and Harris, 1998).
1.7. CuZnSOD Mutations and Familial Amyotrophic Lateral Sclerosis A crucial breakthrough in our understanding of amyotrophic lateral sclerosis (ALS) comes from the finding that many cases of familial ALS (FALS) are associated with mutations in the CuZnSOD gene. The protein products of these mutations retain nearly identical SOD activity, but they take on altered properties related to oxidative stress, possibly involving a gain-of-function peroxidase activity (Wiedau-Pazus et al., 1996). Consistent with these findings, transgenic mice overproducing a human FALS CuZnSOD mutant display increases in protein carbonyls, suggestive of increased hydroxyl radical production or lipoxidation-derived radicals (Andrus et al., 1998). Also, using in vivo microdialysis, increased hydroxyl radical production in the striatum was seen for mice overexpressing mutant CuZnSOD relative to mice overexpressing the wildtype human enzyme (Bogdanov et al., 1998), as determined by conversion of 4-hydroxybenzoic acid to 3,4-dihydroxybenzoic acid. The hypothesis that mutant SOD-induced neurodegeneration is associated with disturbances in neuronal free radical homeostasis is further supported by observations made on several neuronal cell cultures expressing the mutant SOD (Ghadge et al., 1998). The link between the SOD mutations and oxidative stress indicators appears not to be simply due to increased production of hydroxyl radicals, however, since there are no increases in hemeoxygenase. Adducts are seen in vitro for the Gly93 to Ala and Ala4 to Val mutant enzymes relative to the wild-type enzyme (Singh et al., 1998). Recent studies have shown that the mutant and wild-type SODs differ neither in their rates of superoxide dismutation nor in H202-mediated inactivation (Liochev et al., 1998; Goto et al., 1998). Structural analysis of the mutant enzymes did reveal, in some cases, alterations such as subunit asymmetry that suggest aberrant copper-mediated redox chemistry due to
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
11
less tight folding and, thus, more open "active sites" (Corson et al., 1998; Hart et al., 1998). Therefore, the gain-of-function activity may reflect a "rechanneling" of the enzyme to oxidize biomolecules that would usually never gain access to the SOD oxidative half-reaction. Alternatively, the mutant SOD may possess weakened affinities for zinc or copper, leading to a fraction of enzyme with abnormal activity (Singh et al., 1998) or oxidative reactions associated with copper leakage (Goto et al., 1998). For the predominant, sporadic form of ALS, an imbalance of trace metal ions, possibly tied to increased oxidative stress, has been considered for some time. Recent studies provide evidence for decreases in copper in cerebrospinal fluid and serum, as well as increases in manganese in the serum of affected individuals versus age-matched controls.
2. CONCLUSIONS There has been an increasing awareness of the role that redox-active transition metals play in a variety of neurodegenerative diseases. The next step is to critically examine the importance of these basic research findings as they are translated into therapeutic modalities, such as antioxidants and chelating agents, to be used clinically. Hopefully, these treatments will yield promising results.
REFERENCES Andrus PK, Fleck TJ, Gumey ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amytrophic lateral sclerosis. J Neurochem 1998; 71:2041-2048. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush Al. Dramatic aggregation of Alzheimer Afi by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273:12817-12826. Bogdanov MB, Ramos LE, Xu Z, Beal MR Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998; 71:1321-1324. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by P-amyloid. Brain Res 1998; 799:91-96. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar H. The cellular prion protein binds copper in vivo. Nature 1997; 390:684-687. Brown DR, Schmidt B, Kretzschmar HA. Effects of copper on survival of prion protein knockout neurons and glia. J Neurochem 1998; 70:1686-1693.
12
Taddeo MA et al.
Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281:1851-1854. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic Parkinsonism: similarities and differences. Neurology 1994; 44:1583-1586. Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 1995; 696:268-271. Castellani RJ, Smith MA, Nunomura A, Harris PLR, Perry G. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 1999; 26:1508-1512. Castelnau PA, Garrett RS, Palinski W, Witztum JL, Campbell IL, Powell HC. Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol 1998; 57:268-282. Corson LB, Strain JJ, Culotta VC, Cleveland DW. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci USA 1998; 95:6361-6366. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 1998; 70:2492-2499. Ghadge GD, Lee JP, Bindokas VP, Jordan J, Ma L, Miller RJ, Roos RP. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: Molecular mechanisms of neuronal death and protection. JNeuwsci 1998; 17:8756-8766. Goto JJ, Gralla EB, Valentine JS, Cabelli DE. Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studies by pulse radiolysis. J Biol Chem 1998; 273:30104-30109. Ham D, Schipper HM. Heme oxygenase-1 induction and mitochondrial iron sequestration in astroglia exposed to amyloid peptides. Cell Mol Biol 2000; 46:587-596. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998; 67:S972-S977. Hart PJ, Liu H, Pellegrini M, Nersissian AM, Gralla EB, Valentine JS, Eisenberg D. Subunit asymmetry in the three-dimensional structure of a human CuZnSOD mutant found in familial amyotrophic lateral sclerosis. Protein Sci 1998; 7:545-555. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 47:S161-S170. Kakimura J-I, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-|3 clearance induced by exogenous heat-shock proteins. FASEB J 2002; 10.1096/fj.01-0530fje. Kwon OJ, Lee SM, Floyd RA, Park JW. Thiol-dependent metal-catalyzed oxidation of copper, zinc superoxide dismutase. Biochim Biophys Acta 1998; 1387:249-256. Liochev SI, Chen LL, Hallewell RA, Fridovich I. The familial amyotrophic lateral sclerosisassociated amino acid substitutions E100G, G93A, and G93R do not influence the rate of inactivation of copper- and zinc-containing superoxide dismutase by H 2 0 2 . Arch Biochem Biophys 1998; 352:237-239.
Metal-Catalyzed Redox Activity in Neurodegenerative Disease
13
Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ, Dick RD, Troyer MD, Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 1996; 738:265-274. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158:47-52. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993; 61:1171-1174. Markesbery WR. The role of oxidative stress in Alzheimer's disease. Arch Neurol 1999; 56:1449-1452. Melov S, Schneider JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, Crapo JD, Wallace DC. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nature Genetics 1998; 18:159-163. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, Masters CL, Beyreuther K. Copper-binding amyloid precursor undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998; 37:7224-7230. Pantopoulos K, Hentze MW. Activation of iron regulatory protein-1 by oxidative stress in vitro. Proc Natl Acad Sci USA 1998; 95:10559-10563. Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem 1998;273:33107-33110. Perez M, Valpuesta JM, de Garcini EM, Quintana C, Arrasate M, Lopez Carrascosa JL, Rabano A, Garcia de Yebenes J, Avila J. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol 1998; 152:1531-1539. Perry G, Smith MA. Alzheimer's disease. In: Adelman G, Smith BH, editors. Encyclopedia ofNeuroscience, 2nd edition. Amsterdam: Elsevier Science BV, 1999: 59-61. Perry G, Nunomura A, Avila J, Perez M, Rottkamp CA, Atwood CS, Zhu X, Aliev G, Cash AD, Smith MA. Oxidative damage and antioxidant responses in Alzheimer's disease. In: Iqbal K, Sisodia SS, Winblad B, editors. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester: John Wiley & Sons, 2001: 371-378. Perry G, Nunomura A, Raina AK, Smith MA. Amyloid-P junkies. Lancet 2000; 355:757. Pezzella A, d'Ischia M, Napolitano A, Misuraca G, Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 1997; 40:2211-2216. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 1995; 65: 1399-1402. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev 1998; 27:257-267. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynold GP, Jellinger K, Youdim MBH. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 1989; 52:515-520.
14
Taddeo MA et al.
Sayre LM, Perry G, Harris PLR, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000; 74:270-279. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001; 8:721-738. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995; 37:758-768. Schipper HM. Astrocytes, brain aging, and neurodegeneration. Neurobiol Aging 1996; 17:467^180. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astroctye mitochondria: A substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998; 152:188-196. Singh RJ, Karoui H, Gunther MR, Beckman JS, Mason RR Kalyanaraman B. Re-examination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated CuZn superoxide dismutase mutants and H 2 0 2 . Proc Natl Acad Sci USA 1998; 95:6675-6680. Smith MA, Taneda S, Richey PL, Miyata S, Yan S-D, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc Natl Acad Sci USA 1994; 91:5710-5714. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94:9866-9868. Smith MA, Wehr K, Harris PLR, Siedlak SL, Connor JR, Perry G. Abnormal localization of iron regulatory protein (IRP) in Alzheimer's disease. Brain Res 1998; 788:232-236. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer's disease. Antiox Redox Signal 2000a; 2:413^120. Smith MA, Joseph JA, Perry G. Arson: tracking the culprit in Alzheimer's disease. Ann NY Acad Sci 2000b; 924:35-38. Sziraki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ, Chiueh CC. Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism. Neuroscience 1998; 85:1101-1111. Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, Zweier JL. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postishemic injury. Proc Natl Acad Sci USA 1998; 95:4556-4560. Wiedau-Pazus M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, Valentine JS, Bredesen DE. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996; 271:515-518. Williams MD, Van Remmen H, Conrad CC, Huang TT, Epstein CJ, Richardon A. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J Biol Chem 1998; 273: 28510-28515. Yoshida T, Tanaka M, Sotomatsu A, Hirai S, Okamoto K. Activated microglia cause irondependent lipid peroxidation in the presence of ferritin. Neuro Report 1998; 9:1929-1933.
CHAPTER 2
Metals Distribution and Regionalization in the Brain Margherita Speziali, Edoardo Orvini
ABSTRACT A review of the literature on trace element levels in normal and diseased human brain is undertaken in an attempt to recognize possible distribution patterns of aluminum, iron, copper, and zinc. Trace element concentration changes are known to occur in brain areas of subjects affected with neurodegenerative diseases. We have considered the levels of the four metals in Alzheimer's disease, Parkinson's disease, and Western Pacific Parkinsonism-dementia along with amyotrophic lateral sclerosis. For each disease, we selected articles that consider well-defined brain sites for which the element values observed in controls were found to be significantly different from those determined in patients. For a more complete picture statistically not significant differences of the same element concentrations in the same regions, whenever available, were also taken into consideration. Keywords: Trace elements; human brain; brain areas; brain regions; Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis.
1. TRACE ELEMENT DISTRIBUTION IN NORMAL HUMAN BRAIN Minor and trace element levels appear to be unevenly distributed throughout the human central nervous system. Several studies have reported on different metal concentrations in various areas of the brain (encephalon) in the same subjects; sometimes, they also focus on possible changes in relation to age. We have considered aluminum (Al), iron (Fe), copper (Cu), 15
16
Speziali M & Orvini E
and zinc (Zn). Generally, the authors found the amounts of these four elements to be higher in gray than in white matter. When comparing the metal content of various sites, the relative composition of both matters could not be negligible.
1.1. Aluminum, Iron, Copper and Zinc Distribution in Normal Human Brain Sites in Relation to Age We summarize the data on autoptic samples taken from individuals with no signs of neurologically related diseases ("controls") in an attempt to identify possible distribution patterns of Al, Fe, Cu and Zn in "normal" human brain regions. We consider experiments in which the number of sites examined were not very low, as our purpose could be attained whether or not the areas taken into account in the different experiments were mostly the same. In trace element determination, every scientific team analyzed brain samples in different number, areas, and gray/white matter ratio. Most Authors published tables with all the values obtained, while others pulished selective information.
1.2. Aluminum McDermott et al. (1977) determined Al concentration in the frontal cortex/ hippocampus of three younger controls and six elderly controls (age not reported). They found a double Al level in the elderly compared to the younger subjects. McDermott et al. (1979) analyzed Al concentration in the lobe cortices, cerebellum and corpus callosum of three controls (25-65 y) and in another six controls (75-99 y). Considered together, the highest Al concentrations in the nine subjects were found in the hippocampus, the lowest in corpus callosum (white matter). In bulk brain, the mean Al content in the elder group was found to be considerably higher than in the younger one. Ehmann et al. (1980) analyzed Al levels in the brains of 20 controls in five different age groups. They observed a positive correlation between an abundance of Al and age. Markesbery et al. (1981), in their study of 28 controls (0-85 y) derived the same results. Ehmann et al. (1982) and Markesbery et al. (1984) published the results of a systematic study on minor and trace element concentrations over the
Metals Distribution and Regionalization in the Brain
17
whole human life span. Aluminum levels were determined in a very high number of brain regions in 29 adult controls (age 19-85) and seven infants (premature - 6 months). They found that the mean Al levels were highest in globus pallidus (GP), putamen, and middle temporal lobe, and lowest in the superior parietal lobule. No data on other areas were reported. Aluminum exhibited a significant increase in the brain with advancing age. Roider and Drasch (1999) evaluated Al concentration in brain gray matter and white matter (sulcus lateralis), nucleus lentiformis, brainstem (pons) and cerebellum (arbor vitae) of 140 adults in dependence of age. The highest Al concentrations were found in gray matter, the lowest in white matter, with a statistically high significance difference. The differences in Al contents of gray matter, nucleus lentiformis and cerebellum were also shown to be highly significant statistically. The dependence of Al values on age appeared biphasic: there was an increase with age up to a first maximum at approximately 40 years followed by a plateau or even a small decrease at up to 70 years. A second increase then followed in the eighth and ninth decades of life. No significant gender differences in Al concentrations in the brain were noticed. Taking into account papers not related to Al changes in the different periods of life, Yoshimasu et al. (1976 and 1980) published Al determination in 10 brain sites of three Japanese controls (28^-0 y); the highest value was in gyrus praecentralis, the lowest in capsula interna (CI). Yoshimasu et al. (1982) analyzed Al in 20 brain areas of three Chamorro (from Guam island) controls (57-87 y); gyri praecentralis and postcentralis showed the highest contents, followed by parietal and temporal cortices; CI, putamen and cerebellar white matter had the lowest levels. Rajput et al. (1985) and Uitti et al. (1989) determined Al in frontal cortex, nucleus caudatus (NC), substantia nigra (SN), and cerebellum in nine (no age given) and 12 individuals (average age = 70 y), respectively. The highest amounts were found in NC. Yasui (1991a and 1991b) evaluated Al contents in three areas of five control brains (65-75 y); gyrus praecentralis showed higher levels than CI and cms cerebri. Yasui et al. (1992) reported Al values in 10 areas of the same brains; the highest contents were found in SN, nucleus ruber (NR), pons and cerebellar cortex; the lowest was found in GR Xu et al. (1992) analyzed Al levels in the middle frontal gyrus, hippocampus, inferior parietal lobule, and superior and middle temporal gyri
18
Speziali M & Orvini E
of 10 controls (57-93 y). Middle frontal gyrus and inferior parietal lobule contained higher values than the other two areas. Andrasi et al. (1989) studied Al in 10 regions of nine controls (65-75 y). The highest amounts were found in GP and cerebellar cortex, the lowest in putamen and pulvinar thalami. In another study (1994), they evaluated Al contents in 12 sites of 11 (no age given) subjects; they found the highest Al levels in NR and SN, the lowest in pulvinar thalami, putamen and NC. In a later study (1995), they determined Al concentrations in 20 (average age = 70 y) individuals. Samples from the cortices, thalamus and GP showed the maximum levels, while NC, Ammon's horn and other cortical specimens showed the minimum levels. Rajan et al. (1997) determined Al contents in 12 regions of eight individuals (50-60 y); they found the highest amounts in the temporal cerebrum and thalamus, the lowest in pons and cerebellum. In the case of aluminum, only GP, SN, and NR were analyzed and found to be the richest in Al by different teams. A positive correlation between Al amounts in the brain and age was observed.
1.3. Iron Hallgren and Sourander (1958) published the levels of nonhemin Fe in 16 brain sites of 37-59 individuals (30-100 y). The highest Fe values were found in the structures of the extrapyramidal system: the maximum amount occurred in the GP, while somewhat lower levels were obtained for NR and SN, followed by putamen, nucleus dentatus (ND) and NC. As for the cerebral cortex, the highest concentrations were observed in the motor cortex followed by the occipital, sensory and parietal cortices; the lowest levels were found for the prefrontal and temporal cortices. An increase in nonhamin Fe occurred with advancing age in all regions examined, except in the medulla oblongata. The rise in Fe values was rapid during the first two decades of life, and then became more gradual. Sundermann and Kempf (1961) analyzed Fe content in the brainstem ganglia of 100 human brains divided into 10 age groups. The Fe value was richest in GP followed by, in order of decreasing content, putamen, NC, thalamus, cerebral cortex, NR and cerebral medulla. While the increase in iron content with increasing age could be proven statistically for GP, putamen, and NC, the thalamus and cerebral cortex showed a clear increase in
Metals Distribution and Regionalization in the Brain
19
iron content only up to the fourth or fifth decade of life. In old age, however, a sharp tendency towards reduction appeares. Schicha et al. (1971) analyzed Fe in 16 brain sites of six subjects (newborn - 74 y). In four adults (34-74 y), the highest Fe concentration was found in GP and the lowest in NR. NC and putamen showed the same intermediate concentration. In cortical areas considerably lower Fe levels than in the basal ganglia were observed. The average Fe concentration in the brain of a newborn is only 20% that of an adult and about 60% that of a 4-year-old child. The Fe values in adults appeared to be reached between seven and nine years of age. The Fe concentration in Broca's center of speech and the motor cerebral cortex was, in all cases, higher in the left hemisphere than in the right. Volkl and Ule (1972 and 1974) determined the Fe concentration in 13 defined areas of the brain in 33 subjects (newborns - 80 y). The highest values were found in GP, putamen, and NC; the lowest in the oliva inferior and corpus callosum (CC), with intermediate values in the frontal and occipital cortices. The Fe content, in relation to age, seemed to differ considerably among the various areas examined. There was a sharp rise in the basal ganglia during the first year of life followed by a gradual leveling off. The increase in Fe content in the cerebral cortex was observed to be much less marked. Both the thalamus and hippocampus showed little change in their Fe content during life, while the olives tended to lose iron. Volkl and Ule (1974) analyzed Fe contents in 13 regions of six infant (two were born premature, three were born at full term, and one infant was 21 months old) and juvenile (3 children of 6-11 y) brains, and compared these levels to those of adult brains. Fe rose in the juvenile years in gray matter, exhibiting intermediate values; in white matter, Fe rose by approximately 50% compared to perinatal levels. Along with the increase in Fe, typical regional distributions developed until the juvenile years thereby resembling the distribution in an adult brain. Ehmann et al. (1982) and Markesbery et al. (1984) observed the highest mean Fe values in the GP and putamen; the cerebellar vermis and hippocampus contained the lowest concentrations. Iron appeared to peak between 40 and 79 years of age before declining, although this trend was not significant. Connor et al. (1992) studied Fe contents in the superior temporal gyrus, motor cortex, and occipital cortex (both white and gray matters in each site) of nine normal adults (mean age, 55 years; range, 44 to 64 years) and 11 elderly (mean age, 71.6 years; range, 65 to 80 years).
20
Speziali M & Orvini E
In both groups, Fe was highest in the motor cortex. In the gray matter in the occipital cortex, there was a 130% increase in Fe with age; in the white matter, no statistically significant increase occurred with age. Loeffler et al. (1995) determined Fe concentration in eight young adult controls (<65 years) and eight elderly controls (3=65 years). In the former, Fe concentration was greatest in GP, whereas it was in SN in the later. For both groups, Fe content in the frontal cortex was less than that of other regions. Fe concentration increased by >80% with age in SN, NC, and putamen, but decreased by 46% in GP; these differences were not statistically significant. Hebbrecht et al. (1999) determined Fe levels in the cerebral and cerebellar cortex, white matter, basal ganglia, and brainstem of 18 individuals (7-79 y) to assess any changes related to age. They observed an age-related increase in Fe concentration. Zecca et al. (2001) measured the concentration of Fe in SN from normal subjects aged one to 90 years old. Fe levels in SN appeared to increase by the fourth decade of life and to remain stable until 90 years of age. Hill (1988) reviewed the distribution of iron in the brain in relation to age. Dealing with papers not related to Fe changes in aging, Harrison et al. (1968) analyzed Fe contents in 10 regions of 35 individuals (no age given). The highest Fe amounts were found in the GP, putamen, and NC; the lowest in the corpus callosum and cerebellar white matter. Hock et al. (1975) determined Fe amounts in 27 sites of seven brains (23-66 y). The maximum level of Fe was detected in the GP, followed by the putamen, NC, and SN; the minimum in the cms fornicis, corpus callosum, corpus geniculatus lateralis, and corpus semiovale (white matter). Goldberg and Allen (1979 and 1981) studied Fe amounts in six sites of three control subjects (no age given). They observed the maximum Fe level in SN and elevated contents in GP, NC, and putamen, while the minimum level was found in the hippocampus and cerebral cortex. Duflou et al. (1989) analyzed Fe contents in about 50 brain sites of 12 subjects (7-69 y). They found the highest Fe concentrations in the plexus choroideus, GP, SN, and putamen. The lowest concentrations were observed in the pyramid, tractus corticospinalis, and nucleus olivaris inferior. Kornhuber et al. (1994) measured Fe in seven brain regions of 12 individuals (41-91 y). The highest amounts were detected in NC and the corpus mamillare, the lowest in the hypothalamus and gyrus cinguli. Bush et al. (1995) analyzed gray and white matters of the lobes along with
Metals Distribution and Regionalization in the Brain
21
six other areas of 30 subjects (18-85 y). The highest Fe values were found in the putamen, SN, GP, and NC, while the lowest values were found in the white matter of the occipital and parietal lobes. Rajan et al. (1997) observed the highest Fe concentrations in the frontal, temporal, and parietal cerebrum, and the lowest in the medulla oblongata and pons. Andrasi et al. (1999) determined Fe amounts in 20 sites of five control subjects (>65 years). The highest concentrations were found in the putamen, followed by GP, NC, and SN; the lowest concentrations were found in NR and gyrus cinguli. Most authors found the highest Fe concentrations in GP, followed by the putamen, NC (caput), and SN. The metal showed a different increase with age in various areas.
1.4. Copper Ule et al. (1974) and Volkl and Ule (1974) determined Cu amounts in 13 brain areas of 29 and 33 subjects (age 0-80 y), respectively. In adults, the highest concentrations of Cu appeared to occur in SN, which was significantly different from the frontal cortex. High levels were also observed in the occipital cortex, neostriatum, and nucleus dentatus, while the lowest levels were seen in the thalamus and centrum semiovale. The Cu level of newborns was found to be somewhat lower than that of adults, while between the fourth and seventh decades of life these values remained independent of age. Volkl et al. (1974) observed that Cu rose during the juvenile years in the gray matter; in white matter, Cu changed little during maturation. Along with the increase in Cu, typical regional distributions developed until the juvenile years, thereby resembling the distribution in an adult brain. Saito et al. (1993 and 1994) analyzed Cu levels in the brains of 14 subjects (4-54 y) in five brain regions (lobes and cerebellum). The concentration of Cu in the cerebellum appeared to be significantly higher than that in the temporal lobe. No relation to age was observed. Tandon et al. (1994) examined 17 controls (age 33-85) and observed a significant positive correlation between Cu content in bulk brain and age. Considering experiments not related to age, Warren et al. (1960) and Thompson (1961) reported the results of analyses of Cu contents in 26 areas of nine brains (no age given). The highest amounts were found in the
22
Speziali M & Orvini E
locus coeruleus, followed by SN, ND, and parietal cortex (all samples were gray matter); the lowest amounts were found in the optic chiasma, base of pons, and corpus callosum (all made of white matter). SmeyersVerbeke et al. (1974) evaluated the distribution of Cu in 13 brain areas of 11 subjects (no age given). The maximum values were observed in the cerebellar cortex followed by the occipital cortex and basal ganglia, while the lowest values were found in the brainstem and corpus callosum. Harrison et al. (1968) detected the highest Cu amounts in the cerebellar gray matter, putamen, and NC; the lowest amounts were found in the corpus callosum, thalamus, and frontal and cerebellar white matter. Smeyers-Verbeke et al. (1974) verified the distribution of Cu in the brain. The highest values were observed in the cerebellar and occipital cortices and basal ganglia; the lowest values were found in the corpus callosum and brainstem. Goldberg and Allen (1981) observed maximum Cu level in SN and elevated contents in the putamen and NC, while the minimum levels were found in the hippocampus and cerebral cortex. Bonilla et al. (1984) determined Cu concentrations in 38 brain areas of seven subjects (11-75) y. The highest Cu levels were detected in the olfactory bulb, gyrus postcentralis superior, NC (tail), and calcarine cortex (cuneus); the lowest levels were found in the frontal, occipital, and parietal lobes' white matter along with the optic chiasma and thalamus. Duflou et al. (1989) found the highest Cu concentrations in SN, ND, lobulus flocculo-nodularis cerebelli, paraflocculus ventralis cerebelli, and putamen. The lowest concentrations were observed in chiasma opticum, tractus corticospinalis, and corpus fornicis. In Kornhuber et al. (1994), the maximum levels were detected in NC, followed by the hypothalamus and cortex; the lowest levels were found in the hippocampus and corpus mamillare. Deibel et al. (1997) analyzed Cu contents in 13 regions of five subjects (no age given). They found the highest levels in the amygdala and cerebellum, with the lowest levels in the cerebellum and hippocampus. In Rajan et al. (1997), the highest Cu concentrations were determined in the cerebellum and midbrain, with the lowest levels in the pons and thalamus. Andrasi et al. (1999) found the highest concentrations of Cu in SN, NR, and putamen, and the lowest in the genu corporis callosi. Most authors found the highest concentrations of Cu in SN, ND and other cerebellar regions, putamen, and NC. Copper seemed to increase at least until adult age, possibly by the fourth decade of life.
Metals Distribution and Regionalization in the Brain
23
1.5. Zinc Hu and Friede (1968) determined Zn in 24 regions of five adults (34-87 y). They found the maximum level in Amnion's horn, SN, ND, and amygdala, and the lowest level in the pyramids, optic chiasma, and cerebral peduncle. In 17 areas of two newborns (four to five days' old), Amnion's horn, SN, cerebellar white matter, and cortex showed the highest Zn concentrations; the frontal and occipital white matters showed the lowest concentrations. Ule et al. (1974) and Volkl and Ule (1974) found the highest zinc concentrations in adults in the hippocampus, followed by the frontal cortex, NC, oliva inferior, and SN; in the last three sites, the Zn levels sometimes appeared to increase with age. The lowest values were seen in the centrum semiovale. Between the fourth and seventh decades of life, the Zn values remained independent of age. Volkl et al. (1974) observed that Zn rose during the juvenile years in regions of gray matter; in white matter, Zn changed little during maturation. The perinatal distribution pattern of Zn was already similar to that found in adult brains. Ehmann et al. (1982), Markesbery et al. (1984), and Ehmann et al. (1984) reported on Zn levels in 29 adult controls (age 19-85) and seven infants (=S6 months of age), by considering many regions. For controls aged 20 and above, the highest mean Zn levels were found in the hippocampus, NC, amygdala, and cerebellar vermis, and the lowest in SN, middle frontal lobe, and GP. Among infants, Zn concentrations were observed to be highest in the posterior occipital lobe, middle frontal lobe, and putamen; the lowest concentrations were detected in the thalamus. The difference between the infants and the adults was significant. Zn concentrations in controls aged above one exhibited a highly significant positive correlation with age. However, if the 19-year-old patient was eliminated from the group, the Zn concentration showed no significant correlation with age. In the hippocampus, the Zn level reached a maximum in those aged between 40 and 59, but declined gradually afterwards. This was also true of the putamen and superior parietal lobe. No regular patterns, as a function of age, were observed for any of the other brain regions in the adult control group. Saito et al. (1994) found that Zn concentration in the frontal lobe was significantly related to age. Hebbrecht et al. (1999) observed an age-related increase in Zn concentration.
24
Speziali M & Orvini E
Regarding works in which Zn possible changes in aging are not considered, Kornhuber et al. (1994) found the highest Zn values in the hippocampus and cortex, and the lowest in the corpus mamillare and hypothalamus. Rajan et al. (1997) observed the highest levels in parietal cerebrum and medulla oblongata, and the lowest in the hippocampus, hypothalamus, and pons. In Smeyers-Verbeke et al. (1974), the highest Zn values were seen in the temporal, frontal, and cerebellar cortices, while the lowest levels were seen in the corpus callosum centrum ovale, and CI. Hock et al. (1975) found the highest Zn levels in the epiphysis, gyrus dentatus, hippocampus, and insula, and the lowest in the corpus callosum, crus fornicis, and centrum semiovale (white matter). In Harrison et al. (1968), the hippocampus and frontal gray matter showed the highest Zn amounts, while the frontal and cerebellar white matter, together with the corpus callosum, showed the lowest. Duflou et al. (1989) found the highest Zn concentrations in the epiphysis, uncus hippocampi, plexus choroideus, and amygdala. The lowest concentrations were observed in the radiatio optica, pedunculus cerebri, CI, and genu corporis callosi (all samples were of white matter). Andrasi et al. (1999) found the highest Zn concentrations in the gyrus frontalis medius, putamen, and NC (caput), and the lowest amount in the genu corporis callosi. From the papers examined, it appears that several authors found the highest concentrations of Zn in the hippocampus, amygdala, NC, and epiphysis. Zn seems to increase until adult age, depending on the areas being considered.
2. TRACE ELEMENT IMBALANCES IN NEURODEGENERATIVE DISEASES The biochemical role that the redox-active transition metals, especially Fe, Cu, and Zn, play as mediators of oxidative stress in a variety of neurodegenerative diseases has recently been reviewed by Sayre et al. (1999 and 2000), Bush (2000), and Campbell et al. (2001). The last paper also considers Al. The role of metal ions (mainly Fe and possibly Cu) in oxidative processes and aging was reviewed by Floyd and Carney (1993). In single elements, the role of Al in human brain disease was explained by Yase (1980), Crapper McLachlan and De Boni (1980a and
Metals Distribution and Regionalization in the Brain
25
1980b), Crapper McLachlan et al. (1983), Crapper McLachlan and Farnell (1985), Wisniewski et al. (1985), Wisniewski and Sturman (1989), Savory et al. (1991), Youdim (1994 and 2001), and Yokel (1997). The function of Cu in neurodegenerative diseases was described in Scheinberg (1988), Waggoner et al. (1999), Rotilio et al. (2000), Brown (2001), and Strausak et al. (2001). The implication of Fe in neurodegenerative diseases was elucidated by Beard et al. (1993), Gelman (1995), Qian et al. (1997), Pinero and Connor (2000), and Thompson et al. (2001). Fe and Al homeostases in neural disorders were treated by Joshi et al. (1994). A book on Fe metabolism in Central Nervous System disorders was published by Riederer and Youdim in 1993. Gerlach et al. (1994 and 2000) also reviewed, besides metabolic studies, papers on Fe evaluation in different brain regions in several neurodegenerative diseases. The role of Zn in the same disorders was discussed by Wallwork (1987), Cuajungco and Lees (1997a), and Yasui et al. (1997). Sandyk (1991) has examined the relationship between Zn deficiency and cerebellar diseases, and a review on Zn, human diseases, and aging was published by Fabris and Moccheghiani in 1995. Cu and Zn functions and levels in the brain in health and neurological disease were reviewed by Cumings (1965). Analytical studies on trace element imbalances in agerelated neurological diseases were published by Ehmann et al. in 1987 and 1993. Markesbery and Ehmann (1988) have reviewed the possible trace element (especially Al and Zn) concentration changes in dementing disorders; while Ehmann and Vance (1996) have reviewed studies of trace element involvement in neurodegenerative diseases using activation analysis. For this overview, we have taken into consideration literature data on the tissue level, with concentrations expressed as the amount of element per gram of tissue or protein. Concentrations as a ratio between a couple of elements were not considered, as well as observations at the cellular or subcellular level. For each neurological disease, original papers with analytical data on both control subjects and patients were retrieved from the literature. Of these, those reporting on Al, Fe, Cu, and Zn concentration values in bulk samples, in wide regions such as lobes, lobe cortices, cerebellum, or in not so clearly delimited sites were excluded. We selected only articles that consider well-defined brain sites in which the element
26
Speziali M & Orvini E
values were significantly or highly significantly different between the control and patient groups. To provide a more complete picture, statistically not significant (NS) differences of the same element concentrations in the same regions, whenever available, were reported in the tables. Captions valuable for all tables are shown in Fig. 1.
SD = standard deviation; M = male, F = female; S* = significant or highly significant difference; pS = possibly significant difference;
SEM = standard error of the mean; av = average; mS = marginally significant difference; NS = not significant difference.
w = concentration expressed on a wet weight basis. To allow a comparison among all the values, the data were converted to a dry weight basis; the values obtained are reported, in parentheses, beside. When possible (Thompson et al., 1988 and Cornett et al., 1998b) conversion was made using the FD/WET weight ratio provided by the authors; in the other cases, the data were calculated using the ratio 0.21. v subjects from Eastern Canada; * combined data for olfactory bulb, tract and olfactory trigone; A data converted from nmol/g;
A subjects from United Kingdom; • combined data for olfactory bulb, tract and nucleus; 0 data expressed as mg Fe/g of protein.
E in Griffits et al., 1989, the site is named Substantia Nigra Pars Reticulata. ® precise data are reported in Galazka-Friedman and Friedman, 1997. C = Controls, not better specified; JC = Japanese Controls; ChC = Chamorro Controls; AD = Alzheimer's Disease patients; PD = Parkinson's Disease patients; PD<*i = Mild or moderate stage of PD patients; PDV = Severe grade of PD patients; GPD = Parkinsonism-Dementia patients from Guam; PD1 = Severe stage of PD with Dementia of Alzheimer's Type patients (Sofic et al., 1991); ALS = Amyotrophic Lateral Sclerosis patients, nor better specified; GALS = Amyotrophic Lateral Sclerosis patients from Guam island; KALS = Amyotrophic Lateral Sclerosis patients from the Kii Peninsula of Honshu island, Japan. INAA = Instrumental Neutron Activation Analysis; CNAA = Pre-irradiation chemical separation NAA; MS = Mossbauer Spectrometry; ICP= Inductively Coupled Plasma; ICP-AES = ICP- Atomic Emission Spectrometry;
Fig. 1. Captions for all tables.
RNAA = Radiochemical NAA; AAS = Atomic Absorption Spectrometry; PIXE = Proton Induced X-ray Emission; ICP-MS = ICP- Mass Spectrometry; Spectroph. = Spectrophotomertry.
Metals Distribution and Regionalization in the Brain
27
2.1. Aluminum, Iron, Copper and Zinc in Alzheimer's Disease Alzheimer's Disease (AD) is the most common cause of senile dementia. Etiologically, it is a heterogeneous condition in which several factors control the expression of the disease. The first structure to show pathological changes is the cerebral cortex (Braak and Braak, 1994). Al plays a major role in the AD pathogenesis (McLachlan et al., 1996). The role of Al, Fe, Cu, and Zn in the pathogenesis of AD was recently reviewed by Atwood et al. (1999). The relationship between Al and AD was described by Edwardson et al. (1986 and 1991), Crapper McLachlan (1986 and 1990), Birchall and Chappell (1988a and 1988b), Kruck and Crapper McLachlan (1989), Sturman and Wisniewski (1988), Wisniewski (1991), Wisniewski and Wen (1992), McLachlan (1994 and 1996), Lukiw (1997), and Campbell (2002). Al toxicity and content in AD were described by Crapper McLachlan et al. (1978); the evidence for a possible link between Al and AD was reviewed by Markesbery and Ehmann (1993). Chazot and Broussolle (1993) reviewed Al and Zn alterations in aging and in AD. Ehmann and Markesbery (1994) presented a summary of Al results determined in their laboratory and explored the reasons for the discrepancies among data obtained in various studies carried out in theirs and in other laboratories. Al and Zn alterations in AD were reviewed by Markesbery and Ehmann in 1988; Al, Fe, and Zn changes by Markesbery and Ehmann (1994). The implication of Fe in AD was suggested by Youdim (1988); Fe levels in AD were reviewed by Gerlach et al. in 1994 and 2000. Cu and Zn involvement in AD was described by Moir et al. in 1999. The role of Zn in AD was discussed by Constantinidis and Tissot (1982), as well as by Constantinidis in 1990 and 1997. Nachev and Larner (1996), besides describing the role of Zn in AD, also reviewed the concentration levels. Several original papers were retrieved on Al, Fe, Cu, and Zn determination in brain samples of both AD patients and non-AD controls at the tissue level: Hallgren and Sourander (1958, controls; 1960, patients), Crapper McLachlan et al. (1973, 1974, 1976, and 1980c), Constantinidis et al. (1977), McDermott et al. (1977 and 1979), Trapp et al. (1978), Yoshimasu et al. (1980), Traub et al. (1981), Markesbery et al. (1981 and 1983), Hershey et al. (1984), Ehmann et al. (1984 and 1986), Yoshimasu
28
Speziali M & Orvini E
(1985), Thompson et al. (1988), Plantin et al. (1987), Ward and Mason (1987), Jacobs et al. (1989), Corrigan et al. (1993), Xu et al. (1992), Dedman et al. (1992), Griffiths and Crossman (1993), Tandon et al. (1994), Andrasi et al. (1994 and 1995), Samudralwar et al. (1995), Deibel et al. (1996), Cornett et al. (1996, 1998a, and 1998b), Kala and Hasinoff (1996), Bjertness et al. (1996), Danscher et al. (1997), Stedman and Spyrou (1997), Rao et al. (1999 and 2000), Rulon et al. (2000), Panayi et al. (2000 and 2001). Two original works with only data on patients, VanDalsem et al. (1995) and Ishihara et al. (1999), were also found. Connor et al. (1992) and Loeffler et al. (1995) reported on Fe levels in both control and AD subjects as the amount of Fe per gram of protein. Corrigan et al. (1991) considered patients affected with senile dementia of Alzheimer's type. Tables 1 to 4 list the concentration values of Al, Fe, Cu, and Zn in brain sites of both control and AD subjects. The data show the significant difference between the two groups in some brain areas, along with other data that do not show a significant difference for the same elements in the same regions. In analytical studies on AD, the hippocampus and amygdala were sites where the concentrations of each element were most frequently found to be significantly different between the control and AD groups. Table 1 shows the data for Al. The amount of Al in the hippocampus of AD subjects was found to be increased in most papers, significantly or not; only one paper (McDermott et al., 1979) showed the same values. A significant enrichment in patients was reported in the inferior parietal lobule and in the superior and middle temporal gyrus, while a marginally significant increase was found in the gyrus postcentralis. Other results in the same sites were not available in the literature. Table 2 shows data on Fe. Fe values in the hippocampus are conflicting. In some experiments (Deibel et al, 1996; Cornett et al., 1998b), a significant elevation was detected in the AD group. In Thompson et al. (1988), the higher amount was only marginally significant and in GalazkaFriedman et al. (1996), not significant. Plantin et al. (1987) observed the same data in both the control and patient groups. On the other hand, Corrigan et al. (1993) found a significant Fe decrease in the AD group. Ward and Mason (1987) observed a possibly significant reduction in subjects from the United Kingdom and a not significant reduction in those from Eastern Canada. In the amygdala, either significantly (Thompson
T3
oo
< <
ON
a 2 o U
% OH
00
ON
^
CO
y CO NO
>n 00
^o
1 in
CN in
w
o
iH
ON
rON
00
o
3 ON
CN
t
-i ca X
oo
CN ON ON
oo
< <
oo
<; <
in
CO ON in
in 00 CN in
in 00
co"
^H
K
(N NO
in CM
t~ in
in
CO 00 CO
^
* CN • *
d
(N
t-~ ^f 00
* r* oo r~ CO o d
o o
*
TT • *
d
T-*
o r-
o
NO
ON
in
o
ca
H H
C/l
00
g
Z
on
< < ON
r- o
NO CO
^ H
CO
1 00 c- t— CM
o
^H
NO in
o o
o
o Ji OH
-3
"3 ' c 2
o
a Q Q Q u < o < u < u <
NO in
CN * * oo
1
ON
ON ON
ca
Z
on
Yoshima OH OH
PH
0}
ca
r
<S1 ON
ca
6 J3
o
a o <
o
< z
Yos
HH
9
|
in
& S £ S X
< < Z
u CN
J^ NO PH
+ ri
GO ©'
rn
•s
Xue
Metals Distribution and Regionalization in the Brain
Pi
CN
in
o (N
oc
©
£
• *
McD INAA
00
z
< < z u ON
in
O
P-,
PH in
ON
PH
r- t— rts r- >n
in
NO
BH in
o
o"
m of
sS
+ + + + GO GO"
in
* *
O
d d
o 1 co in
1
o"
1
CO
1
in
u <
1M+2F
60 •
< '
O
Z 2
o
in
Q
'•D o oo • * r* ^r s *S—' ^H'
0.08
j- W C
,—1 • *
^T 00 »T) NO CN i—-
'—'
0.07 3)
2 "> PS
r~ CO • *
T—i
Q
u < u <; o
o OH
C.
2M+10F
7)
29
<
SH
ID
as
QJ
U
u
< z
PH
m
J_,
a\ ON
•a
XH
o
c
>—'
a
< Z
<M
oo oo
in
*— £'
m
CM in CM
ON ON
S tN
00s OO tN
^j
t
3
«
TO
B
z
to
Q
HH
Q
s
_
0.
art
00
£
Speziali M & Orvini E
to
r .C
z
in
5= 00
NO
ON
^ H
o ^ H
en
S-
< <
00
z a!
s
in
r*i
CO
,_, cd s i&
o
^j • o o C; S N m £= S
^ ^ ^"
^ NO
1 5 — s' CN in
a<
3
CO
B
o
#
4=
K
CNJ
E Ki
s
O.
DH
o
o
o OH o.
3
D,
a
a CO
Q
OH
o
O M
^ H i n NO
%
PH PH
z o
O^ M h i n >T) i n
in
z o
PH
ON NO
PH
(N -H -H -H -H
o
r, PH
[7? r-- in o ^
+ + + + + + ++
00
PH
r E 13 .S> 2? « -d 2 -
o H
J3
C2
1/5
< z I
ON
ON m OO I NO
c i in NO
in NO
^o CM
& * *o •*
CNl ON
^ O ON
CM
Q
OH
CO
B nJ DH OH
o O
3
E o
3
Cfl
u
2
00 r- g H i n o O N f ) ( N r o h c-f n" S o" 12 *-< ^ J^ od o" od o
e'en 5=
C*l
oo
CO
3
O.
E CC O
O
a.
s
&, OH
UIO
Pi
CD
4H
Mas<
< <
Come etal. Ward
s
H
J3
i
in
0)
3
E «j
to
^f
00
(N
CN
o
NO
1 +1 + 1 O r-PH
00
si Ji^
•S
in (N
^r
ON
ro
o
NO
'
J^ NO
S
N
in
O
NO
00
"3 13
C3
Q Q < U <
NO
ON
-2
<:
>-. >> B E <
"3 -o 00
U
•>t
oo
NO
O
13
pson ., 198 dralw INAA
to
z
•
- H
IT)
^ ^ ON
in
O 00
Q <
CO
ON
O
O.
'3
E es
o o a,
2 3& •a 3&
15M +4F
00 '
x> i> 3 T3 to C
O
Z
>- w W o Q CO
C^H
Q
o <; CO
3 PH
E cd
o O D. OH
+4F
INAA
pson
£
Lobe
mpoi ippoc
2M+10F
sue
ences
X> OO ON ON
OO
4
u "3 Q
NO
"a "CD
OO ON
ON
13 0}
E
X> 00 ON ON
13 O
^ O E
o O
< <
z
<; < z 00
X)
oo ON ON
00
ON ON ON ON
oo oo
o O
XI y o u Ooo N
ji
E Uo
<; < z
C/5
< < z ^
OO
o 00
r-^ ^f i — i
OO ON1 ON1 ON1 ON1 ON1 ON1 NO in NO in NO in
ALZ
-
O
NO -
.
2
NO-
— I - H - , 0 0 ^ ,
—i
.
OO
m
ON
^^ oo OO en
NO -
_,
ON
• *
^f
^^
Q
m
NO
•ar
in ON
ON
^r o 1 00
r-
<* S
l
„
&o
C/1
u 13 t/3
NO ON ON
Q
< < Z
< < z C-; 1—1
00
BH
03
> > BH 00
§ mS 2
-H
£. o r- r» NO
* T-,
Q
Q
r- r-- ^ !ON p-| r-
JQ
r-
Q
tN
Cs)
OO
O rmO. O T-, - H - H
en
o
ON NO
^—'
S o) ^f
NO
^—' in
r-
S
in
m
o
ON NO
Q
z
amudi alwar
^
amudr alwar I
ieib
|Ic ^-I| ^-I 8- .§ ^g £ B^ ;Io2
„
in ON ON
in
13 o XI y oo u o ON E o ON U J
C/5
Z OO ON
+ + 2 NO
o ~ ^r t CO
r-
CNI
Q
Q
% 0
„
in ON ON •a
w H-H 14—
ON ON
§
i2
c "3
ON
C
ON
sma
c« w 2 ,-s O u U
u
C/5
O
C/5
< < en en oo
t/3
< NO OO IN OO
^C
> > >
en c^i
00
NO
ON OO
is* *
NO
2 *>
1
o
ON
oo
^ NO ON
Q
OO
^f
o o
ss
00 t^
OO
D. a.
1
r-
rn NO NO
!i! U D.S^
Q
NO ^^ ^^ J* ON oo o c -o ON o V3 o cd ^ 1—' '3 u os ON
00
1 °>>n °> A\
NO
i ON
NO
r-H ^f
oeffl
I ! g 0
sma
Metals Distribution and Regionalization in the Brain
13
E
QJ Jj
o U
< < Z 00
00
in
^f t? m
^^ en in
^—^
Q
IB £
27F
> > 27F
ON ON
2 ...
;-,' * • < *
Q
§ (E
1 w(9
NO-
Tf
ON
S 5 ^r m
m
.^ , ^
Q
B
Th —' '—'
s
oo o m o ON
B
<
2.2 w (10.3
15F
ON1 ON1 NO in
PL, 00
15F 27F 15F
+ + + + + + + + + + + +
15F
Heb 199 29*
riff
9.7 20.8 18.3
15F 27F
31
32
Speziali M & Orvini E
et al., 1988; Samudralwar et al., 1995; Cornett et al., 1998b) and not significantly (Deibel et al., 1996) higher amounts were observed. In the inferior parietal lobule and olfactory region, a similar situation was found. GP, considered in toto, showed a significant Fe enrichment in AD patients, while in the lateral and medial parts, analyzed separately, a not significant elevation was found. The unique experiment where the frontal pole and temporal pole were analyzed demonstrated a significant Fe enrichment in the AD group in both sites. In the piriform cortex, a significant Fe increase in patients was reported by Samudralwar et al. (1995). Table 3 reports on the Cu levels. The amount of Cu in the hippocampus appeared to decrease, significantly or not, except for Canadian subjects examined by Ward and Mason (1987). In the amygdala, the unique datum (Deibel et al., 1996) indicated a significant decrease. For Zn (Table 4), the data published in the literature on the hippocampus are conflicting. Ward and Mason (1987), who examined two populations, and Corrigan et al. (1993) found a significant decrease in the patient groups. In contrast, Deibel et al. (1996) and Cornett et al. (1998b) observed a significant elevation, while Plantin et al. (1987) and Rulon et al. (2000) evaluated the higher amount as not significant. Thompson et al. (1988) found the same results in both control and AD subjects. In the amygdala, according to four papers, significantly higher Zn contents were observed in patients; only Rulon et al. (2000) considered the increase as not significant. In the olfactory region, the enrichment of Zn was found to be significant by Samudralwar et al. (1995) and not significant by Cornett et al. (1998b). A significant Zn increase in AD patients was reported in the frontal pole and temporal pole (Cornett et al., 1998b), as well as in the inferior parietal lobule (Deibel et al., 1996; Cornett et al., 1998b). Thompson et al. (1988) found a marginally significant Zn increase in the nucleus basalis of Meynert.
2.2. Factors Affecting the Final Results Several factors can influence the final results of trace element determination in humans: biological/environmental factors of variation, such as age, gender, genetic factors, possible environmental exposure to specific elements, lifestyle, diseases, and medical treatments; preanalytical factors (control of contamination and losses) due to post-mortem changes, sample collection
•
60 •
Z
oo
Q oo
•3
f~
rS
o
TO
x;
CN
• * •
ON
m'
n
NO NO
m1 »n
g
FT,
•*
^f
NO
£ £ i—<
O. Q.
Q
in
O.
£
Q
--^
•3
<
s
00
ON
^c > i
60
13 T3
E
<
Q
o en
2
ON
13 ^o
o\ ia ON „ u
§ 1
oo
in
J_I
E°o ^
z
rr
in in \o
°T
a«a Z
oo
-° a ^ a -p £
oo
o y
oo
Z <
§
§ 7
(N
m
CM O • * '
e.
B
« Q.
o o
£
Q
o
in oo m CN oo (N ^ CN rt £! m cN
+ + + + + +
[i, fc B . ft , in O m O b
in
o\ rJ (N vi a K 1 oo VO
2 S
*
^
< <
*
^_<
NO (N
c*i
D.
Q
D,
B m o o D<
P.
s
o o o.
B ft
3
o O o* o-
B ft
NO
00
ON
s
z
00
Ov
»n ro o
*
O.
o
Pi
•
Q
Metals Distribution and Regionalization in the Brain
<
o
Z
w
•
00
'~H
CO
& &
NO
q en
o o
B ft
o.
a u < £ 13 i-< o
D.
B
o. Si
2
(24.
w(2 w(3 1>
sue
rror or SEM!
34
T3
o
'-3 a
£
*
on •s
b T3 g" CX
OH
3
00
o
J3
u
NO
z u
BH
in
OS
O
in in
^
„
5
o m
in
„
CM
o m
t~
ci in
Q
&
s 03 O
o o.
&
Q
in
o
3
&
s ca o
o u. o.
3
t~ ND
„ 00
o
S
^ M
ON
m
NO
00
—' ^ 3
o
o c Q.
CS D.
Q
2 °<=
5=
mo o in en ON ON en en CN'
>n rn
O
1
00
+ + + + +
D-,
NO
OO ON r1 I 1 CO in
PH
Hi O
s oo s2 s2 ci
in
..CM
PH in
'g3- z
3
U
*CO z1*
4>
vT o
bo < >>
S
IF 3
Z
c 4-. o o bo 6
s N
•a c
1 c o
•a
N
0
2M + 10F C/J
sue
<
<
Z
HH
^
oo m
t-
o 2
u
<
^
<
ft 1J tN
+ + + +
H
H -
0
•*
w
on Z
ei
00
I—I
+ < < < z z
H
1 «
^
c °° 5
Speziali M & Orvini E
1 «
on
-
z
I
"* 00
» £
1 1 "* en NO en ^i- CN • * ( N
-tf —
*
>n oo o o
rt
m
1—I
>-H
I
en
ON 00
I
Tf
i 2
& s *
o
ON
^J- ^O
(SI in"
J-H
^o oo in o o o
00
,-H in
en t-~ J
en ^
CN
oo (^
00
[^
r-
h- oo
•*
O
R ~
^H
•*
^ o
i-i
._ E
r-
00
• — '
Q
o
S
13
Q
• — i
1-H
1 — I
• « *
T—t
Q U < U
^
13 •a 60
Q <
3
a.
B
o
>, 6 <
C3
•D.&
o D.
S
o OH
2
C3 O
a B
3
U
Q <
^—'N—' 's—' ~~-* "^-^ ,^-/ s—' "—' s—' ^—' ^ £ £ ^ 5 ^ ^ ^ » in£ CN 00
• — <
^r-
So oo ^
n
m „ ^ ® £ ° *-H"
' '
1-1
T-H
o »o c oo o
3
Q
3
a o
a o
o
D. D.
o ex a.
cd
< z r-„ OO
NO"
o o o CM
• *
oo
in"
1 co r— r- r-
1
ON
in
,—<" +1
ON ON
NO
in ON ON
CO
ON NO
1
ON
OO
+ < < < <$ < < < 3 S S z
z
C/3
e;
I 8J o
z
00 ON
in
T T
ON NO
(N
S
s§ « In
« w
«r
ON
z
< <
ON ON
z
< <
OO
d > 00>
IN
NO
oo" in
in
1
ON
00
ON
oo ON
ON ON
>n
00 •* ON
NO
ON
f"-;
ON ON
00
00
z< 00
ON ON
00
00
OO
NO
T T ? ON in
1
ON ON
00 ON NO
1 ON T
1 1
in
ON
ON
00
< z
Metals Distribution and Regionalization in the Brain
ON
™ *n _ r 3
CN
O
3 —; u g ca xi 5 - 'S
z OO (N
- o
> >
• d* + 1 + 1 00 oo
^r CN o NO r- r-
ON"
^r oi
ca •n toll
ON"
o
Q
>, E <
• * ' NO
* * ts
13 -a so
Q
>% E <
• *
00
NO
ON
NO O
00 I"-;
rn
' '
r4 cj d ^ 3 3 3 3 o in
Q
NO t~
3
co" oo
o d
CO
• cad •a 00
>. E <
Q
-cS 5 T) 01
>> E <;
NO
f*N
Q
• *
en
00
oq
OO
'
^H
o d
• *
r-;
(N
ON
ON • *
00
o
•
in CO CN d CN jf, en ci * * co ~, 3 3 3 3 3 3 3 3 CN CN 3 3 o r- Tf ^> dNO d^r dr- dNO d d oi •
NO
Q
ON
^H
Q
5
in
»
(N
Q
n O
1 § z *° £
^r
^r
Q
_
r-
•g -3 £5 o
4)
U <
a
•it
•=t
Q U <
CN
.7 w (75) ,6w(79) 70.6 84.6 .5 w (80) ,4w(91) 4w(60) ,9w(71) ,5w(61) .7 w (69) ,lw(68) .5 w (82) 56.7 62.0 2w(59) 5w(68)
c-
8M+1F 15M+4F , 3M+8F , 7M + 3F 6M + 15F 58, 31M+27F 1M+5F 2M+3F 39, 33M+6F 62 6M+15F 58, 31M+27F 11 11 6M+15F 58, 31M+27F 21, 6M + 15F 58, 31M+27F , 3M+8F , 7M+3F 6M+15F 31M+27F
76.0 85.6 75.9 89.9 ,6w(66)
36
Speziali M & Orvini E
and handling, storage, and preanalytical chemical treatments; analytical techniques (choice of suitable, specific, and sensitive techniques); and data quality control (accuracy tested with the use of appropriate standard or certified reference materials; precision assessed by running replicate analyses of splits of the same sample). Statistical data treatments for significance are important to draw conclusions. Dealing with brain Al in AD, problems associated with the abovementioned factors and the possible reasons leading to discordant or conflicting results, already examined in some of the selected original publications, were discussed in great detail by Markesbery and Ehmann (1993) and by Ehmann and Markesbery (1994). In these reviews, special attention was paid to Al determination in brain samples by Instrumental Neutron Activation Analysis (INAA), which can be greatly affected by interference from phosphorus. As the correction factor can exceed 40% of the Al signal, the analytical results, if not corrected, are questionable. Crapper McLachlan et al. (1980c) and Krishnan et al. (1987, 1988a, and 1988b) considered the influence of sample size, case selection, and the technique employed on the results of analyses. Taylor (1994) and Lovell et al. (1996) pointed out the problems and approaches to the measurement of Al in AD studies. Markesbery and Ehmann (1994) critically reviewed data on Al, Fe, and Zn concentrations. Fe levels in AD were also commented on by Gerlach et al. (1994 and 2000); their reviews were mainly on Parkinson's disease (PD). Zn levels were also reviewed by Nachev and Larner (1996) and Cuajungco and Lees (1997b).
2.3. Aluminum, Iron, Copper and Zinc in Parkinson's Disease PD is a common neurodegenerative disorder. The core pathology of PD is the destruction of pigmented brainstem nuclei, particularly the SN pars compacta (Dexter et al., 1993). A central role in this disease is played by Fe, as explained by Youdim (1988, 1994 and 2001), Youdim et al. (1989, 1990, 1991, and 1993), Montgomery (1995), Hirsch and Faucheux 1998), and Berg et.al. (2001). The implications of alterations in trace element in the brain in PD and other neurological diseases were described by Dexter et al. (1993), Dexter
Metals Distribution and Regionalization in the Brain
37
and Jenner (1997), and Good et al. (1997). The amount of Fe in the SN in PD, the techniques used, and sampling conditions were debated by Gerlach et al. (1997) and Friedman et al. (1997). Galazka-Friedman and Friedman (1997) reviewed the controversies on Fe in controls and in the SN of PD patients. Gerlach et al. (1994 and 2000), besides describing the role of Fe in neurodegenerative diseases, reviewed the alterations of Fe, Cu, Zn, and Al in these conditions. The papers retrieved on Al, Fe, Cu, and Zn determination in brain samples from both PD patients and non-PD controls were Earle (1968), Traub et al. (1981), Rajput et al. (1985), Dexter et al. (1987a, 1987b, 1989, 1991, and 1992), Sofic et al. (1988 and 1991), Uitti et al. (1989), Riederer et al. (1989), Griffiths et al. (1989 and 1999), Griffiths and Crossman (1993), Yasui et al. (1992), Galazka-Friedman et al. (1996). Loeffler et al. (1995) and Mann et al. (1994) reported Fe levels in both control and PD subjects as milligrams of Fe per gram of protein. Tables 5 to 8 list the concentration values of Al, Fe, Cu, and Zn in brain sites of both control and PD subjects. They report on the significantly different values between the two groups in some brain areas, along with other data that do not show a significant difference for the same elements in the same regions. In the analytical studies on PD, the SN, in toto or in parts (compacta and reticulata, oral and caudal), was the site where each element was most frequently found to show significantly different concentrations between the controls and PD patients. The Al contents are shown in Table 5. Al in the whole SN appeared to increase in patients, significantly or not, in comparison with the controls. In the GP as a whole and in the gyrus hippocampalis, the unique datum retrieved for Al indicated a significant enrichment in PD patients. In NC, the significant Al elevation found by Yasui et al. (1992) was not confirmed. A not significant decrease was shown in two papers by another team. Fe concentrations are listed in Table 6. Fe in SN in patients was found to be significantly increased in some experiments. In others, the difference between the two groups was not significant. Fe in the zona reticulata was significantly increased in the studies by Griffiths and co-workers, but not significantly varied in Sofic et al. (1991). Referring to the zona compacta, a significantly higher level was reported in two papers. In the oral and caudal parts, NS enrichment was observed in the unique paper considering both sites (Riederer et al., 1989). In the total GP, the Fe concentration was
38
o Z
Pi
o
z
3
00
ON
o
< <
in
^H
z
CO
+ + in
en
l-H
^j-~
m
00
cN
O
•IS to
Z
1
on Z
W
c/3
< (i u
G
<;
r„ w
<;
OT
„
< Z
ON
J S
co Z
F^
Q
^-< rn
Q
Q
CN
^H
,
C
CM
oo
3 C\
._
rr-j i n
en
BH
BH
l >n o >o r-
BH
i^-
en
s
oo i>
Tf"
+ + 2+ en
£
in -^
^o
^H
c
o o. 13
C O
i
5
w
o
ex 5 o o Da
cd
«3
cNcn
s c n c n
•
^
—»
« O
"cS T3 3
3
T3 'u 3 ^
I
*
Speziali M & Orvini E
•a
, z
C/i
O
ft W < y <: z oo cs
M
< Z "
en >n co i n o r-
Q
^e—i-—icncNcn
3
> > cfl
o in c~- ^c
cs
CN
CN en (N en i n •*" vT •>*"
It B. L II.
> m ra *o (X, 1
\0 a\
en *-* en ^ + en + + + + +
~ ^
i n p ^r rn CN en c4 t~
, 8M+4F
d> 3
g*
s
s <*
*—<
G
3
rti
^ O N ^ ^ t ^ < N O \ v q \ £ ) i r i o ^ t t ^ a cN m
Q
LH
00
'8
bsta igra obus
oo
Z
•
cs
* <
eg
r—5
__;
and Regionalization
O^
o
OH
U
ON
r-
I
OH
>
t—-
NO
NO
oo I
CL,
I
ON
00
ON CM CM
^
m o cd O £H
oo on
in
OH
>
<s
00
U
J-
& «
'-C c
C/J
•B e
^f
'—' *—'
C
e
OH
Q ents
1
•a
in the Brain
0} C S3
D
U
B
c/3
Q OH
J3
cd
c
i i
[i,
W-l
Soy
U ffi OH
1 £ I §3 i) ^ o 2 o 2 5 2
OH
U
ON
U
o o oo 00 i n r-
^o ^ ^ \o $
OH
cd i-i 00
J
OH
o ^r r-
O
«
)ext er, et a r, U
® ON 00 ON
D
OH
§ N
a"
#
•S y
13 O
o oo
H U W OH
00
® ON
ON
ON
5 & r-
js
OH
•S
U
§
t
cd
o
2 •3
o
J" oC
00
ON
NO
< <
00
""!
;_,'
+
NO
° ° ON
2 §
o8 ta
5
c
« B & ^3 cd -S .&
N
cd
a a X
T)
ON
^
Griff its et a 9, 199' Griffits an Cro ssman,
Metals Distribution
60
<
*
OJ X 3 •a w c 4-H (U o M d
Z lH
00
s w
o
o
'•S c a rt bo
bo
vels
w
3 OO
•a a a
1
igni incre
rro
39
uio:
40
60
O
Z
Pi
c/3
Q C/3
a ®
0}
8 ON
ON
g® u
2? «
G
d
G
r-
(3
C-) NO
fl
NO ON ON
O
z
o NO r~ o
NO
5
i/~i
C~l
o in
Q
PH
G
• < *
TT NO
3
ON
& en NO
r, O
G
ON
cd
5
<3
s (N
S %S
A
+
m
ON'
NO
+ 00
CO
3
rt"
-
Speziali M & Orvini E
O
N tf -3O< "3 rt< « -3 — 2 CL
t/3
CL
z
5 " t/3
ON
z
0}
Z
rt
<*>
on
•*
m
C/3
I
o m
in NO NO
NO
Q
(N
G
OH
3
a
D O K O
S i
o
u S
O OO
PH
z
^
"3 S O < SH O < M B! < w US
5 s ft " a ft
z
O
to
B!
•*
(T)
o o Tf
m *t
Q
u o,
00
z
CO in NO
«3
CL
ON
IT)
00
s* CL,
audal
55
2
U
=3 cd
If
(77( (75" igra bsta igra bsta igra
91w 433; 405;
:666
"-'
Q\ CO ON
1 2
S
"n 1H
E t>
CO CO
u
•c
o
ON
ON"
ON
^
oC ON
£
;*,
OO
£ o
t-; en
' '' '
CO
rn o
CO
t>
t/3
991
ON
CO
1—1
Q a*
rrv
ON
PH
u
1
r-H
IN
ON
#
i
»2
^ (D
ON ON
c03 g X
™ fe
rt
K ^ c/>
j-,
- -J" "
'H
)u
£
"2
Metals Distribution and Regionalization in the Brain
O
t/3
<;
+
s o NO
in
oi
S S r-
' '
OH
u
OH
Q
Total educed b
an, :
Gril Cro )ext Total reduced by 29% in patient g roup 163.8 w (780
ON
_
•J
U
207.0 w (986 295.0 w ( 1405)
Q
ON
>n
c CT\
<-4-l
D
O
HJ
M
NO
UJ
O O C/3
t-M
in
Z
00 00 ON
OH
> Q
1) T3 O
£ co
z
U
o
3
w 3 X>
OH M
o
C\ CO
o\
OH
8 Q
I £
7 7
u K + o SF S as < ft a!
^
yo *o
oo^
u
OO NO
«- NO (N
oo ^
c
Q
c« 3
eg
3
OH
cfl
W
3
OH
12 W5
o
3 X)
W
OH
u
«
^9
o
3 X)
Q OH
41
42
•TT)
CO
X> 3 <4-H
o 6 Z o
&
tH
u
-a c
s
fc pq m C/3
OH
O
i--
u
o
< O
•*
00 NO
< o *
•
*
• * •
(N
•
•tf
a
00
U
S
O
•
*
NO t~
< <
*
CN NO •
^S
to
o -2
(N
ON
m
P
NO
^ Tf
c3
13
i
1/5 CO
f;
-
Speziali M & Orvini E
hn
O
X>
.£? Q
J3
g
t/5
.5 _e u 'c3
s§ 1^" -T CO
5-1 °^
en
CO ON CN
cd
u
00 00 CO
^
°a^ ^
fican
CO
z
ON ON
roo
as
3 "">
» tl
•rH
ON OO
ON
3 ON
Q
Q
Pi
CO
3
ri- m
OO ON ON t—
ON
o
1^1
tN
>o r-
OH
Q
r,
CJ OH U
rl
Q 0-
Q
5 B
ri
3 a «•§
U
O
K
s < < < < C; oo as in so ON
u
z
CS
JZJ
T3
OH
CO
.s
u
« & T
,-s =-
c 5? Op
t3 Q
o
Z
Q
CO
P«
ON
in
\0
1) to
U a •< u
^
V~i
c4 r^
h
Q
OH
z
^O
Q
oo
CO
^O
op '3
-e •% -B •%
NO
z
0\ t> G\ 0\
U
OH
Metals Distribution and Regionalization in the Brain
00
<
S ^ -3- en
Q
ON
in oo o oq \o oo ri ro in oo co oo ^O
00
'S
I
ific Not
44
t/3
o
* z
^»
r-« ^
X.
l>
en CO
CO
t-;
00
C--
00
CO NO
PH
Q
ON en en p oo
u
5
< <
sa
H-H
ON
HI
8 Q
Cu
'8 .o .£? Q
o
Z
o
w
TO
17
ON
•3 oo ID
C/3
i-H
z
^
z
C/3
ON
,-H
00 NO
Q PH
on
t/3
uy
PH
z
y
Z
-^ >/-> • *
NO
o
NO
^- rN p r-; c*t co H (S m (*i ^ \ t
O
2 ^ 2 2 o> «
y
!Z1
C/3
y <
PU
+
s NO
>/-> i/S
Xf t~ f-
Q OH
Speziali M & Orvini E
•a
2
T
g
c
cfl
'3 c/3
U
Cu
8 Q
jo
HI
ains
o
Z
,—H
p CN NO
U
r^
Q Cu
•E
Raphe reticu lar
t~-
u
C
3
Putamen
E
- -
B 3 a
r-
—<
£3 C3
| S o -2 8. 3 " ft
s -a a 2
Total p
Metals Distribution and Regionalization in the Brain
45
significantly increased or not varied. The data for Fe in the lateral GP are conflicting. Both a significant elevation and a significant reduction in the PD groups were published by two teams. In the medial part of GP, the experiments carried out by the same two teams showed, however, a significantly lower content in patients. Cu levels are shown in Table 7. Cu concentration in the whole SN is significantly decreased in most papers (not significantly only in one). The unique datum on the zona compacta confirms the significance of the decrease. A significant increase in PD patients was observed in the raphe plus reticular formation (Riederer et al., 1989). The levels for Zn are shown in Table 8. The Zn amount was found to be significantly higher in the whole SN of PD patients by Dexter and associates (1987a and 1991). The increase was found to be not significant by Rajput et al. (1985), while Uitti et al. (1989) and Mann and co-workers (1994) found a not significant decrease. In the SN zona compacta, Dexter et al. (1991) found significant enrichment in the PD group. In the NC, the Zn increase, estimated as significant in one paper, was not significant in two papers. In the total putamen and medial part, no significant changes in the Zn levels were found. On the other hand, in the lateral part significant enrichment was reported. A significantly higher amount of Zn was observed in PD patients in the raphe plus reticular formation (Riederer et al., 1989). The importance of factors affecting the final results (see comments on the tables in the AD section) was examined in several original papers and in Gerlach et al. (1994 and 2000), together with the reasons for the discrepancies in the results obtained in different experiments. For analytical problems in Al determination by INAA, see also the comments in the AD section.
2.4. Aluminum, Iron, Copper and Zinc in Western Pacific Parkinsonism-Dementia The Mariana island of Guam is the focus of an epidemic of neurodegenerative diseases with features of both amyotrophic lateral sclerosis (ALS; see the next section) and Parkinsonism, known as ALS/Parkinsonismdementia complex (ALS/PDC) of Guam. There is an extensive overlap among the neuropathological changes found in clinically described cases
46
Speziali M & Orvini E
of ALS and Parkinsonism-dementia, as reported by Good et al. (1997). ALS, Parkinsonism, and dementia may occur individually or, more commonly, in association with the other two (Lilienfeld et al., 1994). Other high-incidence foci of ALS/PDC in the Western Pacific are in the Kii Peninsula of Honshu Island in Japan and in western New Guinea (Auyu and Jakai populations). These areas are geochemically poor in calcium and magnesium, but rich in Al and manganese. In Guam, the disease affects mainly adults of the Chamorro population, male more frequently than female (Chen and Yase, 1985). The influence of metals in Parkinsonism-dementia was reviewed by Lilienfeld et al. (1994); their role and alterations were reviewed by Chen and Yase (1985) and Markesbery and Ehmann (1988). The importance of Fe in this disease was also described by Good et al. (1997), and the role ofZnby Yasuietal. (1997). The original papers on Al, Fe, Cu, and Zn determination in brain samples from both Parkinsonism-dementia and control subjects retrieved were Yoshimasu et al. (1980, 1982, and 1985), Traub (1981), Yoshida (1987 and 1988), and Yasui et al. (1993). Of these, only two papers with metal (Al and Cu) levels in well-defined sites of the encephalon were found, describing experiments carried out by the same team using INAA. For Cu, only data on patients were published by Yoshimasu et al. (1980). Table 9 reports data on Al. Yoshimasu et al. (1980) observed significant enrichment in the GP of diseased patients in Guam compared to Japanese controls. In their experiment in 1982, Al was also significantly higher in the GP of Guam patients than in Chamorro controls. In 1980, they found that the Al increase in the insula of the patient group was marginally significant, whereas the elevation in the capsula interna and pons were considered not significant. Yoshimasu et al. (1982) observed a significant Al increase in the putamen, thalamus, NC (areas not analyzed in the previous experiment) and in capsula interna and pons, whose Al content was previously not significant. For Cu (see Table 10), only one value (in putamen), indicating a significant decrease of the metal in the patient group from Guam, was published in Yoshimasu et al. (1982). For results of Al determination by INAA, see comments in the AD section.
5
< <
t~
< <
in
in
W)
m
in
m
t
CO
z
in
in
in
CS
in
< < z
in
CS
m
+ + 5+ n § CO <* ^H s
CS
VO
in
t—i
in
tN
en
ft,ft,ft, CS
+ + +
5 s s en
CO CO
<5
z
< < z
on
\D
CS
CO
ft.ft.ft.ft,ft,ft, CO
TJ* en -^f en ^
CO
s
+
o
3
r-;
^ en ^ en o o
«3 -3
o
-3
u
£
Q r > Q r) Q C) Q D Q r) Q Q Q u Q JS ft,.c % J3 ft, r )ft,J3ft, ft,JZ 4< J3 ft,CJ O u O u O o u O O O u o y o o o
r^^HCNteNpr^in^HO^^Hen t O \ 0 \ ^ r n m t ' j d H ' - <
o
47
ft,
c--
z
in
z <
r-
C/5
z oo rin
s <: z O OO CM
CO
o oo r- »n o oo oo o
on
Metals Distribution and Regionalization in the Brain
f*
Z
•<
VD
CS
't m
CO
ft,ft,ft,ft,ft, CS
n
sH ^
+ + + + + + + + % ssssS2 rH s "
CO
6-6
inr- ; (N«n'-H(N'-Hen-^' 1 ^; o o r - : ( N p r ^ ' - ; < N o o o q o o
t
8-4 6-6 7-8 0-7
5
o oo r^
2
cs
8-4 6-6 7-8 0-7 7-8 0-7
en
6-6 7-8 0-7 7-8 0-7 7-8
I 5< 00 '
tH
T)
•s, XJ 3 6U
Q
c u
O O
Z t.
Erro
48
Speziali M & Orvini E
Table 10. Copper concentration values in brain sites of control and Western Pacific Parkinsonismdementia subjects (ppm, dry weight). Site Putamen
Mean
Error (SD)
No. of subjects, gender
Age
Subjects ChC GPD
48.3 28.0
5.5 7.7
3, 1M+2F 4, 3M+1F
(y)
Technique
S* orNS
57-87 50-75
INAA
S
References Yoshimasu et al., 1982
Comparing the tables on PD and Parkinsonism-dementia, it is evident that the brain sites considered in the literature with significant Al and Cu differences between the control and diseased subjects are not the same, except, in the case of Al, GP and NC. In GP, a significantly increased Al concentration in the patient group was found in two papers on Parkinsonism-dementia (Table 9) and in one paper on PD (Table 5). In NC, Yoshimasu et al. (1982; see Table 9), whilst examining controls and patients from Guam, found a significant Al elevation in the diseased subjects. The same results were observed by Yasui et al. (1992; see Table 5). In PD patients, however, an Al decrease, evaluated as statistically not significant by the authors, was found in two papers published by Rajput et al. (1985) and Uitti et al. (1989).
2.5. Aluminum, Iron, Copper and Zinc in Amyotrophic Lateral Sclerosis ALS, or motor neuron disease (MND), is an adult-onset, progressive, and neurodegenerative disorder. Three clinical variants are recognized, including a classical sporadic variant, an autosomal dominantly inherited variant, and the Western Pacific variant. An overlap with PD may occur, particularly in the Western Pacific variant (Strong and Garruto, 1997; see section on Parkinsonism-dementia). According to Lilienfeld et al. (1994), most cases of ALS in Guam were diagnosed among the Chamorros. The importance of heavy metals and trace elements in ALS was described by Mitchell (1987 and 2000), Kasarskis et al. (1993), Strong and Garruto (1997), and Yase et al. (2001). The involvement of elements in ALS and their levels in brain sites were reviewed by Yanagihara (1982), Kasarskis et al. (1990), Kasarskis (1991), and Ehmann and Vance (1996). The role of Al in ALS was described by Yase (1980, 1987, and
Metals Distribution and Regionalization in the Brain
49
1988) and Wisniewsi et al. (1985). The involvement of Fe in ALS was explained by Youdim (1994) and Good et al. (1997), and the importance of Cu by Waggoner et al. (1999). The role of Zn in ALS was elucidated by Cuajungco and Lees (1997a) and Yasui et al. (1997). The original papers retrieved on Al, Fe, Cu, and Zn determination in brain samples from both patients affected by ALS (not better defined) and non-ALS controls were Yoshimasu et al. (1976 and 1980), Yase (1978), Yoshida et al. (1988), Khare et al. (1990), and Tandon et al. (1994). The papers with data on controls and patients affected by the Western Pacific variant of ALS were Yoshimasu et al. (1982), Traub et al. (1981), Yoshida (1987 and 1988), Yasui et al. (1991a, 1991b, and 1993). For Cu, only data on patients were published by Yoshimasu et al. (1980). Due to the scarcity of data and lack of description of the race of the subjects examined, we have listed the values for all the variants in a unique series of tables. Similar to Western Pacific Parkinsonism-dementia, all the papers reporting on metal (Al and Cu) levels in well-defined sites of the encephalon for ALS found in the literature were published by Japanese scientists from the Wakayama Medical College who used the same technique (IN A A). They also examined, besides the controls and ALS patients from Japan, subjects from the Chamorro population of Guam or those from the Kii Peninsula, areas that are the foci of the Western Pacific variant of ALS. The Al concentrations are shown in Table 11. In only one paper was Al determined in the SN; both the controls and patients were from Guam and a significant elevation was observed in the AD group. A particular situation was retrieved for the insula. In fact, in the experiment on subjects from Guam, the mean difference between the two groups was significant. In one experiment on Japanese subjects, the variation was marginally significant while, according to two other papers, it was not significant. For pons, in the work on the Guam subjects, a significant Al increase was observed in the patients; in other experiments on Japanese individuals, the difference was not significant. In gyrus praecentralis, when the controls (their origins were not specified) and two patients in the severe stage of ALS from the Kii Peninsula were compared (Yasui et al., 1991a and 1991b), a significantly higher Al content was found in the diseased women. In the study by Yoshimasu et al. (1982), where the Al levels were evaluated in both groups from Guam, the decrease appeared to be not
50
al 00
z
;-„ ^
5? >.
SO
I
< z
+g +
H, d, rN (N
s
~-< in
£
< z
t
^
,_ H
r r03
z
t
^
-
C3
~
03
22 O
Os ^
tr<*
2
l>
CTs rH
r
;£ O
i.l
CT\ ,H
< z '
JD T3
Speziali M & Orvini E
r ^5
CON en ^ ffl
a £ ™ J3 55 O
I
CO
<
z M
z
l
CO
t
z
^
Z
<
z t
on
.s cs J.a3 OOo
J3 25 ON
^
sS -
< z W
+ + +
H< H , ft, CN CN CN
'
PL,
^
+ + (N
^
+
l l l l l l l l l l l l l l l l l r--0\ooooooooc--0\ooooooooininoooo in-^cNmrNcoin^l-cNroolmsoincNco
^
r-r-o^-o^-r-r-OTi-o^ririoo^M
o
< z >
0O
r•n H*
+
(N
s
^
cs ^f oq in so ^-< r- co
c o On
C O 0<
CO •J
U
£
CO
<
u
O
o
•
*
ntralis KALS JC ntralis JALS
o
Z so ^ o\ oo ^ q 6 0\ (S \D "^ "n —i m ^H (N -^
H
u <
o\ m ^ f - i n o s i n o o o O N ^ i n ^ o c n ^ ^so o\ O t-^ so o \d in cN M" r- *-* m ^ en CN o" CM
HH
ChC GALS
CO Q CO
s
HH
^ Sfi ^ u < u <
CO
1=>
igra
cd
o 3 ta
cd 1) 3 w cd
UII
.o >-•
o
o 00 Os
cd
OS 1)
UII SO
U 3 c« Cd ON
r-
J3 c«
,o
>*
Cd J2
cd CJ 3 c« cd
in the Brain
o cd"
, ; as cd ID
Os
3
M
cd
e a
z
oo
z
oo
z
00
><
K
£
OS J3 £> « -a s J3 OO ~J '3 C;N va va Os w S S >.O 5H S ? ,o S £ p H i
oo
U-)
i/"j CN
o
<'>
_<
ID
f-t\
U
3
cd
m
BH
cd
I
m
!n I
in
rco I
^f
t— ^ I
u
ft
i
ft
o
00 (N
+ +
*
U
U
•*
^f
ft ft rn I N
ss
•~o tN
•& m
=S
ON eN en
S
-3 E 3 E
O <
^
oo oo r-- os
TT
z
^
s
E
cd
o
o t
Z
O
< < z O
•<*•
i^l
-^j- i/-)
PH
M3
I l I I in i n oo oo
oo
Z
z
ft (N
r-
< < z
><
P S
•s
UII
ft
(N
r-\
r
cd
u
^
m + + + & +< s + s s s "° S
(N
and Regionalization
cd 0) 3 w cd
Ko
>-
oo J3 as t «
UII
00 •§ os
oo
< z
z
< z
z
z <~i
T
00
i-~
T
^t"
^1" o ^i- o <*f 1 1 1 on no oo oo oo en (N rn (N en
ON ^D oo n
^1r
rd *—'
^H it^
~i
N"
O oo
CM
1 os on
t-^
T
oo
< z r-
00 I rin
ft ft
en
-H
od
p m '>
,
l
^H
r
K i
oo \o ^-J
OO
M'N *-
ON
00
r*i
00
CO
S
d y <
o
fl
U •<
c O
d cD C
O
U <
O
o o y
o
J3
o
j-<
__L
CN od
ss
+ +
CM
• *
z
g J3 « .o > (N
Metals Distribution
3
Yas DOStC
•S s
a A
&
yrus postc yrus
S
ON OS
00
J3
£
< Z
SO
OO ON
5
ft
r-
oo
(N
-^
I u
51
52
Speziali M & Orvini E
Table 12. Copper concentration values in brain sites of control and amyotrophic lateral sclerosos subjects (ppm, dry weight). Subjects
Mean
Error (SD)
No. of subjects, gender
Age
Site Putamen
ChC GALS
48.3 31.1
5.5 9.3
3, 1M+2F 6
57-87
(y)
S* Technique or NS INAA
S
References Yoshimasu et al., 1982
significant. Other papers which reported on results obtained in controls and patients from the Japanese population showed no significant increase. In gyrus postcentralis, a significant elevation in the Al amounts of a Japanese ALS group was shown in one experiment, whereas in others no significance was found. Yoshimasu et al. (1982), taking into account the two groups from Guam, observed a nonsignificant Al enrichment in patients. As far as CI is concerned, only the papers which considered controls not better described and the two ALS subjects from the Kii Peninsula showed a significant Al elevation in the patients. In other experiments which examined controls and patients from Japan, as well as one that takes into account normal and diseased people from Guam, the higher Al amounts observed in the ALS groups were not significant. A significant increase was found by Yasui et al. (1991a and 1991b) in the cms cerebri of two ALS patients from the Kii Peninsula; Yoshimasu et al. (1982) considered the Al elevation in the Guam patient group as not significant. An overview of the results published on gyrus praecentralis, gyrus postcentralis, and CI suggests that the significance of the difference in Al levels between the controls and patients appears to be unrelated to the race of the subjects studied. For Cu (Table 12), only one value (in the putamen), indicating a significant decrease of the metal in ALS patients from Guam, was published by Yoshimasu et al. (1982). Al was determined by INAA. Yasui et al. (1991a and 1991b) applied a correction for the interference from phosphorus. (See comments in the AD section.)
3. FINAL REMARKS In normal brains, several authors found the highest Al levels in the GP, SN, and NR. In the studies on AD, a significant increase in Al amounts was found in the hippocampus and, according to a single experiment, in the inferior parietal lobule and superior and middle temporal gyri.
Metals Distribution and Regionalization in the Brain
53
In PD, SN, GP, NC, and gyrus hippocampalis were sites in which at least one experiment found an Al elevation in patients. In Western Pacific Parkinsonism-dementia, GP, putamen, thalamus, NC, capsula interna, and pons, at least in one work each, showed an Al enrichment in samples taken from diseased individuals. For ALS, the Japanese detected significantly higher Al amounts in the patient group in at least one experiment in several sites (SN, insula, pons, gyrus praecentralis, gyrus postcentralis, CI, and cms cerebri). In the controls, most authors found the highest Fe concentrations in GP, putamen, NC, and SN. Some scientists observed significant Fe changes in AD subjects in the hippocampus (with conflicting results) and an increase in the amygdala; in at least one paper, a significant elevation of the metal in the frontal pole, temporal pole, inferior parietal lobule, piriform cortex, olfactory region, and GP of patients was reported. As far as PD is concerned, some authors found a significant Fe enrichment in total SN in afflicted subjects. In two papers, Fe elevation resulted also in SN zona compacta and, in another experiment, in SN zona reticulata. In total GP, Fe appeared to be significantly higher in patients in one paper; for lateral GP, conflicting data were found, whilst for medial GP a significant reduction was discovered by two different teams. In the normal brain, most authors found the highest Cu concentrations in SN, ND, putamen, and NC. A significant decrease in Cu in AD subjects was found in the hippocampus by two teams, and by one in the amygdala. In PD, a decrease was observed, according to some papers, in SN whereas an increase was found, in a single work, in the raphe plus reticular formation. Only one paper reported a significant decrease in Cu in the putamen from patients with both Parkinsonism-dementia and ALS. In the controls, several teams detected the highest Zn concentrations in the hippocampus, amygdala, NC, and epiphysis. Significant changes in Zn in AD patients were detected in the hippocampus, with conflicting results; in amygdala, higher amounts were determined in different experiments. An elevation in Zn in diseased subjects was observed in two works in the inferior parietal lobule and, at least in one paper, in the olfactory tract, frontal pole, and temporal pole. In PD, the total SN, SN zona compacta, NC, lateral putamen, and raphe plus reticular formation from the patient group contained, according to at least one experiment, significantly higher Zn amounts than the
54
Speziali M & Orvini E
corresponding sites in the controls. The authors had analyzed a wide number of regions. These areas were chosen according to those parts of the brain known to be as prominently affected by the specific disease being studied.
ACKNOWLEDGMENT The authors are grateful to Stelio Locchi, Department of General Chemistry, University of Pavia, Italy, for valuable suggestions.
REFERENCES Andrasi E, et al. Several methods to determine heavy metals in the human brain. Spectrochimica Acta Part B 1999; 54:819-825. Andrasi E, et al. Al, Zn, Cu, Mn and Fe levels in brain in Alzheimer's disease. Arch Gerontology and Geriatrics 1995; 21:87-97. Andrasi E, et al. Classification of human brain parts using pattern recognition based on ICP-AES and INAA. Chemometrics and Intelligent Laboratory Systems 1994; 22:107-114. Andrasi E, et al. Study of trace element distribution in human brain by solid sample and solution analytical methods. Acta Chimica Hungarica 1989; 126:341-346. Atwood CS, et al. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Metal Ions in Biol Systems 1999; 36:309-364. Beard JL, et al. Iron in the brain. Nutr Rev 1993; 51:157-170. Berg D, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001;79:225-236. Birchall JD, Chappell JS. Aluminum, chemical physiology and Alzheimer's disease. Lancet 1988a; 2:1008-1010. Birchall JD, Chappell JS. The chemistry of aluminum and silicon in relation to Alzheimer's disease. Clin Chem 1988b; 34:265-267. Bjertness E, et al. Content of brain aluminum is not elevated in Alzheimer's disease. Alzheimer's Disease and Associated Disorders 1996; 10:171-174. Bonilla E, et al. Copper distribution in the normal human brain. Neurochem Res 1984; 9:1543-1548. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia: Saunders Company, 1994: 585-613. Brown DR. Copper and prion disease. Brain Res Bull 2001; 55:165-173. Bush Al. Metals and neuroscience. Curr Opin Chem Biol 2000; 4:184-191. Bush VJ, et al. Essential and toxic element concentrations in fresh and formalin-fixed human autopsy tissues. Clin Chem 1995; 41:284-294. Campbell A. The potential role of aluminum in Alzheimer's disease. Nephrol Dialysis Transplantation 2002; 17:17-20.
Metals Distribution and Regionalization in the Brain
55
Campbell A, et al. Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Res Bull 2001; 55:125-132. Chazot G, Broussolle E. Alterations in trace elements during brain aging and in Alzheimer's disease. In Prasad AS, editor. Essential and Toxic Trace Elements in Human Health and Disease: An Update, Progress in Clinical and Biological Research, Vol. 380. New York: Wiley-Liss, 1993: 269-281. Chen KW, Yase Y. Parkinsonism-dementia, neurofibrillary tangles and trace elements in the Western Pacific. In Hutton and Kenny, editors. Senile Dementia of the Alzheimer Type. New York: Alan R Liss, Inc., 1985: 153-173. Connor JR et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992; 31:327-335. Constantinidis J. Zinc toxicity in Alzheimer's disease: An emerging hypothesis. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 147-156. Constantinidis J. Maladie d'Alzheimer et la theorie du zinc. U Encephale 1990; 16:231-239. Constantinidis J, Tissot R. Degenerative encephalopathies in old age: Neurotransmitters and zinc metabolism. In: Terry RD, Bolis CL, Toffano G, editors. Neural Aging and Its Implications in Human Neurological Pathology, Vol. 18. New York: Raven Press, 1982: 53-59. Constantinidis J, et al. Demences degeneratives de Pick et d'Alzheimer et metabolisme du zinc. Medecine et Hygiene 1977; 35:3706-3710. Cornett CR, et al. Trace elements in Alzheimer's disease pituitary glands. Biol Trace Element Res 1998a; 62:107-114. Cornett CR, et al. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998b; 19:339-346. Cornett CR, et al. Pituitary gland levels of mercury, selenium, iron, and zinc in an Alzheimer's disease study. Transactions 1996; 74:6. Corrigan FM, et al. Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals 1993; 6:149-154. Corrigan FM, et al. Reductions of zinc and selenium in brain in Alzheimer's disease. Trace Elements in Medicine 1991; 8:1-5. Crapper McLachlan DR, et al. Aluminum, altered transcription, and the pathogenesis of Alzheimer's disease. Environmental Geochem Health 1990; 12:103-114. Crapper McLachlan DR. Aluminum and Alzheimer's disease. Neurobiol Aging 1986; 7:525-532. Crapper McLachlan DR, Farnell BJ. Aluminum and neuronal degeneration. In: Gabay S, Harris J, Ho BT, editors. Metal Ions in Neurology and Psychiatry. New York: Alan R Liss, Inc., 1985: 69-87. Crapper McLachlan, et al. Aluminum in human brain disease. In: Sarkar B, editor. Biological Aspects of Metals and Metal-related Diseases. New York: Raven Press, 1983: 209-218. Crapper McLachlan DR, De Boni U. Aluminum in human brain disease: An overview. Neurotoxicology 1980a; 1:3-16.
56
Speziali M & Orvini E
Crapper McLachlan DR, De Boni U. Aluminum. In: Spencer PS, Schaumburg HH, editors. Experimental and Clinical Neurotoxicology. Baltimore: Williams and Wilkins, 1980b: 326-335. Crapper McLachlan, et al. Brain aluminum in Alzheimer's disease: Influence of sample size and case selection. Neurotoxicology 1980c; 1:25-32. Crapper McLachlan DR, et al. Aluminum and other metals in senile (Alzheimer) dementia. In: Katzman R, Terry RD, Bick KL, editors. Alzheimer's Disease: Senile Dementia and Related Disorders. Vol. 7. New York: Raven Press, 1978: 471^189. Crapper McLachlan DR, et al. Aluminium, neurofibrillary degeneration and Alzheimer's disease. Brain 1976; 9:67-80. Crapper McLachlan DR, et al. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Trans Amer Neurol Assoc 1974; 98:17-20. Crapper McLachlan DR, et al. Brain aluminium distribution in Alzheaimer's disease and experimental neurofibrillary degeneration. Science 1973; 180:511-513. Cuajungco MP, Lees GJ. Zinc metabolism in the brain: Relevance to human neurodegenative disorders. Neurobiol Disease 1997a; 4:137-169. Cuajungco MP, Lees GJ. Zinc and Alzheimer's disease: Is there a direct link? Brain Res Rev 1997b; 23:219-236. Cumings JN. Trace elements in the brain in health and in neurological disease. Scientific Basis Med Ann Rev 1965: 37-57. Danscher G, et al. Increased amount of zinc in hippocampus and amygdala of Alzheimer's diseased brains: A PIXE spectroscopic analysis of cryostat sections from autopsy material. JNeurosci Methods 1997; 76:53-39. Dedman DJ, et al. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's disease and chronic renal dialysis patients. Biochem J 1992; 287:509-514. Deibel MA, et al. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996; 143:137-142. Deibel MA, et al. Non-destructive analysis of Cu in human brain tissue by neutron activation analysis using coincidence and anti-coincidence techniques. J Radioanalytical Nucl Chem 1997; 217:153-155. Dexter DT, Jenner P. Alterations in iron in neurodegenerative disorders: Implications and possible therapeutic agents. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 365-378. Dexter DT, et al. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. In Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in Neurology, Vol. 60. New York: Raven Press, 1993: 273-281. Dexter DT, et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 1992; 32:S94-S100. Dexter DT, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
Metals Distribution and Regionalization in the Brain
57
Dexter DT, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989; 52:1830-1836. Dexter DT, et al. Increased nigral iron content in postmortem Parkinsonian brain. Lancet 1987a; 2:1219-1220. Dexter DT, et al. Alterations in the content of iron and other metal ions in Parkinsonian brain. Br J Pharmacology 1987b; 91:427. Duflou H, et al. Regional distribution of potassium, calcium and six trace elements in normal human brain. Neurochem Res 1989; 14:1099-1112. Earle KM. Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Experimental Neurol 1968; 27:1-14. Edwardson JA, et al. Alzheimer's disease and the aluminium hypothesis. In: Nicolini M, Zatta PF, Corain B, editors. Aluminum in Chemistry, Biology and Medicine. New York: Raven Press, 1991:85-96. Edwardson JA, et al. Aluminosilicates and the aging brain: Implications for the pathogenesis of Alzheimer's disease. In: Everd D, O'Connor M, editors. Silicon Biochemistry, CIBA Foundation Symposium, Vol. 121. Chichester: Wiley, 1986: 160-179. Ehmann WD, Vance DE. Studies of trace element involvement in human disease by in vitro activation analysis. J Radioanalytical Nucl Client 1996; 203:429-445. Ehmann WD, Markesbery WR. A multi-technique approach to the study of aluminum in Alzheimer's disease brain. Life Chem Reports 1994; 11:11-28. Ehmann WD, et al. Activation analysis in a multi-technique study of trace element imbalances in age-related neurological diseases. J Radioanalytical Nucl Chem 1993; 168:223-231. Ehmann WD, et al. Applications of neutron activation analysis to the study of age-related diseases. Biol Trace Element Res 1987; 13:19-33. Ehmann WD, et al. Brain trace elements in Alzheimer's disease. Neurotoxicology 1986; 7:197-206. Ehmann WD, et al. Quantitation, localization, and variations of brain zinc with aging by instrumental neutron activation analysis. In: Frederickson CJ, Howell GA, Kasarskis EJ, editors. The Neurobiology of Zinc. Part A: Physiochemistry, Anatomy and Techniques. New York: Alan R Liss, Inc., 1984: 329-342. Ehmann WD, et al. Trace elements in human brain tissue by INAA. J Radioanalytical Chem 1982; 70:57-65. Ehmann WD, et al. INAA studies of normal and diseased human brain. In: Proceedings of the 4th International Conference on Nuclear Methods in Environmental and Energy Eesearch, April 14-7, 1980, University of Missouri, Columbia USA. USA: Department of Energy, 1981:459^169. Fabris N, Moccheghiani E. Zinc, human disease and aging. Aging in Clin Experimental Res 1995; 7:77-93. Floyd RA, Carney J. The role of metal ions in oxidative processes and aging. Toxicology and Industrial Health 1993; 9:197-214. Friedman A, et al. Reply to Gerlach M, et al. Movement Disorders 1997; 12:259-260. Galazka-Friedman J, Friedman A. Controversies about iron in Parkinsonian and control substantia nigra. Acta Neurobiol Experimentalis 1997; 57:217-225.
58
Speziali M & Orvini E
Galazka-Friedman J, et al. Iron in Parkinsonian and control substantia nigra: A Mossbauer spectroscopy study. Movement Disorders 1996; 11:8-16. Gelman BB. Iron in CNS disease. J Neuropathol Experimental Neurol 1995; 54:477^-86. Gerlach M, et al. Brain iron and other trace metals in neurodegenerative diseases. In: Storch A, Collins MA, editors. Neurotoxic Factors in Parkinson's Disease and Related Disorders. Amsterdam: Kluwer Academic/Plenum Publishers, 2000: 259-276. Gerlach M, et al. Iron in the Parkinsonian substantia nigra. Movement Disorders 1997; 12:258-259. Gerlach M, et al. Altered brain metabolism of iron as a cause of neurodegenerative diseases? JNeurochem 1994; 63:793-807. Goldberg WJ, Allen N. Determination of Cu, Mn, Fe and Ca in six regions of normal human brain by AAS. Clin Chem 1981; 27:562-564. Goldberg W, Allen N. Nonspecific accumulation of metals in the globus pallidus in Hallervorden-Spatz disease. Trans Amer Neurol Assoc 1979; 104:106-108. Good PF, et al. LAMMA studies of iron, oxidative stress, and neuroprotective strategies in Parkinson's Disease. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 379-390. Griffiths PD, et al. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryoelectron microscopy. Brain 1999; 122:667-673. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993; 4:61-65. Griffiths PD, et al. Iron levels and transferrin binding sites in the post-mortem brains of Parkinsonian patients and age-matched controls. In: Neural Mechanisms in Disorders of Movement. London: John Libbey Press, 1989: 291-295. Hallgren B, Sourander P. The non-haemin iron in the cerebral cortex in Alzheimer's disease. JNeurochem 1960; 5:307-130. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3:41-51. Harrison WW, et al. Trace elements in human brain: Copper, zinc, iron and magnesium. Clinica Chimica Acta 1968; 21:55-60. Hebbrecht G, et al. Brain trace elements and aging. Nucl Instruments and Method Physical ResB 1999;150:208-213. Hershey LA, et al. Zinc content in CSF, brain, and other tissues in Alzheimer's disease and aging, In: Frederickson CJ, Howell GA, Kasarskis EJ, editors. The Neurobiology of Zinc. Part B: Deficiency, Toxicity and Pathology. New York: Alan R Liss, Inc., 1984: 325-334. Hill JM. The distribution of iron in the brain. In: Youdin MBH, editor. Brain Iron Neurochemical and Behavioural Aspects. London: Taylor and Francis, 1988: 1-24. Hirsch EC, Faucheux B A. Iron metabolism and Parkinson's disease. Movement Disorders 1998; 13:39^15. Hock A, et al. Trace element concentration in human brain. Brain 1975; 98:49-64.
Metals Distribution and Regionalization in the Brain
59
Hu KH, Friede RL. Topographic determination of zinc in human brain by atomic absorption spectrometry. J Neurochem 1968; 15:677-685. Ishihara R, et al. PIXE analysis of low concentration aluminum in brain tissues of an Alzheimer's disease patient. In: Duggan JL, Morgan IL, editors. Applications of Accelerators in Research and Industry. The American Institute of Physics, 1999: 468^171. Jacobs RW, et al. A re-examination of aluminum in Alzheimer's disease: Analysis by energy dispersive X-ray microprobe and flameless atomic absorption spectrophotometry. Canadian J Neurol Sci 1989; 16:498-503. Joshi JG, et al. Iron and aluminum homeostasis in neural disorders. Environmental Health Perspectives 1994; 102:207-213. Kala SV, Hasinoff BB. Brain samples from Alzheimer's patients have elevated levels of loosely bound iron. Int J Neurosci 1996; 86:263-269. Kasarskis EJ, et al. Trace metals in human neurodegenerative diseases. In: Prasad AS, editor. Essential and Toxic Trace Elements in Human Health and Disease: An Update. Progress in clinical and biological research, Vol. 380. New York: Wiley-Liss, 1993: 299-310. Kasarskis EJ. Neurotoxicology: Heavy metals. In: Smith R, editor. Handbook of Amyotrophic Lateral Sclerosis. New York: Marcel Dekker, 1991: 559-574. Kasarskis EJ, et al. Toxic and essential elements in amyotrophic lateral sclerosis. In: Rose FC, Norris FH, editors. ALS: New Advances in Toxicology and Epidemiology. London: Smith-Gordon, 1990: 181-187. Khare SS, et al. Trace element imbalances in amyotrophic lateral sclerosis. Neurotoxicology 1990; 11:521-532. Kornhuber J, et al. Iron, copper, zinc, magnesium and calcium in postmortem brain tissue from schizophrenic patients. Biol Psychiatr 1994; 36:31-34. Krishnan SS, et al. Aluminum toxicity in humans. In Prasad AS, editor. Essential and toxic trace elements in human health and disease. New York: Alan R Liss, Inc., 1988a: 645-59. Krishnan SS, et al. Aluminum toxicity to the brain. Sci Total Environment 1988b; 71:59-64. Krishnan SS, et al. Origin and resolution of the aluminum controversy concerning Alzheimer's neurofibrillary degeneration. Biol Trace Element Res 1987; 13:35^-2. Krishnan SS, Crapper McLachlan DR. Aluminum: Is it toxic to the human brain? Sci Total Environment 1985; 41:203-205. Kruck TPA, Crapper McLachlan DR. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: Ion-specific chelation. In: Iqbal K, Wisniewski HM, Winblad B, editors. Alzheimer's Disease and Related Disorders. Progress in Clinical and Biological Research, Vol. 317. New York: Alan R Liss, Inc., 1989: 1155-1167. Lilienfeld DE, et al. Guam neurodegeneration. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia: Saunders Company, 1994: 895-908. Loeffler DA, et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995; 65:710-716. Lovell MA, et al. Standardization in biological analyses of aluminum: What are the needs? J Toxicol Environmental Health 1996; 48:637-648.
60
Speziali M & Orvini E
Lukiw WJ. Alzheimer's disease and aluminum. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 113-126. Mann VM, et al. Complex I, iron, and ferririn in Parkinson's disease substantia nigra. Ann Neurol 1994; 36:876-881. Markesbery WR, Ehmann WD. Brain trace elements in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer's Disease. New York: Raven Press, 1994: 353-367. Markesbery WR, Ehmann WD. Aluminum and Alzheimer's disease. Clin Neurosci 1993; 1:212-218. Markesbery WR, Ehmann WD. Trace elements in dementing disorders. In: Morely JE, et al. (editors), Nutritional Modulation of Neural Function. San Diego: Academic Press, 1988: 179-190. Markesbery WR, et al. Brain trace element concentrations in aging. Neurobiol Aging 1984; 5:19-28. Markesbery WR, et al. Bulk brain aluminum concentrations in Alzheimer's disease. In: Proceedings of the Conference on Aluminum Analysis in Biological Materials. University of Virginia, Charlottesville, 1983: 103-110. Markesbery WR, et al. Instrumental Neutron Activation Analysis of brain aluminum in Alzheimer's disease and aging. Ann Neurol 1981; 10:511-516. McDermott JR, et al. Brain aluminum in aging and Alzheimer's disease. Neurology 1979; 29:809-814. McDermott JR, et al. Aluminum and Alzheimer's disease. Lancet 1977; 2:710-711. McLachlan DR, et al. Alzheimer's disease and other aluminum-associated health conditions. In: Chang LW, editor. Toxicology ofMetals. Boca Raton: Lewis Publishers, 1996: 387^104. McLachlan DR. Inorganic neurotoxins in dementia caused by neurodegeneration. In: Calne DB, editors. Neurodegenerative Diseases. Philadelphia: Saunders Company, 1994: 241-249. Mitchell JD. Amyotrophic lateral sclerosis: Toxins and environment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000; 1:235-250. Mitchell JD. Trace elements, neurological disease and amyotrophic lateral sclerosis. In: Chazot G, Abdulla M, Arnaud P, editors. Proceedings of the International Symposium on Current Trends in Trace Elements Research. December 1987, Paris, France. London: Smith-Gordon Nishimura 1989: 116-124. Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurologic Clinics 1987; 5:43-60. Moir RD, et al. Mounting evidence for the involvement of Zn and Cu in AD [Commentary]. Eur J Clin Investigation 1999; 29:569-570. Montgomery EB. Heavy metals and the etiology of Parkinson's disease and other movement disorders. Toxicology 1995; 97:3-9. Nachev PC, Larner AJ. Zinc and Alzheimer's disease. Trace Elements and Electrolytes 1996; 13:55-59.
Metals Distribution and Regionalization in the Brain
61
Panayi AE, et al. Differences in trace element concentrations between the right and lefthemispheres of human brain using INAA. J Radioanalytical Nucl Chem 2000; 244:205-207. Panayi AE, et al. Differences in trace element concentrations between Alzheimer and "normal" human brain tissue using INAA. J Radioanalytical Nucl Chem 2001; 249:437^141. Pinero DJ, Connor JR. Iron in the brain: An important contributor in normal and diseased states. Neuroscientist 2000; 6:435^153. Plantin LO, et al. Trace elements in the human central nervous system studied with neutron activation analysis. Biol Trace Element Res 1987; 13:69-75. Qian Z, et al. Brain iron and neurological disorders. Chinese Medical Journal 1997; 110:455^158. Rajan MT, et al. Quantification of trace elements in normal human brain by ICP-AES. J Neurol Sci 1997; 146:153-166. Rajput AH, et al. Distribution of metals in Parkinson's disease and control brains. Neurology 1985; 35:224. Rao RV, Rao KSJ. Trace elemental inter-relations in normal and Alzheimer's human brain and cerebrospinal fluid. J Alzheimer's Disease 2000; 2:341-342. Rao KSJ, et al. Trace elements in Alzheimer's disease brain: A new hypothesis. Alzheimer's Reports 1999; 2:241-246. Riederer P, Youdim MBH. Iron in Central Nervous System Disorders. New York: Springer-Verlag, 1993. Riederer P, et al. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 1989; 52:515-520. Roider G, Drasch G. Concentration of Al in human tissues. Investigations on an occupationally non-exposed population in Southern Bavaria (Germany). Trace Elements Electrolytes 1999; 16:77-86. Rotilio G, Carri MT, Rossi L, Ciriolo MR. Copper-dependent oxidative stress and neurodegeneration. IUBMB Life 2000; 50:309-314. Rulon LL, et al. Serum zinc levels and Alzheimer's disease. Biol Trace Element Res 2000; 75:79-85. Saito K, et al. Dynamics of trace and ultra-trace elements in the brain. In: Saito K, editor. Dynamics of Trace Elements in Human Body and Diseases. Hokkaido University Medical Library Series, 1994; 31:11-17. Saito K, et al. Changes in brain trace element concentration by aging. In: Proceedings of the 8th International Symposium on Trace Elements in Man and Animals-TEMA 8. May 16-21, 1993, Dresden, Germany. Gerdsorf: Verlag Media Touristik, 1993: 967-970. Samudralwar DL, et al. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 1995; 130:139-145. Sandyk R. Zinc deficiency and cerebellar disease. Int J Neurosci 1991; 60:21-26.
62
Speziali M & Orvini E
Savory J, et al. Aluminum and neurodegenerative disorders. In: Nicolini M, Zatta PF, Corain B, editors. Aluminum in Chemistry Biology and Medicine. New York: Raven Press, 1991: 45-52. Sayre M, et al. The role of metals in neurodegenerative diseases. Cell Molecular Biol 2000;46:731-741. Sayre M, et al. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 1999; 3:220-225. Scheinberg H. The neurotoxicity of copper. In: Bondy SC, Prasad KN, editors. Metal Neurotoxicity. Boca Raton: CRC Press, 1988: 55-60. Schicha H, et al. Eisen-Konzentrationen in verschiedenen abschnitten des menschlichen Gehirnes und ihre Beziehungen zum Lebensalter. Beitrage zur Pathologie 1971; 142:268-274. Smeyers-Verbeke J, et al. Distribution of Cu and Zn in human brain tissue. Clin Chimica Acta 1974;51:309-314. Sofic E, et al. Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 1991; 56:978-982. Sofic E, et al. Increased iron(III) and total iron content in post-mortem substantia nigra of Parkinsonian brain. J Neural Transmission 1988; 74:199-205. Stedman JD, Spyrou NM. Elemental analysis of the frontal lobe of "normal brain" tissue and that affected by Alzheimer's disease. J Radioanalytical Nucl Chem 1997; 217:163-166. Strausak D, et al. Copper in disorders with neurological symptoms: Alzheimer's, Menkes and Wilson diseases. Brain Res Bull 2001; 55:175-185. Strong MJ, Garruto RM. Motor neuron disease. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 107-112. Sturman JA, Wisniewski HM. Aluminum. In: Bondy SC, Prasad KN, editors. Metal Neurotoxicity. Boca Raton: CRC Press, 1988: 62-85. Sundermann VA, Kempf G. Uber den physiologischen Eisengehalt einiger Stammhirnganglien und seine Abhongigkeit vom Lebensalter Zeitung fur Alterforschung 1961; 15:97-105. Tandon L, et al. RNAA for arsenic, cadmium, copper and molybdenum in CNS tissues from subjects with age-related neurodegenerative diseases. J Radioanalytical Nucl Chem 1994; 179:331-339. Taylor A. Problems and approaches to the measurement of aluminum in studies of Alzheimer's disease. Life Chem Reports 1994; 11:3-10. Thompson CM, et al. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 1988; 9:1-8. Thompson KJ, et al. Iron and neurodegenerative disorders. Brain Res Bull 2001; 55:155-164. Thomson RHS. The regional distribution of copper in human brain. In: Kety SS, Elkes J, editors. Regional Neurochemistry. New York: Pergamon Press, 1961: 102-106.
Metals Distribution and Regionalization in the Brain
63
Trapp GA, et al. Aluminum levels in brain in Alzheimer's disease. Biol Psychiatr 1978; 13:709-718. Traub RD, et al. Brain destruction alone does not elevate brain aluminum. Neurology (Ny) 1981;31:986-90. Uitti RJ, et al. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Canadian J Neurol Sci 1989; 16:310-314. Ule G, et al. Spurenelemente im menschlichen Gehirn-II. Kupfer-, Zink-, Calcium- und Magnesiumkonzentration in 13 verschiedenen Hirnregionen wahrend der 4. bis 8. Lebensdekade im Vergleich zum Hirneisen Z. Neurol 197'4; 206:117-128. Van Dalsem DJ, et al. A novel approach to aluminum determination in biological tissues using a pair of pneumatic tube irradiation facilities. J Radioanalytical and Nucl Chem 1995;192:131-138. Volkl A, et al. Trace elements (Cu, Fe, Mg, Zn) of the brain during chilhood. Neuropadiatrie 1974; 5:236-242. Volkl A, Ule G. Spurenelemenfkonzentration und ihre Altersabhangigkeit in ausgewahlten Positionen des menschlichen Gehirns. Verhandlungen-Anatominscen Gesellshaft 1974; 68:367-373. Volkl A, Ule G Spurenelemente im menschlichen Gehirn—Altersabhangigkeit der Eisenkonzentration in 13 verschiedenen Hirnregionen. Zeischrift fur Neurologie 1972; 202:331-338. Waggoner DJ, et al. The role of copper in neurodegenerative diseases. Neurobiol Disease 1999; 6:221-230. Wallwork JC. Zinc and the central nervous system. Progress in Food and Nutrition Science 1987; 11:203-247. Ward NI, Mason JA. Neutron activation analysis techniques for identifying elemental status in Alzheimer's disease. J Radioanalytical Nucl Chem 1987; 113:515-526. Warren PJ, et al. The distribution of copper in human brain. Brain 1960; 83:709-717. Wisniewski HM, Wen GY. Aluminum and Alzheimer's disease. Ciba Foundation Symposium 1992; 169:142-164. Wisniewski HM. Association of aluminum and Alzheimer's disease. In: Nicolini M, Zatta PF, Corain B, editors. Aluminum in Chemistry Biology and Medicine. New York: Raven Press, 1991: 115-117. Wisniewski HM, Sturman JA. Neurotoxicity of aluminum. In: Gitelman HJ, editor. Aluminum and Health: A Critical Review. New York: Marcel Dekker, Inc., 1989: 125-165. Wisniewski HM, et al. Aluminum and the central nervous system. J Environmental Pathol Toxicol Oncol 1985; 6:1-8. Xu N, et al. Brain aluminum in Alzheimer's disease using an improved GFAAS method. Neurotoxicology 1992; 13:735-744. Yanagihara R. Heavy metals and essential minerals in motor neuron disease. In: Rowlands LP, editor. Human Motor Neuron Disease. New York: Raven Press, 1982: 233-247. Yase Y et al. Kii ALS dementia. Neuropathology 2001; 21:105-109.
64
Speziali M & Orvini E
Yase Y. Metal studies of ALS: Further development. In: Tsubaki T, Yase Y, editors. Amyotrophic Lateral Sclerosis. Amsterdam: Elsevier Science Publishers, 1988: 59-65. Yase Y. The pathogenic role of metals in motor neuron disease. Adv Experiment Med Biol 1987; 209:89-96. Yase Y. The role of aluminum in CNS degeneration with interaction of calcium. Neurotoxicology 1980; 1:101-109. Yase Y. The basic process of amyotrophic lateral sclerosis as reflected in Kii Peninsula and Guam. In: den Hartog Jager WA, Bruyn GW, Heijistee APL, editors. Proceedings of the 11th World Congress on Neurology. Amsterdam: Elsevier Science Publishers, 1978: 413^27. Yasui M, et al. Role of zinc in the central nervous system. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 139-145. Yasui M, et al. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and Parkinsonism-dementia. Neurotoxicology 1993; 14:445-450. Yasui M, et al. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992; 13:593-600. Yasui M, et al. High aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula, Japan: Two case reports. Neurotoxicology 1991a; 12:277-284. Yasui M, et al. Aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula of Japan. Neurotoxicology 1991b; 12:615-620. Yasui M, et al. Zinc concentration in the central nervous system in a case of multiple sclerosis: Comparison with other neurological diseases. No To Shinkei 1991c; 43:951-955. Yokel RA. The metabolism and toxicokinetics of aluminum relevant to neurotoxicity. In: Yasui M, Strong MJ, Ota K, Verity MA, editors. Mineral and Metal Neurotoxicology. Boca Raton: CRC Press, 1997: 81-89. Yoshida S, et al. Comparative trace-elemental study on amyotrophic lateral sclerosis (ALS) and Parkinsonism-dementia (PD) in the Kii Peninsula of Japan and Guam. Wakayama Medical Reports 1988; 30:41-53. Yoshida S, et al. Trace elemental study on amyotrophic lateral sclerosis (ALS) and Parkinsonism-dementia (PD) in the Kii Peninsula of Japan and Guam. Clinical Neurology 1987; 27:79-87. Yoshimasu F, et al. Aluminum in Alzheimer's disease in Japan and Parkinsonism-dementia in Guam. J Neurol 1985; 232:61. Yoshimasu F, et al. Studies on amyotrophic lateral sclerosis by neutron activation analysis. 3. Systematic analysis of metals on Guamanian ALS and PD cases. Folia Psychiatrica Neurologica Japonica 1982; 36:173-179. Yoshimasu F, et al. Studies on amyotrophic lateral sclerosis by NAA. 2. Comparative study of analytical results on Guam PD, Japanese ALS and Alzheimer's disease cases. Folia Psychiatrica Neurologica Japonica 1980; 34:75-82.
Metals Distribution and Regionalization in the Brain
65
Yoshimasu F, et al. Studies on amyotrophic lateral sclerosis by neutron activation analysis. Folia Psychiatrica Neurologica Japonica 1976; 30:49-55. Youdim MBH. Deficiency and excess of iron in brain function and dysfunction. Nutrition flev2001;59:S83-S85. Youdim MBH. Inorganic neurotoxins in neurodegenerative disorders without primary dementia. In: Calne DB, editor. Neurodegenerative Diseases. Philadelphia: Saunders Company, 1994: 251-276. Youdim MBH, et al. The possible role of iron in the etiopathology of Parkinson's disease. Movement Disorders 1993; 8:1-12. Youdim MBH, et al. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 1991; 31:34-40. Youdim MBH, et al. The role of iron in the basal ganglion. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, editors. Advances in Neurology, Vol. 53: Parkinson's disease: Anatomy pathology and therapy. New York: Raven Press, 1990: 155-162. Youdim MBH, et al. Is Parkinson's disease a progressive sclerosis of substantia nigra resulting in iron- and melanin-induced neurodegeneration? Acta Neurol Scand 1989; 126:47-54. Youdim MBH. Iron in the brain: Implications for Parkinson's and Alzheimer's diseases. Mount Sinai J Med 1988; 55:97-101. Zecca L, et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes. J Neurochem 2001; 76:1766-1773.
This page is intentionally left blank
CHAPTER 3
The Olfactory Pathway as a Route of Entry of Metals into the Brain Hans Tjalve, Jonas Tallkvist
ABSTRACT The central nervous system (CNS) is partially protected from circulating toxicants by the blood-brain barrier. However, for xenobiotics which are excluded from the CNS the olfactory pathway provides an alternative route of passage into the brain. Thus, in the olfactory epithelium the primary olfactory neurons have dendrites in contact with the nasal lumen and axons which project to the olfactory bulbs. Materials which come into contact with the olfactory epithelium may be taken up in the primary olfactory neurons and transported to the olfactory bulbs and even further into other areas of the brain. The article deals with the uptake and transport of metals in the olfactory system. Metals discussed are mainly manganese, cadmium, nickel, aluminum, zinc, cobalt and mercury. Among these metals manganese has a unique capacity to be taken up via the olfactory pathway. Thus, following transport along the primary olfactory neurons to the olfactory bulbs manganese continues via secondary and tertiary olfactory neurons and further connections to all parts of the brain and even into the spinal cord. Cadmium is transported along the axons of the primary olfactory neurons to the olfactory bulb, but this metal appears unable to leave the terminal arborizations of the axons in the glomeruli of the bulb. Studies with nickel, zinc, cobalt and mercury indicate that these metals are transported along the primary olfactory neurons and accumulated in the olfactory nerve layer and the glomerulular layer of the bulbs. In addition, low levels of these metals leave the terminations of the primary olfactory neurons. There is evidence that mercury also may undergo axonal transport in the primary olfactory neurons following uptake in these neurons from the systemic circulation. This may be a part of a more general ability of mercury to be taken up in neurons with access to the systemic circulation and reach the CNS via transport in these neurons. There is evidence 67
68
Tjdlve H & Tallkvist J that aluminum is transported along the olfactory pathway, but the fate of this metal in the olfactory system is not yet known in detail. The olfactory pathway is a route by which metals may circumvent the blood-brain barrier and reach the central nervous system. The possibility that uptake and transport of metals in the olfactory pathways may induce olfactory dysfunction and neurotoxicity should be taken into account in risk assessments of occupational metal exposure via inhalation. Keywords: Alzheimer's disease; Parkinson's disease; olfactory; neuronal transport; manganese; cadmium; nickel; aluminum; zinc; cobalt; mercury.
1. INTRODUCTION This article is built upon observations that metals can be efficiently transported via olfactory pathways to the brain. This area of research is important since it suggests that the nasal cavity and the olfactory pathways may serve as a critical route for deposition, absorption and transport of metals into the central nervous system (CNS). Thus, the role of the olfactory pathway must be taken into account in future risk assessments of occupational metal exposure via inhalation. Traditionally researchers have focussed on uptake of metals via the lung and it is considered that the lung may serve as a long-term reservoir of metals deposited in the lower airways. The CNS is partially protected from uptake of metals present in the circulation by the blood-brain barrier. Therefore, metals taken up in the blood from the lung may have a limited ability to pass to the brain. The olfactory epithelium is a unique tissue in which the olfactory neurons have dendrites in contact with the environment in the nasal cavity and axons, which reach the glomeruli of the olfactory bulbs. In addition to metals several other materials may enter the CNS via this route. This applies to organic xenobiotics, such as dyes (Holl, 1980), organic solvents (Ghantous et al., 1990), polychlorinated biphenyls (Apfelbach et al., 1998), benzo(a)pyrene (Persson et al., 2002) and aflatoxin Bj (Larsson and Tjalve, 2000), protein tracers, such as albumin labelled with Evans blue, horseradish peroxidase and the conjugate between horseradish peroxidase and wheat-germ agglutinin (Kristensson and Olsson, 1971; Shipley, 1985; Stewart, 1985; Baker and Spencer, 1986; Itaya, 1987; Thome et al., 1995), several neurovirulent viruses (Johnson, 1964; Monath et al., 1983; Charles et al., 1995) and some endogenous materials, such as carnosine, taurine, amino acids and proteins (Gross and Kreutzberg, 1978; Burd et al., 1982; Lindquist et al., 1983).
The Olfactory Pathway as a Route of Entry of Metals into the Brain
69
In this article metal transport into the brain via the olfactory route is reviewed. The outline of the article is as follows: (i) anatomy of the olfactory system; (ii) deposition of inhaled materials on the olfactory epithelium; (iii) uptake mechanisms into olfactory neurons; (iv) mechanisms of neuronal transport; (v) transport of metals in the olfactory system (manganese, cadmium, nickel, aluminum, zinc, cobalt, mercury); (vi) abundance of metals in the olfactory bulb; (vii) metal transfer into the cerebrospinal fluid via the olfactory pathway; (viii) concluding remarks.
2. ANATOMY OF THE OLFACTORY SYSTEM The dorsal and caudal portions of the olfactory cavity are lined with olfactory epithelium. The major cells in the olfactory epithelium are the primary olfactory neurons (or receptor cells) and the sustentacular cells (or supporting cells) (Fig. 1). The primary olfactory neuron is a bipolar cell in which a single dendrite extends to the olfactory mucosal surface, where it enlarges to a dendritic knob. From the knob fine olfactory cilia extend into a layer of mucus, which covers the epithelium. The receptor cells and the supporting cells form typical tight junctions with one another (Farbman, 1992). The basal cell constitutes a third cellular component in the olfactory epithelium. Bowman's glands, situated in the lamina propria mucousa, provide most of the mucus which covers the olfactory epithelium (Getchell and Mellert, 1991). These cells and the supporting cells contain high levels of xenobiotic metabolizing enzymes, including cytochromes P450 (Dahl and Hadley, 1991). The axons of the primary olfactory neurons pass through the lamina propria of the olfactory mucosa and the cribriform plate of the ethmoid bone to the glomeruli of the olfactory bulb, in which they synapse onto the dendrites of the mitral and tufted cells. The axons of these cells, which constitute the secondary olfactory neurons, project to the olfactory cortex. This area includes the anterior olfactory nucleus, the olfactory tubercle and the pyriform, amygdaloid and entorhinal cortices (Allison, 1953; Heimer, 1968; Scott, 1986; Haberly, 1990; Greer, 1991; Farbman, 1992). In the olfactory cortex synapses are formed with dendrites of pyramidal cells, which constitute the tertiary olfactory neurons. The axons of these cells distribute to multiple subcortical and cortical regions (Allison, 1953;
70
Tjalve H & Tallkvist J
Heimer, 1968; Haberly, 1990; Price, 1985; Scott, 1986; Greer, 1991; Farbman, 1992) (Fig. 1).
3. DEPOSITION OF INHALED MATERIALS ON THE OLFACTORY EPITHELIUM There are indications that in the rat about 15% of the inspired air pass over the olfactory mucosa during normal breathing (Jaillardon et al., 1992). Similar values have been obtained in human models (Hahn et al., 1993). In the rat nasal mucosa deposition efficiency of particles follows a bimodal distribution: For larger particles (>l|jim) the deposition efficiency increases with increasing particle size, whereas for particles ranging from 0.2 to 0.005 |xm deposition fraction increases with decreasing particle size (Cheng et al., 1990). Only a proportion of the inhaled particles can be expected to reach the olfactory mucosa, but the degree of regional uptake in the olfactory area is not known at present (Lewis et al., 1994). The nasal mucociliary apparatus may remove particles from the respiratory mucosa, but such a clearance does not appear to occur from the olfactory mucosa (Morgan et al., 1984). When extrapolations are made from experiments in animals to the human situation interspecies differences in nasal anatomy should be considered. In rodents and several other mammals the olfactory mucosa covers a larger proportion of the nasal cavity than in humans and the olfactory route of brain delivery may therefore be less important in humans than in some animals.
4. UPTAKE MECHANISMS INTO OLFACTORY NEURONS An important component of the olfactory mucosa is the mucus layer, which covers the epithelium. Inhaled odor molecules are trapped in this layer as they pass the olfactory mucosa. Toxic materials, which reach the olfactory mucosa, may also be trapped in the mucus. The mucus contains mucopolysaccharides (Getchell and Mellert, 1991) and can be expected to bind metal cations. However, the degree of binding of different metals and the potential effect this may have on the penetration to the underlying cell-surfaces are not known at present.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
71
Fig. 1. Overview of the anatomy of the olfactory mucosa, the olfactory bulb and the efferent neuronal projections from the olfactory bulb. The figure indicates the essential morphology of the olfactory mucosa and the main neuronal elements in the olfactory bulb as well as most of the main efferent connections from the olfactory cortex. 1, mucus layer; 2, dendritic knob; 3, cilia containing the olfactory receptors; 4, olfactory receptor cell; 5, sustentacular cell; 6, basal cell; 7, basement membrane; 8, Bowman's gland; 9, blood vessel; 10, Schwann cell; 11, cribiform plate of the ethmoid bone; AC, amygdaloid cortex; AON, anterior olfactory nucleus; EC, entorhinal cortex; OT, olfactory tubercle; PC, pyriform cortex; epl, external plexiform layer; g, glomerulus; gel, granular cell layer; gl, glomerular layer; mc, mitral cell; mcl, mitral cell layer and internal plexiform layer; onl, olfactory nerve layer; pgc, periglomerular cell; tc, tufted cell. The asterisc given at the neocortex indicates that the neocortical areas are localized in the dorsal bank of the sulcus rhinalis (from Tjalve and Henriksson, 1999; with permission).
72
Tjalve H & Tallkvist J
The uptake of materials in neurons may occur by different mechanisms. Thus, the uptake may involve a binding of the materials to specific binding sites at the cell surface. This mechanism is termed adsorptive endocytosis. Alternatively materials may also be passively trapped in an endocytotic vesicle along with extracellular fluid in a process termed fluid phase endocytosis. Some metals, such as cadmium and mercury, have a strong affinity for SH-groups and other negatively charged groups on proteins (Berlin, 1986; Friberg et al., 1986). Conceivably, a binding to such groups on the olfactory receptor cell membrane may result in internalization of these metals, according to the mechanism of adsorptive endocytosis. Other metals may be taken up in the olfactory receptor cells by fluid phase endocytosis. However, even a weak electrostatic interaction with the cell surface may facilitate the uptake. This has been shown to be the case in axonal terminals. Thus, studies by Olsson and Kristensson (1981) have shown that, following injection in the vibrissae muscles of mice, cationized ferritin is more avidly accumulated in the facial nerve nucleus as compared to native ferritin. It was considered that the positive charge of the cationized ferritin interacts with negatively charged macromolecules on the neuronal surface, in turn facilitating uptake in the axonal terminal. A similar facilitated uptake of positively charged metal cations may take place in the olfactory receptor cells. The knobs of the dendritic processes of the olfactory receptor cells, which extend to the surface of the olfactory epithelium, are rich in endocytic vesicles, indicating that they are actively engaged in the uptake of exogenous materials from the environment (de Lorenzo, 1970; Bannister and Dodson, 1992). Particulate materials, such as the silver-coated colloid gold particles examined by de Lorenzo (1970), appear to be taken up from the overlying mucus by internalization together with the surface membrane (de Lorenzo, 1970; Bannister and Dodson, 1992). There may also be specific transport processes, which mediate the uptake of some metals. These processes may vary depending on the metal in question. As concerns manganese, it has been shown that this metal can enter nerve terminals via calcium channels during nerve action potentials (Narita et al., 1990). The metal also passes through calcium channels in myoepithelial cells (Anderson, 1979). Manganese permeates presynaptic calcium channels and induces dopamine release from depolarized nerve endings (Drapeau and Nachsen, 1984). Conceivably, manganese may be
The Olfactory Pathway as a Route of Entry of Metals into the Brain
73
taken up in the olfactory receptor cells via calcium channels. Mercury might enter these cells via sodium or calcium channels, as has been proposed as the mode of uptake of this metal in motor nerve terminals in frog muscle (Miyamato, 1983). Recent studies have revealed the presence of metal transporters for iron (Divalent Metal Transporter 1 /DMT1/) (Gunshin et al., 1997) and zinc (Zrt, Irt-like Proteins /ZIP/) (Gaither and Eide, 2001) in various tissues. These transporters have also been shown to act on other metals, such as manganese, cadmium and nickel (Gunshin et al., 1997; Gaither and Eide, 2001). Conceivably, these transporters may be involved in the uptake of metals in the olfactory neurons.
5. MECHANISMS OF NEURONAL TRANSPORT Since biosynthetic processes are largely restricted to the perikaryal regions of nerve cells there is a need for transport of materials along the axons and the dendrites to their terminals. In the anterograde direction — from the cell body to the periphery — there appears to be at least two components of transport: Fast and slow. In the retrograde direction — from the periphery to the cell body — the transport occurs at a rate, which is similar to that of fast anterograde transport. The anterograde transport is necessary for synaptic function and maintenance of neuronal constituents, whereas the retrograde transport may serve the purpose of shipping constituents back to the cell body for re-use or final degradation. Biochemical research during the last decades has revealed that the fast anterograde transport and the retrograde transport are microtubule-associated processes, in which kinesin generates the movement in the antero-grade direction and cytoplasmic dynein is the motor protein in the retrograde direction (Okabe and Hirokawa, 1989; Cyr and Brady, 1992; Hammerschlag et al., 1994). The molecular mechanism of the slow transport is still not known. The calculated values for the rate of the fast anterograde transport varies in different experimental models (rate -20-400 mm/day). This involves predominantly particulate materials, such as membrane proteins and lipids and neurotransmitter-containing synaptic vesicles. There is also evidence for fast neuronal transport of low-molecular-weight materials, such as amino acids and calcium (Hammerschlag et al, 1975; Knull and Wells, 1975; Gross and Kreutzberg, 1978). The slow anterograde transport (rate -0.1-4 mm/day)
74
Tjalve H & Tallkvist J
involves cytoskeletal proteins and various soluble enzymes, including cytoplasmic enzymes of intermediary metabolism (Vallee and Bloom, 1991; Nixon, 1992). Materials transported in the retrograde direction consist of pinocytotic vesicles and lysosomal organelles, as well as transmittercontaining vesicles and mitochondria. Neuronal transport of metals is a phenomenon, which in addition to the olfactory system, is known to occur in other areas of the CNS and also in the peripheral nervous system. It can be assumed that the metals are bound to some endogenous neuronal constituent(s) during this transport. The binding of metals to components in the olfactory neurons will be discussed below when the olfactory transport of the various metals is described.
6. TRANSPORT OF METALS IN THE OLFACTORY SYSTEM Transport of metals in the olfactory system was first observed for cadmium and has then been shown for several other metals, such as manganese, nickel, aluminum, zinc, cobalt and mercury. Among these metals manganese is the only one that so far has been shown to readily distribute in the entire brain following uptake via the olfactory pathways.
6.1. Manganese We have examined the uptake of 54Mn2+ in the brain via olfactory pathways in pike, brown trout and rat (Tjalve et al., 1995, 1996; Rouleau et al., 1995). The results showed that manganese is taken up from the olfactory mucosa to the olfactory bulbs and then passes transneuronally to various parts of the brain. In our study in the rat, in which 54MnCl2 was applied in the nasal cavity, it was possible to follow the transfer of 54 Mn 2+ in the brain. Thus, initially the metal passed from the olfactory bulbs to the basal forebrain areas, which constitute the terminal regions of the secondary olfactory neurons (the olfactory cortex; see Fig. 1). The results indicated that from these areas the 54 Mn 2+ continued along tertiary olfactory neurons — as shown in Fig. 1 — in the anterior commissure to areas reached via this pathway and to the hypothalamus, thalamus, habenula, hippocampus and the neocortex dorsal to the fissura rhinalis. At long survival intervals the 54 Mn 2+ was seen to be spread to various grey matters at the base of the cerebral hemisphere, including the basal ganglia, and also to the
The Olfactory Pathway as a Route of Entry of Metals into the Brain
75
grey matter in various areas of the cerebral cortex, and eventually to the cerebellum and the spinal cord (Fig. 2). Other authors have shown transport of manganese in the olfactory system following topical application of MnCl2 on the olfactory mucosa of rats (Gianutsos et al., 1997) and mice (Pautler et al., 1998). Brenneman et al., (2000) demonstrated uptake of manganese in the olfactory system of rats following inhalation exposure to 54MnCl2. Vitarella et al. (2000) showed uptake of manganese in the olfactory bulb of rats exposed to manganese phosphate via inhalation. Manganese phosphate is the primary respirable manganese compound emitted from automobile exhaust-pipes following combustion of methylcyclopentadienyl manganese tricarbonyl (MMT), which is added to gasoline as an octane enhancer. Normandin et al. (2002) showed a dose-dependent increase of the manganese concentration in the olfactory bulb of rats following subchronic inhalation of manganese phosphate. In this study a dose-dependent increase in manganese concentration was also seen in the caudate/putamen. These authors concluded that the olfactory bulb is the brain target for manganese accumulation and that uptake of manganese into the brain may occur via the olfactory pathway. Studies by Dorman et al. (2001) showed higher brain manganese in rats exposed via inhalation to soluble MnS0 4 compared to insoluble Mn 3 0 4 . Studies by Fechter et al. (2002) showed uptake of manganese into the brain via the olfactory pathway in rats exposed via inhalation to small-particle aerosols (up to 1.3 |xm) of Mn0 2 , but not to large-particle aerosols (up to 18 |jim) of Mn0 2 . Studies in the California ground squirrel, which is a fossorial animal, indicate that manganese, and also cadmium, present in soil are taken up in the olfactory bulb via the olfactory pathway (Bench et al., 2001). The application of 54 Mn 2+ (as 54MnCl2) in the olfactory chambers of pike resulted in transport of the metal in the olfactory neurons towards the olfactory bulbs at a rate of about 2.9 mm/hour at 10 °C (Tjalve et al., 1995). This rate falls into the category of fast axonal transport. Sloot and Gramsbergen (1994) injected Mn 2+ in the substantia nigra or the striatum of rats and showed an anterograde transport of the metal, both in dopaminergic nigral neurons and in -y-aminobutyric acidergic striatal neurons. They reported that the manganese-transport was inhibited by injections of colchicine, which is an inhibitor of cellular functions dependent on microtubules.
76
Tjalve H & Tallkvist J
It can be assumed that manganese adheres to and moves along with some protein(s), which undergo fast axonal transport. Cell fractionations and gel chromatography of the olfactory nerve and bulb and the telencephalon of the pike given manganese in the olfactory chambers showed that the metal was present both in the soluble cell fraction (cytosol) and in association with various particulate cell constituents (Tjalve et al., 1995). A similar subcellular distribution of manganese was seen in the olfactory epithelium and various parts of the brain in rats in which the metal was applied in the nasal cavity (Henriksson et al., 1999). Unlike many other metals manganese does not possess a high affinity for any endogenous ligand, such as e.g., SH-groups, and it is possible that manganese relatively easily can move between different tissue constituents within the olfactory system, as well as in the brain. One also has to consider that the administered Mn 2+ partly may undergo oxidation to Mn 3+ . Mn 3+ appears to have a slower elimination rate than Mn 2+ , which may be related to a higher affinity of the trivalent manganese than the divalent species to endogeneous ligands (Gibbons et al., 1976). Mn 3+ is bound to transferrin. Sloot and Gramsbergen (1994) proposed that manganese may be transported from the substantia nigra to the striatum and vice versa bound to transferrin. However, our study in the rat indicated that the major proportion of the metal is not bound to transferrin at the transport along olfactory-related pathways of the brain (Henriksson et al., 1999). There is also a possibility that the binding pattern of the manganese in the neurons may change over time. It is well known that chronic exposure to manganese can cause neurologic symptoms, usually manifested by an extrapyramidal syndrome resembling Parkinson's disease. Neuropathology is induced in the basal ganglia with lesions being localized in the substantia nigra and, in addition, at other sites, such as the globus pallidus, nucleus caudatus and putamen and also the thalamus. Lesions may, in addition, be found throughout the cerebrum, the brain stem and the cerebellum (Donaldson, 1987; Mergler, 1996). The results discussed above indicate that the olfactory route may be an important pathway through which inhaled manganese gains access to the CNS. Manganese intoxications have been observed primarily at occupational exposure among workers involved in steel manufacturing and welding and in mining and processing of manganese ores, and have been related exclusively to inhalation of manganese-containing dusts or fumes (Barbeau, 1984; Donaldson, 1987). Manganese is also ubiquitously
The Olfactory Pathway as a Route of Entry of Metals into the Brain
11
present in ambient air due to industrial activities and release from crustal sources. There is, in addition, an increasing interest in the neurotoxicity of this metal because of the use of MMT as a gasoline octane enhancer. The risk posed to the general population by chronic environmental manganese exposure is unknown, but aging may be a susceptibility factor, and there may be individuals which are especially sensitive (Mergler, 1996). The main cellular target for the damage in neurological manganism has not been identified with certainty, and the crucial biochemical events which cause the neurotoxicity remain unknown. Several authors have proposed that the mechanism of manganese toxicity may involve formation of free radicals in the presence of catecholamines (Donaldson et al., 1982; Graham, 1984; Halliwell, 1984). Recently several authors have proposed that the astrocytes may be the primary targets of manganese toxicity in the brain. Manganese has been shown to affect processes in the astrocytes such glutamate uptake, expression of glyceraldehyde-3-phosphate dehydrogenase and nitric oxide synthesis (Hazell and Norenberg, 1997; Spranger et al., 1998; Hazell et al., 1999). Astrocytes play an important role in normal brain functions, such as regulation of ion homeostasis, uptake of transmittors and contribution to the CNS immune system (Aschner, 1998). Manganese is avidly taken up in astrocytes in vitro (Aschner et al., 1992). Sloot and Gramsbergen (1994) showed that striatal injection of manganese resulted in a higher uptake of the metal into a quinolinic acidlesioned striatum, which is depleted of intrinsic nerve cells and contains an abundant amount of glia cells, than into a non-lesioned striatum. We have recently shown that intranasal administration of manganese in rats results in decreased levels of the astrocytic proteins GFAP (glial fibrillary acidic protein) and S-lOOb (a low-molecular-weight calcium binding protein) in the olfactory cortex, the hypothalamus, the thalamus and the hippocampus — brain regions with prominent connections to the olfactory bulb (Henriksson and Tjalve, 2000). We assume that the decreased levels of GFAP andS-lOOb are due to adverse effects of manganese on the astrocytes.
6.2. Cadmium Transport of cadmium in the olfactory system was first shown in fish exposed to the metal via the water. Thus, whole-body autoradiography in brown trout exposed to 109CdCl2 via aquarial water showed an accumulation of l09 Cd 2+ in the olfactory rosette, the olfactory nerve and the anterior part
78
Tjalve H & Tallkvist J
of the olfactory bulb (Tjalve et al., 1986). Studies in pike, in which 109Cd2+ was applied in the olfactory chambers, confirmed that cadmium is transported along the olfactory nerve and is accumulated in the anterior part of the olfactory bulb of the brain (Gottofrey and Tjalve, 1991). The uptake of the metal in the olfactory bulb was confined to the anterior part, whereas in other brain areas the level of the metal remained low, indicating that cadmium accumulates in the terminal parts of the olfactory axons, but is unable to continue along secondary olfactory neurons. The results showed a wave of 109Cd transported along the olfactory nerve with a maximal velocity of about 2.4 mm/hour at the experimental temperature (+ 10°C). This rate falls into the category of fast axonal transport. Hastings and Evans (Hastings and Evans, 1991; Evans and Hastings, 1992) applied 109Cd intranasally in rats and found an accumulation of the metal in the olfactory bulb on the side of the application, whereas the level in the contralateral bulb was low. There was no accumulation of 109Cd2+ in the forebrain of the rats. We performed autoradiography in rats given 109 Cd2+ intranasally and found an accumulation of the metal in the anterior part of the olfactory bulb, whereas the levels in other brain areas remained low (Tjalve et al., 1996) (Fig. 2). Gamma spectrometry confirmed that intranasal administration of 109Cd2+ results in a selective accumulation of the metal in the olfactory bulb (Tjalve et al., 1996). As mentioned studies in the California ground squirrel indicate that cadmium (as well as manganese) present in soil is taken up in the olfactory bulb via the olfactory pathway (Bench et al., 2001). Recent studies in rats and pikes indicate that cadmium administered by intranasal administration induces metallothionein synthesis in the olfactory receptor cells in the olfactory mucosa and that the metal is transported as a cadmium metallothionein complex along the axons of these cells to the olfactory bulbs of the brain (Tallkvist et al., 2002) (Fig. 3). These data also implies that metallothionein is transported in the olfactory neurons at the same rate as cadmium. The affinity for metallothionein may render cadmium prone not to leave the primary olfactory neurons, resulting in an accumulation in the terminal parts of the olfactory axons. It has been reported in several clinical studies that occupational exposure to cadmium results in olfactory dysfunction (Friberg, 1950; Adams and Crabtree, 1961; Rose et al, 1992). Baader (1952) reported that a worker exposed to cadmium oxide dust for 16 years had an atrophic nasal mucosa
The Olfactory Pathway as a Route of Entry of Metals into the Brain
79
Fig, 2. Details of a whole-body autoradiograms (sagittal sections) of rats killed three weeks after intranasal instillations of (A) 54 Mn 2+ (0.6 |xg) or (C) 109Cd2+ (3,3 fig) in the right nostrils, (B) and (D) are the tissue section corresponding to A and C, respectively. White areas in the autoradiograms denote high levels radioactivity. (From Tjalve et al„ 1996; with permission.)
Tjalve H & Tallkvist J
80
rb
lb
rb onl
onl 8
lm
rm
B
ns n nf
b Bg
nf
A Fig. 3. Immunohistochemical staining for metallothionein in sections of the olfactory system of a rat, killed 48 h after intranasal instillation of cadmium (5 \ig) in the right nostril. (A) Section showing the left and right olfactory mucosa, turbinates and bulbs. The immunohistochemical staining is much higher on the right than on the left side. (B) Section showing the right and left olfactory bulb. Higher levels of metallothionein are present in the olfactory nerve layer of the right bulb than of the left bulb. A homogeneously distributed staining is present in the glomeruli of the right olfactory bulb, whereas in the left bulb the glomerular staining shows a mesh-like pattern. (C) Detail of the right olfactory mucosa. Metallothionein-staining is present in neuronal, sustentacular, and basal cells. Nerve fascicles in the lamina propria also show a marked immunoreactivity. The staining in Bowman's glands is low. Legends: b, basal cell; Bg, Bowman's glands g, glomeruli; lb, left olfactory bulb; lm, left olfactory mucosa; n, olfactory nerve cell nf, nerve fascicles; ns, nasal septum; onl, olfactory nerve layer; rb, right olfactory bulb rm, right olfactory mucosa; s, sustentacular cell. Magnification: (A)X12, (B) X60 (C) X180 (from Tallkvist et al., 2002; with permission).
and the olfactory bulbs were stained bright yellow. Although olfactory dysfunction is a common finding in cadmium-exposed workers, no effects on olfaction were observed in an experimental study in rats exposed to cadmium oxide dust for 20 weeks (Sun et al., 1996). One possible explanation for this finding is that a long latency period is required (in man up to 20 years) before the development of anosmia. Cadmium has a noxious effect on the olfactory epithelium and is a strong inhibitor of olfactory
The Olfactory Pathway as a Route of Entry of Metals into the Brain
81
function in fish (Stromberg et al., 1983; Rehnberg and Schreck, 1986). It is possible, therefore, that low levels of cadmium in the water may be injurious to the olfactory sense in fish.
6.3. Nickel We have studied the uptake of nickel in the olfactory system of rats and pikes (Henriksson et al., 1997; Tallkvist et al, 1998). It was found that intranasal instillation of 63 Ni 2+ (as 63NiCl2) in rats resulted in an uptake of the metal in the olfactory epithelium and a migration along the primary olfactory neurons to the glomeruli of the olfactory bulb. The metal was then seen to pass to the interior of the bulb and further to the olfactory peduncle and tubercle and to the rostral parts of the prepyriform, frontal and cingulate cortices. The experiments in pike, in which 63NiCl2 was applied in the olfactory chambers, showed a transport of the metal in the olfactory neurons at a rate of about 0.13 mm/hour at 10°C. This is about 20 times slower than the transport-rate for cadmium and manganese. Cellular fractionations and gel chromatography showed that nickel in the olfactory system of pikes and rats was present both in the cytosol and in association with various particular cell constituents (Tallkvist et al., 1998). We assume that nickel undergoes slow axonal transport bound to these constituents. There is also a possibility that the movement of nickel in the olfactory system might be explained by diffusion. However, the observation that the transport of nickel in the olfactory nerve of the pike occurs at a constant rate (Tallkvist et al., 1998) does not support this assumption. In addition, it seems less likely that diffusion of the metal would occur over such long parts of the olfactory nerve as was observed in the pike. Exposure to soluble nickel compounds in electrorefining factories has been shown to impair the olfactory sense (Tatarskaya, 1960; Kucharin, 1970). Abnormal olfactory function has also been observed in rats exposed experimentally to this metal (Benson et al., 1987, 1988; Evans et al., 1995).
6.4. Aluminum Rabbits that received nasal implants of gelfoam pads impregnated with soluble aluminum salts developed granulomas in the olfactory bulb and
82
Tjalve H & Tallkvist J
cerebral cortex (Perl and Good, 1987). Laser microprobe mass analysis (LAMMA) revealed presence of aluminum in cytoplasmic granules of macrophages in the granulomas, whereas adjacent neurons had no evidence of aluminum. Zatta et al. (1993) showed accumulation of aluminum in the olfactory bulb, hippocampus, cerebellum and pons-medulla in rats exposed via inhalation to aluminum acetylacetonate. Divine et al. (1999) showed accumulation of aluminum in the olfactory bulb of rats exposed via inhalation to aluminum chlorohydrate. It is possible that the disposition of aluminum in the olfactory system may vary depending on the aluminum compound in question. Additional studies on the uptake and distribution of aluminum in the olfactory system would be of interest. Aluminum is a known neurotoxic metal, which is present in high concentration in dust particles. There are indications that aluminum is present in senile plaques and in the neurofibrillary tangles of Alzheimer's disease (Itzhaki, 1994). It has been proposed that aluminum may be taken up the brain via the olfactory route and play a role in the etiology of Alzheimer's disease (Roberts, 1986; Perl and Good, 1991; Zatta, 2000).
6.5. Zinc Zinc (as 65ZnCl2) applied on the olfactory mucosa of rats or pikes resulted in an uptake of the metal in the olfactory epithelium and a transport along the primary olfactory neurons to their terminations in the olfactory bulbs (Persson et al., 1998; and unpublished observations). Low levels of 65 Zn 2+ passed these terminals and continued into the interior of the bulbs. In rats 65 Zn 2+ was also detected in the anterior parts of the olfactory cortex. Studies by Takeda et al. (1997) indicate that zinc injected into the olfactory bulb or the amygdaloid nuclei undergoes anterograde axonal transport in the secondary olfactory neurons. In another study, Takeda etal. (1998) found that injection of zinc into the striatum resulted in a transport of the metal in striato-nigral 7-aminobutyric acid (GAB A)-ergic neurons, whereas injection of zinc in the substantia nigra resulted in transport of the metal in nigro-striatal dopaminergic neurons. Zinc homeostasis in the brain is very complex. Zinc is an essential element and a component of a number of metalloenzymes. In the brain about 90% of the total zinc is bound in zinc proteins (Frederickson, 1989). A separate pool of zinc is present as free or loosely bound ions in some neurons of the brain. These neurons ("zinc-containing neurons") contain
The Olfactory Pathway as a Route of Entry of Metals into the Brain
83
a pool of histochemically stainable zinc localized in presynaptic vesicles of nerve terminals and are believed to be a subset of glutamatergic neurons (Jo et al., 2000; Frederickson and Bush, 2001). The olfactory bulb contains high concentrations of zinc. Most of this zinc is found in the glomerular layer and the granular cell layer of the olfactory bulb. It is believed that the terminals of the primary olfactory neurons contain vesicles in which glutamate is present together with zinc and that these two constituents are co-released (Joet al., 2000). Palmiter et al. (1996) have identified a zinc transporter (ZnT-3), which is essential for the transport of cytosolic zinc into the glutamate containing synaptic vesicles. ZnT-3 has been reported to be present in presynaptic vesicles of olfactory neurons together with zinc (Jo et al., 2000). Our results showed that there was an accumulation of zinc in the terminals of the primary olfactory neurons in the glomeruli. It is possible that following axonal transport in these neurons the zinc may be taken up in presynaptic vesicles, resulting in cellular sequestration. The zinc may then be released into the synapses in the glomeruli as a response of action potentials. Metallothionein is considered to be involved in intracellular zinc homeostasis. In the brain metallothionein-I and metallothionein-II are induced by heavy metals, such as zinc and copper (Ebadi et al., 1995; Hidalgo and Carrasco, 1998). Metallothionein-III is highly expressed in zinc containing glutamatergic neurons (Masters et al., 1994). This metalloprotein may be an important regulator of neuromodulatory zinc in the brain, including the olfactory system. Occupational exposure to zinc-containing dusts or fumes occurs in some industrial environments, such as in galvanization plants and at welding of galvanized iron or steel (Walsh et al., 1994; Barceloux, 1999). This may result in accumulation of the metal in the nasal pathways and an uptake of the metal in the brain via the olfactory route. It is not known whether this may cause neurotoxicity. However, it can be noted that zinc dysregulation leading to increased extracellular Zn 2+ , has been implied to play a role in Alzheimer's disease by inducing precipitation of amyloid beta (Frederickson and Bush, 2001).
6.6. Cobalt Studies in rats in which 57CoCl2 was applied intranasally showed a similar picture as observed for 65ZnCl2 (Persson et al. 1998; and unpublished observations). Thus, 57 Co 2+ was transported along the olfactory neurons
84
Tjalve H & Tallkvist J
and accumulated in the olfactory nerve layer and the neuronal terminals in the glomerular layer of the bulb. In addition, low levels of cobalt were seen in the interior of the bulbs and the anterior parts of the olfactory cortex indicating that cobalt is able to leave the terminals of the primary olfactory neurons. Occupational exposure to cobalt occurs mainly by inhalation and is considerable and widespread. Cobalt is a technically important metal used mainly as a constituent of many alloys and as a binder in hard-metal industry. Its salts are used e.g. in electroplating and electrochemical industries and as colorating agents in ceramics (Jensen and Tuchsen, 1990). It is not known whether uptake of cobalt into the brain via the olfactory route may cause neurotoxicity. However, it has been reported that workers exposed to cobalt-containing dust may suffer from memory deficits (Jordan et al., 1997). The mechanism for this condition is not known, but one possibility is that cobalt taken up into the brain via olfactory pathways may play a role in the etiology.
6.7. Mercury Studies in pike, in which inorganic mercury (as 203HgCl2) was applied in the olfactory chambers, showed a transport along the olfactory neurons to the anterior part of the olfactory bulb (Borg-Neczak and Tjalve, 1996). In rats intranasal instillation of the metal resulted in an uptake of the metal along the olfactory axons to the olfactory nerve-layer and the glomerular layer of the bulb (Henriksson and Tjalve, 1998). Low levels of the metal were also discernible in the external plexiform layer, indicating that a small part of the 203jjg2+ ] e a v e s m e terminal arborizations of the axons in the glomeruli. There is evidence that mercury may undergo axonal transport in the primary olfactory neurons following uptake from the systemic circulation. Thus, autoradiography in rats injected i.p. with inorganic mercury (203HgCl2) showed a labeling of the glomerular layer of the olfactory bulbs which exceeds the labeling of other brain areas (Henriksson and Tjalve, 1998) (Fig. 4). There was also an uptake of the 203 Hg 2+ in the olfactory mucosa, and it was proposed that the metal may be taken up from the blood into the primary olfactory neurons and then move along the axons to their terminations in the bulbs. The capillary bed, which underlies the olfactory neuroepithelium, is composed of conventional fenestrated capillaries.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
85
Fig. 4. (A) Detail of an autoradiogram of the head (horizontal section), showing the nasal cavity, the olfactory bulbs and the anterior parts of the olfactory cortex, of a rat killed three weeks after i.p. injection of 203 Hg 2+ (6.7 |xg). (B) The corresponding tissue-section. Legends: e, olfactory epithelium; gl, glomerular layer of the olfactory bulbs. White areas denote high levels of 2
Blood-bome mercury may therefore diffuse into the extracellular space and then have direct access to the unmyelinated olfactory neurons. Alternatively, mercury may be taken up from the circulation into the cellbodies of the olfactory receptor cells.
86
Tjalve H & Tallkvist J
For most people mercury released from dental amalgam fillings is the main source of exposure to the inorganic mercury (Halbach, 1994). Mercury is released from the amalgam surface mainly as mercury vapor (Hg°). The Hg° will be oxidized to Hg 2+ by the H202-catalase pathway, which is ubiquitously present in various tissues (Sichak et al., 1986; Clarkson, 1989). The fate of the Hg° before it becomes oxidized to Hg 2+ is not known in detail, but it is assumed that the Hg° is distributed throughout the oral and the nasal cavities and also via respiration will be transferred to the lungs, which are considered to be the major sites of uptake of the metal. It is considered that the Hg° partly is oxidized to Hg 2+ in the lungs and the red blood cells, but the oxidation is considered to be slow enough to allow the lipophilic Hg° to reach the brain and diffuse through the blood-brain barrier into the nervous tissues. In the brain the Hg° can be oxidized to Hg 2+ which binds to cellular nucleophiles (Sichak et al., 1986; Clarkson, 1989). In the blood the Hg 2+ will become distributed in roughly equal concentrations between the plasma and the red blood cells (Ekstrand et al., 1998). Little attention has been paid so far to the fate of the Hg° in the nasal tissues. However, there are indications that the Hg° is oxidized to Hg 2+ in the nasal mucosa (Khayat and Dencker, 1984). It has been proposed that Hg° released from amalgam fillings will reach the primary olfactory neurons in the olfactory epithelium and become oxidized to Hg 2+ in these cells (Henriksson and Tjalve, 1998). The intracellular Hg 2+ may then be transported along the axons to the olfactory bulbs. Occupational exposure to Hg° by inhalation occurs in gold mining and is a widespread problem in several countries of South America and Africa and also in Indonesia and the Philippines (Asano et al., 2000). The Hg° is used for amalgamation of gold and mercury is released by evaporation at reburning sites. The tissue disposition of the occupationally inhaled Hg° can be assumed to be similar as for the Hg° released from dental amalgam fillings, as described above. In humans exposure of the nasal olfactory epithelium to Hg°, released from amalgam fillings or related to occupational inhalation, as well as an uptake of Hg 2+ in the olfactory neurons from the blood, may result in considerable concentrations of the metal in the olfactory bulbs. Maas and coworkers (1996) examined the concentration of mercury in the olfactory bulbs of 55 deceased persons and found significantly higher levels of the metal in
The Olfactory Pathway as a Route of Entry of Metals into the Brain
87
the bulbs than in the occipital lobe cortex (geom. mean 17.4 |Jig/kg w.wt. compared to 9.2 |xg/kg w.wt). However, the levels of mercury in the olfactory bulbs could not be correlated to the number of amalgam fillings. Mercury is known to alter olfaction and olfaction-related behavior in fish (Hara et al., 1976; Baatrup et al., 1990). To our knowledge the potential toxicity of mercury to the olfactory sense has not been examined in mammals. In view of the observation that Hg 2+ appears to be taken up in the olfactory neurons from the circulation and with regard to the possible oxidation of Hg° in these cells, this is an issue which needs to be explored. The ability of mercury to be taken up from the blood into the primary olfactory neurons may be a part of a more general capacity of mercury to be taken up in neurons with access to the systemic circulation and then reach the CNS via transport in these neurons. In the study in rats given 203 HgCl2 i.p. (Henriksson and Tjalve, 1998) we observed a labeling of the superior and inferior colliculi which exceeded the background labeling of the brain. We also found a labeling of the optic nerves. The superior colliculi are terminals of the axons of the retinal ganglion cells. It is possible that mercury is taken up in these cells from the circulation and then is transported in the optic nerves to the superior colliculi. The inferior colliculi are terminals of the central auditory tract. Conceivably mercury, in a similar manner as in the optic nerves, is taken up from the circulation into ganglion cells in the inner ear and then is transported to the inferior colliculi. Studies by Arvidson (1992) in rats have indicated that mercury is taken up in motoneurons from the circulation. Thus, following parenteral injection of mercuric chloride mercury deposits were observed in motoneurons of the brainstem and of the anterior horns of the spinal cord. Unilateral ligation of the hypoglossal nerve prior to the injection of the mercuric chloride prevented accumulation of mercury deposits in the ipsilateral hypoglossal nucleus. It was assumed that the mercury via the circulation reaches the neuromuscular junctions (which are situated outside the blood-brain barrier) and that the metal then, following uptake into the nerve terminals, is transported to the motoneurons in the brainstem and the spinal cord (Arvidson, 1992). Studies at our department in trout exposed to inorganic mercury via aquarial water indicate that the metal reaches the CNS via axonal transport in various water exposed sensory neurons (Rouleau et al., 1999). This applies to the olfactory neurons and in addition to neurons innervating mechanoreceptors of the lateral line organs,
88
Tjalve H & Tallkvist J
neurons innervating cutaneous sensory cells, such as tactile, pressure and nociceptive sensory cells, and neurons innervating receptor cells of taste buds in the oral mucosa. Transport along these nerves allows waterborne mercury to circumvent the blood-brain barrier and reach the central nervous system.
7. ABUNDANCE OF METALS IN THE OLFACTORY BULB In addition to mercury, there is a relative abundance of some other metals in the olfactory bulb, compared to other regions of the brain. Thus, it has been shown that the concentration of cadmium in the olfactory bulb is much higher than in the remaining brain in untreated rats (Suzuki and Arito, 1975; Clark et al., 1985). Bonilla et al. (1982) reported higher levels of manganese in the olfactory bulbs than in other brain regions in human brains sampled at autopsy. In untreated control rats Fechter et al. (2002) reported higher manganese levels in the olfactory bulbs than in other brain regions. In two strains of untreated mice Ono and Cherian (1999) found higher levels of zinc and copper in the olfactory bulbs than in several other parts of the brain. Domingo et al. (1996) reported much higher levels of aluminum in the olfactory bulbs than in other areas of the brain in untreated control rats. It is possible that the high levels of metals in the olfactory bulbs are related to metal transport in the primary olfactory neurons following uptake from the circulation. The metals may reach the unmyelinated olfactory neurons by diffusion through the walls of the fenestrated capillaries underlying the olfactory epithelium. Thus, this may be a route which can be used by several metals to circumvent the blood-brain barrier and gain access to the CNS.
8. METAL TRANSPORT INTO THE CEREBROSPINAL FLUID VIA THE OLFACTORY PATHWAY It has been shown that some drugs and other xenobiotics applied on the olfactory mucosa will penetrate into the cerebrospinal fluid (Jackson et al., 1979; Mathison et al., 1998; Ilium, 2000). Two possible routes for this passage have been considered: One is an intraaxonal transport along the olfactory neurons to the olfactory bulb followed by a diffusion from the bulb into the cerebrospinal fluid (designated "the
The Olfactory Pathway as a Route of Entry of Metals into the Brain
89
olfactory nerve pathway"); the other is a movement of molecules along the perineural space that is continuous with the subarachnoid space (designated "the olfactory epithelial pathway"). The latter pathway could explain the very rapid movement of molecules into the cerebrospinal fluid reported by some authors. The transfer of metals into the cerebrospinal fluid via the olfactory pathway is less well documented. However this phenomenon has been observed for manganese. Thus, studies in pike showed that manganese which moved along the olfactory nerve to the olfactory bulb penetrated into the cerebrospinal fluid of the surrounding meningeal sac (Tjalve et al., 1995). It was proposed that manganese diffuses into this fluid from the synaptic nerve clefts through the extracellular space of the bulb. Manganese moves at a constant rate by fast axonal transport in the long olfactory neurons to the olfactory bulbs, in which high levels of the metal are obtained. It is unlikely that manganese will reach the meningeal fluid via diffusion in the perineural space. As described above other metals such as mercury, nickel, zinc and cobalt, have been shown to accumulate in the terminal parts of the olfactory nerves in the glomeruli of the bulb and low levels will also leave the synapses in the glomeruli. It is possible that the metals in this way may diffuse in the extracellular space of the bulbs and then reach the cerebrospinal fluid, but this possibility has not been tested experimentally. Czerniawska (1970) injected colloidal gold (198Au) under the mucous membrane of the nasal olfactory region in rabbits and found a penetration of the metal into the cerebrospinal fluid surrounding the olfactory bulb. The author concluded that there is a connection between the mucous membrane of the olfactory region of the nose and the cerebrospinal fluid. However, it is not known whether the gold will be transferred via "the olfactory nerve pathway" or "the olfactory epithelial pathway" or via both these pathways. It should be noted that in the olfactory mucosa the receptor cells and the sustentacular cells form tight junctions with one another (Farbman, 1992). Therefore transfer of metals and hydrophilic or large-molecular-weight organic xenobiotics from the surface of the olfactory epithelium to the extracellular compartment of the olfactory mucosa probably occurs to a very limited extend. The transfer of such materials from the surface of the olfactory mucosa to the cerebrospinal fluid can therefore be assumed to occur mainly via uptake in the primary olfactory neurons and a transfer via "the olfactory nerve pathway".
90
Tjdlve H & Tallkvist J
9. CONCLUSIONS In this article we have reviewed literature demonstrating that the olfactory epithelium can serve as a direct pathway to the CNS, bypassing the systemic circulation and therefore also the blood-brain barrier. An important question that remains unresolved is the relative importance of the olfactory transport route to the brain in humans. In this connection models which allow extrapolations between species is of great importance (Kimbell et al., 2001). Even if the significance of the entry of toxic metals into the CNS via the olfactory pathway in humans is unknown the role of this route must be taken into account in future risk assessments of occupational metal exposure via inhalation. It is known that severe involvement of the olfactory system occurs early and frequently in patients with neurodegenerative diseases such as Alzheimer's and Parkinson's disease (Herzog and Kemper, 1980; Pearson et al., 1985; Doty, 1991; Doty et al, 1995). It is not yet known whether the preferential olfactory system pathology represents the initiation of the diseases or whether it reflects a part of the general neurodegenerative processes. However, it has been proposed that the entry of toxic metals or other neurotoxins into the CNS via the olfactory route may in part contribute to the etiology of these disorders (Roberts, 1986; Ferrera-Moyano and Barragan, 1989; Perl and Good, 1991; Zatta, 2000).
ACKNOWLEDGMENTS Our studies have been supported by the Swedish Council for Working Life and Social Research and the Foundation for Strategic Environmental Research (MISTRA).
REFERENCES Adams RG, Crabtree N. Anosmia in alkaline battery workers. Br J Ind Med 1961; 18:2162-21. Allison AC. The morphology of the olfactory system in the vertebrates. Biol Rev 1953; 28:195-244. Anderson M. Mn 2+ ions pass through Ca 2+ channels in myoepithelial cells. J Exp Biol 1979; 82:227-238. Apfelbach R, Engelhart A, Behnisch R Hagenmaier H. The olfactory system as a portal of entry for airborne polychlorinated biphenyls (PCBs) to the brain? Arch Toxicol 1998; 72:314-317. Arvidson B. Inorganic mercury is transported from muscular nerve terminals to spinal and brainstem motoneurons. Muscle and Nerve 1992; 15:1089-1094.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
91
Asano S, Eto K, Kurisaki E, Gunji H, Hiraiwa K, Sato M, Sato H, Hasuike M, Hagiwara N, Wakasa H. Acute inorganic mercury vapor inhalation poisoning. Path Int 2000; 50:169-174. Aschner M. Astrocytic functions and physiological reactions to injury: The potential to induce and/or exacerbate neuronal dysfunction — a forum position paper. 1998; 19:7-17. Aschner M, Gannon M, Kimmelberg HK. Manganese uptake and efflux in cultured astrocyes. J Neurochem 1992; 58:730-735. Baader EW. Chronic cadmium poisoning. Ind Med Surg 1952; 21:427^-30. Baatrup E, D0ving KB, Winberg S. Differential effects of mercurial compounds on the electroolfactogram (EOG) of salmon (Salmo salar L). Ecotoxicol Environ Saf 1990; 20:269-276. Baker H, Spencer RE Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 1986; 63:461^73. Bannister LH, Dodson HC. Endocytic pathways in the olfactory and vomeronasal epithelia of the mouse: Ultrastructure and uptake of tracers. Microsc Res Tech 1992; 23:128-141. Barbeau A. Manganese and extrapyramidal disorders. Neurotoxicology 1984; 5:13-36. Barceloux DG. Zinc. Clin Toxicol 1999; 37:279-292. Bench G, Carlsen TM, Grant PG, Wollett Jr JS, Martinelli RE, Lewis JL, Divine KK. Olfactory bulb uptake and determination of biotransfer factors in the California ground squirrel (Spermophilus beecheyi) exposed to manganese and cadmium in environmental habitats. Environ Sci Technol 2001; 35:270-277. Benson JM, Burt DG, Carpenter RL, Eidson AF, Hahn FF, Haley PJ, Hanson RL, Hobbs CH, Pickrell JA, Dunnick JK. Comparative inhalation toxicity of nickel sulfate to F344/N rats and B6C3F; mice exposed for 12 days. Fundam Appl Toxicol 1988; 10:164-178. Benson JM, Carpenter RL, Hahn FF, Haley PJ, Hanson RL, Hobbs CH, Pickrell JA, Dunnick JK. Comparative inhalation toxicity of nickel subsulfide to F344/N rats and B6C3F! mice exposed for 12 days. Fundam Appl Toxicol 1987; 9:251-256. Berlin M. Mercury. In: Friberg L, Nordberg GF, Vouk VB, editors. Handbook on the Toxicology of Metals. Vol II, 2nd Edition. Amsterdam-New York-Oxford: Elsevier Science Publishers BV, 1986: 387^145. Bonilla E, Salazar F, Villasmil JJ, Villalobos R. The regional distribution of manganese in the normal human brain. Neurochem Res 1982; 7:221-226. Borg-Neczak K, Tjalve H. Uptake of 203 Hg 2+ in the olfactory system in pike. Toxicol Lett 1996;84:107-112. Brenneman KA, Wong BA, Buccellato MA, Costa ER, Gross EA, Dorman DC. Direct olfactory transport of inhaled manganese (54MnCl2) to the rat brain: Toxicokinetic investigations in a unilateral nasal occlusion model. Toxcol Appl Pharmacol 2000; 169:238-248. Burd GA, Davis BJ, Macrides F, Grillo M, Margolis FL. Carnosine in primary afferents of the olfactory system: An autoradiographic and biochemical study. J Neurosci 1982; 2:244-255.
92
Tjdlve H & Tallkvist J
Charles PC, Walters E, Margolis F, Johnston RE. Mechanism of neuroinvasion of Venezuelan equine virus in the mouse. Virology 1995; 208:662-671. Cheng YS, Hansen GK, Yeh HC, Su YF, Yeh HC, Morgan KT. Deposition of ultrafine aerosols in rat nasal models. Toxicol Appl Pharmacol 1990; 106:222-233. Clark DE, Nation JR, Bourgeois AJ, Hare MF, Baker DM, Hinderberger EJ. The regional distribution of cadmium in the brains of orally exposed rats. Neurotoxicology 1985; 6:109-114. Clarkson TW. Mercury. J Am Coll Toxicol 1989; 8:1291-1295. Cyr JL, Brady ST. Molecular motors in axonal transport. Cellular and molecular biology of kinesin. Neurobiology 1992; 6:137-155. Czerniawska A. Experimental investigations on the penetration of from nasal mucous membrane into cerebrospinal fluid. Acta Otolaryngol 1970; 70:58-61. Dahl AR, Hadley WM. Nasal cavity enzymes involved in xenobiotic metabolism: Effects on the toxicity of inhalants. CRC Crit Rev Toxicol 1991; 21:345-372. de Lorenzo AJD. The olfactory neuron and the blood-brain barrier. In: Wolstenholme GF, Knight J, editors. Taste and Smell in Vertebrates. London: Churchill, 1970: 151-176. Divine KK, Lewis JJ, Grant PG, Bench G. Quantitative particle-induced X-ray emission imaging of rat olfactory epithelium applied to the permeability of rat epithelium to inhaled aluminum. Chem Res Toxicol 1999; 12:575-581. Domingo JL, Llorens J, Sanchez DJ, Gomez, M, Llobet JM, Corbella J. Age related effects of aluminum ingestion on brain aluminum accumulation and behavior in rats. Life Sci 1996;58:1387-1395. Donaldson J, McGregor D, LaBella F. Manganese neurotoxicity: A model for free radical mediated neurodegeneration? Can J Physiol Pharmacol 1982; 60:1398-1405. Donaldson J. The physiopathologic significance of manganese in brain: Its relation to schizophrenia and neurodegenerative disorders. Neurotoxicology 1987; 8:451^-62. Dorman DC, Struve MF, James AR, Marshall MW, Parkinson CU, Wong BA. Influence of particle solubility on the delivery of inhaled manganese to rat brain: Manganese sulfate and manganese tetroxide pharmacokinetics following repeated (14 d) exposure. Toxicol Appl Toxicol 2001; 170:79-87. Doty RL. Olfactory dysfunction in neurodegenerative disorders. In: Getchell TV, Bartoshuk LM, Doty RL, Snow Jr JB, editors. Smell and Taste in Health and Disease. New York: Raven P ress, 1991: 735-751. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: presymptomatic detection. Neurodegeneration 1995; 4:93-97. Drapeau P, Nachsen DA. Manganese fluxes and manganese-dependent neurotransmitter release in presynaptic nerve endings isolated from rat brain. J Physiol 1984; 3348:493-510. Ebadi M, Iversen PL, Hao R, Cerutis DR, Rojas P, Happe HK, Murrin LC, Pfeiffer RF. Expression and regulation of brain metallothionein. Neurochem Int 1995; 27:1-22. Ekstrand J, Bjorkman L, Edlund C, Sandborgh-Englund G. Toxicological aspects on the release and systemic uptake of mercury from dental amalgam. Eur J Oral Sci 1998; 106:678-686.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
93
Evans J, Hastings L. Accumulation of Cd(II) in the CNS depending on the route of administration: Intraperitoneal, intratracheal or intranasal. FundamAppl Toxicol 1992; 19:275-278. Evans JE, Miller ML, Andringa A, Hastings L. Behavioral, histological and neurochemical effects of nickel(II) on the rat olfactory system. Toxicol Appl Pharmacol 1995; 30:209-220. Farbman AI. Cell Biology of Olfaction. Cambridge: University Press, 1992. Fechter L, Johnson DL, Lynch RA. The relationship of particle size to olfactory nerve uptake of a non-soluble form of manganese into the brain. Neurotoxicology 2002; 23: 177-183. Ferrera-Moyano H, Barragan E. The olfactory system and Alzheimer's disease. Int J Neurosci 1989; 49:157-197. Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 1989;3:145-238. Frederickson CJ, Bush AI. Synaptically released zinc: Physiological functions and pathological effects. BioMetals 2001; 14:353-366. Friberg L. Health hazards in the manufacture of alkaline accumulators with special reference to chronic cadmium poisoning. Acta Med Scand 1950; Suppl 240. Friberg L, Kjellstrom T, Nordberg GF. Cadmium. In Friberg L, Nordberg GF, Vouk VB, editors. Handbook on the Toxicology of Metals, Vol II, 2nd Edition. AmsterdamNew York-Oxford: Elsevier Science Publishers BV, 1986: 130-184. Gaither LA, Eide DJ. Eukaryotic zinc transporters and their regulation. BioMetals 2001; 14:251-270. Getchell ML, Mellert TK. Olfactory mucus secretion. In: Getchell TV, Bartoshuk LM, Doty RL, Snow Jr JB, editors. Smell and Taste in Health and Disease. New York: Raven Press, 1991: 83-95. Ghantous H, Dencker L, Gabrielsson J, Danielsson BRG, Bergman K. Accumulation and turnover of metabolites of toluene and xylene in nasal mucosa and olfactory bulb in the mouse. Pharmacol Toxicol 1990; 66:87-92. Gianutsos G, Morrow GR, Morris JB. Accumulation of manganese in rat brain following intranasal administration. Fundam Appl Toxicol 1997; 67:102-105. Gibbons RA, Dixon SN, Hallis K, Russell AM, Sansom BF, Symonds HF. Manganese metabolism in cows and goats. Biochim Biophys Acta 1976; 444:1-10. Gottofrey J, Tjalve H. Axonal transport of cadmium in the olfactory nerve of the pike. Pharmacol Toxicol 1991; 69:242-252. Graham DG. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 1984; 5:83-96. Greer CA. Structural organization of the olfactory system. In: Getchell TV, Bartoshuk LM, Doty RL, Snow JB Jr, editors. Smell and Taste in Health and Disease. New York: Raven Press, 1991: 65-81. Gross WG, Kreutzberg GW. Rapid axoplasmic transport in the olfactory nerve of the pike: basic transport parameters for proteins and amino acids. Brain Res 1978; 139:65-76. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger, MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388;482-488.
94
Tjalve H & Tallkvist J
Haberly LB. Olfactory cortex. In: Shepherd GM, editor. The Synaptic Organization of the Brain. New York-Oxford: Oxford University Press, 1990: 319-345. Hahn I, Scherer PW, Mozell MM. Velocity profiles measured for airflow through a large scale model of the human nasal cavity. J Appl Physiol 1993; 75:2273-2287. Halbach S. Amalgam tooth fillings and man's mercury burden. Hum Exp Toxicol 1994; 13:496-501. Halliwell B. Manganese ions, oxidation reactions and the superoxide radical. Neurotoxicology 1984; 5:113-117. Hammerschlag R, Cyr JL, Brady ST. Axonal transport and the neuronal cytoskeleton. In: Siegel GJ, Agranoff BW, Wayne Albers R, et al., editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 5th Edition. New York: Raven Press, 1994: 545-571. Hammerschlag R, Dravid AR, Chin AY. Mechanism of axonal transport: a proposed role for calcium ions. Science 1975; 188:273-275. Hara TJ, Law YMC, Macdonald S. Effects of mercury and copper on the olfactory response in rainbow trout, Salmo gairdneri. J Fish Res Board Carr 1976; 63:1568-1573. Hastings L, Evans JE. Olfactory primary neurons as a route of entry for toxic agents into the CNS. Neurotoxicology 1991; 12:707-714. Hazell AS, Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 1997; 22:1443-1447. Hazell AS, Desjardins P, Butterworth RF. Increased expression of glyceraldehyde3-phosphate dehydrogenase in cultured astrocytes following exposure to manganese. Neurochem Int 1999; 35:11-17. Heimer L. Synaptic distribution of centripetal and centrifugal nerve fibres in the olfactory system of the rat. An experimental anatomical study. J Anal 1968; 103:413-432. Henriksson J, Tallkvist J, Tjalve H. Uptake of nickel into the brain via olfactory neurons in rats. Toxicol Lett 1997; 91:153-162. Henriksson J, Tjalve H. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats. Environ Res 1998; 77:130-140. Henriksson J, Tallkvist J, Tjalve H. Transport of manganese via the olfactory pathway in rats: dosage dependency of the uptake and sucellular distribution of the metal in the olfactory epithelium and the brain. Toxicol Appl Pharmacol 1999; 156:119-128. Henriksson J, Tjalve H. Manganese taken up into the CNS via the olfactory pathway in rats affects the astrocytes. Toxicol Sci 2000; 55:392-398. Herzog AG, Kemper TL. Amygdaloid changes in aging and dementia. Arch Neurol 1980; 37:625-629. Hidalgo J, Carrasco J. Regulation of the synthesis of brain metallothioneins. Neurotoxicology 1998; 19:661-666. Holl A. Selektivdarstellung der Riechsinneszellen des Zwergwelses Ictalurus nebulosus mit Procionfarbstoffen. Z Naturforsch 1980; 35c:526-528. Ilium L. Transport of drugs from the nasal cavity to the central nervous system. Eur J PharmSci 2000; 11:1-18. Itaya SK. Anterograde transsynaptic transport of WGA-HRP in rat olfactory pathways. Brain Res 1987; 409:205-214.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
95
Itzhaki RF. Possible factors in the etiology of Alzheimer's disease. Molec Neurobiol 1994; 9:1-13. Jackson RT, Tigges J, Arnold W. Subarachnoid space of the CNS, nasal mucosa, and lymphatic system. Arch Otolaryngol 1979; 105:180-184. Jaillardon E, Astic L, Cattarelli M, Gay B. A numerical model of the flow in a rat nasal cavity. Chem Senses 1992; 17:884. Jensen AA, Tiichsen F. Cobalt exposure and cancer risk. Crit Rev Toxicol 1990; 20:427^137. Jordan CM, Whitman RD, Harbut M. Memory deficits and industrial toxicant exposure: A comparative study of hard metal, solvent and asbestos workers. / Neurosci 1997; 90:113-128. Jo SM, Won MH, Cole TB, Jensen SM, Palmiter RB, Danscher G. Zinc enriched (ZEN) terminals in mouse olfactory bulb. Brain Res 2000; 865:227-236. Johnson RT. The pathogenesis of herpes virus encephalitis. I. Virus pathways to the nervous system of suckling mice demonstrated by fluorescent antibody staining. J Exp Med 1964; 119:343-356. Khayat A, Dencker L. Organ and cellular distribution of inhaled metallic mercury in the rat and marmost monkey (Callithrix jacchus): Influence of ethyl alcohol pretreatment. Acta Pharmacol Toxicol 1984; 55:145-152. Kimbell JS, Subramaniam RP, Gross EA, Schlosser PM, Morgan KT. Dosimetry modeling of inhaled formaldehyde: Comparisons of local flux predictions in the rat, monkey, and human nasal passages. Toxicol Sci 2001; 64:100-110. Knull HRJ, Wells WW. Axonal transport of cations in the chick optic system. Brain Res 1975;100:121-124. Kristensson K, Olsson Y. Uptake of exogeneous proteins in mouse olfactory cells. Acta Neuropathol 1971; 19:145-154. Kucharin GM. Occupational disorders of the nose and nasal sinuses in workers in an electrolytic nickel refining plant. Gig Trud Prof Zabol 1970; 14:38^4-0. Larsson P, Tjalve H. Intranasal instillation of aflatoxin B] in rats: Bioactivation in the nasal mucosa and neuronal transport to the olfactory bulb. Toxicol Sci 2000; 55:383-391. Lewis JL, Hahn FF, Dahl AR. Transport of inhaled toxicants to the central nervous system. In: Isaacson RL, Jensen KP, editors. The Vulnerable Brain and Environmental Risks, Vol 3: toxins in air and water. New York: Plenum Press, 1994: 77-103. Lindquist NG, Lyden A, Narfstrom K, Samaan H. Accumulation of taurine in the nasal mucosa and the olfactory bulb. Experientia 1983; 39:797-799. Maas C, Briick H, Heffner H-T, Schweinsberg F. Investigations on cerebral mercury from dental amalgam fillings through a direct nose-brain transport. Zentralbl Hyg 1996; 198:275-291. Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL, Palmiter RD. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 1994; 14:5844-5857. Mathison S, Nagilla R, Kompella B. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 1998; 5:415—441. Mergler D. Manganese: The controversial metal. At what levels can deleterious effects occur? Can J Neurol Sci 1996; 23:93-94.
96
Tjalve H & Tallkvist J
Miyamoto MT. Hg 2+ causes neurotoxicity at an intracellular site following entry through Na and Ca channels. Brain Res 1983; 267:375-379. Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest 1983; 48:399^410. Morgan KT, Jiang XZ, Patterson DL, Gross EA. The nasal mucociliary apparatus: correlation of structure and function in the rat. Am Rev Respir Dis 1984; 130:275-281. Narita K, Kawasaki F, Kita H. Mn and Mg influxes through Ca channels of motor nerve terminals are prevented by verapamil in frogs. Brain Res 1990; 510:289-295. Nixon RA. Slow axonal transport. Curr Opinion Cell Biol 1992; 4:8-14. Normandin L, Carrier G, Gardiner PF, Kennedy G, Hazell AS, Mergler D, Butterworth RF, Philippe S, Zayed J. Assessment of bioaccumulation, neuropathology, and neurobehavior following subchronic (90 days) inhalation in Sprague-Dawley rats exposed to manganese phosphate. Toxicol Appl Pharmacol 2002; 183:135-145. Okabe S, Hirokawa N. Axonal transport. Curr Opinion Cell Biol 1989; 1:91-97. Olsson Y, Kristensson K. Neuronal uptake of iron: somatopetal axonal transport and fate of cationized and native ferritin, and iron-dextran after intramuscular injections. Neuropathol Appl Neurobiol 1981; 7:87-95. Ono SI, Cherian MG. Regional distribution of metallothionein, zinc, and copper in the brain of different strains of rats. Biol Trace Elem Res 1999; 69:151-159. Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Nat Acad Sci USA 1996; 92:14934-14939. Pearson RCA, Esiri M, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortax in Alzheimer's disease. Proc Natl Acad Sci USA 1985; 82:4531-4534. Perl DP, Good PF. Aluminum, Alzheimer's disease and the olfactory system. Ann NY Acad Med 1991; 640:8-13. Perl DP, Good PF. Uptake of aluminum into central nervous system along nasal/olfactory pathways. Lancet 1987; 1:1028. Persson E, Henriksson J, Tjalve H. Uptake of cobalt and zinc from the nasal mucosa into the brain via olfactory pathways in rats. J Trace Elem Exp Med 1998; 11:450-451. Persson E, Larsson P, Tjalve H. Cellular activation and neuronal transport of intranasally instilled bezo(a)pyrene in the olfactory system of rats. Toxicol Lett 2002; 133:211-219. Price JL. Beyond the primary olfactory cortex: Olfactory related areas in the neocortex, thalamus and hypothalamus. Chem Senses 1985; 10:239-258. Pautler RG, Silva AC, Koretsky AP. In vivo neuronal tract tracing using manganeseenhanced magnetic resonance imaging. Magn Reson Med 1998; 40:740-748. Rehnberg BC, Schreck CB. Acute metal toxicology of olfaction in coho salmon: Behavior, receptors, and odor-metal complexation. Bull Environ Contam Toxicol 1986; 36:79-86. Roberts E. Alzheimer's disease may begin in the nose and may be caused by alumino silicates. Neurobiol Aging 1986; 7:561-567. Rose CS, Heywood PG, Costanzo RM. Olfactory impairment after chronic occupational cadmium exposure. J Occup Med 1992; 34:600-605. Rouleau C, Tjalve H, Gottofrey J, Pelletier E. Uptake, distribution and elimination of 54Mn(II) in the brown trout (Salmo trutta). Environ Toxicol Chem 1995; 14:483—490.
The Olfactory Pathway as a Route of Entry of Metals into the Brain
97
Rouleau C, Brog-Neczak K, Gottofrey J, Tjalve H. Accumulation of waterbome mercury(II) in specific areas offish brain. Environ Sci Technol 1999; 33:3384-3389. Scott JW. The olfactory bulb and central pathways. Experientia 1986; 42:223-232. Shipley MT. Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull 1985; 15:129-142. Sichak SP, Mavis RD, Finkelstein JN, Clarkson TW. An examination of the oxidation of mercury vapor by rat brain homogenate. J Biochem Toxicol 1986; 1:53-68. Sloot WN, Gramsbergen JBR Axonal transport of manganese and its relevance to selective neurotoxicity in rat basal ganglia. Brain Res 1994; 657:124-132. Spranger M, Schwab S, Desiderato S, Bonmann E, Krieger D, Fandrey J. Manganese augments nitric oxide synthesis in murine astrocytes: A new pathogenetic mechanism in manganism? Exp Neurol 1998; 149:277-283. Stewart WB. Labeling of olfactory bulb glomeruli following horseradish peroxidase lavage of the nasal cavity. Brain Res 1985; 347:200-203. Stromberg PC, Ferrante JG, Carter S. Pathology of lethal and sublethal exposure of fathead minnows, Pimephales promelas, to cadmium: A model for aquatic toxicity assessment. J Toxicol Environ Health 1983; 11:247-259. Sun TJ, Miller ML, Hastings L. Effects of inhalation of cadmium on the rat olfactory system: Behavior and morphology. Neurotoxical Teratol 1996; 18:89-98. Suzuki Y, Arito H. Cadmium content of the olfactory bulb of Cd-administered rats for a long term. Ind Health 1975; 13:77-79. Takeda A, Ohnuma M, Sawashita J, Okada S. Zinc transport in the rat olfactory system. NeurosciLett 1997; 225:69-71. Takeda A, Kodama Y. Ohnuma M, Okada S. Zinc transport from the striatum and substantia nigra. Brain Res Bull 1998; 47:103-106. Tallkvist J, Henriksson J, d'Argy R, Tjalve H. Transport and subcellular distribution of nickel in the olfactory system of pikes and rats. Toxicol Sci 1998; 43:196-203. Tallkvist J, Persson E, Henriksson J, Tjalve H. Cadmium-metallothionein interactions in the olfactory pathways of rats and pikes. Toxicol Sci 2002; 67:108-113. Tatarskaya AA. Occupational diseases of upper respiratory tract in persons employed in electrolytic nickel refining departments. Gig Trud ProfZabol 1960; 6:35-38. Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995; 692:278-282. Tjalve H, Gottofrey J, Bjorklund I. Tissue disposition of 109Cd2+ in the brown trout (Salmo trutta) studied by autoradiography and impulse counting. Toxicol Environ Chem 1986; 12:31-^5. Tjalve H, Mejare C, Borg-Neczak K. Uptake and transport of manganese in primary and secondary olfactory neurones in pike. Pharmacol Toxicol 1995; 77:23-31. Tjalve H, Henriksson J, Tallkvist J, Larsson BS, Lindquist NG. Uptake of manganese and cadmium from the nasal mucosa into the central nervous system via olfactory pathways in rats. Phamacol Toxicol 1996; 79:347-356. Tjalve H, Henriksson. Uptake of metals in the brain via olfactory pathways. Neuwtoxicology 1999; 20:181-196.
98
Tjalve H & Tallkvist J
Vallee RB, Bloom GS. Mechanisms of fast and slow axonal transport. Annu Rev Neurosci 1991;14:59-92. Vitarella D, Wong BA, Moss OR, Dorman DC. Pharmacokinetics of inhaled manganese phosphate in male Sparague-Dawley rats following subacute (14 d) exposure. Toxicol Appl Pharmacol 2000; 163:279-285. Walsh CT, Sandstead HH, Prasad AS, Newberne PM, Fraker PJ. Zinc: Health effects and research priorities for the 1990s. Environ Health Perspect 1994; 102 (suppl):5^16. Zatta P, Favarato M, Nicolini M. Deposition of aluminum in the brain tissues of rats exposed to inhalation of aluminum acetylacetonate. Neuro Report 1993; 4:1119-1122. Zatta P. Aluminum neurotoxicity: implications in neurodegenerative diseases. In: Centeno JA, Collery P, Vernet G, Finkelman RB, Gibb H, Etienne JC, editors. Metal Ions in Biology and Medicine, Vol. 6. Paris: John Libbey Eurotext, 2000: 443^146.
CHAPTER 4
Aluminum in Neurological Disorders and Systemic Chelation Therapy Theo P Kruck, Walter J Lukiw
ABSTRACT Human neurological disorders that display complex pathogeneses involve multiple etiologic factors. Aging remains the most significant risk factor for the development of any neurological disorder and this in itself suggests collective and cumulative effects over decades of life. Alzheimer's disease (AD), a common, progressive degeneration of the human brain characterized by memory loss and the deterioration of higher cognitive function, is the leading cause of acquired neurological dysfunction in our aging population. A highly intricate maze of factors appears to contribute to the development and progression of AD. Mutations and/or susceptibility polymorphisms in gene coding or control regions, traumatic head injury, previous viral infection of the brain, cerebral vascular disease, ischemia and hypoxia are factors that appear to contribute substantially to the development and/or progression of AD. In addition, numerous epidemiological studies suggest that relatively high concentrations of neurotoxic metal ions, such as copper, iron, zinc, and in particular aluminum, are important environmental factors contributing to the development and/or progression of AD neuropathology. Systemic chelation therapies dealing with the removal of these environmental metallic toxins from living brain tissues therefore represent one reasonable and attractive strategy to alleviate the development and/or progression of neurological disorders which are linked to metal ion intoxication. The following chapter will briefly review the postulated role of aluminum in neurological disease, focusing on AD, and the potential application of systemic aluminum chelators such as desferrioxamine (DFO) and Feralex-G in the treatment and amelioration of this devastating disorder of the human mind. 99
100
Kruck TP & Lukiw WJ Keywords: Aluminum; Alzheimer's disease; amyloid-(3; chelation therapy; desferoxamine; Feralex-G; molecular shuttle chelation.
1. INTRODUCTION Human neurological disorders display complex pathogeneses involving multiple etiologic factors. Alzheimer's disease (AD), a common, progressive degeneration of the human brain characterized by memory loss and the deterioration of higher cognitive function, is the leading cause of acquired neurological dysfunction in our aging population. Aging remains the most significant risk factor for the development of neurological dysfunction and this, in itself, suggests collective and cumulative effects over decades of life. A highly intricate maze of factors appears to contribute to the development and progression of neurological dysfunction and neural degeneration in AD. Mutations and/or susceptibility polymorphisms in gene coding or control regions, traumatic head injury, cerebrovascular disease, ischemia, and hypoxia are factors that may contribute substantially to the development and/or progression of AD (Terry and Katzman, 1983; Smith et al., 2000; Bazan and Lukiw, 2002). In addition, numerous epidemiological studies suggest that di- and tri-valent neurotoxic metal ions, such as copper, iron, zinc, and in particular aluminum, are important environmental factors contributing to the development and/or progression of AD neuropathology (Crapper McLachlan et al, 1991; Hollosi et al, 1994; Cuajungco et al., 2000; Cherny et al., 2000; Exley and Korchazhkina, 2001; Lukiw, 2001; Carpenter, 2001). Systemic chelation therapies dealing with the removal of these environmental toxins from living brain tissues, therefore, represent a reasonable strategy to alleviate the development and/or progression of neurological disorders such as AD. This chapter will briefly review the postulated role of aluminum in neurological disease, focusing on AD, and the potential application of systemic aluminum chelators, such as desferoxamine (DFO) and Feralex-G, in the treatment and/or amelioration of this devastating disorder of the human brain.
2. METAL NEUROTOXICITY AND ALZHEIMER'S DISEASE Unique to the more evolutionarily recent structures of the human neocortex, AD represents a progressive degeneration of the brain's synaptic circuitry culminating in cognitive dysfunction. Classically, two argyrophilic
Aluminum Chelation in Alzheimer's Disease
101
brain lesions, neurofibrillary tangles (NFTs) and amyloid-beta (A3) peptides have been correlated with AD development, progression, and severity (Terry and Katzman, 1983; Uylings and de Brabander, 2002). NFTs are composed of hyperphosphorylated bundles of microtubule-associated tau protein; A(3 peptides are derived from nonhomeostatic beta- and gammaO-7) secretase cleavage of the membrane spanning gylcoprotein amyloid-beta protein precursor (ApJPP). Importantly, the integral membrane proteins presenilin-1 and -2 (PS1 and PS2) appear to have a determining role in the generation of A3 peptides from A(3PP. Neocortical densities and the degree of aggregation of NFTs, in particular A(3 peptides, are correlated with neurotoxic mechanisms that culminate in brain cell dysfunction and death. Normal neural cell functions are also directly compromised via A3 peptide-mediated microglial activation. Release from activated microglia of toxic cytokines, such as interleukin-l(3, and microglia-associated elevations of reactive oxygen species (ROS), such as OH-, 0 2 -, and H 2 0 2 , and other oxidative disturbances appear to be central to the development and propagation of AD etiopathology (Joshi, 1991; Vyas and Duffy, 1995; Lukiw and McLachlan, 1995; Smith et al, 2000; Lukiw and Bazan, 2000; Lukiw, 2001; McGeer and McGeer, 2001). In particular, highly condensed A3 peptides, which form the senile plaque, are thought to lie at the core of an accelerated brain-specific inflammatory response in the AD brain (Nilsson et al., 1998; Kurihara and Pardridge, 2000; Lukiw and Bazan, 2000; Kontush, 2001; McGeer and McGeer, 2001). NFT formation and, to an even greater extent, amyloidosis, A3 processing, crosslinking, aggregation, and stabilization have been associated with elevated brain copper (Atwood et al., 1998; Multhaup et al., 1998; Miura et al., 2000; Zou and Sugimoto, 2000; Regland et al., 2001; Kontush, 2001), iron (Bodovitz et al., 1995; Cuajungco et al., 2000; Rottkamp et al., 2001), zinc (Huang et al., 1997, 2000; Miura et al., 2000; Yang et al, 2000; Regland et al., 2001), and in particular aluminum (Crapper et al., 1980; Lukiw et al., 1987, 1989, 1989a, 1992; Vyas and Duffy, 1995; Murayama et al., 1999; Lukiw, 2001; Hamai et al., 2001; Szutowicz, 2001; Carpenter, 2001; Strong, 2001; Perl et al., 2001; Rondeau and Commenges, 2001; Savory et al., 2001; Kiss and Hollosi, 2001; Shin, 2001; Exley and Korchazhkina, 2001; Campbell et al., 2002; Pratico et al., 2002). Notably, the neurotoxicity of aggregated NFTs and A3 peptides may be modulated by the nonphysiological actions of these metals through elevations in the intercellular concentrations of ROS which, in turn, drive pathological
102
Kruck TP & Lukiw WJ
responses at the plasma and nuclear membrane, as well as at the extracellular, intracellular, and genetic levels. Apart from the role of PS1 and PS2 in facilitating the processing of AfSPP into A|3, their roles in moderating metal-mediated neurotoxicity in neurodegenerative disease are not known.
3. ALUMINUM AND ALZHEIMER'S DISEASE Aluminum has been repeatedly associated with the etiopathology of several neurological disorders, including AD (reviewed by Crapper et al., 1980; Kruck and McLachlan, 1989; Joshi, 1991; Lukiw, 2001; Hamai et al., 2001; Carpenter, 2001; Szutowicz, 2001; Rondeau and Commenges, 2001; Pratico et al., 2002; Kruck et al., 2002, 2002a). Once aluminum has bypassed important epithelial, gastrointestinal, physiological, and blood-brain barriers, this environmentally abundant trivalent neurotoxin has been shown to adversely affect the physiological, intracellular, neurochemical, and genetic integrity of mammalian nervous tissue. Compartmentalization of aluminum or localized accumulation of a critical mass of metabolic errors resulting from this neurotoxin, rather than a single intoxicating event, superimposed over a time course of aging (typically for many decades) may be essential to collectively precipitate neurological diseases, such as AD (Joshi, 1991; Lukiw and McLachlan, 1995; Lukiw, 2001; Kruck et al., 2002). Apart from its strong effect on the processing, crosslinking, aggregation, and stabilization of NFT and A(3, aluminum may have a particular and focused attraction for the genetic material of brain cells; in fact, one recent review summarizes the deleterious effects of aluminum on the structure and function of neural genetic material from 27 independent international laboratories using 45 different bioanalytical and biophysical methods (Lukiw, 2001).
4. SYSTEMIC CHELATION THERAPY FOR PHYSIOLOGICALLY BOUND NEUROTOXIC METALS Recent clinical trials in patients showing neurological symptoms, animal and neurochemical models involving chelation therapy for aluminum, copper, iron, and zinc overload cases using l-n-butyl-2-methyl-3hydroxypyridin-4-one (HNBP; Bondy et al., 1998), the alpha-ketohydroxypyridine chelator l,2-dimethyl-3-hydroxypyrid-4-one (HDDP; L1JNN/
103
Aluminum Chelation in Alzheimer's Disease
OH O
O
OH O
O
OH O
NH2(CH2)5N-C(CH2)2CNH(CH2)5N-C(CH2)2CNH(CH2)5N-C-CH3 Fig. 1. Desferoxamine.
BAN: deferiprone; Kontoghiorghes, 1995; Blanusa et al., 2000; Yokel, 2002), penicillamine (McDonald and Lake, 1995; Cherny et al., 2000), clioquinol (Regland et al., 2001; Gouras and Beal, 2001), trientine, bathophenanthroline and bathocuproine (Cherny et al., 2000), various pyridyl donors (Caravan et al., 1997), DFO (Fig. 1; Crapper McLachlan et al., 1991; Ye and Connor, 1999; Cherny et al., 2000), and [1,2-dimethyl3-hydroxypyrid-4-one + DFO together] (Blanusa et al., 2000) have demonstrated varying degrees of pharmacological success (Gouras and Beal, 2001; Yokel, 2002). Those published studies involving copper, iron, and zinc chelation will not be considered further here.
5. POTENTIAL OF SYSTEMIC ALUMINUM CHELATION THERAPY In one 256-day distribution and retention study in rats receiving intravenous infusions of aluminum-transferrin or aluminum-citrate containing 26-aluminum at concentrations which approximated physiological conditions, approximately 0.005% of the 26-aluminum entered the brain and repeated DFO treatments were shown to accelerate the reduction of brain aluminum (Yokel et al., 2001). In one 24-month clinical trial study wherein the aluminum chelating agent DFO was administered to 25 patients with advanced AD and compared to a 23-member control group, a statistically significant difference in the rate of mental deterioration between the DFO-treated and untreated groups was found. Based upon assessment of activities of daily living, and employing a battery of standardized clinical tests and videotaped measures of activities to assess the effects of DFO, the average rate of mental decline was half as rapid for the DFO-treated group as for the control group that received oral lecithin as placebo or no drug treatment (Crapper McLachlan et al., 1991; Kruck et al., 2002). In another study, post-mortem brain aluminum measurements also showed that, in 21 neocortical regions of three controls and three
104
Kruck TP & Lukiw WJ
DFO-treated, age-matched AD patients, whole tissue aluminum content was reduced from mean values of 4.09 (xg/gm to 2.69 |Jig/gm dry weight of cerebral gray matter, respectively (Kruck et al., 2002, 2002a). In addition, analysis of small cortical blood vessels excised from areas affected by AD pathology showed a significant reduction in aluminum content between the control and DFO-treated group, from a mean value of 10.5 |JLg/gm to 5 |xg/gm, respectively. These preliminary data, therefore, suggest that DFO treatment in AD reduces total neocortical aluminum concentrations to near control values. This reduction appears to be associated with a slowing down of the clinical progression of AD and an improvement in the quality of life for the AD patient (Crapper McLachlan et al., 1991; McLachlan et al., 1993; Kruck et al, 2002a). These preliminary studies indicate that aluminum chelation therapy may be a rational route for the treatment of AD.
6. EXPERIMENTAL REMOVAL OF ALUMINUM FROM NUCLEI TREATED WITH ALUMINUM LACTATE: CONCEPT OF MOLECULAR SHUTTLE CHELATION The hypothesis that known aluminum chelators in tandem combination might be more efficient than singly administered chelators in removing aluminum from physiological systems has been tested in human brain nuclei. Such chelation of aluminum for potential neurobiological applications has been investigated using a newly developed technique, which we have called "molecular shuttle chelation" (Kruck et al., 1990, 2002, 2002a). In this in vitro technique, chelating agents with a high affinity for aluminum were employed in tandem combination with DFO for the removal of aluminum from normal human neocortical nuclei that were preincubated with aluminum lactate (Table 1). These experiments were carried out to examine the reversibility of aluminum binding to human neocortical nuclei in vitro, and to more closely examine the high affinity of the aluminum cation for DNA containing structures of human neocortical nuclei (Lukiw et al., 1989, 1989a; Hamai et al., 2001). Briefly, aluminum, in the form of a freshly prepared aluminum lactate solution, was added to a suspension of nuclei and 1,895 ng of aluminum cation was added for each 150 |xg of Deoxyribonucleic acid (DNA), a concentration which approximates nuclear heterochromatin or Brodman
Aluminum
Chelation in Alzheimer's
Disease
105
Table 1. Molecular shuttle chelation.
Chelation Method
Al
Li
CIT
ASC
3
— 3 30 3 30 -
— 3 30 3 30
30 3 30 -
DFO
A
B
1
99
1 10 10 1 1 10 10 1 1 10 10
99 86 89 87 88 82 86 79 80 87 83
— 84 85 79 80 75 75 85 81
Al = aluminum, ASC = ascorbate, CIT = citrate, DFO = desferrioxamine, Li = lithium.
A22 dinucleosome aluminum levels in the AD brain (Lukiw et al., 1987, 1992; Lukiw and McLachlan, 1995; Lukiw, 2001). Several chelators were employed, either by themselves or in tandem combination, in an attempt to remove aluminum which had bound to the nuclear compartment. In each case, DFO was used as the ultimate aluminum acceptor. After preincubation with aluminum, two methods were used to treat nuclei with chelating agents: (A) Nuclei with aluminum were incubated for 18 hours at zero to 4°C followed by incubation with prechelators for 18 hours at zero to 4 °C. This was followed by application of DFO for three hours at zero to 4°C followed by centrifugation at 16,000 G av for 30 minutes, and by electrothermal atomic absorption spectroscopic (EAAS) analysis of high-speed supernatants and pellets. (B) Nuclei with aluminum were incubated for 18 hours at zero to 4°C followed by incubation with prechelators and DFO for 18 hours at zero to 4°C. This was followed by centrifugation at 16,000 G av for 30 minutes followed by EAAS analysis of high-speed supernatants and pellets.
106
Kruck TP & Lukiw WJ
A summary of some preliminary experiments using the above methods is shown in Table 1 (Kruck et al., 2002). The numbers under columns A or B represent the mean of three to five separate experiments. Note that the vast majority of the added aluminum (75% to 99%) remains bound to the nuclear compartment and is inaccessible to the chelating agents used in this in vitro test system. This emphasizes the concept that once aluminum has accessed brain-specific compartments containing electron-rich structures, such as the genetic material, it tends to remain there and is highly refractory to removal by systemic chelation (Lukiw et al., 1992; Lukiw, 2001; Yokel et al., 2001). Also, note that method B (prechelators and DFO incubated together) had a slightly higher chelation efficiency than was observed with method A. It is also apparent in this in vitro system that combinations of ascorbate (ASC) and DFO combinations using method B showed the most promise for therapeutic removal of aluminum bound to nuclear ligands. Using molar ratios of ASC to DFO of three to one, for example, 25% of nuclear bound aluminum could be removed in vitro using molecular shuttle chelation. The enhanced chelation efficiency using the combination of ASC with DFO is especially interesting, since co-administration of ASC with DFO greatly enhances the excretion of iron complexes in vivo in patients with chronic iron storage disease (Kruck et al., 2002, unpublished observations). In the latter case, ASC may reduce biologically bound iron (Fe3+) to Fe 2+ , thereby changing the affinity for its biological ligands and allowing its dissociation followed by DFO chelation. However, since aluminum cannot be reduced by physiological oxido-reductive processes, the enhancement of aluminum removal in the simultaneous presence of ASC with DFO may follow an alternate mechanism and is probably due to the greater accessibility to nuclear bound aluminum by ASC (MW= 176.12) when compared to DFO (MW = 560.71). It is suggested that the nuclear bound aluminum is initially chelated by ASC at its binding site and subsequently transported, or "shuttled" to an extra nuclear matrix compartment where DFO can competitively remove the aluminum, thereby liberating free ASC that can re-enter the nuclear matrix and start the cycle again. Hence, the concept of molecular shuttle chelation. Even though nuclear bound aluminum is particularly refractory to removal, the application of this novel chelation technique might be useful in the treatment of human diseases, such as AD, where aluminum
Aluminum Chelation in Alzheimer's Disease
107
accumulates on DNA containing structures of the nucleus (reviewed by Lukiw, 2001; Kruck et al., 2002, 2002a).
7. EXPERIMENTAL REMOVAL OF ALUMINUM FROM HYPERPHOSPHORYLATED PAIRED HELICAL FILAMENT-TAU PROTEIN Paired helical filaments (PHFs), forming in part the NFT, form an essential part of the AD pathology. These structures are formed from hyperphosphorylated PHF-tau protein. Utilizing a specific antibody against hyperphosphorylated PHF-tau and DFO to chelate aluminum in hippocampal AD brain sections, it was shown that aluminum removal released antigenic sites revealed by specific antibody staining of hyperphosphorylated PHFtau. It was further demonstrated that aluminum binding was phosphorylation state-dependent and its action was cumulative. It should be noted that in order for DFO to react with physiologically bound aluminum, the preparations had to be autoclave-treated. Furthermore, PHF-tau aggregation by A1C13 has been shown in vitro (Murayama et al., 1999). Phosphorylation state-dependent direct aluminum PHF-tau interaction provides strong evidence implicating aluminum ions in the stabilization or generation of the PHF part of the NFTs. Together, the co-localization of aluminum in NFTs and in the nuclear compartment, both constituting critical sites of toxic challenge to cell survival, supports the idea that aluminum removal from these sites might mitigate or even revert some of the toxic effects. At the same time, it points out the difficulty in finding a chelator and a chelation treatment regimen that removes aluminum from both specific and critical subcellular sites.
8. SYNTHESIS OF FERALEX-G: A NOVEL ALUMINUM/IRON CHELATING COMPOUND Recognizing the need for having available for use as a medicine an in vivo applicable Al 3 + /Fe 3 + chelation compound for treatment of toxic aluminum overload conditions, a novel chelation compound, 2-deoxy-2(N-carbamoylmethyl-[N'-2'-methyl-3'- hydroxypyrid-4'-one] )-D-glucopyranose (Feralex-G), was designed and subsequently synthesized from
108
Kruck TP & Lukiw WJ
readily available and naturally occurring nontoxic products, namely, glucosamine, glycine, and maltol. First, maltol was chemically linked to glycine via a highly efficient aminolysis reaction resulting in the intermediate product l-carboxymethyl-3-hydroxy-2-methylpyrid-4-one, also named "TPAK-G". TPAK-G was then subsequently joined to glucosamine via a di-cyclo-hexyl-carbodiimide-promoted peptide coupling method to produce Feralex-G, which is the desired end product. This product was subjected to physical and chemical analysis; nuclear magnetic resonance (NMR) analysis permitted assignment of resonant frequencies for all covalently attached hydrogen atoms, which are consistent with the proposed molecular structure. Analysis by electron spray ionization mass spectroscopy yielded the expected molecular mass of 344 (Kruck and Burrow, 2002; Kruck et al., 2002). The stoichiometric formula is given in Fig. 2.
9. FERALEX-G IN VITRO CHELATION STUDIES To test Fe 3+ and Al 3+ binding by Feralex-G, proton displacement analysis was performed. This analytical pH titration technique is based on earlier work by Kruck and Sarkar (1973). Briefly, the maltol moiety of the
OH
Fig. 2. Feralex-G.
OH
Aluminum Chelation in Alzheimer's Disease
109
Feralex-G molecule (Fig. 2) carries a high pH dissociable proton, part of the 3'-hydroxy group in maltol, which can be used to study metal complex formation. Al 3+ and Fe 3+ both bind to the maltol group by coordination with the oxygen of the 4' keto group and the oxygen of the 3' hydroxy group, thus displacing the proton from the 3' hydroxy group as a result of bond formation. This proton displacement can be measured by pH base titration analysis and is related to co-ordination bond formation. Applying this proton displacement analysis yielded three Feralex-G molecules bound to one central Al 3+ or Fe 3+ ion over the measurable pH range of three to 10.5. Since the Fe 3+ maltol complexes are colored (red to purple) the observation range can be extended beyond the pH range. On lowering the pH, colored Fe 3+ maltol complexes persist down to pH = 1 and below (fading of color). Since Al 3+ maltol complexes do not show light absorption in the visible range, no conclusion can be inferred beyond the lower measurable, instrumental pH limit (Kruck and Burrow, 2002).
10. ALUMINUM REMOVAL FROM HYPERPHOSPHORYLATED PHF-TAU IN HUMAN HIPPOCAMPAL BRAIN SECTIONS The experimental system to show direct Al3+-PHF-tau interaction, as developed by Murayama et al. (1999), was used to compare the efficiency of Feralex-G in removing hippocampal PHF-tau bound Al 3+ , which is considered to be involved in the pathogenic process. The experiment using DFO to remove PHF-tau bound Al 3+ was repeated with comparable molar concentrations of Feralex-G. It became evident that Feralex-G was a stronger chelator than DFO, since it removed Al 3+ at 37 °C compared to DFO, which required autoclave heating to achieve Al 3+ removal (Shin and Kruck, submitted, 2002). This tight Al 3+ binding to PHF-tau, which is considered a prime determinant of the AD pathology and the relatively low efficiency of DFO to effect Al 3+ removal in the in vitro study, might explain why, in the human clinical trial subjecting AD patients to DFO chelation therapy, two years are needed for treatment to become effective (Crapper McLachlan et al., 1991). Therefore, Feralex-G might prove, in the future, to be more effective than DFO for systemic aluminum chelation therapy in the treatment of AD patients, and shows promise as a component of the molecular shuttle chelation strategy.
110
Kruck TP & Lukiw WJ
11. COMPLICATIONS The development of novel, systemic, and orally effective chelators with increased Al selectivity is a highly desired goal of pharmacology. However, the design of aluminum-selective chelators is a difficult challenge due to the affinity of these compounds for iron, copper, magnesium, zinc, and other essential trace metals. Replacement therapy with these latter essential metal ion co-factors may be a necessary adjunct to any current systemic aluminum chelation therapy. For example, the bidentate 3-hydroxypyridine-4-ones have been shown to increase urinary excretion of aluminum in rabbits and rats, but have toxicities comparable to or greater than DFO (Yokel, 1994; Yokel et al., 1996). This suggests that they also have an effect in chelating other essential trace metals. Alternatively, these compounds may have differential access to compartmentally restricted toxic Al 3+ or Fe 3+ deposits. Molecular shuttle chelation strategies may provide another reasonable approach using recently designed aluminum chelators, such as Feralex-G. This approach requires further study. To prevent the development of anemic conditions through chelation-induced iron elimination in the clinical DFO treatment trial involving AD patients (Crapper McLachlan et al, 1991), treatment protocols were designed to allow intermittent treatment and/or no treatment periods (three days of DFO followed by one day without drug, then by two days of DFO followed by one day without drug). In addition, dietary iron was supplemented to replenish the body's physiological iron requirements. In this study, over the two-year treatment period, no iron deficiency was detected. Iron supplementation on no-drug days was considered; however, in this case, no additional iron supplement was required. In conclusion, differential chelation combined with molecular shuttle chelation and biologically essential trace metal replacement (such as iron replacement) are components to be considered in designing chelation compounds for metal toxicity treatments. Further studies will show whether Feralex-G will be useful as a primary chelator in conjunction with, or without, molecular shuttle chelators.
12. SUMMARY Neurological disorders represent graded disturbances in rational thought, cognition, emotion and creativity. Due partly to the demographics of our
Aluminum Chelation in Alzheimer's Disease
111
aging population, the number of cases of human neurological dysfunction is rising rapidly and, without treatment, will overwhelm our healthcare system and ability to adequately care for afflicted people. There is currently no cure for any human neurological disorder, including Alzheimer's disease (AD), which represents the single most prevalent form of senile dementia. Human neurological disorders involve highly varied etiopathologies. Besides aging, an intricate maze of factors appears to contribute to the development and progression of neurological dysfunctions, such as AD, and molecular genetic evidence indicates considerable etiopathologic heterogeneity in the predisposition to AD. While specific genotypes are associated with different relative risks and age of onset distributions for AD etiopathology, genetic variation also influences several aspects of clinical AD phenotype, such as severity, symptomatology, and duration. Environmental metal toxins are strongly implicated in the onset of the most common form of AD, which is idiopathic and of unknown origin. The use of metal-specific chelators to reverse metalinduced neurological deficits has been described; compounds such as DFO and Feralex-G hold promise in those instances where aluminumtriggered neurological dysfunctions are indicated.
ACKNOWLEDGMENTS The authors thank Dr. Hilary Thompson, Department of Ophthalmology, for statistical analysis and Vittorio Colangelo, Carla Cline, Carole Lachney, and Aileen Pogue for expert technical assistance; Dr. Moire Percy for helpful suggestions and critically editing the manuscript. This work was supported, in part, by the United States Public Health Service grant AG 18031 (WJL) from the National Institute on Aging, National Institutes of Health, Bethesda, Maryland, and by a grant from the Ear, Eye, Nose and Throat Foundation of the State of Louisiana.
REFERENCES Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273:12817-12826. Bazan NG, Lukiw WJ. COX-2 and PS1 gene expression induced by IL-lbeta and Abeta 42 is potentiated by hypoxia in primary human neural cells. J Biol Chem 2002; 277:30359-30367.
112
Kruck TP & Lukiw WJ
Blanusa M, Prester L, Vamai VM, Pavlovic D, Kostial K, Jones MM, Singh PK. Chelation of aluminum by combining DFO and LI in rats. Toxicology 2000; 147:151-156. Bodovitz S, Falduto MT, Frail DE, Klein WL. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J Neurochem 1995; 64:307-315. Bondy SC, Tseng H, Orvig C. Active oxygen species formation in synaptosomes exposed to an aluminum chelator. Neurotoxicology Teratology 1998; 20:317-320. Campbell A, Yang EY, Tsai-Turton M, Bondy SC. Pro-inflammatory effects of aluminum in human glioblastoma cells. Brain Res 2002; 933:60-65. Caravan P, Rettig SJ, Orvig C. Effect of pyridyl donors in the chelation of aluminum(III), gallium(III), and indium(III). Inorganic Chem 1997; 36:1306-1315. Carpenter DO. Effects of metals on the nervous system of humans and animals. Int J Occupational Med Environmental Health 2001; 14:209-218. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Chelation and intercalation: Complementary properties in a compound for the treatment of Alzheimer's disease. J Structural Biol 2000; 130:209-216. Crapper McLachlan DR, Dalton AJ, Kruck TPA, Bell M, Smith W, Kalow W, Andrews DE Effect of desferoxamine on the clinical progress of Alzheimer's disease. Lancet 1991;337:1304-1307. Crapper DR, Quittkat S, Krishnan DS, Dalton AJ, De Boni U. Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy and experimental aluminum encephalopathy. Acta Neuropathol (Berlin) 1980; 50:19-24. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann New York Acad Sci 2000; 920:292-304. Exley C, Korchazhkina O. The association of aluminum and p-amyloid in Alzheimer's disease. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 421-433. Gouras GK, Beal MR Metal chelator decreases Alzheimer beta-amyloid plaques. Neuron 2001;30:665-676. Hamai D, Bondy SC, Becaria A, Campbell A. The chemistry of transition metals in relation to their potential role in neurodegenerative processes. Curr Topics Med Chem 2001; 1:541-551. Hollosi M, Shen ZM, Perczel A, Fasman GD. Stable intrachain and interchain complexes of neurofilament peptides: A putative link between Al 3+ and Alzheimer's disease. Proc Natl Acad Sc USA 1994; 91:4902-4906. Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, Bush AI. Zinc-induced Alzheimer's Abetal-40 aggregation is mediated by conformational factors. J Biol Chem 1997; 272:26464-26470. Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, beta-amyloid protein and zinc. J Nutrition 2000;130:S1488-S1492. Joshi JG. Neurochemical hypothesis: Participation by aluminum in producing critical mass of co-localized errors in brain leads to neurological disease. Comparative Biochem Physiol 1991; 100:103-105.
Aluminum Chelation in Alzheimer's Disease
113
Kiss T, Hollosi M. The interaction of aluminum with peptides and proteins. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 361-392. Kontoghiorghes GJ. New concepts of iron and aluminum chelation therapy with oral LI (deferiprone) and other chelators. Analyst 1995; 120:845-851. Kontush A. Amyloid-beta: An antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radicals Biol Med 2001; 31:1120-1121. Kontush A. Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. Cell Mol Neurobiol 2001a; 21:299-315. Kruck TPA, Serrao C, Rytwinski PJ, McLachlan DRC, Lukiw WJ. Molecular shuttle chelation: Studies on desferrioxamine- and Feralex-based chelation of aluminum for neurobiological applications. 2002, in preparation. Kruck TPA, Krischnan SS, McLachlan DRC, Percy ME. Intramuscular injection of desferrioxamine lowers brain aluminum concentration in patients with Alzheimer's disease. In: Khassanova L, Collery Ph, Maymord I, Khassanova Z, Etienne JC, editors. Metal ions in Biology and Medicine, Vol 7. Paris: John Libbey Eurotext, 2002a: 189-192. Kruck TP, Burrow TE. Synthesis of Feralex: a novel aluminum/iron chelating compound. J Inorganic Biochem 2002b; 88:19-24. Kruck TP, Fisher EA, McLachlan DR. Suppression of desferrioxamine mesylate treatmentinduced side effects by co-administration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ion-specific chelation. Clin Pharmacol Therapy 1990; 48:439^146. Kruck TP, Lukiw WJ, Serrao C, McLachlan DR. Molecular shuttle chelation: Studies on desferrioxamine-based chelation of aluminum for neurobiological application. Neurobiol Aging 1990a; 11:342. Kruck TP, McLachlan DR. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: Ion-specific chelation. Progress Clin Biol Res 1989; 317:1155-1167. Kruck TPA, Sarkar B. Equilibria of the simultaneously existing multiple species in the copper (II)-L-histidine system. Canadian J Chem 1973; 21:3549. Kurihara A, Pardridge WM. Bioconjugated peptide radiopharmaceuticals for brain amyloid imaging: (111) In chelation, conjugation to poly (ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjugational Chem 2000; 11:380-386. Lukiw WJ. Aluminum and gene transcription in the mammalian central nervous system. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 47-68. Lukiw WJ, Bazan NG. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res 2000; 25:1173-1184. Lukiw WJ, McLachlan DRC. Neurotoxicology of aluminum. In: Chang L, Dyer R, Dekker M, editors. Handbook of Neurotoxicology II: Effects and Mechanisms. New York: Marcel Dekker, 1995: 105-142. Lukiw WJ, Bergeron C, Wong L, McLachlan DRC. Nuclear compartmentalization of aluminum in Alzheimer's disease. Neurobiol Aging 1992; 13:115-121.
114
Kruck TP & Lukiw WJ
Lukiw WJ, Kruck TPA, McLachlan DR. Linker histone-DNA complexes: Enhanced stability in the presence of aluminum lactate and implications for Alzheimer's disease. Fed Eur Biol Soc (FEBS) Lett 1989; 253:59-62. Lukiw WJ, Kruck TPA, Crapper McLachlan DR. Aluminum, intracellular liganding and the nuclei. Lancet 1989a; i:781-782. Lukiw WJ, Kruck TP, McLachlan DR. Alterations in human linker histone-DNA binding in the presence of aluminum salts in vitro and in Alzheimer's disease. Neurotoxicology 1987; 8:291-302. McDonald LV, Lake CR. Psychosis in an adolescent patient with Wilson's disease: Effects of chelation therapy. Psychosomatic Med 1995; 57:202-204. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging 2001; 22:799-809. McLachlan DR, Smith WL, Kruck TP. Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monitoring 1993; 15:602-607. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochem 2000; 39:7024-7031. Monteagudo FS, Cassidy MJ, Folb PI. Recent developments in aluminum toxicology. Medical Toxicology and Adverse Drug Exposure 1989; 4:1-16. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, Masters CL, Beyreuther K. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochem 1998; 37:7224-7230. Murayama H, Shin RW, Higuchi J, Shibuya S, Muramoto T, Kitamoto T. Interaction of aluminum with PHF-tau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Amer J Pathol 1999; 155: 877-885. Nilsson L, Rogers J, Potter H. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. Frontiers of Bioscience 1998; 3:434-436. Perl DP. The association of aluminum and neurofibrillary degeneration in Alzheimer's disease: A personal perspective. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 133-146. Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VM. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J 2002; 16:1138-1140. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG. Treatment of Alzheimer's disease with clioquinol. Dementia, Geriatrics and Cognitive Disorders 2001; 12:408^-14. Rondeau V, Commenges D. The epidemiology of aluminum and Alzheimer's disease. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 37-57.
Aluminum Chelation in Alzheimer's Disease
115
Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA. Redox-active iron mediates amyloid-beta toxicity. Free Radicals Biol Med 2001; 30:447^150. Savory J, Ghribi O, Forbes MS, Herman MM. The rabbit model system for studies of aluminum-induced neurofibrillary degeneration: Relevance to human neurodegenerative disorders. In: Exley C, editor. Aluminum and Alzheimer's Disease: the Science that Sescribes the Link. New York: Elsevier Press, 2001: 203-219. Shin R.-W. Aluminum, tau and neurofibrillary degeneration. In: Exley C, editor. Aluminum and Alzheimer's Sisease: The Science that Describes the Link. New York: Elsevier Press, 2001: 411—420. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer's disease. Antioxidants and Redox Signaling 2000; 2:413-420. Strong MJ. Aluminum as an experimental neurointoxicant: The neuropathology and neurochemistry. In: Exley C, editor. Aluminum and Alzheimer's Disease: The Science that Describes the Link. New York: Elsevier Press, 2001: 189-202. Szutowicz A. Aluminum, NO, and nerve growth factor neurotoxicity in cholinergic neurons. J Neuroscience Res 2001; 66:1009-1018. Terry RD, Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 1983; 14:497-506. Uylings HB, de Brabander JM. Neuronal changes in normal human aging and Alzheimer's disease. Brain Cognition 2002; 49:268-276. Vyas SB, Duffy LK. Stabilization of secondary structure of Alzheimer beta-protein by aluminum(III) ions and D-Asp substitutions. Biochem Biophys Res Comm 1995; 206:718-723. Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE. Examining the zinc binding site of the amyloid-beta peptide. Eur J Biochem 2000; 267:6692-6698. Ye Z, Connor JR. Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells. Biochem Biophys Res Comm 1999; 264:709-713. Yokel RA. Aluminum chelation principles and recent advances. In: Zatta P, editor. Coordination Chemistry Reviews. Recent Topics in Aluminium Chemistry 2002; 228:97-113. Yokel RA, Rhineheimer SS, Sharma P, Elmore D, McNamara PJ. Entry, half-life, and desferrioxamine-accelerated clearance of brain aluminum after a single (26) Al exposure. Toxicol Sci 2001; 64:77-82. Yokel RA, Ackrill P, Burgess E, Day JP, Domingo JL, Flaten TP, Savory J. Prevention and treatment of aluminum toxicity including chelation therapy: Status and research needs. J Toxicol Environ Health 1996; 48:667-683. Yokel RA. Aluminum chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J Toxicol Environ Health 1994; 41:131-174. Zou J, Sugimoto N. Complexation of peptide with Cu2+ responsible for inducing and enhancing the formation of alpha-helix conformation. Biometals 2000; 13:349-359.
This page is intentionally left blank
CHAPTER 5
Aluminum and Central Nervous System Morphology in Hemodialysis Erich Reusche
ABSTRACT Aluminum is a well-known neurotoxicant that causes encephalopathies in long-term hemodialysis and discussed in Alzheimer's disease for decades. Using silver staining variants, we were able to demonstrate the morphology of Alzheimer's disease and, for the first time, the characteristic morphological changes in hemodialysis patients. This so-called dialysis-associated encephalopathy is, nowadays, apparently caused by long-term ingestion of aluminum-containing drugs (up to 2.5 kg of "pure" aluminum). It comprises pathognomonic aluminum-induced argyrophilic, proteinaceous, lysosomalderived inclusions in the cytoplasm of choroid plexus, gray matter glia, and neurons of the cortex and brainstem. Statistically, there was no increase in the morphology of Alzheimer's disease in 50 hemodialysis patients, but in patients over 60 years normally age related AD changes (pA4 p< 0.001, tangles p< 0.001). However, there was a correlation between the degree of dialysisassociated encephalopathy and ingested amounts of aluminum-containing drugs (p< 0.001). Laser microprobe revealed significant aluminum signals in the neuronal cytoplasm of dialysis-associated encephalopathy and, to a lesser degree, in the nuclei of neurons and glia in dialysis-associated encephalopathy and controls. In conclusion, our results suggest that aluminum does not cause an increase in the morphology of Alzheimer's disease, at least not in terms of bioavailable aluminum in drugs or hemodialysis. Keywords: Aluminum; atomic absorption spectrometry; dialysis; encephalopathy; laser microprobe; morphology.
117
118
ReuscheE
1. ALUMINUM AND THE ENVIRONMENT Aluminum (Al) is, after oxygen and silicon, the third most abundant element in the earth's crust, of which it comprises 8%. It occurs only in combined form: as an oxide in bauxit, and in complex aluminosilicates such as micas and feldspars. In contrast to its abundance in the earth's crust, its concentration in the ocean is below 1 |xg/L; natural water contains an insignificant amount of Al. With the advent of acid rain, metal ions such as Al, mercury, and lead escape from mineral deposits and appear in fresh waters (Martin, 1991). In food supply, Al originates from natural sources, including water, food additives, and contamination by Al utensils and containers. Most adults consume 1 mg to 10 mg of Al daily. Intake from Al food additives varies from zero to 95 mg daily, with a median intake of about 24 mg daily (Greger et al., 1985; Greger, 1992). In Al-rich foods, such as processed American cheese, home-made cornbread, and yellow cake with icing, food additives were the major source of Al (Pennington and Jones, 1989). Plants, such as tea, accumulate A13 + ; older leaves contain, for example, up to 3% of A13 + , while younger ones contain only 0.01%, a three hundred fold increase. Generally, the intake of Al from foods is less than 1% that of pharmaceuticals consumed, such as antacids, buffered analgesics, antidiarrheal agents, and certain ulcer drugs (Lione, 1983, 1985). For instance, 840 mg and 5,000 mg are possible daily doses in buffered analgesics and antacids, respectively (Lione, 1985). Citrate is the low molecular weight, and transferrin the main high molecular weight, carrier of A13+ in rat serum (Van Ginkel et al., 1990). Most brain Al entry is probably through the blood-brain barrier by transferrin receptor-mediated endocytosis (Roskams and Connor, 1990; Zatta et al. 1991). There appears to be a transporter-mediated brain Al efflux, probably as Al citrate (Yokel, 2001); a proton-dependent monocarboxylate transporter is at least partially mediating the efflux of Al from the brain's extracellular fluid (Ackley and Yokel, 1998). Removal of Al is effective by chelation with desferrioxamine (DFO) and oral administration of hydroxypyridones in rats (Florence et al., 1995; Gomez et al., 1998, 1999).
Aluminum and CNS Morphology in Hemodialysis
119
2. ALUMINUM NEUROTOXICITY IN EXPERIMENTS AND INDUSTRY Experimentally, the neurotoxicity of Al was first demonstrated in animals by Dollken (1897). Subcutaneous inoculation of Al solutions resulted in bulbar paralysis, tremor, spasticity, weight loss, and spinal cord changes. Kopeloff et al. (1942) induced recurrent epileptic seizures by direct application of Al paste to the cortex of monkeys. Al was shown to be a potent experimental neurotoxicant. It can induce metabolic disturbances by modifications of cytoskeletal protein gene expression, such as the inhibition of DNA repair mechanisms, reduced rate of DNA synthesis, increased DNA replication errors, inhibition of chromatindependent RNA synthesis, or suppression of cytoskeletal mRNA steadystate levels. On the other hand, there are modifications of cytoskeletal proteins, such as increased microtubule-associated protein phosphorylation. Furthermore, there are alterations in membrane stability (with increased membrane rigidity, oxidative injury, and cholinergic effects) and signal transduction, including alterations in calcium homeostasis and activation of pro-apoptotic pathways (see references in Strong, 2001). Industrially, in 1921, a 46-year-old man who had been dipping red-hot metal articles into concentrated nitric acid using an Al holder was reported to have developed "loss of memory, tremor, jerking movements, and impaired co-ordination" (Spofforth, 1921). In 1962, a 49 year-old Al worker was reported to have inhaled Al dust and rapidly developed progressive encephalopathy with epileptiform seizures (McLaughlin et al., 1962). Years before his death, he suffered from short-term memory loss and speech impairment followed by increased muscle twitching. The electroencephalogram was abnormal, showing generalized slowing and spike activity; his cerebral state deteriorated irresistibly. After his death from bronchopneumonia, high levels of Al were found in all tissues examined, including the brain (480 |xg/g dry weight, normal range 0.6 (xg/g dry weight). In 1985, three patients who had worked for more than 12 years in the same Al smelting plant were reported to be suffering from neurological disorders (Longstreth et al., 1985). In 1990, this series was expanded to include 25 symptomatic workers from the same Al melting plant. The results of this study supported the existence of a syndrome characterized
120
Reusche E
by poor co-ordination and memory, impairment in abstract reasoning, and depression. Al exposure in the potroom seemed to be the most likely cause (White et al., 1990). The Mclntyre powder, a mixture of Al and Al oxide, was used as a prophylactic agent against silicotic lungs between 1944 and 1979 in the mines of northern Ontario in Canada. Neurotoxic effects were studied in a morbidity prevalence study between 1988 and 1989. Exposed miners performed less well than unexposed miners on cognitive state examinations; the proportion of men with scores in the impaired range was greater in the exposed than in the nonexposed group. The likelihood of scores in the impaired range increased with duration of exposure, findings which were consistent with the putative neurotoxicity of chronic Al exposure (Rifat et al., 1990). The Camelford incident had exposed Al neurotixicity by water contamination. In 1988, 20 tonnes of Al sulphate were accidentally emptied into the treated water reservoir at Lowermoor Water Treatment Works, which supplied water to 20,000 people in the Camelford area of Cornwall. Within a few days, local residents and holiday-makers reported rashes, gastrointestinal disturbances, and mouth ulcers. The water was heavily contaminated with Al (up to 620 |xg/L; the European guideline for tap water is less than 0.2 |xg/L). In the weeks and months following the incident, exposed individuals complained of joint and muscle pains, malaise, fatigue, and impairment of concentration and memory (Clayton, 1991). A number of veterinary reports emerged, most notably that of fishes dying from Al poisoning in the local rivers following their contamination (Allen and Samson, 1989). Two years later, approximately 400 people were suffering from symptoms attributed to the incident. The standardized hospital discharge ratios in the five years following the incident were far greater than other areas of Cornwall, although no single diagnosis prevailed (Owen and Miles, 1995). Almost three years after the Camelford incident, 55 people were studied who had problems with poor short-term memory and concentration following exposure to the contaminated water (Altmann et al., 1989, 1999; Altmann, 2001).
3. DIALYSIS ENCEPHALOPATHY The introduction of long-term hemodialysis (HD) in chronic renal failure caused a new endemic picture of lethal encephalopathies, of unknown
Aluminum and CNS Morphology in Hemodialysis
121
origin, characterized by EEG abnormalities, dementia, myoclonic jerks, and seizures (Alfrey et al., 1972). After the introduction of flameless atomic absorption spectrometry (AAS), Alfrey et al. (1976) discovered that Al-contaminated dialysis fluids of tap water was the obvious cause of this fatal "dialysis encephalopathy" (DE). They found gray matter Al values of 25 ppm in a group of uremic patients on dialysis who died from DE compared to 2.2 ppm in a control group. Both gross and microscopical neuropathologic abnormalities were minimal. (Because of clinical similarities to the Creutzfeldt-Jacob syndrome, one patient's brain was injected into primates, which was lacking in result after 3.5 years). Sabouraud et al. (1978) reported 16 patients with progressive myoclonic encephalopathy, which appeared after a mean duration of 32 months of HD, leading to death in 4.5 months and characterized by myoclonus, speech disorders, epileptic seizures, and changes in the mental status. DE-like symptoms have also been reported in undialyzed patients. Bakir et al. (1986) described four patients — two were undialyzed, one with HD for one month and one with peritoneal dialysis — who developed acute hyperaluminemic encephalopathy with myoclonus, refractory convulsions, coma, and rapid fatal course within one month. All had been taking Al hydroxide as a phosphate binder and Shol's solution, a buffer of citric acid and sodium citrate as an alkalinizing agent. They had clearly died from excessive Al absorption from the bowel. Two patients were diabetic, a state believed to increase Al absorption. On the other hand, the concomitant ingestion of Al hydroxide and large doses of Shol's solution might have facilitated Al absorption because citric acid in the solution is a strong chelator of Al. Another 12 undialyzed patients with DE were cited, with resolution of the symptoms upon cessation of Al intake. Russo et al. (1992) reported two undialyzed patients with DE. The first had used large amounts of Al-containing phosphate binders for two years; her serum Al level was 25.34 (xmol/L. Despite chelating therapy with DFO and HD, she died. An autopsy of the cerebral cortex revealed elevated Al levels of 19 mcg/gm. The second patient had never taken phosphate binders, but ingested several grams of citrate for at least six months. The discontinuation of citrate and additional HD resulted in a resolution of symptoms and the return of the Al level to normal. Bolla et al. (1992) studied neurocognitive effects of Al in 35 HD patients. As Al levels increased, patients with lower vocabulary scores
122
Reusche E
showed a decline in attention/concentration and frontal lobe functions, while patients with higher vocabulary scores revealed no Al-related decline. These results suggested that patients with lower verbal intelligence may possess less well-developed compensatory strategies to overcome the toxic neurocognitive effects associated with Al. Morphologically, only unspecific cerebral changes have been found in DE, including lipofuscinosis, loss of neurons, and neurofibrillary degeneration, especially in the motor cortex, red nucleus, and dentate-olivary system. The intracellular binding of Al was shown by a histochemical fluorescent Morin stain (Sabouraud et al., 1978). Burks et al. (1976) reported shrinkage of neurons, increased paired astrocytes, microglial reactions, and spongiform changes in the second and third cortical layers, changes which were no different from those found in the brains of dialysis patients dying from other causes. In the latest report, the neuropathologic aspects of DE "have remained obscure. ... Spongy changes of the cerebral cortex consisted of vacuoles in the neuropil and inside nerve cell bodies and astrocytic processes. Thus, DE is a disease of neurons and astrocytes ..." (Winkelman and Ricanati, 1986).
4. DIALYSIS-ASSOCIATED ENCEPHALOPATHY In 1991, we reported new effective methods for the demonstration of Alzheimer morphology by applying new silver staining variants of the Ag NOR method (Howell and Black, 1980; Reusche, 1991; Reusche, 1997). Paraffin sections were silver stained as follows: a colloidal developer of 2% gelatine — the use of type 4078 or 4070 (Merck, Darmstadt, Germany) is recommended to obtain optimal results — was dissolved in 1 % formic acid and left stable for several weeks in the dark. A 50% solution of silver nitrate — at room temperature "maturing" for two weeks or at 60°C overnight (Quinn and Conklin, 1996) and left stable for more than one year in the dark — was prepared. Developer and silver were mixed at a ratio of one to two immediately before the staining procedure. Sections of 10 |jim thick were incubated with the mixed solution in a horizontal position at room temperature for 30 to 45 minutes in the dark and covered with a coverslip. For optional lightening of the background, the sections were dipped in 0.1% goldchloride for two minutes. This was followed by repeated rinsing with distiled water and a two-minute incubation in
Aluminum and CNS Morphology in Hemodialysis
123
a 3% sodium thiosulfate solution. After rinsing in tap water for 30 minutes, the sections were dehydrated and mounted in a synthetic resin. In 1993, 30 years after the introduction of HD, we demonstrated — for the first time — characteristic changes in long-term hemodialyzed patients by applying our new silver staining variants (Reusche and Seydel, 1993). Unlike the clinical lethal dialysis of dementia in the 1960s and 1970s this so-called "dialysis-associated encephalopathy" (DAE) comprises a morphological term. Nowadays — using modern techniques of water purification deionized fluids are applied in HD — DAE is caused mainly by long-term ingestion of Al-containing drugs to control hyperphosphatemia, up to 2.5 kg of "pure" Al (Reusche et al., 1996). Morphological changes in a post-mortem study of 10 patients who had undergone long-term HD have demonstrated pathognomonic argyrophilic inclusions. These Al-induced degradation products were silver stained in the cytoplasm (but not in lysosome-free nuclei) of choroid plexus epithelia ("kidney of the brain"), cortical/subcortical glia, and numerous neurons of the cortex and brainstem. In addition, a manifold increase in Al was demonstrated in the subcellular structures of neurons and glia by laser microprobe mass analysis (LAMMA).
4.1. Correlation of DAE Morphology, Al Intake, and Long-Term HD The CNS tissue and peripheral organs of 50 patients with chronic renal failure and HD were evaluated for Al-containing inclusions. Morphological alterations were correlated with the duration of HD and the amount of ingested Al-containing drugs. Significant correlations were found between the degree of morphological changes and Al intake of up to 2.5 kg "pure" Al (p = 0.0003), as well as morphology and duration of long-term HD of up to 178 months (p = 0.001). Beside well-known deposits in the choroid plexus, glia, and neurons of the CNS, typical argyrophilic Al-containing inclusions were found in the neurons of autonomic ganglia, heart muscle, ovary, testis, parathyroid, and adrenal and pituitary glands. Deposition of degradation products seemed to be almost irreversible. Even after renal transplantation with termination of drug-related Al intake and normalized renal Al excretion, proteinaceous inclusions remained in the cellular cytoplasm in an unchanged fashion for up to 10 years (Reusche et al., 1996).
124
Reusche E
5. ALUMINUM, HEMODIALYSIS, AND ALZHEIMER'S DISEASE In 1964, the same year that HD was introduced in chronic renal failure, neurofibrillary changes of neurons were induced experimentally in rabbit nerve cells with the injection of Al salts for the first time. Since then, the technique has been reproduced repeatedly in different applications and species (Klatzo et al., 1965; Terry and Pena 1965; Wisniewski and Wen, 1992; Savory et al., 2001). A comparison of Al-induced neurofibrils with neurofibrillary tangles (NFTs) of the Alzheimer type revealed differences in peptide composition, protofilament composition, immunoreactivity, fluorescence after thioflavin S stain, and birefringence after congo red stain. Moreover, NFTs of the Alzheimer type are also found in amyotrophic lateral sclerosis, Down's syndrome, Picks's disease, Hallervorden-Spatz disease, dementia pugilistica and head trauma, and Guam Parkinson dementia (Wisniewski and Wen, 1992). Nevertheless, both events — experimentally Al-induced neuronal changes and Al-induced dialysis dementia — have given rise to more than 30 years of speculation as to whether morphological alterations associated with Alzheimer's disease (AD) may, in fact, be linked to Al metabolism. The subject remains controversial, having both its supporters and its opponents. Two short review articles, published in the same issue of Archives of Neurology, demonstrate the controversy of opinions associated with this problem and subject: Forbes and Hill (1998) claim that exposure to aluminum is indeed a risk factor for the development of Alzheimer's disease' while Munoz (1998) is of the view that this is not true. In particular, controversial epidemiological results were obtained by a number of studies, which addressed the problem of Al in drinking water that was used as dialysate in the 1960s and 1970s, in connection with the incidence of AD. Both positive results (Flaten, 1990; McLachlan et al., 1996) and a lack of correlation (Broe et al., 1990; Forster et al., 1995) were found. Interestingly, Martyn et al. (1989) reported a correlation between the incidence of AD and drinking water. In a subsequent paper, they concluded that "there was little association between AD and higher aluminum or lower silicon concentrations in drinking water when cases were compared with any of the control groups" (1997). These two articles, albeit from the same group, are a telling example that serve to highlight the controversy of opinion associated with this problem and subject.
Aluminum and CNS Morphology in Hemodialysis
125
The possibility to visualize AD and DAE morphology simultaneously in silver stained paraffin sections provides a new tool to collect new information about the role of Al in the pathogenesis of AD.
5.1. Differences in Morphology of AD and DAE The morphologies of AD and DAE are completely different. On the one hand, silver stained AD morphology (Reusche, 1991) is characterized by the well-known amyloid-beta 4 (A£4) and NFTs consisting of paired helical filaments (Reusche and Seydel, 1993). On the other hand, DAE presents pathognomonic argyrophilic, Al-containing, lysosomal-derived inclusions in the cytoplasm of the choroid plexus epithelia (Fig. 1), gray
Fig. 1. Choroid plexus. (A) Laser microprobe mass analysis (LAMMA) spectrum with prominent mass signal at m/z 27 as evidence for marked Al storage ("kidney of the brain"). Note the lack of silver at 107/109 in nonsilver stained specimen (arrow). Inset: laser perforations. (B) Silver stained paraffin section with numerous (Al-containing) argyrophilic cytoplasmic inclusions. (C) Electron micrograph with mostly electron dense (arrow) Al=aluminum.
126
Reusche E
Fig. 2. Gray matter glia. (A) Paraffin section with silver stained delicate astrocytic processes (arrows) (magnification X200). (B) Electron micrograph with irregular astrocytic, cytoplasmic electron dense inclusion (magnification X7,200).
matter glia (Fig. 2), and neurons in the cortex and brainstem (Fig. 3) (Reusche and Seydel, 1993).
5.2. Epidemiology of AD and DAE The investigation of nearly 1,000 cases of suspected AD never presented characteristic argyrophilic inclusions of the DAE type. On the other hand, microscopic evaluation of 127 long-term dialysis patients revealed only one single 72-year-old patient, which demonstrated light and electron microscopically argyrophilic neuronal and glial deposits of the DAE type, as well as and distinct amounts of age-related neuropil threads and NFT of the Alzheimer type. Both morphological changes were intertwined with each other, but can be distinguished easily and unequivocally (Reusche, 1997). In addition, one single case with severe neurological symptoms also presented distinct DAE changes and age-related Ap4 of the AD type. (Reusche et al., 1999).
5.3. Statistical Study of 50 Long-Term Hemodialyzed Patients A study has examined the role of Al in the etiology of AD morphology. To this end, modified silver stain enabled the morphological demonstration and clear, simultaneous discrimination of AD changes from that of DAE on paraffin sections of the hippocampal and frontal regions and subcortical
Aluminum and CNS Morphology in Hemodialysis
127
Fig. 3. Hypoglossal neuron. (A) Paraffin section with numerous fine granular, deeply black argyrophilic exclusively cytoplasmic inclusions (silver stain, magnification X920). (B) Electron micrograph with irregular, partly electron-lucent (asterisk), partly electrondense cytoplasmic inclusion. Note the lack of inclusions in the neuronal nucleus and nucleolus (arrow).
gray matter. Statistically, we studied 50 brains from patients with a long history of HD. The cumulative amounts of "pure" Al ingested in Alcontaining drugs (prescribed for the control of hyperphosphatemia and gastric complaints) were recorded retrospectively. Data were collected from 60 hospitals and dialysis units in Hamburg and Northern Germany.
128
Reusche E
The accurate Al content of each drug, recorded in the prescriptions, was calculated in detail. The morphological criteria of CERAD were used to quantify A04 (Mirra et al., 1991) and NFT (Mirra et al., 1993) of the Alzheimer type on a three-point scale. DAE changes were assessed semi-quantitatively in a similar manner, using a three-point scale (Reusche et al., 2001a), thus enabling some comparison with the morphological changes of AD. No apparent microscopic increase in AD morphology was found. No AD changes were seen in patients below the age of 60, despite a long history of HD with ingestion of "pure" Al of up to 2.5 kg. Patients above 60 years of age occasionally presented with sparse deposits of A(34 and/or a low incidence of NFT of the Alzheimer type. In accordance with CERAD criteria, AD changes were identified as normal, age-related phenomena (p < 0.001 for A(34 and p < 0.001 for NFT) (Figs. 4 and 5).
3.0-
2.0" 'o
I < 1.0-
o.o- • -0.5-P—n 30
• ••>^<^.
• 35
•
,
,
,
,
,
,
,
,
,
,
40
45
50
55
60 Age
65
70
75
80
85
90
Fig. 4. Correlation of A(34 deposition with age of 50 patients with long-term hemodialysis or dialysis-associated encephalopathy. Degree of deposition was determined by CERAD criteria (Mirra et al, 1991). Reprinted from Reusche et al., 2001a, courtesy of the publisher.
Aluminum and CNS Morphology in Hemodialysis
129
Fig. 5. Correlation of amounts of neurofibrillary tangles with age of 50 patients with long-term hemodialysis or dialysis-associated encephalopathy. Degree of deposition was determined by CERAD criteria (Mirra et al., 1993). Reprinted from Reusche et al., 2001a, courtesy of the publisher.
However, a significant statistical difference was found between the amounts of drug-related Al ingested and the degree of DAE-related morphological changes (p< 0.001) (Table 1).
5.4. LAMMA Investigation of Al Content in DAE and AD Finally, subcellular Al content was evaluated by LAMMA in the hippocampal neurons, glial nuclei, and neuropil of seven age-matched controls and six patients with DAE. The data were averaged by cells to make cell-to-cell comparisons possible. In addition, a relation between the aluminum-related peak at m/z 27 and all other peaks was made to correct interferences of differences due to sample thickness and background. In each specimen, the neuronal cytoplasm, nucleus, glial nuclei, and neuropil were investigated.
130
Reusche E
3000
2500 2000
ao ^ 1500 8 1000
04 I
500
*15 021
| -
'
|
-500
19 0
17 1
Fig. 6. Correlation of ingested amount of aluminum with the degree of histological alterations in dialysis-associated encephalopathy. *Comparison of four independent samples was done by the Kruskal-WaTiis test (alpha = 0.05); groups are defined by histological grading. Reprinted from Reusche et al, 2001a, courtesy of the publisher.
Table 1. Statistical analysis of 50 patients with a long history of HD. Variable HD by DAE Al in drugs by DAE Age by AD-amyloid Age by AD-NFT DAE by AD-amyloid DAE by AD-NFT Al in drugs by AD-amyloid Al in drugs by AD-NFT HD by AD-amyloid HD by AD-NFT DAE by age DAE by gender
Chi-square
df
p value
18.006 28.987 15.147 16.724 0.296 0.022 4.746 5.493 3.278 7.526 1.081 0.077
6 6 1 1 2 2 4 3 4 4 2 2
0.006 0.0001 0.0001 0.0004 0.862 0.989 0.559 0.139 0.512 0.111 0.583 0.962
AD = Alzheimer's disease, Al=aluminum, DAE=dialysis-associated encephalopathy, df = degrees of freedom, HD=hemodialysis, NFT= neurofibrillary tangle.
Aluminum and CNS Morphology in Hemodialysis
131
The Al content in the cytoplasm of DAE neurons was statistically significantly different compared with the controls. Apparently, and due to long-term failing autolysosomal processes, Al is enriched in characteristic proteinaceous, therefore argyrophilic inclusions. (Lysosome-free) nuclei of the DAE neurons and glial nuclei presented Al signals within the range of neurons and glial nuclei of the control group (see box-plot diagram in Fig. 7).
300
275 -
Zytopl Nukleus Astrozyt Oligod Neuropil 7 7 7 Control
6 6 6 6 6 Dialysis-assoc.
Fig. 7. Box-plot diagram of background corrected Al values of six subjects with DAE and seven control cases CON. In each case, different areas were investigated: cytoplasm, nucleus, astrocytes oligodendrocytes, and neuropil (including NFTs) in AD. AD=Alzheimer's disease, Al=aluminum, CON=control cases, DAE=dialysis-associated encephalopathy, NFTs=neurofibrillary tangles.
132
Reusche E
6. SUBACUTE FATAL AL ENCEPHALOPATHY AFTER RECONSTRUCTIVE OTONEUROSURGERY A 52-year-old female was reported who underwent otoneurosurgery in order to resect acoustic neurinoma (Reusche et al., 2001b). Bone reconstruction was performed with an Al-containing cement. Six weeks later, the patient suffered loss of conciousness, myoclonic jerks, and persistent grand mal seizures, clinical symptoms that resembled those of lethal DE of the 1960s and 1970s. She died six months later from septic complications. Light and electron microscopic investigation of CNS revealed Al-containing intracytoplasmic, argyrophilic inclusions in the choroid plexus epithelia, neurons, and cortical glia. AAS revealed an increase in mean bulk Al concentration of the cortex and subcortex of up to 9.3 (xg/g (normal range, <2|jLg/g; Table 2a). LAMM A demonstrated an increase in Al in the subcellular structures (Table 2b). This unique case again demonstrates the extraordinary neurotoxicity of Al. The Al encephalopathy described here presented similar clinical signs as four patients from France (Renard et al., 1994) and Belgium (Hantson et al., 1994), which were reported in Lancet, comprising limited clinical and laboratory information, but no morphological results or details. All five patients underwent translabyrinthine approach for otoneurosurgery followed by bone reconstruction with "Ionocem" cement. All of them presented retroauricular CSF collections, obviously due to an incomplete closure of dural defects. Regular dural closure is of paramount importance to ensure the avoidance of any direct contact of brain tissue with Al ions/ compounds. Al had apparently been released from "Ionocem" directly into the subarachnoid space by CSF leakages, which subsequently infiltrate the brain parenchyma. Elevated Al levels in CSF had been documented in all five patients. In our patient, a small amount of approximately 30 mg Al might have initiated the fatal clinical course with refractory grand mal seizures (1.5 g "Ionocem" cement contained approximately 20% Al; a loss of about 10%, observed in surgical repair, amounts to 30 mg Al). After the presentation of our results, Ionos Company became bankrupt. In conclusion, our morphological, epidemiological, and statistical results show a pathognomonic morphology in long-term HD, due apparently to the ingestion of large amounts of Al-containing drugs. There is a significant statistical correlation between DAE morphology and HD/A1containing drugs. On the other hand, the results suggest that Al does not
-g 'o u
o U
c o
(N
°^ ° ; ON
in
+1
od
*Tl
13 13 "d
-H
T-H
+ 1 +1 *? en en as m ^_; OS •*
+1 en
^t
+1 d d d
so
so
-6 d d
C-;
en
d +1
•
T3
o T3 "O 13 +1 d c d
+ 1•a
en d OS
SO
d
oo
O
.
m
SO
00
>n +1 so
r-
+ 1d
^H
£ 2
OO -tf
d +1 OS SO
as
OH
ts
O O U U
< Q
•poo § M £ w
r-
CM
+i ?° +i
oi l
d V V
d d
m r-
PH
C " O J3
a,
3 T3
u U
Aluminum and CNS Morphology
3 Q •3
i a o u
•S u J3 co
•z, u
oo
IGO
c
00
<
1
Hemodialysis
CO
z,
U o
s
cd
o o T3 C C O
S
.
O
„ ^
Xi
">
o a o
PH
CT
Si
o pq M GO
W GO
W CO
o 00
<
x? 3 co
CN
o
CN
o o o
00
n „ d "1 ^H
SO
t * •*
«!
<"i
oo in
—I S O
oo ° H >o +1 ii +1 +1 ^ o -: ^ -H
as
as
-H
S +1 +1
iri •*
tN m'
H r~-
2 2 ^
-H
«
pi * -H
(S
os ^r OO
+1 +1 ^H
^
00 m
so ^*
O0
-H
OS 4
+1 as
CM in
o
^H
en u-i ' : i-i r- so ^H ^H ^H
+1
so
B c o o U U
as
c
\B cd &H
(X
ID •jj ctf
.tro]
< tSi
3 C
•a
f5
ent
#
133
134
ReuscheE
cause an increase in AD morphology, at least not in terms of bioavailable Al in drugs or long-term HD. Iatrogenic Al-induced fatal encephalopathy confirms, again, the extraordinary neurotoxicity of Al/Al compounds in direct contact with CNS parenchyma.
ACKNOWLEDGMENT Support for this work was provided by Deutsche Forschungsgemeinschaft Grant RE 1301 1/2.
REFERENCES Ackley DC, Yokel RA. Aluminum transport out of brain extracellular fluid is protondependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1). Toxicology 1998; 127:59-67. Alfrey AC, Mishel JM, Burks J, Contiguglia SR, Rudolph H, Lewin E, Holmes HJ. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. TASAIO 1972; 18:257-261. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med 1976; 294:184-188 Allen WM and Samson BF. Accidental contamination of the public water supply at Lowermoor Camelford: An assessment of the possible veterinary consequences. Veterinary Record 1989; 124:479^182. Altmann P. Aluminum-induced disease in subjects with and without renal failure: Does it help to understand the role of aluminum in Alzheimer's disease? In: Exley C, editor. Aluminum and Alzheimer's Disease. Amsterdam: Elsevier, 2001: 1-36. Altmann P, Danesha U, Hamon C, Cunningham J, Blair J, Marsh F. Disturbance of cerebral function by aluminum in hemodialysis patients without overt aluminum toxicity. Lancet 1989; ii:7-12. Altmann P, Cunningham J, Danesha U, Ballard M, Thompson J, Marsh F. Disturbance of cerebral function in people exposed to drinking water contaminated with aluminum sulphate: Retrospective study of the Camelford water incident. Br Med J 1999; 319:807-811. Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. TASAIO 1986; 12:171-176. Bolla KI, Briefel G, Spector D, Schwartz BGS, Wieler L, Herron J, Giminez L. Neurocognitive effects of aluminum. Arch Neurol 1992; 49:1021-1026. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC. A case control study of Alzheimer's disease in Australia. Neurology 1990; 40:1698-1707. Burks JS, Alfrey AC, Huddlestone J, Norenberg MD, Lewin E. A fatal encephalopathy in chronic hemodialysis patients. Lancet 1976; 1:764—768.
Aluminum and CNS Morphology in Hemodialysis
135
Campbell A. The potential role of aluminum in Alzheimer's Disease. Nephrol Dial Transplant 2002; 17:17-20. Clayton B. Water pollution of Lowermoor, North Cornwall (second report). London: Department of Health, 1991. Dollken V. Uber die Wirkung des Aluminiums mit besonderer der durch das Aluminium verursachten Lasionen im Centralnervensystem. Arch Exp Pathol Pharmacol 1897; 40:98-120. Flaten TP. Geographical associations between aluminum in drinking water and death rates with dementia (including Alzheimer's disease), Parkinson's disease and amyotrophic lateral sclerosis in Norway. Environ Geochem Health 1990; 12:152-167. Florence AL, Gauthier A, Ward RJ, Crichton RR. Influence of hydroxypyridones and desferrioxamine on the mobilization of aluminum from tissues of aluminum-loaded rats. Neurodegeneration 1995; 4:449-455. Forbes WF, Hill GB. Is exposure to aluminum a risk factor for the development of Alzheimer's disease? Yes. Arch Neurol 1998; 55:740-741. Forster DP, Newens M, Kay DW, Edwardson JA. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: A case control study in northern England. J Epidemiol Community Health 1995; 49:253-258. Gomez M, Esparza JL, Domongo JL, Singh PK, Jones MM. Comparative aluminum mobilizing actions of desferoxamine and four 3-hydroxypyrid-4-ones in aluminum-loaded rats. Toxicology 1998; 130: 175-181. Gomez M, Esparza JL, Domongo JL, Singh PK, Jones MM. Chelation therapy in aluminum-loaded rats: Influence of age. Toxicology 1999; 137:161-168. Gorsky JE, Dietz AA, Spencer H, Osis D. Metabolic balance of aluminum studied in six men. Clin Chem 1976; 25:1739-1743. Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB, Raskind M. A case control study of Alzheimer's disease. Ann Neurol 1990; 28:744-766. Greger JL. Dietary and other sources of aluminum intake. In: Proceedings of CIBA Foundation Symposium an Aluminum in Biology and Medicine. New York: John Wiley & Sons, 1992: 26^19. Greger JL, Goetz W, Sullivan D. Aluminum levels in foods cooked and stored in aluminum pans, trays and foil. J Food Prot 1985; 48:772-777. Hantson P, Mahieu P, Gersdorff M, Sindic CJ, Lauwerys R. Encephalopathy with seizures after use of aluminum-containing cement. Lancet 1994; 344:1647. Heyman A, Wilkinson WE, Stafford JA, Helms MG, Sigmon AH, Weinberg T. Alzheimer's disease: A case study of epidemiological aspects. Ann Neurol 1984; 15:335-341. Howell WM, Black DA. Controlled silver staining of nucleolus organizer regions with a protective colloidal developer: A one-step method. Experientia 1980; 36:1014—1015. Klatzo I, Wisniewski H, Streicher E. Experimental production of neurofibrillary degeneration. JNeuropathol Exp Neurol 1965; 24:187-199. Kopeloff LM, Barrera SE, Kopeloof N. Recurrent convulsive seizures in animals produced by immunologic and chemical means. Am J Psych 1942; 98:881-902.
136
Reusche E
Lione A. The prophylactic reduction of aluminum intake. Food Chem Toxicol 1983; 21:103-109. Lione A. Aluminum intake from nonprescription drugs and sucralfate. Gen Pharmacol 1985; 16:223-228. Longstreth WT, Rosenstock L, Heyer NJ. Potroom pals? Neurologic disorders in aluminum smelting workers. Ann Int Med 1985; 145:1972-1975. Martin RB. Aluminum in biological system. In: Nicolini M, Zatta PF, Corain B, editors. Aluminum in Chemistry, Biology and Medicine. New York: Raven Press, 1991: 3-20. Martyn CN, Osmond C, Edwardson JA, Barker DJP, Lacey RE Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet 1989; 1:59-62. Martyn CN, Coggon DN, Inskip H, Lacey RF, Young WF. Aluminum concentrations in drinking water and risk of Alzheimer's disease. Epidemiology 1997; 8:281-286. McDermott JR, Smith IA, Ward MK, Parkinson IS, Kerr DNS. Brain aluminum concentration in dialysis-encephalopafhy. Lancet 1979; 1:901-904. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996; 46:401^105. McLaughlin AIG, Kazantzis G, King E, Teare D, Porter RJ, Owen R. Pulmonary fibrosis and encephalopathy associated with the inhalation of aluminum dust. Brit J Indust Med 1962; 19:253-263. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes MS, Van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486. Mirra SS, Hart MD, Terry RD. Making the diagnosis of Alzheimer's disease. Arch Pathol Lab Med 1993; 117:132-144. Munoz DG. Is exposure to aluminum a risk factor for the development of Alzheimer's disease? No. Arch Neurol 1998; 55:737-739. Owen PJ and Miles DP. A review of hospital discharge rates in a population around Camelford in North Cornwall up to the fifth anniversary of an episode of aluminum sulphate absorption. J Public Health Medicine 1995; 17:200-204. Pennington J AT, Jones JW. Dietary intake of aluminum. In: Gitelman HJ, editor. Aluminum and health: A Critical Review. New York: Marcel Dekker, 1989: 67-100. Quinn B, Conklin L. Alzheimer impregnation: studies with the Reusche method. Lab Invest \996;1A:U2A. Renard JL, Felten D, Bequet D. Post-otoneurosurgery aluminum encephalopathy. Lancet 1994; 344:63-64. Reusche E. Silver staining of senile plaques and neurofibrillary tangles in paraffin sections: A simple and effective method. Pathol Res Pract 1991; 187:1045-1048. Reusche E. Argyrophilic inclusions distinct from Alzheimer neurofibrillary changes in one case of dialysis-associated encephalopathy. Acta Neuropathol 1997; 94: 612-616.
Aluminum and CNS Morphology in Hemodialysis
137
Reusche E, Seydel U. Dialysis-associated encephalopathy: Light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis. Acta Neuropathol 1993; 86:249-258. Reusche E, Ogomori K, Diebold J, Johannisson R. Electron microscopic study of paired helical filaments and cerebral amyloid using a novel en bloc silver staining method. VirchArchivA 1992;420:519-525. Reusche E, Koch V, Friedrich HJ, Niinninghoff D, Stein P, Rob PM. Correlation of drug-related aluminum intake and dialysis treatment with deposition of argyrophilic aluminum-containing inclusions in CNS and organ systems of patients with dialysisassociated encephalopathy. Clin Neuropath 1996; 15:342-347. Reusche E, Gerke P, Kriiger S, Rohwer J, Lindner B, Rob PM. Long-term organic brain syndrome and stroke-like brainstem symptoms in undiagnosed dialysis-associated encephalopathy. Dtsch Med Wschr 1999; 124:176-181. Reusche E, Koch V, Friedrich HJ, Harrison AP Alzheimer morphology is not increased in hemodialysis and dialysis-associated encephalopathy. Acta Neuropathol 2001a; 101:211-216. Reusche E, Pilz P, Oberascher E, Gloeckner K, Trinka K, Iglseder E, Lindner B, Ladurner P. Subacute fatal aluminum-encephalopafhy after otoneurosurgery. Hum Pathol 2001b; 32:1136-1140. Rifat SL, Eastwood MR, McLachlan DR, Corey PN. Effect of exposure of miners to aluminum powder. Lancet 1990; 336:1162. Roskams AJ and Connor JR. Aluminum access to the brain: A possible role for transferrin and its receptor. Proc Natl Acad Sci USA 1990; 87:9024-9027. Russo LS, Beale G, Sandroni S, Ballinger WE. Aluminum intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psych 1992; 55:697-700. Sabouraud O, Chatel M, Menault F, Dien Peron J, Carder F, Garre M, Gary J, Pecker S. Progressive myoclonic encephalopathy in dialysis patients. Clinical, electroencephalographic and neuropathological study. Pathogenetic discussion. Rev Neurol (Paris) 1978; 134:575-600. Savory J. et al. The rabit model system for studies of aluminum-induced neurofibrillary degeneration: Relevance to human neurodegenerative disorders. In: Exley C, editor. Aluminum and Alzheimer's Disease. Amsterdam: Elsevier, 2001: 203-220. Spofforth J. Case of aluminum poisoning. Lancet 1921; 1:1301. Strong MJ. Aluminum as an experimental neurotoxicant: The neuropathology and neurochemistry. In: Exley C, editor. Aluminum and Alzheimer's Disease. Amsterdam: Elsevier, 2001: 189-202. Terry RD, Pena C. Experimental production of neurofibrillary degeneration. / Neuropathol Exp Neurol 1965; 24:200-210. Van Ginkel WF, van der Voet GB, van Eijk HG, de Wold FA. Aluminum binding to serum constituents: A role for transferrin and its receptors. J Clin Chem Clin Biochem 1990; 28:459-463.
138
Reusche E
White DM, Longstreth, WJ, Rosenstock L, Claypoole KH, Brodkin CA, Townes BD. Neurologic syndrome in 25 workers from an aluminum smelting plant. Arch Int Med 1990; 152:1443-1448. Winkelman MD, Ricanati ES. Dialysis encephalopathy: Neuropathologic aspects. Hum Pathol 1986; 17:823-833. Wisniewski HM, Wen GY. Aluminum and Alzheimer's disease. CIBA Foundation Symposium 1992; 169:142-154. Yokel RA. Aluminum and the blood-brain barrier. In: Exley C, editor. Aluminum and Alzheimer's Disease. Amsterdam: Elsevier, 2001: 233-260. Zatta PF, Nicolini M, Corain B. Aluminum (III) toxicity and blood-brain barrier. In: Nicolini M, Zatta PF, Corain B, editors. Aluminum in Chemistry, Biology and Medicine. New York: Raven Press, 1991: 96-112. Zatta PF, Suwalsky M. Aluminum, membranes and Alzheimer's disease. In: Exley C, editor. Aluminum and Alzheimer's Disease. Amsterdam: Elsevier, 2001: 279-292.
CHAPTER
6
Zinc, Brain, and Aging Eugenio Mocchegiani, Mario Muzzioli, Robertina Giacconi, Tiziana Casoli, Giuseppina DiStefano, Patrizia Fattoretti
ABSTRACT Zinc is relevant to the maintenance of brain functions. It is involved in glutaminergic transmission in the gene expression of transcriptional factors and in nerve growth factor activity. Zinc turnover in the brain is mediated by metallothionein (MT) and the zinc traffic into the brain is due to ZnTl-4 transporter proteins. Alterations in zinc turnover lead to brain dysfunction. During aging, zinc turnover is altered, coupled with decreased brain functions and impaired cognitive performances. This decrease may lead to neurodegeneration. One of the causes of altered zinc turnover in aging may be due to altered zinc-bound MT homeostasis, which transforms from being a protective shield against stress into a harmful factor in aging because of the exclusive sequestration of zinc and lack of subsequent zinc release by MT for brain functions. The beneficial effect of zinc supplementation is discussed in aging and neurodegeneration. Keywords: Zinc; brain; behavior; zinc supplementation; aging; neurodegeneration.
1. INTRODUCTION Zinc (Zn) is a relevant trace element in the body. The discovery of its essentiality in 1930 was followed by extensive studies on its physiological role, which has extraordinarily enlarged the impact of Zn in various cell and body functions (Mills, 1989). Some of the most relevant findings include the role of Zn as a catalytic component of more than 200 enzymes, its requirement as a structural constituent of many proteins, and, most likely, its function in preventing free radical formation (McCall et al.,
139
140
Mocchegiani E et al.
2000). The ensuing relevance to cell division and differentiation, as well as for programmed cell death, gene transcription, biomembrane functioning, and many other enzymatic activities, have led to the consideration of Zn as a leading element in ensuring the correct functioning of various tissues, organs, and systems. Of great interest is the importance of Zn in neurobiology, which has been acknowledged and reviewed by several authors (Sandstead, 1985; Smart et al., 1994; Takeda, 2000a). Pioneering studies on the fundamental role of Zn in brain functions were carried out by Hurley and Swenerton (1966), Agpar (1968), and Caldwell et al. (1970) in Zn-deficient rat embryos displaying abnormal development of the central nervous system (CNS) with subsequent altered behavior. Further studies have shown that the involvement of Zn in the CNS occurs throughout ontogenesis. In rodents, early prenatal Zn impoverishment seriously impairs embryonic neurulation and development of the primitive neural tube (Hurley and Shrader, 1972), and results in a high incidence of exencephalus and spina bifida, which together represent the most severe type of Zn-related neural defects (Dreosti, 1983). More recent studies have focused Zn on in various parts of the brain, particularly on the hippocampus where it is found to accumulate in the mossy fiber pathway, neurons, and synaptic vesicles (Weiss et al., 2000). High concentrations in the synaptic vesicles of the special "Zn-containing" neurons in the forebrain (Frederickson et al., 2000), together with its function in biochemical myelination and release of neurotransmitters such as 7-aminobutyric acid (GABA) (Ben-Ari and Cherubini, 1991) and glutamate, indicate that Zn is a key modulator of neuronal excitability. There is also evidence that Zn deficiency results in lowered levels of long co-3 and co-6 chains, thereby causing impaired fatty acid metabolism in the neurons (Wauben et al., 1999). Moreover, Zn is important for neurogenesis, neuronal migration, and synaptogenesis; its deficiency interferes with neurotransmission and subsequent neurophysiological development (Colvin et al., 2000; Frederickson et al., 2000). Zn is also important in p-adrenoreceptor density in the brain cortex (Viticchi et al., 1999), as well as in the release of hormonal factors from the hypothalamus (Fabris et al., 1997b). Of these, thyrotropin-releasing hormone (TRH) and somatostatin are of interest because both affect the turnover of thyroid hormones which, in turn, influences the CNS (Morley et al.,
Zinc, Brain, and Aging
141
1980). Moreover, Zn is also required for "Zn-fingers" proteins involved in the developing brain (LIMK-1, LIMK-2, Krox-20, and zif268) (Mori et al., 1997) and in maintaining circadian rhythms from brain genes clock (c-fos, egr-3, and nur77) in the suprachiasmatic nucleus (Morris et al., 1998); the maintenance of circadian rhythms is indispensable in conferring plasticity on the many homeostatic mechanisms of the human body, which ensures good health (Mocchegiani et al., 2002b). From these considerations, it can be seen that Zn is pivotal for brain functions (development and maintenance). The mechanisms by which Zn is taken up in the brain, as well as transport into the brain, are still undefined. The brain barrier system (Takeda, 2000a), proteins (metallothioneins [MTs]) (Aschner, 1997), and ZnTl-T4 transporter peptides family (McMahon and Cousins, 1998) have been suggested in the traffic and uptake of Zn in the brain. During aging, Zn ion bioavailability is low in both the brain and at the periphery (Mocchegiani et al., 2001). This fact leads to an impairment in the functionality of many organs and systems, including brain functions (Fabris, 1997a). Many authors reported that Zn deficiency in aging alters some brain functions (synaptic transmission, GABA and N-methylD-aspartate (NMDA) receptors' activity, and neuronal excitability) and impairs the release of the most relevant factor of growth of neurons, such as nerve growth factor (NGF) (Rylett and Williams, 1994). Such biological alterations are coupled with impairments in cognitive functions in animals put on a Zn-deprived diet, old rats, and the elderly (Mills, 1989; Bhatnagar and Taneja, 2001). It is also intriguing and, at the same time, of interest that some age-related neurodegenerative diseases— amyotrophic lateral sclerosis (ALS), brain ischemia, Parkinson's disease (PD), and Alzheimer's disease (AD)—display low Zn bioavailability with impairments in brain functions (Fabris and Mocchegiani, 1995). In this chapter, we analyze the role of Zn in brain functions and cognitive performance under normal conditions, during aging, and in neurodegeneration. We also discuss the possible mechanisms involved in Zn alteration in the brain. The intervention or prevention, by means of Zn supplementation or other antioxidants, in brain dysfunctions is also discussed in the elderly and in some age-related neurodegenerative diseases, such as PD and AD.
142
Mocchegiani E et al.
2. BIOLOGY OF ZINC IN THE BRAIN AND AGING 2.1. Zinc Release, Uptake, Receptors' Interaction, and Aging Zinc concentration in the brain increases with growth after birth and remains constant in the adult brain (Markesbery et al., 1984). The intracellular Zn concentration in the brain was estimated to be approximately 150 |jLmol/L, judging from the average total brain Zn concentration (Takeda, 2000a). Serum Zn concentration is approximately 15 (xmol/L. On the other hand, the concentration of free Zn ions in mammalian serum and in some organelles has been estimated to be as low as 10~9 to 10~10M (Magneson et al., 1987). Therefore, the brain has the same high Zn content as all organs. In particular, neurons and glia cells display a higher Zn content. However, the distribution of Zn ions is not uniform, with higher concentrations found in gray than white matter, and the highest concentrations are present in certain forebrain regions, including the hippocampus, amygdala, and cortex (Frederickson, 1989). During aging, the distribution of Zn in the brain changes in relation to the area involved. Decrements are observed in the cerebellum and cerebral cortex, while increments occur in the hippocampus and dentate gyrus of old rats (Sawashita et al., 1997). Using the model of senescenceaccelerated mouse prone 10 (SAMP-10), which displays brain atrophy and defects in learning and memory, the Zn content is low in eight regions of the brain, including the hippocampus and cerebral cortex, with a strong imbalance in other metals, such as calcium (Ca) (Saito et al., 2000). Such an imbalance also occurs in the human brain, indicating that the balance between Zn and Ca is fundamental to the maintenance of brain functions during aging (a schematic representation is reported in Fig. 1). The uptake of Zn in neurons and its transport into the brain occur with various mechanisms. One mechanism of Zn transport into the brain is via the brain barrier system. It has been reported that the transport of Zn into the brain may occur by means of binding it to L-histidine (His) using bloodbrain barrier. Zn-His transfers Zn ions to the plasma membrane protein DCT1, which is a divalent metal transporter (Gunshin et al., 1997). DCT1 mediates active transport, that is, proton-coupled and strictly dependent on the membrane potential of the cells (Gunshin et al., 1997). Alternatively, Zn is transported into the brain via the blood-CSF barrier. This is shown
Zinc, Brain, and Aging
143 Zn efflux into neurons from extracellular compartment
(A)
Free radicals
(B) limited effect of GSH on Zn released from MT
Endonuclease n activity
PARP n activity
I
I
No prevention of apoptosis
No DNA repair
Y
Na+/K+ ATPase J vity
No membrane depolarization
Y
PKC activity'
nNOS n activity
I
\
T
Y
Krox-20, NF-kB, Sp1 c-fos, c-jun n
NO
No protein Altered intercellular phosphorylation signaling
Altered circadian rhythms
Impaired neuronal functions
Fig. 1. Schematic representation of the role of Zn starting from the extracellular compartment until its entry into neurons in aging, and the possible effect on glutaminergic transmission and MT homeostasis leading to dysfunctions in the brain's biochemical pathways (PARP-1 activity, NO production, PKC activity, membrane depolarization, and brain genes clock functions related to circadian rhythms). (A) The reduced number of zn ions present in the extracellular compartment during aging are transported into neurons preferentially by ZnTl-T4 transporter proteins. Low Zn ion bioavailability in the extracellular compartment may provoke low Ca + + regulation, leading to dysfunctions in the glutaminergic system. (B) When Zn ions enter the neurons, they are captured by MT. This leads to the limited release of Zn by MT due to altered glutathione activity, which is caused by persistent stress in aging. This condition provokes a series of altered Zn-dependent biochemical pathways, finally resulting in impaired neuronal functions. AMPA=alpha-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid, DNA=deoxyribonucleic acid, GABA=7-aminobutyric acid, GSH=glutathione, GSSG=glutathione desulfide, MT=metallothionein, NMDA=N-methyl-D-aspartate, NO= nitric oxide, PARP=poly (ADP-ribose) polymerase, PKC=protein kinase C, Zn=zinc.
in the increased amount of Zn in the choroid plexus after one hour of 65 Zn injection. On the third day after injection, relatively high levels of 65Zn were seen in the dentate gyrus and CA3 region of the hippocampus and cerebral cortex (Takeda et al., 1994). After Zn is transported into the brain
144
Mocchegiani
E et al.
via the blood-brain barrier, the uptake in the brain parenchyma occurs by means of the Zn transporter proteins family (ZnTl-4), which acts as a pump in order to maintain a balance between intra- and extracellular Zn concentration (McMahon and Cousins, 1998). As such, Zn is taken up by the neurons and glia cells, and is then incorporated into Zn-binding proteins, mainly MT-III (McMahon and Cousins, 1998). Concomitantly, the Zn-T3 protein in Zn glutaminergic neurons transports Zn ions in presynaptic vesicles and are then utilized as neuromodulators (Frederickson, 1989). Zn-Tl, Zn-T2, and Zn-T4 transport the excess Zn ions out of the cells across the plasma membrane (McMahon and Cousins, 1998). MT-III is also a key protein in intracellular Zn traffic. It is expressed only in the brain and is preferentially located in regions that have a high density of Zn-containing neurons, such as the hippocampus (Masters et al., 1994). Mice lacking the MT-III gene display normal Zn in their Zncontaining boutons (Erickson et al., 1997), indicating that MT-III is not an obligatory carrier in the process of getting Zn into neurosecretory vesicles. Other MT isoforms (I+11) are also involved in trafficking Zn into the brain (Mocchegiani et al., 2001). The main task of MT-III is to sequester and release Zn under transient stress, such as in freeze lesioned rat brain (Carrasco et al., 1999), into brain Zn-dependent enzymes in order to prevent oxidative damage. The absence of MT-III has been suggested in the development of AD (Uchida et al., 1991; Uchida, 1994). However, high concentrations of MT (I+11) are present in the brains of AD patients (Zambenedetti et al., 1999) and old rats (Mocchegiani et al., 2001), coupled with Zn deficiency in both conditions (Fabris and Mocchegiani, 1995). These last findings suggest that Zn-bound MT (all isoforms) plays a pivotal role in brain Zn homeostasis during development and aging (see next section). In contrast, Zn-T3 is more involved in trafficking and concentrating Zn within the secretory vesicles destined for the boutons. Knockout mice lacking the Zn-T3 gene display no histochemically reactive Zn in their vesicles (Federickson et al., 2000) and they are especially seizure-prone (Cole et al., 2000). It has also been reported that the gene expression of Zn-T3 is markedly reduced in the hippocampal region of a young SAMP-10 mouse (Saito et al., 2000). In this context, no data are available in the old brain. In any case, findings in the SAMP-10 mouse suggest that Zn transport by Zn-T3 is impaired during aging, with subsequent
Zinc, Brain, and Aging
145
deficiencies in the synaptic vesicles of the mossy fiber and low glutaminergic excitotoxicity in the hippocampal neurons (Saito et al., 2000). On the other hand, reduced Zn in the mossy fibers (Mocchegiani et al., 2001) and decreased synaptic number are also reported in old rats with impaired synaptic plasticity (Bertoni-Freddari et al., 1996). The uptake of Zn in the cytosol for transport into the vesicles by Zn-T3 may also occur via the voltage-gated calcium channel, NMDA receptor, and calcium permeable alpha-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA)/kainate receptor (Weiss et al., 2000). From these findings, the relevance of Zn in the synaptic vesicles is evident, particularly in the hippocampal mossy fiber system. From the presynaptic vesicles, Zn is released into the post-synaptic vesicles via the NMDA receptor, assuming thus the role of a neuromodulator. However, the physiological role of presynaptic Zn release is relatively little understood. In any case, it is clear that Zn is involved in the function of glutaminergic synapses. It has been reported that Zn is co-released with glutamate from the presynaptic vesicles into the post-synaptic vesicles via the NMDA and AMPA receptors present in the post-synaptic vesicles (Smart et al., 1994). Electrophysiological studies on cultured neurons found that Zn weakens the NMDA receptor-mediated response through both voltage-dependent and voltage-independent mechanisms, and potentates the AMPA-receptor-mediated response (Smart et al., 1994; Dingledine et al., 1999). Thus, the co-release of Zn with glutamate might have the net effect of shifting the excitation from the NMDA receptors to favor the net activation of AMPA and/or kainate receptors. Indeed, recent electrophysiological studies have shown that Zn release from the mossy fibers provides tonic inhibition of the NMDA receptors on CA3 pyramidal neurons (Vogt et al., 2000). Ca + + ions use independent NMDA or AMPA receptors for synaptic transmission (Dingledine et al.,1999). Thus, Zn is a regulator of Ca + + channels in synaptic transmission. However, excess Zn may also translocate in post-synaptic vesicles, thereby inducing neurotoixicity (Weiss et al., 2000), which is due to the interaction of Zn with both ionotropic and metabotropic glutamate receptors (Bresink et al., 1996). But, at the same time, the remaining Zn ions are taken up by glia cells for Zn translocation to the presynaptic vesicles in the newly regulated NMDA and AMPA receptors for Ca + + transmission (Takeda, 2000a). Thus, if the second uptake of Zn ions is low, a defective circle appears with subsequent
146
Mocchegiani E et al.
impaired glutaminergic transmission. Therefore, correct Zn ion homoestasis may be relevant to normal synaptic transmission. Although this assumption requires further study, neurodegenarative diseases, such as PD, display Zn deficiency (Forsleff et al., 1999), dysfunction in the NMDA receptors (Le and Lipton, 2001), and altered glutaminergic transmission (Eisen and Calne, 1992). Studies in aging revealed that the brain glutaminergic system is weakened, particularly in the frontal cortex, hippocampus, and striatum (for a review, see Segovia et al., 2001). Although Palmer (2000) reports that NMDA receptors are unaffected by aging, data abounds which show defects in the NMDA receptors during aging in both animals and human. The hippocampus and neocortex area are the most involved, leading to impaired learning and memory (Clayton et al., 2002; Magnusson, 2000a; Magnusson et al., 2000b, 2002; Villares and Stavale, 2001; Cady et al, 2001; Kuehl-Kovarik et al, 2000; Migani et al., 2000; Newman et al., 2002). Moreover, AMPA receptors decrease in certain areas of the old brain (Magnusson and Cotman, 1993), while kainate receptors are unaffected by age (Nicolle et al., 1996). Caloric and dietary restriction, but not Zn-restricted diet, restores NMDA and AMPA receptors' activity in old rats (Eckles-Smith K et al., 2000; Magnusson, 2001). As described above, low Zn concentration is present in these areas of the old brain. Therefore, Zn ion bioavailability is fundamental to glutaminergic neurotransmission and subsequent synaptic plasticity during development and aging. Besides these effects on glutamate receptors, Zn binds to the GABA receptors and weakens the GABA-mediated response, particularly on immature neurons that possess receptors which incorporate the 7-subunit (Smart et al., 1994). Conversely, in the adult brain, Zn enhances synchronized GABA release (Smart et al., 1994). Because Zn is released at glutaminergic terminals, the direct GABA receptor-mediated effect is uncertain. Interactions between glutaminergic and GABA receptors may then take place. Indeed, neuronal death in cerebral ischemia is partly due to the ratios of glutamate, glycin, and GABA released extracellularly (excitotoxic index) (Globus et al., 1991). Interaction of Zn with these receptors could, therefore, modify the excitotoxic index and be regionspecific due to the localization of neurons containing vesicular Zn. Indirect evidence of the interactions between Zn and these receptors include the collapse of GABA receptors by high Zn release in kindling
Zinc, Brain, and Aging
147
models of epilepsy displaying aberrant mossy fiber sprouting (Coulter, 2000). Zn modulates both the glutamate and GABA responses of neurons that contain only specific splice-variant receptor subunits of NMDA and GABA, respectively (White and Gurley, 1995). The dissociation constants for Zn antagonism of NMDA and GABA responses are approximately 13 (jumol/L and 11 |xmol/L, respectively (Mayer and Vyklicky, 1989). These dissociation constants are quite similar and are well within the concentrations released during synaptic activity. This implies a delicate balance between the NMDA and GABA responses via Zn, with subsequent Zn involvement in the regulation of neurotransmission. On aging, there is a paucity of data on GABA receptors and Zn. GABA receptors and their response, as well as interactions with the glutaminergic system, seem diminished in the nucleus accumbes, but remain unaffected by age in the striatum (Segovia et al., 1999). Other authors have reported an enhancement of GABA in the forebrain neurons of aged rats (Griffith and Murchison, 1995). A decrease in binding site affinity, rather than in receptor density, has been reported in the brains of old rats (Turgeon and Albin, 1994). Further studies are needed to clarify this point.
2.2. Zinc, Enzymes, Neurotransmitters, Hormones, Cytokines, and Aging 2.2.1. Zinc and brain enzymes Several Zn-related enzymes that are relevant to brain development and function are listed in Table 1. The relevance of these enzymes has been studied in the brain during Zn deficiency. Low Zn ion bioavailability is often the cause of diminished activity of Zn-dependent antioxidant enzymes in brain injury (Lewen et al., 2000) and aging, in which oxidative stress and the appearance of free radicals are persistent (Mocchegiani et al., 2000a, 2000b). On the other hand, the relevance of Zn-dependent brain enzymes against persistent oxidative stress has also been observed in accelerated aging in humans (Down's syndrome), displaying Zn deficiency and altered brain functions (Fabris et al., 1993). Observations of the decreased activities of the myelin marker enzyme 2',3'-cyclic nucleotide phosphohydrolase and brain alkaline phosphatase, as a result of Zn deficiency, are important as these enzymes are involved in myelination and brain maturation (Dreosti, 1984). With advancing age,
148
Mocchegiani E et al.
Table 1. Effect of Zn status on the activity of enzymes, neurotransmitters, neurohormones, cytokines, transcriptional factors, and brain genes clock in murine brain*.
Variable 2'-3'-cyclic nucleotide 3' -phosphohy drolase Alkaline phosphatase Glutamate dehydrogenase, in vivo in vitro Dopamine-(3-hydroxylase Phenylethanolamine-N-methyltransferase Glutamate decarboxylase Intracerebral Zn Thymidine kinase Superoxide dismutase
Zn status
+ +
Activity
Brain region Ce Ce, Hi Fetal brain Ce, Hi Hi, Nc Co, Ce, Hi Co, Ce, Hi A, CN, Ht Hi Fetal brain Nc
Neurotransmitters Norepinephrine Dopamime Opioid system Enkephaline
Pvn Pvn Hi Hi
Neurohormones Thyrotropin-releasing hormone Somatostatin Gonadotrophin-releasing hormone Melatonin
Ht Ht Ht SCh
Cytokines Interleukin-1 Interleukin-6 Tumor necrosis factor-a 7S-nerve growth factor
Ps Ps Ps Nerve
Transcriptional factors NF-kB, TFIIIA, SP1 LIMK-1, LIMK-2, Krox-20, Zif-268 (zinc fingers) c-fos, c-jun, egrl, egr3, nur77 (brain genes clock)
Neurons Neurons SCh
*The same alterations also occur in the old brain (see text). For references, see text. — = diminished, + = increased, 0 = unaffected. A = amygdala, Ce = cerebellum, CN = caudate nucleus, Co = cortex, Hi = hippocampus, Ht = Hypothalamus, Nc = neocortex, Pvn = paraventricular nucleus, Ps = paravesicular spaces, SCh = suprachiasmatic nucleus, Zn = zinc.
Zinc, Brain, and Aging
149
the activity of alkaline phosphatase decreases, leading to diminished permeability of the cerebral microvessels and, subsequently, impairment of the blood-brain barrier (Agrawal et al., 1996). Alkaline phosphatase, via adenylate cyclase, is also involved in p-adrenergic receptor activity (Yamashita et al., 1990), which in turn is reduced in the brain cortex (Viticchi et al., 1999) and cerebral microvessels (Mooradian and Scarpace, 1991) of old rats. Another enzyme, superoxide dismutase (SOD), which protects against damage by superoxide radicals, is important as it increases dramatically in the first two months, postnatally in rat brain, and declines thereafter with low activity in aging (Gupta et al., 1991). Such a decline is often associated with brain membrane injury (Prasad, 1993) and, in some cases, with neuronal cell death during oxidative stress, such as in aging (Cookson and Shaw, 1999). SOD protects catecholamines from being oxidated by superoxide. Indeed, during development, its activity is much higher in synaptosomes and catecholaminerich area of the brain (Ledig et al., 1982), and catecholamines decrease in aging (Rehman and Masson, 2001). Changes in the activity of glutamate dehydrogenase, as a result of Zn deficiency, has an important effect on the metabolism of neurotransmitter glutamic acid and glutaminergic neural system (Dreosti, 1984). Thymidine kinase activity, which is related to cell proliferation, is strongly reduced (53%) in brains of Zn-deficient fetuses (Record and Dreosti, 1979). The activity of these last two enzymes declines during aging in the synapses, mitochondria, and cerebellum (Caron and Unsworth, 1978), thereby impairing neurotransmission and spatial memory. Glutamate decarboxylase, an enzyme involved in the synthesis of the inhibitory neurotransmitter GAB A, has been studied in relation to excess cerebral Zn rather than Zn deficiency. Intraventricular injection of Zn into the brains may be epileptogenic (Ebadi and Pfeiffer, 1984). At physiological concentrations, Zn stimulates the enzyme pyridoxal kinase to form the co-factor pyridoxal phosphate, thereby enhancing the activity of glutamate decarboxylase. At supraphysiological levels, Zn inhibits glutamate decarboxylase directly and reduces the binding capacity of GABA receptor sites (Mills, 1989). Epilepsy in humans, as well as epilectic fits in rats, by commissural kindling display indeed increased the level of hippocampal Zn (Mills, 1989). Recently, the activity of glutamate decarboxylase was studied in old mice and rats and, therefore, under the
150
Mocchegiani
E et al.
condition of Zn deficiency. Its activity is gender-dependent and decreases in the neocortex, hippocampus, and striatum (brain area is poor in Zn in aging) in old male mice (Frick et al., 2002). In old rats, glutamate decarboxylase activity is higher in the vestibular nuclei after vestibular lesion, suggesting a recall of Zn for the normal GAB A system (Giardino et al., 2002). The last finding is in line with that of Mills (1989) and reflects the distribution of Zn in various brain areas. Moreover, dopamine-(3-hydroxylase and phenylethanolamineN-methyltransferase enzymes, which convert dopamine to norepinephrine and norepinephrine to epinephrine, respectively, are involved in neurophysicological symptoms. It has been reported that the levels of norepinephrine and dopamine are higher in the brain of Zn-deficient weaning rats with a role in catecholamine alterations (Wallwork et al., 1982). Others have reported that these enzymes are involved in dopamine activity and are decreased in certain regions of Zn-deficient rat brain (Wenk and Stemmer, 1982). However, decrements in norephinephrine and dopamine, especially during the dark period in the paraventricular nucleus from Zn-deprived rats (Huntington et al., 2002) and in aging (Segovia et al., 1999), occur. Therefore, the neurotransmitters norepinephrine and dopamine are altered by Zn deficiency and in aging.
2.2.2. Zinc and brain
neurotransmitters
Of interest is the interaction between zinc and opioid peptides in hippocampal mossy fibers (Table 1). Early findings have shown that Zn ions block [3H]-D-Ala2-Met5-enkephelamide binding to rat membrane in the hippocampus. Thus, Zn plays a role in regulating opioid peptides in the brain regions where they are co-localized (Stengaard-Pedersen et al., 1981). Thiol reducing agents restore the binding capacity of ZnCl2-treated membranes, suggesting that oxidation of opioid receptor SH groups by Zn ions is the mechanism through which Zn blocks opioid binding (Stengaard-Pedersen et al., 1981). The following evidence suggest interactions between Zn and opioid peptides in the hippocampus: Zn and enkephaline-containing opioid peptides are selectively localized in the hippocampal mossy fibers; Zn blocks opioid binding; Zn complexes with enkephalines in vitro; and Zn and opioid peptides, when administered intraventricularly, induce limbic seizures (for a review see Mills, 1989). These findings suggest that opioid peptides and Zn in the mossy fibers interact in the physiological regulation
Zinc, Brain, and Aging
151
of hippocampal excitability. These neurotransmitters (opioids) act synergistically with an excitatory amino acid during hippocampal synaptic transmission. Together, they could effectively regulate the normal excitability and seizure threshold in limbic circuits, possibly by altering the degree of GABAergic inhibition in the hippocampus. It is not a simple coincidence that anorexia displays reduced appetite, impaired synaptic transmission, a strongly altered opioid system, and abnormalities in limbic functions (behavior and cognitive functioning); anorexia is the major symptom of Zn deficiency in the brain (Takeda, 2000a; Takeda et al., 2000b). In this context, it parallels aging, taking into account that Zn deficiency and an altered opioid system followed by abnormalities in the limbic system are also observed in aging (Rehman and Masson, 2001).
2.2.3. Zinc and brain hormones Zinc is essential to a variety of neurohormones (hormone-releasing factors) secreted by the hypothalamus and hormones which secondarily affect brain functions (Table 1). In the first group, TRH and somatostatin are of interest because both affect the pituitary-thyroid axis which, in turn, affects brain functions (Morley et al., 1980). Moreover, gonadotrophin releasing hormone (GnRH) affects the sexual glands. Lack of maturation of the sexual glands provokes hypogonadism, which is characterized by Zn deficiency and delay in brain development (Prasad, 1993). In the second group, melatonin production from the pineal gland in the suprachiasmatic nucleus is peculiar because it affects circadian rhythms, including those related to Zn turnover and brain functionality, such as glucocorticoids (Mocchegiani et al, 1998b). Somatostatin release from the hypothalamus is lower in Zn-deficient rats and in aging (Rains and Shay, 2001), leading to an impairment in limbic functions (Takeda et al., 2000b). In contrast, increased somatostatin, as it occurs in hypothermia, enhances Zn in the mossy fibers by protecting neuronal cells through cell death (Johansen et al., 1993). This supports the notion that Zn in the hypothalamus helps to maintain the brainneuroendocrine network during aging (Fabris, 1997a; Fabris et al., 1997b). Moreover, Zn potentates NMD A receptor activity via somatostatin (Tapia-Arancibia, 1990). Taking into account the fact that somatostatin affects growth hormone/IGF-1 axis, which is in turn Zn-dependent and decreases in aging (Fabris et al., 1997b), the recent discovery of
152
Mocchegiani E et al.
IGF-1 in restoring NMDA receptors in aging (Sonntag et al., 2000) is further evidence of the role of Zn in neurohormones' release and activity. TRH decreases Zn deficiency (Morley et al., 1980). This affects TSH production and turnover of peripheral thyroid hormones, leading to hypothyroidism (Beck-Peccoz and Persani, 1994) with the subsequent appearance of impaired cognitive functions, which occurs in Down's syndrome subjects, the elderly, and experimental hypothyroidism (propyltiouracil treated mice) (Mocchegiani et al., 2002a). Indeed, Zn deficiency and thyroid hormone shortage which occur in both cretinism and myxedema, have similar symptoms, that is, delayed growth, reduced appetite, and activity (Hartoma et al., 1979). Although no correlation exists between Zn and GnRH in the hypothalamus, indirect evidence shows that GnRH release and production is controlled by the Zn-finger protein DAX-1 (Kottler et al., 1999). Decrements in GnRH affect sexual maturation with the appearance of hypogonadism, which displays Zn deficiency and impaired cognitive functions (Ozata et al., 1999). In aging, hypogonadism does not exist, but decrements in GnRH and the production of sexual hormones by peripheral glands do occur (Khoury and Sowers, 1988). As for melatonin production by the pineal gland in the suprachiasmatic nucleus, Zn plays a pivotal role as the nocturnal peak of melatonin decreases in Zn deficiency and in aging (Mocchegiani et al., 1998b). The decrement in melatonin production in aging affects circadian rhythms in adrenocorticotropic release, with increments of glucocorticoids in the nocturnal period (Mocchegiani et al., 1998b) leading to cell death, including neurons (Nichols et al., 2001). A correlation has been shown between decrement in nocturnal melatonin production and affective disorders in multiple sclerosis patients (Sandyk and Awerbuch, 1993), who also display Zn deficiency (Fabris and Mocchegiani, 1995). Although no conclusive data is available on the precise role of Zn in hormone-releasing factors from the hypothalamus, these findings pinpoint on the fact that Zn deficiency in the brain and aging may also affect the neuroendocrine network. This induces an impaired response from the peripheral endocrine glands, which in turn affect brain functions by means of specific receptors in the brain with resultant negative consequences on behavior and cognitive functioning (Morley et al., 1980; Fabris et al., 1997b; Mocchegiani et al., 2002a, 2000b).
Zinc, Brain, and Aging
153
2.2.4. Zinc and brain cytokines Cytokines are various polypeptides that mediate cellular response in immunity and inflammation in the peripheral nervous system and CNS (Rothwell and Hopinks, 1995). An inflammatory condition is known to deplete Zn ion bioavailability (Taubeneck et al., 1995) and inflammation is known to persist in aging (Mocchegiani et al., 2000a, 2000b). A mechanism by which Zn is depleted is through enhanced activities of Zn requiring the enzymes (involved in DNA/nucleic acid synthesis) of mitogen or cytokine-responsive cells (Odeh, 1992). Some cytokines, especially those related to inflammatory status, such as TNF-a, IL-1, and IL-6, have been implicated in agerelated neurological dysfunctions and neurodegenerative conditions (McGeer and McGeer, 1995). These cytokines are Zn-dependent (Fabris et al., 1997b) and, at the same time, affect Zn turnover (Mocchegiani et al., 1998a). TNF-a causes in vivo alterations in Zn metabolism, leading to Zn depletion known as hypozincemia (Taubeneck et al., 1995). Increments of TNF-a induce cell death, via the NF-kB transcriptional factor (Beg and Baltimore, 1996), and are an index of poor prognosis in constant and severe inflammations (Rodriguez-Gaspar et al., 2001). IL-1 (Goldblum et al., 1987) and IL-6 (Mocchegiani et al., 1998a) also induce hypozincemia in inflammation (in aging). However, they are strictly correlated with depressed brain functions, such as synapses number (Bertoni-Freddari et al., 1996), (3-adrenoreceptor density (Viticchi et al., 1999), and altered behavior and cognitive functioning (Reichenberg et al., 2001). Zinc has also been histochemically identified in the oligomer 7S-NGF, a complex with three distinct subunits: a, (3, and 7 (Pattison and Dunn, 1975). 7S-NGF has high affinity for Zn (Dunn et al., 1980). Two molecules of Zn are present in the complex and Zn participates by holding the structure together. It has been observed, in vitro, that chelation of Zn from 7S-NGF using 2,2',2"-terpyridine or 8-hydroxyquinoline-5-sulfonic acid activates the -y-esteropetidase enzyme. This leads to the liberation of a, p, and 7 subunits from the oligomer and inactivation of NGF (Dunn et al., 1980). NGF is required for the survival and development of sympathetic and sensory neurons, as well as for a wide range of other cells. NGF is present on the nucleus and at the synaptic ending (Dunn et al., 1980). NGF also plays a crucial role in cytokine/neurotrophin interaction, particularly in the signaling pathways for neurogenesis (MacDonald et al., 2000).
154
Mocchegiani E et al.
NGF is an antioxidant and interacts with glucocorticoid receptors to prevent apoptosis (McLay et al., 1997). In aging, NGF production decreases. This has been suggested as a cause for the appearance of classical age-related neurodegenerative disorders, such as dementia (Rylett and Williams, 1994). Indeed, treatments with NGF have been suggested to prevent neurodegeneration (Williams, 1995) and to restore the activity of Zn-dependent antioxidant enzymes (Nistico et al., 1992), as well as to improve cognitive functions (Kiprianova et al., 1999).
2.2.5. Zinc, brain metallothionein,
and aging
MT is crucial to Zn homeostasis (Vallee and Falchuk, 1993). It is a low molecular weight protein with 61 to 68 amino acids, 20 of which are represented by cysteine residues in conserved positions. Currently, only the functional mammalian isoforms (MT-I, MT-II, MT-III, and MT-IV) have been identified (Palmiter, 1998). It is able to bind up to seven atom Zn/ molecule of the thionein protein (for a review see Vallee, 1995). MT is ubiquitous in most organs and can be induced, via activation of the factor MTF-1, as a response to stress (Jacob et al., 1999) by different endogenous or exogenous stimuli, including heavy metals, glucocorticoids, proinflammatory cytokines (IL-1, IL-6, and TNF-a) (Kagi and Schaffer, 1988; Vallee, 1995; Mocchegiani et al., 2000b), and Zn (Thakran et al., 1989). MT modulates the transfer and homeostasis of metal ions, of which Zn is pivotal (Kagi and Scahffer, 1988). MT prevents Zn deficiency and toxicity in vivo (Kelly et al., 1996); it acts as a detoxifying agent of reactive metals and free radicals (Sato and Bremner, 1993). In the cultured Ehrlich cell, the cellular concentration of Zn-bound MT is approximately 13 |xmol/L (Krezoski et al., 1988). MT, however, is not a long-term storage for Zn as it has a short biological half-life in these cells (Krezoski et al., 1988). In vesicles, Zn is bound to MT (Palmiter, 1994) and provides a crucial role for Zn homeostasis in the brain. The expression of MT isoforms is tissuespecific. MT-I and MT-II are expressed in most mammalian organs, including the brain, while the MT-III isoform is specific to the brain and MT-IV is present in the squamosa epithelia (Palmiter, 1998). MT-I and MT-II are localized in the astrocytes, perivascular spaces, and pia mater (Nishimura et al., 1992; Penkowa et al., 1999), while MT-III is abundant
Zinc, Brain, and Aging
155
in neurons and hippocampal mossy fibers (Masters et al., 1994). MT-III may be expressed independently by MT-I and MT-II, as evidenced by the increased intensity of Timm's stain in the mossy fibers (Masters et al., 1994). MT-III sequesters Zn, (Mocchegiani et al., 2001). The role of MT isoforms (I and II) is to sequester and release Zn, particularly under stresslike conditions for Zn-dependent antioxidant enzyme activities (SOD and GSH) and other Zn-dependent enzymes involved in base excision DNA repair (PARP-1), cellular proliferation (PKC), and prevention of apoptosis (endonuclease) (Mocchegiani et al., 2000b) (see Fig. 1). Even if the role of MT-III is mainly to sequester excess Zn, which may lead to neurotoxicosis (Palmiter, 1998; Masters et al., 1994), MT-III is also involved in Zn release during stress (Mocchegiani et al., 2001). Therefore, all MT isoforms are involved in Zn homeostasis in the brain. This role of MT is peculiar to transient stress-like conditions, as it may occur in the young adult. In aging, stress-like conditions persist throughout the whole circadian cycle (Mocchegiani et al., 2002b). This provokes continuous sequestration of Zn by MT with no Zn release, leading to low Zn ion bioavailability for many biological functions, including the brain functions (Mocchegiani et al., 2001) described here. Therefore, increments of MT isoforms may transform from being useful under transient stress to being harmful under constant stress, such as aging (Mocchegiani et al., 1998a; Mocchegiani et al., 2000b). Increments of MT-I and MT-II have been found in the astrocytes of old rats (Mocchegiani et al., 2001) and AD patients (Zambenedetti et al., 1998). MT-III gene expression is also enhanced in the hippocampus of old mice (Giacconi et al., 2002). Conversely, MT-III is poorly expressed in the brains of AD patients, thereby implicating it in the development of AD (Uchida et al., 1991; Uchida, 1994). However, the presence of high MT I+II isoforms in the brains of old mice and AD patients leads one to interpret the increments of MT isoforms as being harmful to brain functions in aging and dementia. The existence of low Zn ion bioavailability and impaired brain functions in aging and dementia (Fabris and Mocchegiani, 1995) is in line with this interpretation. However, the presence of compensatory phenomena among the various isoforms of MT (I, II, and III) in the brain (Penkowa and Hidalgo, 2000) gives rise to intriguing aspects of the role of MT isoforms in the brain in aging. This represents an interesting topic for future research in the aged brain.
156
Mocchegiani E et al.
2.2.6. Zinc and gene expression Zinc also plays a key role in DNA "Zn finger" binding motifs. As such, it is involved in the gene expression of many proteins, transcriptional factors, and receptors, which are important to the functioning of body homeostatic mechanisms. Zn fingers are crucial for brain development and maintenance. The removal of Zn provokes an incorrect production of Zn finger proteins and subsequent damage to organs or tissues, including the brain (Ebadi et al, 1990; Vallee and Falchuk, 1993). LIMK-1 and LIMK-2 are two Zn finger motifs expressed preferentially in the CNS during mid-to-late gestation. They are mainly present in the deep nuclei of the cerebellum. In adult life, their expression decreases and are mainly expressed in the cerebral cortex (Mori et al., 1997). This last fact also leads to low gene expressions of these Zn-finger proteins in aging, even if no data are still available. The Zn finger Krox-20 is expressed in the hindbrain and cranial nerves during embryogenesis governing the process of segmentation (Schneider-Maunoury et al., 1993). No data exist in the literature on the role of Krox-20 in aging. However, knockout Krox-20 mice display delayed or absent myelination (Mirsky and Jessen, 1999), which is important in nerve regeneration in CNS injury (Levine et al., 2001) and in aging (Lalonde and Badescu, 1995). The Zn finger Zif268 is involved in synaptic plasticity. It is expressed in hippocampal granule cells and induced by NMDA receptors (Worley et al., 1993). However, its expression is strictly related to other important gene expressions, such as c-fos, c-jun, and egrl, which are also Zn finger proteins (Morris et al., 1998). The lack of expression in c-fos, c-jun, and egrl provokes an impaired synaptic plasticity despite the fact that Zif268 is normally expressed (Worley et al., 1993). This was recently shown in egrl knockout mice (Mataga et al., 2001). Therefore, c-fos, c-jun, and egr-1 gene expressions are crucial to synaptic transmission. The relevance of these proteins is still more intriguing because c-fos, together with egr-1, egr-3, and nur77, is the brain gene clock in the suprachiasmatic nucleus driving circadian rhythms (Morris et al., 1998). Also, egr-3 and nur77 are codified by Zn finger motifs. Taking into account the relevance of circadian rhythms in the maintenance of body homeostatic mechanisms (Touitou et al., 1997), the bioavailability of Zn ions is also crucial to brain circadian rhythms.
Zinc, Brain, and Aging
157
Indeed, preliminary data from our laboratory show that the gene expressions of c-fos and c-jun are low in old mice, coupled with the absence of Zn circadian rhythms, compared to young mice (Mocchegiani, unpublished observation). Zn is also vital for the gene expression of many transcriptional factors and enzymes, which are also relevant to other cell functions. Among them, TFIIIA, Spl, and NF-kB are the most well-known Zn-dependent transcriptional factors involved in brain functions (Cuajungco and Lees, 1997). The removal of Zn by chelation disables TFIIIA, SP1, or NF-kB binding activity to DNA (Yang et al., 1995). The gene expression of the estrogen receptor (EsR), erythroid receptors (GATA-1, NF-E1, and GF-1), and glucocorticoid receptors is also affected by Zn ion in the brain. It is also interesting to note that Zn-dependent enzymes (PKC and PARP-1), Zn-dependent antioxidant enzymes (SOD and GSH), and endonuclease enzymes, which are involved in the prevention of apoptosis, are also affected by Zn in the brain (for a review see Cuajungco and Lees, 1997). During aging, PKC activity is downregulated in the brain, leading to apoptosis (Jin and Saitoh, 1995; Pascale et al., 1998). Poly(ADP-ribose) polymerase-1 (PARP-1) is activated by DNA strand breakage, which induces DNA repair under transient stress and cell death under persistent stress (Szabo and Dawson, 1998). In aging, low Zn ion bioavailability induces PARP-1 towards cell death because of diminished NAD+, which is due to too much energy consumption (Mocchegiani et al., 2000b, 2002c). The activity of endonuclease enzyme, together with low Zn ion bioavailability, is impaired in aging with limited prevention of apoptosis (Barbieri et al., 1992). A plethora of data report that SOD and GSH activities decrease in the old brain. Subsequently, there is no protection against oxidative damage by free radicals (for a review see Melov, 2002). EsRs in the hippocampus are gender-dependent: they decreased in the old male and are maintained in the old female (McEwen et al., 1997). This fact may justify more efficient cognitive functions in the old female than in the old male (Clausen et al., 1989). Erythroid receptors decrease in aging, leading to impaired transferrin transport (Adrian et al., 1996). As for glucocorticoid receptors, they increase in the hippocampus during aging (Carroll, 2002). Knowing the effect of glucocorticoids in inducing apoptosis in aging (Fabris et al., 1997b), the increase in glucocorticoid receptors in the old brain is a sign of cellular brain aging. However, recent
158
Mocchegiani E et al.
data show a decrease in glucocorticoid receptors in the hippocampus during aging, attenuating to the beneficial effect of glucocorticoids on hippocampal memory (Murphy et al., 2002). While this last finding may be in line with the beneficial effect of moderate stress (van der Klink et al., 2001), it contradicts the fact that prolonged stress induces cell death, as in aging (Fabris et al., 1997b). Therefore, more studies are needed to clarify this point.
3. ZINC, BEHAVIOR, COGNITIVE FUNCTIONING, AND AGING The role of Zn in behavior and cognitive functioning has been studied in relation to Zn deficiency during development and in adulthood. There is a paucity of data on this subject in aging. The common symptoms of Zn deficiency are anorexia and growth retardation. Bulimia is also associated with Zn deficiency and cognitive neurological dysfunctions (McClain et al., 1992). Changes in behavior, especially reduced activity and responsiveness, may be one of the components of the regulatory system of Zn that provides a sensitive index of inadequate dietary supply (Golub et al., 1995). Periods of rapid growth, such as pregnancy and infancy, are most susceptible to dietary Zn deficiency (Favier, 1992). Zn deficiency during prenatal development is teratogenic in rats (Hurley and Swenerton, 1966). Zn deprivation in rapid brain growth has effects similar to those of protein malnourishment (Halsted et al., 1972). When behavior was tested during a period of Zn deprivation in immature animals (rat and monkey), lethargy and impaired learning and memory were observed (Halas and Sandstead, 1975; Golub et al., 1994). After a limited period of Zn deprivation during development, the impairment in behavior, learning, and memory persists in to maturity (Halas and Sandstead, 1980). Impairments of cognitive performance, such as visual attention and short-term-memory, by moderate Zn deprivation were observed in young mature monkeys (Golub et al., 1994) and rats weeks of Zn-deficient diet, suggesting that long-term memory is not affected by Zn deprivation (Takeda et al., 2000b). In humans, the earliest observations of an impairment in cognitive functioning were made by Prasad et al. (1961) in poor developing countries (Iran and Egypt), where the diet is low in Zn. Children in these countries had severe growth retardation, hypogonadism, and mental lethargy. Similar observations in other developing countries (Guatemala, India, and
Zinc, Brain, and Aging
159
Bazil), where the diet is low is Zn or contains other substances (phytates and fiber) that induce Zn loss in feces, have confirmed the earlier observations in Iran and Egypt. A paradox seen in humans relates to anorexia and bulimia, where the dopaminergic and serotinergic systems in the hypothalamus are impaired in both conditions (Patrick, 2002). These brain defects lead to depression, anxiety, and somatization disorders in anorexia and bulimia (low in anorexia and high in bulimia). Both conditions are characterized by Zn malabsorption with subsequent Zn deficiency (Patrick, 2002). In aging, a paucity of data exist on cognitive functions related to Zn. Using the Morris water maze, it has been shown that aged rats display an increase in escape latency and low Zn in synaptic vesicles compared to young rats (Guidolin et al., 1992) (Table 2). This finding suggests that spatial memory is strongly reduced in aged rats and is strictly related to Zn content in the hippocampal mossy fibers. This assumption has recently been confirmed by Keller et al. (2001), who showed that old rats have deficits in short-term memory. In the elderly, Clausen et al. (1989) demonstrated impairment in visual and cognitive functions related to low Zn bioavailability. A more precise study has been performed in a human model of accelerated aging (Down's syndrome), which displayed a marked level of low Zn ion bioavailability (Fabris and Mocchegiani, 1995). Impairments in co-ordination and attention (Das et al., 1995),
Table 2. Escape latency and Zn staining in the hippocampus of rats*. Variable
Young rat
Adult rat
Old rat
Escape latency (sec) Zn staining (optical density)
8.5 ± 1.3 0.3 ± 0 . 5
11.4 ± 1.7 0.24 ± 0 . 3
62.5 ± 7.4+ 0.15±0.4t
*Spatial memory was assessed using the Morris water maze task. Each rat received two blocks of four trials per day for five days during the screening week. Escape latency to reach the hidden platform was automatically recorded. A series of l-u,mol/L semi-thin sections of the dorsal hippocampus was obtained. Sections of the CA3 region were stained in Timm's reagents to visualize Zn and be used for light microscopy. Zn granules in the vesicular region were analyzed by a computer-assisted image analysis system (IBAS; Kontron, Germany) and measured as optical density. tp<0.001 when compared to young and adult rats (ANOVA test). Zn = zinc. Redrawn, from Guidolin et al. (1992) with permission.
160
Mocchegiani E et al.
memory (Roeden and Zitman, 1995), and comprehension (Licastro et al., 2001) are observed. These deficits in cognitive functioning are often present in the elderly (Capurso et al., 2000). More studies are, however, required in aging.
4. MECHANISMS WHICH LINK ZINC TO BRAIN AGING AND NEURODEGENERATIVE DISEASES Of all the mechanisms linking Zn to brain aging, oxidative stress and apoptosis play a pivotal role. Both conditions increase in aging and, coupled with a persistent inflammatory status (Mocchegiani et al., 2000a, 2000b), lead to neurodegeneration and correlated diseases, of which PD and Alzheimer-type dementia are the most common. In this context, Zn may be crucial in that it is involved in preventing oxidative damage via Zn-dependent antioxidant enzymes and proteins and, in preventing apoptosis, via endonuclease enzymes or PARP-1 activity. However, Zn may also be toxic in brain functions because, as discussed above, it may accelerate excitotoxicity in the synaptic vesicles with subsequent damage in synaptic transmission (Weiss et al., 2000). Here we discuss oxidative stress and the neurotoxicity of Zn in the brain. For apoptosis, the reader is referred to the excellent review by Troy and Salvesen (2002).
4.1. Oxidative Stress It has been proposed that oxidative stress due to diminished antioxidant defenses and/or increased production of reactive oxygen species (ROS) and free radicals could initiate a cascade of events that lead to neurodegeneration (Olanow, 1993). However, the possibility that the production of free radicals is a consequence of underlying degenerative processes, rather than a major cause of degeneration, requires more corroboration (for a review see Coyle and Puttfarcken, 1993). Recent reports suggest Zn involvement in the regulation of oxidative stress and, in particular, an association with the glutathione (GSH) antioxidative system (Ryu et al., 2002). "Energy release" involves aerobic and anerobic mechanisms. In the aerobic process, the reduction in the flow of molecular oxygen (0 2 ) to water (H 2 0) leads to the formation of ROS (Olanow, 1993). ROS and free radical species, such as superoxide radical (0 2 ), hydrogen peroxide (H 2 0 2 ), peroxynitrite (ONOO ), nitric oxide (NO), hydroxyl radical (OH"), and
Zinc, Brain, and Aging
161
hypochlorous acid (HOC1), can cause oxidative stress and cell death when their rate of production exceeds the cellular capacity to metabolize them (Halliwell and Gutteridge, 1984). The glutathione peroxidase (GPO) family is an important cellular antioxidant defense mechanism (Jenner, 1993). Peroxidases catalyze the reduction of H 2 0 2 to H 2 0 and 0 2 . Oxidation of GSH, catalyzed by GPO, results in the formation of oxidized glutathione (GSSG; glutathione disulfide). Glutathione reductase (GR) catalyzes the reduction of GSSG back to GSH. In vivo depletion of GSH shows a marked correlation with a decrease in GR activity in rat brains, thus reducing the capacity to lower GSSG and increasing the vulnerability to oxidative stress (Barker et al., 1996). GSH may also be converted into mercapturate products catalyzed by glutathione S-transferase (GST) or degraded back to cysteinylglycine and -/-glutamyl-transpeptidase (Jenner, 1993). GSH and GSH-related enzymes are differentially distributed in the CNS (Huang and Philbert, 1995). Disulfide products are abundant in cellular systems and were recently found to interact with MT by facilitating the release of Zn from its clusters (Maret, 1995). Therefore, alterations in the GSH/GSSG ratio that result in increased concentrations of GSSG and other biological disulfides could release and elevate cytoplasmic Zn levels. As a homeostatic response, increased production of MT and/or efflux of Zn may occur (see Fig. 1). Both Zn (Bray and Bettger, 1990) and MT (Sato and Bremner, 1993) have been proposed as antioxidants against ROS and free radicals. However, as discussed in the section on Zn and brain MTs, under constant stress in aging MT isoforms sequester Zn, but are not able to release Zn (Mocchegiani et al., 1998a, 2000b, 2001). While increments in Zn-bound MT may be useful against oxidative stress, low Zn ion bioavailability appears to expedite the efficiency of other brain functions, including synaptic transmission. Hence, an imbalance arises between MT and the GSH oxidative system. This is because the latter needs Zn for its activity (Ryu et al., 2002). Therefore, a correct Zn turnover, via MT and the GSH system, must exist to maintain brain efficiency. The correct balance between Zn turnover and MT is also needed for NO production in the maintenance of the immune response in aging (Mocchegiani et al., 2000b). This is because NO is also involved in Zn release from MT (Zangger et al., 2001). Thus, Zn-bound MT homeostasis, via GSH or NO, is crucial to the maintenance of a correct Zn turnover. Indeed, both low (as discussed above)
162
Mocchegiani E et al.
and high Zn are toxic in many apparatus and systems, including the brain. The interplay among Zn, MT, and GSH or the NO antioxidant system is an important event linking their functions to cellular senescence and death. In the next section, we report evidence of Zn toxicity in the brain.
4.2. Neurotoxicity of Zinc Zn is rather nontoxic compared to other transition metals, such as manganese and iron. However, it has been demonstrated that excess Zn in the extracellular fluid is neurotoxic in the brain (Choi and Koh, 1998). Zn promotes in vitro aggregation of amyloid-(3 protein, the main component of the senile plaques typically observed in the AD brain (Bush et al., 1994). A high concentration of extracellular Zn triggers off the formation of amyloid plaques in the brain (Huang et al., 2000). Synaptically released Zn enters post-synaptic neurons in toxic excess during seizures, resulting in Zn loss in the post-synaptic vesicles. The excessive influx of Zn into post-synaptic neurons leads to neurodegeneration (Choi and Koh, 1998). The translocation of Zn from presynaptic neuron terminals into postsynaptic neurons also occurs after cerebral ischemia (Park and Koh, 1999) and traumatic injury (Suh et al., 2000). After transient forebrain ischemia, Zn released into the synaptic clefts accumulates in neuronal cell bodies followed by degeneration of the neurons (Koh et al., 1996). The prevention of Zn translocation using a Zn chelator has been shown to be neuroprotective in both seizures and ischemia (Koh et al., 1996). Preferential Zn influx through the calcium permeable AMPA/kainate receptor after exposure to NMDA, kainate, or high K + in the presence of 300 |jLmol/L Zn + + causes prolonged mitochondrial superoxide production (Weiss et al., 2000). Zn-dependent production of ROS may be associated with the degeneration of post-synaptic neurons. In the case of exposure of cortical cultures to Zn + + , synaptically released Zn-induced neuronal death exhibits features of both apoptosis and necrosis, and it is mediated by free radical injury (Kim et al., 1999). Recently it has been shown that inZn-T3 null mice, which lack the Zn transporter into the brain, the accumulation of Zn in the synaptic vesicles leads to a degeneration of neurons in the CA1 and CA3 areas of the hippocampus (Lee et al., 2000). In aging, an accumulation of Zn in the synaptic vesicles is not reported. The available data in adult rats (12 months of age) show the highest
163
Zinc, Brain, and Aging
concentration of Zn in CA3 and dentate gyrus, and a decrease in Zn in the cerebellum and cerebral cortex (Sawashita et al, 1997). However, data from our laboratory show a decrease in Zn content in the hippocampus of old rats (28 months of age) (Mocchegiani et al., 2001). This finding suggests that the possible accumulation of Zn in the hippocampus may not occur in aging with no subsequent toxic effect. Thus, it is clear that more studies are necessary to better understand the real reasons why neurodegenerative diseases, such as AD, may appear in aging, since AD has a characteristic accumulation of Zn in the brain as a toxic metal (Bush et al., 1994).
5. ZINC AND AGE-RELATED NEURODEGENERATIVE DISORDERS Zn turnover is different in neurodegenerative disorders. It is diminished in some, but increased in others (see Table 3). In any case, age-related neurodegenerative disorders (AD, PD, and dementia) display diminished Zn levels. Table 3. Plasma Zn status in neurological disorders in humans*. Disorder
Zn status
Alzheimer's disease Dementia Depression Epilepsy Fifth-day fits Mental retardation Pick's disease Schizophrenia Parkinson's disease Multiple sclerosis Amyotrophic lateral sclerosis Brain ischemia Autism Comatose status (brain injury) Anorexia Bulimia
Diminished Diminished Diminished Increased Diminished Diminished Increased Diminished Diminished Diminished Diminished Diminished Diminished Diminished Diminished Diminished
*For references, see Dreosti, 1984; Mills, 1989; McClain et al., 1992; Prasad, 1993; Fabris and Mocchegiani, 1995. Zn=zinc.
164
Mocchegiani E et al.
5.1. Parkinson's Disease Oxidative stress may be an etiologic factor in PD (Jenner et al., 1992). According to Dexter et al. (1989a), post-mortem studies have revealed that the polyunsaturated fatty acid levels in the substantia nigra (SN) of patients with PD were reduced compared to those in other brain regions and in control (normal) tissue. Moreover, malondialdehyde levels were elevated in the SN, suggesting lipid peroxidation (Dexter et al., 1989a). Mitochondrial SOD activities in the SN of patients with PD were also markedly increased (Dexter et al., 1989b; Dexter et al., 1991; Dexter et al, 1992; Jenner et al., 1992), while GSH levels were reduced in both earlyand late-stage PD (Jenner et al., 1992; Sofic et al., 1992). In contrast, there were no significant alterations in the activity of H 2 0 2 degrading enzymes (catalase and GPO) or in the concentrations of free radical scavengers (ascorbic acid and a-tocopherol) (Jenner et al., 1992) and GSSG (Sofic et al., 1992). Recently, it has been shown that Zn deficiency is present in PD (Forsleff et al., 1999). Such a deficiency is correlated with vision problems, olfactory loss, and loss of taste (Forsleff et al., 1999). Conversely, increments in MT have been found in PD (Ebadi et al., 1991). Based on the concepts described above an abnormal increments in Zn-bound MT, which are harmful in aging as no Zn is released due to persistent oxidative stress, it is tempting to ascribe a harmful role to Zn-bound MT in PD by inducing low zinc ion bioavailability. Hence, many brain functions are altered in PD. An intriguing point to support this assumption is the strong increase in NO in PD, with an exacerbation of the disease (Hirsch and Hunot, 2000). An abnormal increase in NO induces limited release of Zn by MT, with subsequent PARP-1 activity towards cell death rather than base excision DNA repair (Mocchegiani et al., 2000b). This condition occurs in damaged immune response in age-related diseases, such as severe infections, and displays high oxidative stress and a persistent inflammatory status (Mocchegiani et al., 2002c). The same mechanism might also occur in the PD brain because it resembles the oxidative and inflammatory status in severe infections in aging.
5.2. Alzheimer's Disease Due to the bulk of data on the biological and biochemical aspects of the AD brain, (see the excellent review by Christen, 2000), we will only
Zinc, Brain, and Aging
165
report on some aspects of the brain in relation to Zn in AD. Zn induces amyloid-fJ aggregation in senile plaque (Bush et al., 1994). As such, the progress of AD may be accelerated because amyloid-(3 aggregation correlates with the expression of the e4 allele of apolipoprotein E, which is a characteristic in late-onset AD (Huang et al., 2000). Zn amyloid-p precipitates at low concentration < 1 0 - 6 M (Bush et al., 1994). However, other studies (Clements et al., 1996; Esler et al., 1996) do not support the report of Bush et al. (1994). Hence, the subject is rather controversial. It is interesting to note that Zn-mediated amyloid- p ^ o precipitation "per se" is not sufficient for neurodegeneration as the co-addition, specifically, of Zn in rat hippocampal primary cultures in a dose-dependent manner reduced amyloid-(31^0 neurotoxicity (Fuson et al., 1996). Post-mortem studies report that Zn is significantly reduced in the temporal lobes, including the hippocampus, and interior parietal and primary visual cortices of AD (Andrasi et al., 1995). Other investigators report no change or an increase in a specific brain area (Deibel et al., 1996). Thus, the specificity and location in brain regions/neurons of any changes in Zn require more study. It is not known if Zn depletion is simply due to a reduction in the number of Zn-containing neurons or the cause of neuronal death in specific areas of AD brains. Decrease in brain Zn concentration contrasts with the role of Zn in amyloid-|3 aggregation. This paradox may be resolved or better understood by taking into account the role of MT in the brain. The absence of MT-III has been reported to be the cause of AD as there is no prevention against aberrant neuronal sprouting and neurofibrillary tangles in AD (Uchida et al., 1991; Palmiter, 1996). Conversely, increments in MT-I+II have been found in AD brains (Zambenedetti et al., 1998). Decrements in MTIII and increments in MT-I+II may be due to compensatory phenomena among MT isoforms, as previously suggested (Penkowa and Hidalgo, 2000). Taking into account the harmful role of MT-I+II because of its exclusive sequestration of Zn with no subsequent Zn release in permanent stress and inflammation, which occurs in aging (Mocchegiani et al., 1998a), it is tempting to interpret MT-I+II as the cause of brain dysfunctions in AD, since it leads to low Zn ion bioavailability. Hence, neuronal cell death occurs with subsequent neurodegeneration. The same phenomena occur in damaged immune response in severe infections in old patients (Mocchegiani et al., 2002c). On the other hand, oxidative stress and
166
Mocchegiani E et al.
persistent inflammatory status are also present in AD (Christen, 2000). Thus, while Zn may be harmful to amyloid-P aggregation, it prevents neuronal death in AD. In this context, Zn-bound MT-I+II homeostasis plays a key role. Therefore, it is necessary to examine, in more detail, this aspect of AD by studying the MT isoforms as a collective group, and not individually as has been done to date. This suggestion is supported by the fact that Down's syndrome subjects who develop AD in the long run display high MT-I+II (Mocchegiani et al., 2002b). Stressed trisomy 16 mouse (experimental model of human Down's syndrome) displays no protective role confered by MT-I+II in the brain (Scortegagna et al., 1998).
6. EFFECT OF ZINC SUPPLEMENTATION IN THE AGING BRAIN Based on the findings and concepts presented in this chapter, it is evident that Zn supplementation may be useful in the aged brain in preventing age-related neurodegenerative disorders. Physiological supplementation with Zn improves and restores the deranged immune-endocrine functions in aging, prolongs the life of old mice (Mocchegiani et al., 2000c), and enhances the resistance to infections in HIV patients (Mocchegiani et al., 1999) and in the elderly (Mocchegiani et al., 2000b). The beneficial effect of Zn supplementation in brain function is controversial in Zn deficiency, aging, and age-related neurodegenerative diseases. Some authors believe that Zn supplementation improves myelination (Dreosti, 1984), while others believe this has deleterious effects (such as cell death or necrosis) since Zn can easily enter the neurons via the Ca ++ -A/K channels, leading to its accumulation in the post-synaptic vesicles and culminating in neuronal toxicity (Weiss et al., 2000). High Zn ion concentrations are certainly toxic due to competition between Zn and other metals, including Ca + + , with the same valence shell electronic structure (Mocchegiani et al., 1998a). Moreover, a high Zn concentration is mitogenic and, as such, might lead to the proliferation of mutated DNA cells, as it does for tumoral cell growth via DNA/RNA polymerase enzyme activity (Mocchegiani et al., 1998a). Therefore, limited bioavailability exists for each metal, being narrow for some and broad for others. The beneficial effect of Zn is strictly dependent on the dose and length of treatment. Physiological doses (two to three times the RDA/day) administered over
Zinc, Brain, and Aging
167
short periods (one to two months) and in periodical cycles are beneficial (Mocchegiani et al., 1998a). Indeed, many authors have reported on the beneficial effect of Zn supplementation (RDA dose of 15 mg Zn ++ /day over a short period of one to seven months) on cognitive functions in children from poor developing countries (for a review see Bhatnagar and Taneja, 2001). The same treatment regimen was found to improve the cognitive function of Down's syndrome subjects (Fabris et al., 1993), the elderly (Clausen et al., 1989), patients with severe head injury (Young et al., 1996), anorexics, and bulimics (Patrick, 2002). Zn supplementation also restores the low activity of (3-adrenoreceptors in the cerebral cortex of old mice (Viticchi et al., 1999). However, caution is necessary in Zn supplementation, since Zn may accelerate amyloid- (34 aggregation in senile plaque with the risk of AD developing (Bush et al., 1994). Therefore, despite the benefits that physiological Zn supplementation confers on the cognitive functions of the elderly and Down's syndrame subjects, caution is required in Zn protocols: one should bear in mind that the former may develop AD with advancing age (Leverenz and Raskind, 1998). Zn supplementation in aging does not lead to further significant increments in the already high MT protein. This suggests that MT is fully saturated by pre-existing Zn ions (Mocchegiani et al., 2002a). Moreover, Zn supplementation provokes faster degradation of MT in lysosomes and favors the complete release of Zn (Klaassen et al., 1994). Therefore, Zn supplementation plays two important roles in aging. First, it gives rise to huge Zn ion bioavailability through faster MT degradation. Second, it avoids continuous sequestration of Zn by MT. Hence, a plateau in the MT protein is maintained with a protective role for MT (Mocchegiani et al., 2002a). Zn supplementation also restores thyroid hormones turnover in aging and Down's syndrome (Fabris et al., 1993), which represents one of the mechanisms involved in improving cognitive functions in both conditions after Zn supply (Licastro et al., 2001). Therefore, good Zn ion bioavailability, via correct Zn-bound MT homeostasis, is crucial to brain function. The satisfactory nutritional profile, good antioxidant activity, normal thyroid hormones turnover, low MT expression, moderate stress, and good cognitive performances in healthy centenarians (Mocchegiani et al., 2002b, 2002c) strongly support this assumption. Altered thyroid status (Thomas et al., 1987), high MT-I+II (Zambenedetti et al, 1998), and low Zn concentration (Andrasi et al., 1995)
168
Mocchegiani E et al.
also appear in AD Even if Zn supplementation is performed as cautioned above, it may benefit the cognitive functions in AD. Alternatively, other antioxidants may be used, especially those related to the Zn pool. Arginine may be useful because its action, other than as a substrate for NO production, is exerted by means of the Zn pool (Fabris and Mocchegiani et al., 1992). In AD, arginine may have two roles. First, it establishes a balance between iNOS and cNOS, which is necessary for NO to go from being neurotoxic to becoming neuroprotective in AD (Law et al., 2001). Second, it leads to endogenous Zn ion bioavailability that avoids the addition of exogenous Zn, which can be harmful. This speculation is supported by the fact that arginine supplementation leads to decreased tumor growth in cancer patients (Fabris and Mocchegiani et al., 1992). Otherwise, they may present increased tumor growth after Zn supplementation due to the mitogenic role of high Zn concentrations (both exogenous and endogenous) (Mills, 1989). It is important to remember that Zn supplementation is always useful in prevention (Mocchegiani et al., 1998a). Therefore, it is recommended in periods of relatively good health. In diseases, it may have contraindications as described in this chapter.
7. CONCLUSIONS AND FUTURE DIRECTIONS It is clear that Zn ion bioavailability plays a crucial role in brain functions during development and aging. It affects synaptic transmission, hormonereleasing factors by the hypothalamus, brain enzymes, gene expression of transcriptional factors, and genes clock (c-fos and egr-1) with reflexes on behavior and cognitive functioning. This complex brain machinery may be regulated by Zn-bound MT homeostasis. Changes in this homeostasis provoke different Zn ion bioavailabilities. Hence, an altered physiological cascade occurs that results in brain dysfunctions. During aging, this physiological cascade is impaired because of the presence of low Zn ion bioavailability, which is due to the continuous sequestration of Zn by MT with no subsequent Zn release. This may lead to reduced uptake of Zn by NMDA and AMPA/kainate receptors, resulting in altered gluatminergic transmission. The exacerbation of this defect may lead to the appearance of agerelated neurodegenerative diseases, particularly PD because Zn is required for correct myelination (Dreosti, 1984). As for AD, the role of Zn is still
Zinc, Brain, and Aging
169
controversial as it can favor amyloid-P aggregation in senile plaque, which may lead to the progression of the dementia. In any case, Zn supplementation in aging is beneficial as it improves cognitive performance and ameliorates the health status. However, the precise role of Zn-bound MT isoforms (I, II, and III) in the aged brain is still not clear due to the presence of compensatory phenomena among the MT isoforms. Hence, the data in the literature are controversial due to the fact that MT-III and MT-I+II have been studied separately. One direction for future research is, thus, to study MT isoforms collectively in an attempt to gain insight into the role of Zn metabolism in the brain during aging and in age-related neurodegenerative diseases. Moreover, no data have been reported on Zn supplementation in PD. An interesting direction for future research is to carry out Zn supplementation in this pathology or, alternatively, to use arginine supplementation in both AD and PD. This is because arginine may act on the endogenous Zn pool and avoid the harmful effects of exogenous Zn in neurodegeneration. However, it is always important to remember that Zn is useful in prevention. Therefore, physiological supplementation of Zn in the healthy elderly is recommended for good health and longevity. Conversely, Zn supplementation must be carried out with caution in the presence of clear neurodegeneration.
ACKNOWLEDGMENTS This paper was supported by the Italian National Research Centers on Aging (INRCA), Italian Health Ministry (RF 99/107 to EM), and CEE (ImAginE project: no. QLK6-CT-1999-02031).
REFERENCES Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, Herbert DC, Walter CA, Weaker FJ, Bowman BH. YY1 and Spl transcription factors bind the human transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci 1996; 51:B66-B75. Agpar J. Comparisons of the effects of copper, manganese and zinc deficiencies on parturition in rats. Am J Physiol 1968; 215:428-432. Agrawal A, Shukla R, Tripathi LM, Pandey VC, Srimal RC. Permeability function related to cerebral microvessel enzymes during aging in rats. Int J Dev Neurosci 1996; 14:87-91. Andrasi E, Farkas E, Scheibler H, Reffy A, Bezur L. Al, Zn, Cu, Mn, and Fe levels in brain in Alzheimer's desease. Arch Gerontol Geriatr 1995; 21:89-97.
170
Mocchegiani E et al.
Aschner M. Metallothionein (MT) isoforms in the central nervous system (CNS): Regional and cell-specific distribution and potential functions as an antioxidant. Neurotoxicology 1998; 19:653-660. Barbieri D, Troiano L, Grassilli E, Agnesini C, Cristofalo EA, Monti D, Capri M, Cossarizza A, Franceschi C. Inhibition of apoptosis by zinc: A reappraisal. Biochem Biophys Res Commun 1992; 187:1256-1261. Barker JE, Heales SJ, Cassidy A, Bolanos JP, Land JM, Clark JB. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res 1996; 716:118-122. Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 1994; 131:331-340. Beg AA, Baltimore D. An essential role for NF-kappa(3 in preventing TNF-alpha-induced cell death. Science 1996; 274:782-784. Ben-Ari Y, Cherubini E. Zinc and GABA in developing brain. Nature 1991; 353:220-221. Bertoni-Freddari C, Fattoretti P, Paoloni R, Caselli U, Galeazzi L, Meier-Ruge W. Synaptic structural dynamics and aging. Gerontology 1996; 42:170-180. Bhatnagar S, Taneja S. Zinc and cognitive development. Br J Nutr 2001; 85:S139-S145. Bray TM, Bettger WJ. The physiological role of zinc as an antioxidant. Free Radic Biol Med 1990; 8:281-291. Bresink I, Ebert B, Parsons CG, Mutschler E. Zinc changes AMPA receptor properties: Results of binding studies and patch clamp recordings. Neuropharmacology 1996; 35:503-509. Bush AI, Pettingell WH, Multhaup G, d' Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265:1464-1467. Cady C, Evans MS, Brewer GJ. Age-related differences in NMDA responses in cultured rat hippocampal neurons. Brain Res 2001; 921:1-11. Caldwell DF, Oberleas D, Clancy JJ. Behavioral impairment in adult rats following acute zinc deficiency. Proc Soc Exp Biol Med 1970; 133:1417-1421. Capurso A, Panza F, Solfrizzi V, Torres F, Capurso C, Mastroianni F, Del Parigi A. Agerelated cognitive decline: Evaluation and prevention strategy. Recenti Prog Med 2000; 91:127-134. Caron PC, Unsworth BR. Alteration of the activity and molecular form of thymidine kinase during development and aging in the mouse cerebellum. Mech Aging Dev 1978; 8:181-195. Carrasco J, Giralt M, Molinero A, Penkowa M, Moos T, Hidalgo J. Metallothionein (MT)-III: Generation of polyclonal antibodies, comparison with MT-I+II in the freeze lesioned rat brain and in a bioassay with astrocytes, and analysis of Alzheimer's disease brains. J Neurotrauma 1999; 16:1115-1129. Carroll BJ. Aging, stress and the brain. Novartis Found Symp 2002; 242:26-36. Choi DW, Koh JY. Zinc and brain injury. Annu Rev Neurosci 1998; 21:347-375. Christen Y. Oxidative stress and Alzheimer's disease. Am J Clin Nutr 2000; 7LS621-S629.
Zinc, Brain, and Aging
171
Clausen J, Nielsen SA, Kristensen PR Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. Biol Trace Elem Res 1989; 20:135-151. Clayton DA, Grosshans DR, Browning MD. Aging and surface expression of hippocampal NMDA receptors. J Biol Chem 2002; 277:14367-14369. Clements A, Allsop D, Walsh DM, Williams CH. Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem 1996; 66:740-747. Cole TB, Robbins CA, Wenzel HJ, Schwartzkroin PA, Palmiter RD. Seizures and neuronal damage in mice lacking vesicular zinc. Epilepsy Res 2000; 39:153-169. Colvin RA, Davis N, Nipper RW, Carter PA. Zinc transport in the brain: Routes of zinc influx and efflux in neurons. J Nutr 2000; 130:S1484-S1487. Cookson MR, Shaw PJ. Oxidative stress and motor neuron disease. Brain Pathol 1999; 9:165-186. Coulter DA. Mossy fiber zinc and temporal lobe epilepsy: Pathological association with altered "epileptic" gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 2000; 41:S96-S99. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262:689-695. Cuajungco MP, Lees GJ. Zinc metabolism in the brain: Relevance to human neurodegenerative disorders. Neurobiol Dis 1997; 4:137-169. Das JP, Divis B, Alexander J, Parrila RK, Naglieri J A. Cognitive decline due to aging among persons with Down syndrome. Res Dev Disabil 1995; 16:461^-78. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996; 143:137-142. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989a; 52:381-389. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 1992; 32:S94-S100. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989b; 52:1830-1836. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51:7-61. Dreosti IE. Zinc and the central nervous system. In: Dreosti IE, Smith RM, editors. Neurobiology of the Trace Elements, Vol.1. New Jersey: Humana Press, 1983: 135-162.
172
Mocchegiani E et al.
Dreosti IE. Zinc in the central nervous system: The emerging interactions. In: Frederickson CJ, Howell GA, Kasarskis EJ, editors. The Neurobiology of Zinc, Part A. New York: Alan R Liss, Inc., 1984: 1-26. Dunn MF, Pattison SE, Storm MC, Quiel E. Comparison of the zinc binding domains in the 7S nerve growth factor and the zinc-insulin hexamer. Biochemistry 1980; 19:718-725. Ebadi M, Murrin LC, Pfeiffer RF. Hippocampal zinc thionein and pyridoxal phosphate modulate synaptic functions. Ann NY Acad Sci 1990; 585:189-201. Ebadi M, Pfeiffer RF. Zinc in neurological disorders and in experimentally induced epileptiform seizures. In: Frederickson CJ, Howell GA, Kasarkis EJ, editors. The Neurobiology of Zinc. New York Alan R Liss, Inc. 1984: 307-327. Ebadi M, Pfeiffer RF, Murrin LC, Shiraga H. Metallothionein and oxidation reactions in Parkinson's disease. Proc West Pharmacol Soc 1991; 34:285-290. Eckles-Smith K, Clayton D, Bickford P, Browning MD. Caloric restriction prevents agerelated deficits in LTP and in NMDA receptor expression. Brain Res Mol Brain Res 2000;78:154-162. Eisen A, Calne D. Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease: Phylogenetic disorders of the human neocortex sharing many characteristics. Can J Neurol Sci 1992; 19:117-123. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD. Disruption of the metallothionein-III gene in mice: Analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 1997; 17:1271-1281. Esler WP, Stimson ER, Jennings JM, Ghilardi JR, Mantyh PW, Maggio JE. Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. J Neurochem 1996; 66:723-732. Fabris N. Zinc, nervous system and aging. Aging 1997a; 9:28-29. Fabris N, Mocchegiani E. Arginine-containing compounds and thymic endocrine activity. Thymus 1992; 19:S21-S30. Fabris N, Mocchegiani E. Zinc, human diseases and aging. Aging 1995; 7:77-93. Fabris N, Mocchegiani E, Albertini G. Psyho-endocrine immune interactions in Down's syndrome: Role of zinc. In Castellss, Wisiniewski KE, editors. Growth Hormone Treatment in Down's Syndrome. New York: John Wiley 1994: 203-218. Fabris N, Mocchegiani E, Provinciali M. Plasticity of neuroendocrine-thymus interactions during aging. Exp Gerontol 1997b; 32:415^29. Favier AE. Hormonal effects of zinc on growth in children. Biol Trace Elem Res 1992; 32:383-398. Forsleff L, Schauss AG, Bier ID, Stuart S. Evidence of functional zinc deficiency in Parkinson's disease. J Altern Complement Med 1999; 5:57-64. Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 1989;31:145-238. Frederickson CJ, Suh SW, Silva D, Thompson RB. Importance of zinc in the central nervous system: The zinc-containing neuron. J Nutr 2000; 130:S1471-S1483.
Zinc, Brain, and Aging
173
Frick KM, Burlingame LA, Delaney SS, Berger-Sweeney J. Sex differences in neurochemical markers that correlate with behavior in aging mice. Neurobiol Aging 2002; 23:145-158. Fuson KS, Boggs LN, May PC. Zinc promotes A(3 aggregation but attenuates A(3 neurotoxicity. Neurobiol Aging 1996; 17:S108-S112. Giacconi R, Cipriano C, Muzzioli M, Gasparini N, Mocchegiani E. Inter-relationships among brain, endocrine and immune response in aging and successful aging: Role of metallothionein-III isoform. Mech Aging Dev 2002, in press. Giardino L, Zanni M, Fernandez M, Battaglia A, Pignataro O, Calza L. Plasticity of GABA(a) system during aging: Focus on vestibular compensation and possible pharmacological intervention. Brain Res 2002; 929:76-86. Globus MY, Ginsberg MD, Busto R. Excitotoxic index: A biochemical marker of selective vulnerability. Neurosci Lett 1991; 127:39^12. Goldblum SE, Cohen DA, Jay M, McClain CJ. Interleukin 1-induced depression of iron and zinc: Role of granulocytes and lactoferrin. Am J Physiol 1987; 252:E27-E32. Golub MS, Keen CL, Gershwin ME, Hendrickx AG. Developmental zinc deficiency and behaviour. J Nutr 1995; 125:S2263-S2271. Golub MS, Takeuchi PT, Keen CL, Gershwin ME, Hendrickx AG, Lonnerdal B. Modulation of behavioral performance of prepubertal monkeys by moderate dietary zinc deprivation. Am J Clin Nutr 1994; 60:238-243. Griffith WH, Murchison DA. Enhancement of GABA-activated membrane currents in aged Fischer 344 rat basal forebrain neurons. J Neurosci 1995; 15:2407-2416. Guidolin D, Polato P, Venturin G, Zanotti A, Mocchegiani E, Fabris N, Nunzi MG. Correlation between zinc level in hippocampal mossy fibers and spatial memory in aged rats. Ann NY Acad Sci 1992; 673:187-193. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388:482^488. Gupta A, Hasan M, Chander R, Kapoor NK. Age-related elevation of lipid peroxidation products: Diminution of superoxide dismutase activity in the central nervous system of rats. Gerontology 1991; 37:305-309. Halas ES, Sandstead HH. Some effects of prenatal zinc deficiency on behavior of the adult rat. PediatrRes 1975; 9:94-97. Halas ES, Sandstead HH. Malnutrition and behavior: The performance versus learning problem revisited. J Nutr 1980; 110:1858-1864. Halliwell B, Gutteridge JM. Free radicals, lipid peroxidation, and cell damage. Lancet 1984;2:1095-1096. Halsted JA, Ronaghy HA, Abadi P, Haghshenass M, Amirhakemi GH, Barakat RM, Reinhold JG. Zinc deficiency in man. The Shiraz experiment. Am J Med 1972; 53: 277-284. Hartoma TR, Sotaniemi EA, Maattanen J. Effect of zinc on some biochemical indices of metabolism. Nutr Metab 1979; 23:294-300.
174
Mocchegiani E et al.
Hirsch EC, Hunot S. Nitric oxide, glial cells and neuronal degeneration in Parkinsonism. Trends Pharmacol Sci 2000; 21:163-165. Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 2000; 130:S1488-S1492. Huntington CE, Shay NF, Grouzmann E, Arseneau LM, Beverly JL. Zinc status affects neurotransmitter activity in the paraventricular nucleus of rats. J Nutr 2002; 132:270-275. Hurley LS, Shrader RE. Congenital malformations of the nervous system in zinc-deficient rats. In: Pfeiffer CC, editor. Neurobiology of the Trace Metals Zinc and Copper. New York: Academic Press, 1972: 7-51. Hurley LS, Swenerton H. Congenital malformation resulting from zinc deficiency in rats. Proc Soc Exp Biol Med 1966; 123:692-697. Jacob ST, Ghoshal K, Sheridan JF. Induction of metallothionein by stress and its molecular mechanisms. Gene Expr 1999; 7:301-310. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 1993; 146:6-13. Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992; 42:2241-2250. Jin LW, Saitoh T. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging 1995; 6:136-149. Johansen FF, Tonder N, Berg M, Zimmer J, Diemer NH. Hypothermia protects somatostatinergic neurons in rat dentate hilus from zinc accumulation and cell death after cerebral ischaemia. Mol Chem Neuropathol 1993; 18:161-172. Kagi JH, Schaffer A. Biochemistry of metallothionein. Biochemistry 1988; 27:8509-8515. Keller KA, Grider A, Coffield JA. Age-dependent influence of dietary zinc restriction on short-term memory in male rats. Physiol Behav 2001; 72:339-348. Kelly EJ, Quaife CJ, Froelick GJ, Palmiter RD. Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. J Nutr 1996; 126:1782-1790. Khoury SA, Sowers JR. Age-related changes in male sexual function. In: Sowers JS, Felicetta JV, editors. Endocrinology of Aging. New York: Raven Press, 1988: 113-134. Kim YH, Kim EY, Gwag BJ, Sohn S, Koh JY. Zinc-induced cortical neuronal death with features of apoptosis and necrosis: Mediation by free radicals. Neuroscience 1999; 89:175-182. Kiprianova I, Sandkuhler J, Schwab S, Hoyer S, Spranger M. Brain-derived neurotrophic factor improves long-term potentiation and cognitive functions after transient forebrain ischaemia in the rat. Exp Neurol 1999; 159:511-519. Klaassen CD, Choudhuri S, McKim JM Jr, Lehman-McKeeman LD, Kershaw WC. In vitro and in vivo studies on the degradation of metallothionein. Environ Health Perspect 1994;102:141-146. Koh JY, Suh SW, Gwag BJ, He YY, Hsu CY, Choi DW. The role of zinc in selective neuronal death after transient global cerebral ischaemia. Science 1996; 272:1013-1016. Kottler ML, Counis R, Bouchard P. Mutations of the GnRH receptor gene: A new cause of autosomal-recessive hypogonadotropic hypogonadism. Arch Med Res 1999; 30:481^185.
Zinc, Brain, and Aging
175
Krezoski SK, Villalobos J, Shaw CF III, Petering DH. Kinetic lability of zinc bound to metallothionein in Ehrlich cells. Biochem J 1988; 255:483^191. Kuehl-Kovarik MC, Magnusson KR, Premkumar LS, Partin KM. Electrophysiological analysis of NMDA receptor subunit changes in the aging mouse cortex. Mech Aging Dev 2000; 115:39-59. Lalonde R, Badescu R. Exploratory drive, frontal lobe function and adipsia in aging. Gerontology 1995; 41:134-144. Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: The putative links between nitric oxide and dementia of the Alzheimer type. Brain Res Brain Res Rev 2001; 35:73-96. Le DA, Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001; 18:717-724. Ledig M, Fried R, Ziessel M, Mandel P. Regional distribution of superoxide dismutase in rat brain during postnatal development. Brain Res 1982; 256:333-337. Lee JY, Cole TB, Palmiter RD, Koh JY. Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: Evidence against synaptic vesicle origin. JNeurosci 2000; 20:79-82. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down's syndrome patients: A regional quantitative analysis. Exp Neurol 1998; 150:296-304. Levine JM, Reynolds R, Fawcett JW. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001; 24:39^17. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000; 17:871-890. Licastro F, Mariani RA, Faldella G, Carpene E, Guidicini G, Rangoni A, Grilli T, Bazzocchi G. Immune-endocrine status and coeliac disease in children with Down's syndrome: Relationships with zinc and cognitive efficiency. Brain Res Bull 2001; 55:313-317. MacDonald NJ, Decorti F, Pappas TC, Taglialatela G. Cytokine/neurotrophin interaction in the aged central nervous system. JAnat 2000; 197:543-551. Magneson GR, Puvathingal JM, Ray WJ Jr. The concentrations of free Mg2 + and free Zn2 + in equine blood plasma. J Biol Chem 1987; 262:11140-11148. Magnusson KR, Cotman CW. Age-related changes in excitatory amino acid receptors in two mouse strains. Neurobiol Aging 1993; 14:197-206. Magnusson KR, Nelson SE, Young AB. Age-related changes in the protein expression of subunits of the NMDA receptor. Brain Res Mol Brain Res 2002; 99:40^15. Magnusson KR, Scanga C, Wagner AE, Dunlop C. Changes in anesthetic sensitivity and glutamate receptors in the aging canine brain. J Gerontol A Biol Sci Med Sci 2000b; 55:B448-B454. Magnusson KR. Aging of glutamate receptors: Correlations between binding and spatial memory performance in mice. Mech Aging Dev 1998; 104:227-248. Magnusson KR. Declines in mRNA expression of different subunits may account for differential effects of aging on agonist and antagonist binding to the NMDA receptor. J Neurosci 2000a; 20:1666-1674.
176
Mocchegiani E et al.
Magnusson KR. Influence of diet restriction on NMDA receptor subunits and learning during aging. Neurobiol Aging 2001; 22:613-627. Maret W. Metallothionein/disulfide interactions, oxidative stress, and the mobilization of cellular zinc. Neurochem Int 1995; 27:111-117. Markesbery WR, Ehmann WD, Alauddin M, Hossain TI. Brain trace element concentrations in aging. Neurobiol Aging 1984; 5:19-28. Massaro TF, Mohs M, Fosmire G. Effects of moderate zinc deficiency on cognitive performance in young adult rats. Physiol Behav 1982; 29:117-121. Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL, Palmiter RD. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 1994; 14:5844-5857. Mataga N, Fujishima S, Condie BG, Hensch TK. Experience-dependent plasticity of mouse visual cortex in the absence of the neuronal activity-dependent marker egrl/zif268. J Neurosci 2001; 21:9724-9732. Mayer ML, Vyklicky L Jr. The action of zinc on synaptic transmission and neuronal excitability in cultures of mouse hippocampus. J Physiol 1989; 415:351-365. McCall KA, Huang C, Fierke CA. Function and mechanism of zinc metalloenzymes. / Atar2000; 130:S1437-S1446. McClain CJ, Stuart MA, Vivian B, McClain M, Talwalker R, Snelling L, Humphries L. Zinc status before and after zinc supplementation of eating disorder patients. J Am Coll Nutr 1992; 11:694-700. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: Implications for cognition and aging. Neurology 1997; 48:S8-S15. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21:195-218. McLay RN, Freeman SM, Harlan RE, Ide CF, Kastin AJ, Zadina JE. Aging in the hippocampus: Interrelated actions of neurotrophins and glucocorticoids. Neurosci BiobehavRev 1997; 21:615-629. McMahon RJ, Cousins RJ. Regulation of the zinc transporter ZnT-1 by dietary zinc. Proc Natl Acad Sci USA 1998; 95:4841-4846. Melov S. Therapeutics against mitochondrial oxidative stress in animal models of aging. Ann NY Acad Sci 2002; 959:330-340. Migani P, Magnone MC, Rossolini G, Piantanelli L. Excitatory amino acid receptors in the prefrontal cortex of aging mice. Neurobiol Aging 2000; 21:607-612. Mills CI. Zinc in Human Biology. London: Spring-Verlag, 1989. Mirsky R, Jessen KR. The neurobiology of Schwann cells. Brain Pathol 1999; 9:293-311. Mocchegiani E, Giacconi R, Cipriano C, Gasparini N, Orlando F, Stecconi R, Muzzioli M, Isani G, Carpene E. Metallothioneins (I+11) and thyroid-thymus axis efficiency in old mice: Role of corticosterone and zinc supply. Mech Aging Dev 2002a; 123:675-694. Mocchegiani E, Giacconi R, Cipriano C, Muzzioli M, Fattoretti P, Bertoni-Freddari C, Isani G, Zambenedetti P, Zatta P. Zinc-bound metallothioneins as potential biological markers of aging. Brain Res Bull 2001; 55:147-153.
Zinc, Brain, and Aging
111
Mocchegiani E, Giacconi R, Cipriano C, Muzzioli M, Gasparini N, Moresi R, Stecconi R, Suzuki H, Cavalieri E, Mariani E. MTmRNA gene expression, via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: Lessons from very old mice and humans. Exp Gerontol 2002b; 37:349-357. Mocchegiani E, Giacconi R, Muzzioli M, Cipriano C. Zinc, infections and immunosenescence. Mech Aging Dev 2000a; 121:21-35. Mocchegiani E, Muzzioli M, Cipriano C, Giacconi R. Zinc, T-cell pathways, aging: Role of metallothioneins. Mech Aging Dev 1998a; 106:183-204. Mocchegiani E, Muzzioli M, Gaetti R, Veccia S, Viticchi C, Scalise G. Contribution of zinc to reduce CD4+ risk factor for "severe" infection relapse in aging: Parallelism with HIV. Int J Immunopharmacol 1999; 21:271-281. Mocchegiani E, Muzzioli M, Giacconi R. Zinc and irnrnunoresistance to infection in aging: New biological tools. Trends Pharmacol Sci 2000b; 21:205-208. Mocchegiani E, Muzzioli M, Giacconi R. Zinc, metallothioneins, immune responses, survival and aging. Biogerontology 2000c; 1:133-143. Mocchegiani E, Muzzioli M, Giacconi R, Cipriano C, Gasparini N, Franceschi C, Gaetti R, Cavalieri E, Suzuki H. Metallothioneins/PARP-l/IL-6 interplay on natural killer cell activity in elderly: Parallelism with nonagenarians and old infected humans. Effect of zinc supplementation. Mech Aging Dev 2002c, in press. Mocchegiani E, Santarelli L, Tibaldi A, Muzzioli M, Bulian D, Cipriano K, Olivieri F, Fabris N. Presence of links between zinc and melatonin during the circadian cycle in old mice: Effects on thymic endocrine activity and on the survival. J Neuroimmunol 1998b; 86:111-122. Mooradian AD, Scarpace PJ. Beta-adrenergic receptor activity of cerebral microvessels is reduced in aged rats. Neurochem Res 1991; 16:447-451. Mori T, Okano I, Mizuno K, Tohyama M, Wanaka A. Comparison of tissue distribution of two novel serine/threonine kinase genes containing the LEVI motif (LIMK-1 and LIMK-2) in the developing rat. Brain Res Mol Brain Res 1997; 45:247-254. Morley JE, Gordon J, Hershman JM. Zinc deficiency, chronic starvation, and hypothalamic-pituitary-thyroid function. Am J Clin Nutr 1980; 33:1767-1770. Morris ME, Viswanathan N, Kuhlman S, Davis FC, Weitz CJ. A screen for genes induced in the suprachiasmatic nucleus by light. Science 1998; 279:1544—1547. Murphy EK, Spencer RL, Sipe KJ, Herman JP. Decrements in nuclear glucocorticoid receptor (GR) protein levels and DNA binding in aged rat hippocampus. Endocrinology 2002;143:1362-1370. Newman HM, Yang RS, Magnusson KR. Effects of developmental exposure to lead, magnesium and zinc mixtures on spatial learning and expression of NMDA receptor subunit mRNA in Fischer 344 rats. Toxicol Lett 2002; 126:107-119. Nichols NR, Zieba M, Bye N. Do glucocorticoids contribute to brain aging? Brain Res Brain Res Rev 2001; 37:273-286. Nicolle MM, Bizon JL, Gallagher M. In vitro autoradiography of ionotropic glutamate receptors in hippocampus and striatum of aged Long-Evans rats: Relationship to spatial learning. Neuroscience 1996; 74:741-756.
178
Mocchegiani E et al.
Nishimura N, Nishimura H, Ghaffar A, Tohyama C. Localization of metallothionein in the brain of rat and mouse. J Histochem Cytochem 1992; 40:309-315. Nistico G, Ciriolo MR, Fiskin K, Iannone M, De Martino A, Rotilio G. NGF restores decrease in catalase activity and increases superoxide dismutase and glutathione peroxidase activity in the brain of aged rats. Free Radio Biol Med 1992; 12:177-181. Odeh M. The role of zinc in acquired immunodeficiency syndrome. J Intern Med 1992; 231:463-469. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16:439^144. Ozata M, Odabasi Z, Caglayan S, Beyhan Z, Vural O, Ozdemir C. Event-related brain potentials in male hypogonadism. J Endocrinol Invest 1999; 22:508-513. Palmer AM. Preservation of N-mefhyl-D-aspartate receptor binding sites with age in rat neocortex. J Gerontol A Biol Sci Med Sci 2000; 55:B530-B532. Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci USA 1998; 95:8428-8430. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci USA 1992; 89:6333-6337. Park J A, Koh JY. Induction of an immediate early gene egr-1 by zinc through extracellular signal-regulated kinase activation in cortical culture: Its role in zinc-induced neuronal death. J Neurochem 1999; 73:450-456. Pascale A, Nogues X, Marighetto A, Micheau J, Battaini F, Govoni S, Jaffard R. Cytosolic hippocampal PKC and aging: Correlation with discrimination performance. Neuroreport 1998; 9:725-729. Patrick L. Eating disorders: A review of the literature with emphasis on medical complications and clinical nutrition. Altern Med Rev 2002; 7:184—202. Pattison SE, Dunn MF. On the relationship of zinc ion to the structure and function of the 7S nerve growth factor protein. Biochemistry 1975; 14:2733-2739. Penkowa M, Hidalgo J. IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brainstem after 6-aminonicotinamide treatment. Exp Neurol 2000; 163:72-84. Penkowa M, Nielsen H, Hidalgo J, Bernth N, Moos T. Distribution of metallothionein I + II and vesicular zinc in the developing central nervous system: Correlative study in the rat. J Comp Neurol 1999; 412:303-318. Prasad AS, Halsted JA., Nadimi M. Syndrome of iron deficiency anemia, hepatosplenomegalia, hypogonadism, dwarfism and geophagia. Am J Med 1961; 31:532-536. Prasad AS. Biochemistry of Zinc. New York: Plenum Press, 1993. Rains TM, Shay NF. Increased protein intake during recovery from zinc deficiency is accompanied by alterations in hypothalamic growth hormone releasing factor and somatostatin. Nutr Neurosci 2001; 4:273-281. Record IR, Dreosti IE. Effects of zinc deficiency on the liver and brain thymidine kinase activity in the fetal rat. Nutr Rep Int 1979; 20:749-753. Rehman HU, Masson EA. Neuroendocrinology of aging. Age Aging 2001; 30:279-287.
Zinc, Brain, and Aging
179
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58:445-452. Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in SIRS general medical patients. Cytokine 2001; 15:232-236. Roeden JM, Zitman FG. Aging in adults with Down's syndrome in institutionally-based and community-based residences. J Intellect Disabil Res 1995; 39:399—407. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci 1995; 18:130-136. Rylett RJ, Williams LR. Role of neurotrophins in cholinergic-neuron function in the adult and aged CNS. Trends Neurosci 1994; 17:486^190. Ryu R, Shin Y, Choi JW, Min W, Ryu H, Choi CR, Ko H. Depletion of intracellular glutathione mediates zinc-induced cell death in rat primary astrocytes. Exp Brain Res 2002; 143:257-263. Saito T, Takahashi K, Nakagawa N, Hosokawa T, Kurasaki M, Yamanoshita O, Yamamoto Y, Sasaki H, Nagashima K, Fujita H. Deficiencies of hippocampal Zn and ZnT3 accelerate brain aging of rat. Biochem Biophys Res Commun 2000; 279:505-511. Sandstead HH. Zinc: Essentiality for brain development and function. Nutr Rev 1985; 43:129-137. Sandyk R, Awerbuch GI. Multiple sclerosis: The role of the pineal gland in its timing of onset and risk of psychiatric illness. Int J Neurosci 1993; 72:95-106. Sato M, Bremner I. Oxygen free radicals and metallothionein. Free Radic Biol Med 1993; 14:325-337. Sawashita J, Takeda A, Okada S. Change of zinc distribution in rat brain with increasing age. Brain Res Dev Brain Res 1997; 102:295-298. Schneider-Maunoury S, Topilko P, Seitandou T, Levi G, Cohen-Tannoudji M, Pournin S, Babinet C, Charnay P. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 1993; 75:1199-1214. Scortegagna M, Galdzicki Z, Rapoport SI, Hanbauer I. In cortical cultures of trisomy 16 mouse brain the upregulated metallofhionein-I/H fails to respond to H 2 0 2 exposure or glutamate receptor stimulation. Brain Res 1998; 787:292-298. Segovia G, Del Arco A, Mora F. Effects of aging on the interaction between glutamate, dopamine, and GAB A in striatum and nucleus accumbens of the awake rat. J Neurochem 1999; 73:2063-2072. Segovia G, Porras A, Del Arco A, Mora F. Glutamatergic neurotransmission in aging: A critical perspective. Mech Aging Dev 2001; 122:1-29. Smart TG, Xie X, Krishek BJ. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Prog Neurobiol 1994; 42:341-393. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142:128-130.
180
Mocchegiani E et al.
Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain aging. J Anat 2000; 197:575-585. Stengaard-Pedersen K, Fredens K, Larsson LI. Enkephalin and zinc in the hippocampal mossy fiber system. Brain Res 1981; 212:230-233. Suh SW, Chen JW, Motamedi M, Bell B, Listiak K, Pons NF, Danscher G, Frederickson CJ. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. Brain Res 2000; 852:268-273. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998; 19:287-298. Takeda A. Movement of zinc and its functional significance in the brain. Brain Res Brain Res Rev 2000a; 34:137-148. Takeda A, Akiyama T, Sawashita J, Okada S. Brain uptake of trace metals, zinc and manganese in rats. Brain Res 1994; 640:341-344. Takeda A, Takefuta S, Okada S, Oku N. Relationship between brain zinc and transient learning impairment of adult rats fed zinc-deficient diet. Brain Res 2000b; 859:352-357. Tapia-Arancibia L, Astier H. Pharmacological properties of the NMDA receptor involved in somatostatin release from cortical neurons. Eur J Pharmacol 1990; 186:319-322. Taubeneck MW, Daston GP, Rogers JM, Gershwin ME, Ansari A, Keen CL. Tumor necrosis factor-alpha alters maternal and embryonic zinc metabolism and is developmentally toxic in mice. J Nutr 1995; 125:908-919. Thakran P, Leuschen MP, Ebadi M. Metallothionein induction in rat hippocampal neurons in primary culture. In Vivo 1989; 3:191-197. Thomas DR, Hailwood R, Harris B, Williams PA, Scanlon MF, John R. Thyroid status in senile dementia of the Alzheimer type (SDAT). Acta Psychiatr Scand 1987; 76:158-163. Touitou Y, Bogdan A, Haus E, Touitou C. Modifications of circadian and circannual rhythms with aging. Exp Gerontol 1997; 32:603-614. Troy CM, Salvesen GS. Caspases on the brain. J Neurosci Res 2002; 69:145-150. Turgeon SM, Albin RL. GABAB binding sites in early adult and aging rat brain. Neurobiol Aging 1994; 15:705-711. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M, The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68-amino acid metallothionein-like protein. Neuron 1991; 7:337-347. Uchida Y. Growth-inhibitory factor, metallothionein-like protein, and neurodegenerative diseases. Biol Signals 1994; 3:211-215. Vallee BL. The function of metallothionein. Neurochem Int 1995; 27:23-33. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev 1993; 73:79-118. Van der Klink JJ, Blonk RW, Schene AH, van Dijk FJ. The benefits of interventions for work-related stress. Am J Public Health 2001; 91:270-276. Villares JC, Stavale JN. Age-related changes in the N-methyl-D-aspartate receptor binding sites within the human basal ganglia. Exp Neurol 2001; 171:391-404.
Zinc, Brain, and Aging
181
Viticchi C, Moresi R, Piantanelli L. Modulation of mouse brain cortex adrenoceptor in old mice by supplementation of zinc and thymomodulin. Gerontology 1999; 45:265-268. Vogt K, Mellor J, Tong G, Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 2000; 26:187-196. Wallwork JC, Botnen JH, Sandstead HH. Influence of dietary zinc on rat brain catecholamines. J Nutr 1982; 112:514-519. Wauben IP, Xing HC, Wainwright PE. Neonatal dietary zinc deficiency in artificially reared rat pups retards behavioral development and interacts with essential fatty acid deficiency to alter liver and brain fatty acid composition. J Nutr 1999; 129:1773-1781. Weiss JH, Sensi SL, Koh JY. Zn(2+): A novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci 2000; 21:395-401. Wenk GL, Stemmer KL. Activity of the enzymes dopamine-beta-hydroxylase and phenylethanolamine-N-methyltransferase in discrete brain regions of the copper-zinc deficient rat following aluminium ingestion. Neurotoxicology 1982; 3:93-99. White G, Gurley DA. Alpha subunits influence Zn block of gamma-2 containing GABAA receptor currents. Neuroreport 1995; 6:461^-64. Williams LR. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev 1995; 7:55-73. Worley PF, Bhat RV, Baraban JM, Erickson CA, McNaughton BL, Barnes CA. Thresholds for synaptic activation of transcription factors in hippocampus: Correlation with longterm enhancement. J Neuwsci 1993; 13:4776^1786. Yamashita A, Kurokawa T, Fujii Y, Yasuda H, Ishibashi S. Difference in sensitivity to alkaline phosphatase treatment between rat reticulocyte membranes in which beta-adrenoceptor desensitization was induced by isoproterenol, dibutyryl cAMP and phorbol ester. Eur J Pharmacol 1990; 188:229-234. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T. Inhibition of the DNA-binding activity of NF-kappa p by gold compounds in vitro. FEBS Lett 1995; 361:89-96. Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, Boddy A, Kupiec JW. Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 1996; 276:538-543. Zambenedetti P, Giordano R, Zatta P. Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease. J Chem Neuroanat 1998; 15:21-26. Zangger K, Oz G, Haslinger E, Kunert O, Armitage IM. Nitric oxide selectively releases metals from the amino-terminal domain of metallothioneins: Potential role at inflammatory sites. FASEB J 2001; 15:1303-1305.
This page is intentionally left blank
CHAPTER 7
Transition Metals, Oxidation, Lipoproteins, and Amyloid-p: Major Players in Alzheimer's Disease Anatol Kontush ABSTRACT Since transition metals are known to accumulate in Alzheimer's disease lesions, increased oxidative stress represents a well-established characteristic of Alzheimer's disease, extracellular fluids of the brain contain lipoproteins that easily carry oxidizable lipids and can be oxidatively modified, and amyloid-p, a peptide containing 39 to 42 amino acids and a major component of amyloid plaques, is associated with lipoproteins and possesses a structure that implies a strong influence on oxidative processes, it is proposed that the complex interplay of transition metals, increased oxidative stress, lipoproteins and amyloid-p plays an underlying role in the pathogenesis of Alzheimer's disease. Increased production of amyloid-p in a form of lipoprotein antioxidant under the action of increased oxidative stress in aging with subsequent chelation of transition metal ions (first of all, copper), accumulation of amyloid-p metal lipoprotein complexes, their maturation into amyloid plaques, production of reactive oxygen species, and neurotoxicity are reviewed and postulated to form the temporal sequence of events in the development of Alzheimer's disease. Chelation of copper by amyloid-P is proposed to be the most important component of this amyloid-P-copper model. Keywords: Alzheimer's disease; amyloid-p; transition metals; oxidation; lipoproteins; antioxidants.
183
184
Kontush A
1. INTRODUCTION Deposition of amyloid-|3 (ApS) is thought to play a central role in the development of Alzheimer's disease (AD). Accumulation of ApJ in the form of senile plaques is a pathological hallmark of the disease. According to the widely accepted amyloid cascade hypothesis, increased production of A(3, especially of its longer and more amyloidogenic form A(342, leads to the formation of amyloid plaques (Hardy, 1997). The extracellularly located plaques subsequently cause the formation of intracellularly located neurofibrillary tangles (NFTs), another essential feature of the AD brain, and neuronal death. There is good experimental evidence to support the primary role of A (3 in this temporal sequence. Mutations which have been linked genetically to AD, that is, those in the genes coding for amyloid-(3 protein precursor (ApPP), presenilin-1 (PS-1), and presenilin-2 (PS-2), bring about alteration in Ap metabolism, resulting in the elevation in the brain of either total Ap or Ap42 (Selkoe, 1998). However, 5% of all cases of AD are associated with such mutations and are classified as familial AD (FAD) (Smith and Perry, 1998), whereas an overwhelming majority of AD cases are sporadic. It remains unexplained how amyloid plaques can be formed in the absence of any genetically determined increase in A|3 synthesis. Remarkably, the amyloid cascade hypothesis does not contain any explanation for the basal ApS production that is known to occur in neurons and many other cells (Haas et al., 1992). It is, therefore, no wonder that a physiologic role of AfJ continues to be a mystery. In contrast to FAD mutations, normal aging represents a factor that is a clear contributor to all AD cases (Smith et al., 2000c), including those of FAD (which do not develop until the brain has aged to a required stage, despite increased levels of A(3 production). It is unclear which factors are responsible for Ap deposition in the aging brain. One of the earliest pathological events in AD is oxidative damage to vulnerable neurons (Smith et al., 2000c). The damage is not limited to AD lesions, but instead involves the neuronal cytoplasm and precedes lesion formation. Increased intracellular production of reactive oxygen species (ROS) by abnormal mitochondria caused by damage to mitochondrial enzymes has been proposed to be responsible for the observed effects (Bonilla et al., 1999). It is surely not a coincidence that qualitatively similar changes are found in normal aging (Shigenaga et al., 1994). Importantly,
Transition Metals, Oxidation, Lipoproteins, and Amyloid-p
185
the cytoplasm of vulnerable neurons shows a striking increase in transition metals, which are potent catalysts of ROS production (Perry and Smith, 1998). Imbalance in the metabolism of transition metals and their extra- and intracellular accumulation in the AD brain have been repeatedly demonstrated (Bush, 2000). Thus, it is feasible that accumulation of ApS in AD is related to increased oxidative stress and imbalanced metabolism of transition metals experienced by the brain in aging. It is important to emphasize that neuronal cells, first of all astrocytes, are the major source of A(3 in brain (Haas et al., 1992; Busciglio et al., 1993). Secreted A(3 is associated with lipoprotein particles (Koudinov and Koudinova, 1997). Thus, ApS is an apolipoprotein. This can be expected, due to the fact that C-terminus of Ap is highly hydrophobic (Brasseur et al., 1997). Taking into account the extracellular location of amyloid plaques, one can assume that A|3 plaque originates from brain lipoproteins. The lipoprotein origin of A(3 in plaques is supported by a close correspondence between the deposition of apolipoprotein E (apoE), the major brain apolipoprotein (Koch et al., 2001), and A(3 in AD brains (Han et al., 1994), as well as by the presence of apoE in amyloid plaques (Wisniewski and Frangione, 1992).
2. TRANSITION METALS Metabolism of transition metals is heavily impaired in the AD brain (Bush, 2000). The brain is a specialized organ that concentrates transition metals. For example, the cerebral cortex contains the highest concentrations of zinc (Zn) in the body (Bush et al., 1994). Therefore, the brain must have efficient mechanisms to prevent abnormal distribution of metals. Transition metals are known to accumulate in two types of AD lesions: amyloid plaques and NFTs. A comparison of neuropil obtained from AD patients and control subjects reveals elevation of Zn, iron (Fe), and copper (Cu) in the former. The highest concentration of transition metals are measured in amyloid plaques (Lovell et al., 1998). Significant elevation of Fe and Zn was observed in multiple regions of the AD brain compared to the controls (Cornett et al., 1998). A significant increase in Zn and Fe was found in the AD hippocampus and amygdala, areas showing severe histopathologic alterations in AD. None of these elements were significantly imbalanced in the cerebellum, which is minimally affected
186
Kontush A
(Deibel et al., 1996). Accordingly, Cu, Fe, and Zn are increased in the cerebrospinal fluid (CSF) of AD patients (Hershey et al., 1983; Basun et al., 1991). Brain homeostasis of Fe is disrupted in AD. In AD brain tissue, Fe is present in the NFTs and amyloid plaques. Both amyloid plaques and NFTs contain redox-active Fe, which is not bound to normal Fe-binding proteins and can catalyze oxidation in situ (Smith et al., 1997). Transferrin, an important Fe-binding protein, is homogenously distributed around amyloid plaques and is apparently extracellular. In addition, transferrin is decreased in AD brain tissue, particularly in the cortical regions (Connor et al., 1992b). Ferritin, another Fe-binding protein, is abundant in amyloid plaques and many blood vessels in AD brains (Connor et al., 1992a). Brain homeostasis of Cu is also severely affected. Ceruloplasmin (CP) is increased by more than 60% in the AD brain compared to elderly controls, in all brain regions (Loeffler et al., 1996). In the cortex, 22% of amyloid plaques contain CP, which is present intracellularly in neurons and astrocytes and extracellularly in neuropil. In AD, CP is also increased in CSF (Loeffler et al., 1994). In addition, metallothionein (MT) III, a strong chelator for Cu and Zn, is reduced in the AD cortex (Yu et al., 2001).
3. OXIDATION Transition metal ions, such as Cu(II) and Fe(III), are capable of promoting oxidative stress by the production of highly reactive hydroxyl radicals via the Fenton reaction. Usually, transition metal ions are tightly bound in a redox-inactive state to their transport or storage proteins. Under some conditions, transition metals may be pathologically released and/or reduced to their highly active low valency form. This makes them potent oxidants. For example, human CP, which contains six to seven Cu atoms per molecule of protein, can efficiently promote oxidation in the presence of superoxide-generating systems that reduce CP Cu (Fox et al., 2000). There has been increasing evidence that metal-catalyzed oxidation is particularly important for AD as pathologically deposited metal ions represent a feature of this disorder (Bush, 2000). There are various studies demonstrating elevated products of lipid peroxidation, including thiobarbituric acid-reactive substances (Lovell
Transition Metals, Oxidation, Lipoproteins, and Amyloid- fi
187
et al., 1995) and 4-hydroxy-2-nonenal (HNE) (Markesbery and Lovell, 1998), in the brain tissue of AD patients compared to the controls. These studies are supported by more recent publications which observe increased F2-isoprostanes, stable markers of peroxidation of arachidonic acid, in the brains of AD patients compared with age-matched controls (Pratico et al., 1998). Interestingly, the differences in F2-isoprostanes are highest in the temporal and frontal cortices, brain regions which are particularly affected in AD. Acrolein, another endproduct of lipid peroxidation which is more toxic than HNE and is produced to a much higher extent, has also been found to be increased in AD brains (Lovell et al., 2001). It is important to mention that increased accumulation of oxidation products in AD is not confined to lipids, but is also relevant to other biomolecules such as proteins and DNA (Smith et al., 2000c). In addition, antioxidant enzymes are frequently elevated in the brains of AD patients, probably in response to increased oxidative stress (Markesbery, 1997). The discovery of increased levels of oxidation in the brains of AD patients led to the measurement of lipid peroxidation in body fluids, especially in CSF. Case-control studies in AD patients reveal a set of alterations in lipid peroxidation in CSF that correspond to the observations made in the brain. Antioxidative vitamins C and E, as well as easily oxidizable polyunsaturated fatty acids (PUFAs), are decreased in the CSF of AD patients (Schippling et al., 2000). In addition, CSF F2-isoprostanes are increased in AD (Pratico et al., 1998; Montine et al., 1999). Elevated levels of oxidation in AD are not restricted to the brain and CSF compartments, but to some extent are also observed as systemic oxidative stress in plasma (Schippling et al., 2000) and urine (Tuppo et al., 2001), body fluids that are more easily available for possible monitoring of antioxidant pharmacotherapy.
4. LIPOPROTEINS Human CSF contains primarily spherical lipoproteins of approximately 13nm to 22 nm in diameter with a density of approximately 1.09 g/mL to 1.15 g/mL, which corresponds to the density of high and very high density lipoproteins (HDL and VHDL) of human plasma (Pitas et al., 1987, Borghini et al., 1995). ApoE and apolipoprotein A-I (apoA-I) are the
188
Kontush A
major CSF apolipoproteins and are contained in separate populations of lipoproteins. The major lipoprotein fraction consists of particles of 13 nm to 20 nm containing apoE and apoA-I, as well as apoA-IV, apoD, apoH, and apoJ (Koch et al., 2001). In the second particle class (13 nm to 18 nm), mainly apoA-I and apoA-II, but no apoE, are detected. In the third class, there is a small number of large particles (18 nm to 22 nm) containing no apoA-I, but apoE, associated with apoA-IV, apoD, and apoJ. CSF also contains low levels of small particles (10 nm to 12nm) with low lipid content containing apoA-IV, apoD, apoH, and apoJ. It is essential to emphasize that lipoproteins with similar properties are expected to be present in extracellular fluids of the brain. Similar to plasma lipoproteins, CSF lipoproteins carry a variety of easily oxidizable lipids and can be oxidatively modified in vitro (Arlt et al., 2000). Interestingly, the CSF lipoproteins of AD patients are more sensitive to in vitro oxidation than those of controls. This was demonstrated in a post-mortem study (Bassett et al., 1999) and antemortem study (Bassett et al., 1999; Schippling et al., 2000). Oxidation of CSF lipoproteins can have similar pathophysiological consequences as oxidation of brain lipids. Oxidized lipids have a plethora of toxic effects towards neuronal cells (Keller et al., 1999). It has been demonstrated that oxidized lipoproteins of human CSF are neurotoxic by disrupting neuronal microtubule organization in neuronal cell culture (Bassett et al., 1999).
5. A3 Soluble A3, a peptide containing 39 to 42 amino acids, is associated with CSF lipoprotein particles of 17 nm and approximately 200 kDa of relative molecular mass (Koudinov et al., 1996). The main ApS species associated with CSF-HDL is A^l-40. Similarly, soluble A|3 is associated with lipoprotein particles in normal human plasma, in particular with the HDL and VHDL fractions where it is complexed to apoJ and, to a lesser extent, to apoA-I (Koudinov et al., 1994). Human hepatoma HepG2 cells secrete soluble A(3 as an apolipoprotein in the culture media. Soluble A(3 in the cell supernatant is detected in 200- to 300-kDa lipoprotein complexes in association with apoA-I, apoJ, phospholipids, triglycerides, and free and esterified cholesterol (Koudinov and Koudinova, 1997). When added to plasma HDL, exogenous Api-40 is bound to many HDL apolipoproteins, mainly to apoA-I, apoA-II, apoE, and apoJ (Koudinov et al., 1998).
Transition Metals, Oxidation, Lipoproteins, and Amyloid-ji
189
Reconstituted, protein-free HDL lipid particles also bind Ap and inhibit its aggregation. ApS is one of several known oblique-oriented peptides that have a hydrophobicity gradient and are partially inserted into lipids by their more hydrophobic C-terminal tail (Brasseur et al., 1997). Ap binding to lipids may play an important role in maintaining the peptide in solution. Ap possesses a structure that implies a strong influence on oxidative processes. A(3 has two major sites that are potentially important for its activity towards oxidation. The first site is located in the hydrophilic Nterminal part of the peptide and consists of three histidine (at positions 6, 13, and 14) and one tyrosine (at position 10) residues, all of which are known to efficiently chelate transition metal ions (Lovstad, 1987). Chelation of transition metals in a redox-inactive form at this site may theoretically serve to inhibit metal-catalyzed oxidation of biomolecules. The second site is found in the lipophilic C-terminal part of A(3 and consists of single methionine residue at position 35. The free sulfhydryl group of the methionine can both scavenge free radicals (Soriani et al., 1994) and reduce transition metals to their high-active low valency form (Lynch and Frei, 1997), thereby possessing both anti- and pro-oxidative properties. Recently, Ap has been shown to be a very efficient chelator for transition metal ions (Atwood et al., 2000). A particularly strong binding is observed for Cu, which is a more efficient catalyst of oxidation than other transition metals. A(31-42 has a higher affinity to Cu(II) than A(3140, with an apparent stability constant of Ap-Cu complexes reaching 2 • 1017 NT 1 and 1.6 • 1010 M _ 1 , respectively (Atwood et al., 2000). This is comparable to the affinity of the best metal chelators ever known, such as ethyleneaminetetraacetic acids. Compared to Cu, Fe is a less suitable ligand for Ap. Ap appears to possess two binding sites for Cu (located between residues 6 to 14), which differ in their affinity. Cu presumably binds to the nitrogen atoms of all three histidine residues of Ap (Miura et al., 2000), as well as to amide groups of the N-terminus (Atwood et al., 2000). Compared to chelation (which occurs instantly), reduction of transition metals by A p is slow. Its rate constant can be estimated at about l O ' l V P ^ 1 (Huang et al., 1999a). It is also only efficient at high (micromolar) concentrations of Ap and presumably occurs through metal interaction with Met35. Reduced metal ions are highly active oxidants and can catalyze further oxidation of biomolecules. It is worth mentioning that
190
Kontush A
A(342 is a more effective reductant than AfS40 (Huang et al., 1999a), which can be related to its higher efficiency as a metal chelator (Atwood et al., 2000). Thus, the efficiency of metal reduction by A(3 can be influenced by the efficiency of metal binding to the peptide. Concurring with this observation, Ap reduces Cu(II) more efficiently than Fe(III).
6. INTERPLAY BETWEEN TRANSITION METALS, LIPOPROTEINS, OXIDATION, AND A0 IN ALZHEIMER'S DISEASE Increased oxidative stress is related to the development of AD (Smith et al., 2000c) and A(3 is considered to be an important pro-oxidant in this process (Markesbery, 1997; Varadarajan et al., 2000). The pro-oxidative properties of A(3 have been known for about a decade. In various biochemical systems, Ap efficiently initiates oxidation of different biomolecules. It induces peroxidation of membrane lipids and lipoproteins, generates H 2 0 2 and HNE in neurons, damages DNA, and inactivates transport enzymes. Importantly, to induce oxidation, Ap must be present at high concentrations, typically in a micromolar range. In addition, Ap preparations must be "aged" (incubated over a relatively long period of time at room temperature) to become aggregated and fibrillated. Fibrillated Ap is able to initiate free radical processes that result in protein oxidation, lipid peroxidation, ROS formation, and cellular dysfunction, leading to calcium ion accumulation and subsequent neuronal death. Chain-breaking antioxidants, such as vitamins E or C, can abrogate these processes (Markesbery, 1997; Varadarajan et al., 2000). The production of H 2 0 2 is thought to be central to Ap toxicity (Behl et al., 1994). To be toxic, Ap must be fibrillated (Iversen et al., 1995). It has been shown that Ap aggregation to fibrils, which are essential to its toxicity and pro-oxidative activity, is caused by traces of transition metals inevitably present in laboratory buffers (Moir et al., 1999). In vitro, Ap is readily aggregated by transition metal ions, such as Cu(II), Fe(III), Zn(II), and Al(III) (Atwood et al., 1998). Transition metals are such efficient precipitation agents that binding of even one atom of Cu or Zn leads to Ap precipitation (Atwood et al., 2000). In contrast, in the absence of metals Ap is monomeric, has a-helix conformation, and does not form
Transition Metals, Oxidation, Lipoproteins, and Amyloid-/3
191
aggregates (Liu et al., 1999). ApJl-42 is more prone to aggregation, probably due to its higher metal affinity, compared to A31-40 (Atwood etal., 1998). The molecular mechanism of A@ aggregation by Zn or Cu includes the formation of intermolecular crosslinks between (3-sheets of A3 by the atoms of metal. The crosslinks are formed between the nitrogen atoms of all three histidine residues in A(3 (Miura et al., 2000). Histidine-13 seems to be essential to A3 aggregation (Liu et al., 1999). As a result, the ApJl40 aggregates formed have about three to four metal atoms per molecule of A3 (Atwood et al., 1998). Of particular importance is the fact that the presence of transition metals is not only required for A3 aggregation, but also for its pro-oxidative activity. Fe is required for the toxicity and pro-oxidative activity of aged preparations of ApS25-35 and A3142 to neuronal cells, whereas Fe chelators protect the cells from A3 (Schubert and Chevion, 1995; Rottkamp et al., 2001). Cu potentiates the neurotoxicity of human Ap (Huang et al., 1999b). Incubation of A|3140 and A|3142 with transition metals leads to the generation of H 2 0 2 (Huang et al., 1999a). Therefore, A3 toxicity is likely to be mediated by a direct interaction between A(3 and transition metals, with the subsequent generation of ROS (Huang et al., 1999b; Rottkamp et al., 2001). Another factor essential to the pro-oxidative activity of A3 seems to be the presence of Met35 (Walter et al., 1997). The triple requirements of fibrillation, transition metals, and presence of Met35 for the pro-oxidative activity of A3 can be understood by taking into account its redox properties. In order to function as a pro-oxidant, A3 must first bind metals to its metal-binding site(s) and then reduce them in its metal-reducing site to produce ROS (such as hydroxyl radicals from H 2 0 2 ). However, metals are bound to the N-terminal hydrophilic part of A3, whereas metal reduction occurs at its C-terminal part. Since metals must be placed in the vicinity of the reductant to be reduced, fibrillation is likely to fulfil this task by forming complexes where metal atoms bound to the N-terminal part of one molecule of A3 are simultaneously available for the reductive Met35 residues belonging to other A3 molecules. The reduced transition metal ions formed can participate in further redox reactions by generating various free radical species. Due to the relatively slow reduction of metals by A3 (Huang et al., 1999a), this mechanism is only operative at high (micromolar) concentrations of the peptide.
192
Kontush A
Thus, to accelerate oxidation, A(3 must be present in concentrations greatly exceeding those usually measured in biological fluids, that is, micromolar versus nanomolar (Kontush, 2001; Kontush et al., 2001a; Markesbery, 1997). In addition, A(5 must be aggregated to fibrils by transition metals. Fibrillated A(3 is highly toxic to neurons and other cells (Iversen et al., 1995). In contrast, at low nanomolar concentrations (that is, those circulating in CSF and plasma), A(3 is monomeric and functions as an antioxidant (Kontush, 2001; Kontush et al., 2001a). At these low concentrations, ApS is nontoxic and even has beneficial effects on neuron survival, axonal length, and neurite outgrowth (Whitson et al., 1990; Yankner et al., 1990; Koo et al., 1993). These activities may be related to the antioxidative properties of the peptide. Moreover, if A(3 is kept monomeric, it functions as an antioxidant even at micromolar concentrations by protecting neurons from transition metals (Zou et al., 2002). Unlike pro-oxidative properties, the antioxidative activity of A@ peptides is hardly studied. Recently, exogenously added A(3 has been demonstrated to inhibit metal-catalyzed oxidation of lipoproteins from human CSF and plasma (Kontush, 2001; Kontush et al., 2001a). More importantly, the effect is observed at the peptide concentration measured in these biological fluids (0.1 nM to 1 nM), whereas at higher A(3 concentrations its antioxidant action is abolished. Both ApS140 and A(3142 are efficient antioxidants, whereas the A(325-35 fragment is much less effective. In contrast, all Afi peptides are unable to considerably influence metal-independent lipoprotein oxidation, suggesting that the antioxidative activity of A(3 is mainly mediated by chelating transition metal ions via its hydrophilic moiety rather than by free radical scavenging through Met35. Nevertheless, the latter mechanism contributes to the antioxidative activity of A(3, since A(325-35 is able to inhibit lipid peroxidation (at low, compared to lipids, concentrations of the peptide) and since replacement of Met35 by Leu considerably weakens the effect (Walter et al., 1997). Endogenous A(3 present in the CSF can also act as an antioxidant. This is suggested by the positive correlation between CSF resistance to oxidation and its levels of A|3 (Kontush et al., 2001b). The level of A£42 correlates better with CSF oxidative resistance than that of A@40 (Kontush et al., 2001b), which accords with stronger metal binding to A(3142 than Apl40 (Atwood et al., 2000). CSF from AD patients has lower oxidative resistance than CSF from control subjects (Schippling
Transition Metals, Oxidation, Lipoproteins, and Amyloid-j8
193
et al., 2000), in accordance with increased oxidative stress known to occur in AD (Smith et al., 2000c). Since Ap has antioxidative properties at its CSF concentrations, this agrees with its lower CSF levels typically measured in AD patients as compared to control subjects (Pirttila et al., 1994; Kontush et al., 2001b). An antioxidant role for A(3 in vivo is in agreement with recent data on the distribution of oxidative damage to AD neurons. 8-Hydroxyguanosine (80HG), a major product of nucleic acid oxidation, markedly accumulates in the cytoplasm of cerebral neurons in AD. Unexpectedly, an increase in A3 deposition in the AD cortex is associated with a decrease in the neuronal level of 80HG, that is, with decreased oxidative damage (Nunomura et al., 1999). A similar negative correlation between A3 deposition and oxidative damage is found in patients with Down's syndrome (DS) (Nunomura et al., 2000). These findings indicate that in brains of patients with AD and DS, A(3 deposition is related to decreased oxidative damage. Thus, the formation of amyloid plaques may be considered as a compensatory response that reduces oxidative stress (Smith et al., 2000c). In lipoproteins, a more hydrophilic metal-binding region of A(3 extends into the aqueous phase where it can bind transition metals (Brasseur et al., 1997). Neuronal cell cultures secrete a high molecular weight product, presumably a lipoprotein complex, that possesses an antioxidative activity (Berndt et al., 1998). Taken together with the antioxidative properties of A(3, these data suggest that A3 is an antioxidant secreted as a part of lipoprotein complexes. A3 can function as a preventive lipoprotein-associated antioxidant that binds transition metal ions in inactive form and prevents them from catalyzing lipoprotein oxidation. Protection from hydroxyl radicals that can be generated by transition metal ions must occur in the nearest vicinity of the protected molecules. This implies that lipoproteins must be protected in their nearest vicinity, a task that is easily performed by a lipoprotein-associated chelator such as A3- The amphiphilic properties of A(3 may allow extracellular chelation of metal ions, which have avoided binding by hydrophilic chelators and reached the lipoproteins. The physiologic relevance of the antioxidative properties of A (3 is determined by its physiologic concentration and level of oxidative stress in vivo. The level of A3 in CSF, that is, 0.1 nM to 1 nM, (Pirttila et al., 1994; Kontush et al., 2001b) corresponds to about one molecule of
194
Kontush A
A(3 per 100 lipoprotein particles. Exogenous A(3 at 0.1 nM, that is, at about one molecule of A(3 per 100 lipoprotein particles, delays autoxidation of tenfold diluted CSF in vitro (Kontush et al., 2001a). This implies that the endogenous level is sufficient to considerably delay autoxidation. Mild oxidation of lipoproteins in vitro (such as autoxidation) should better reflect their hypothetical in vivo oxidation than strong oxidation, such as that induced by micromolar amounts of Cu(II) (see Neuzil et al., 1997). Taken together, these data suggest that A(3 may well function as an antioxidant for CSF lipoproteins under normal physiologic conditions. Altogether, data on the activities of Ap to oxidation imply that it may change from being an antioxidant into a pro-oxidant if its concentration increases enough to induce its substantial fibrillation, and if transition metal ions are available to catalyze this process. Various stress conditions are known to increase A(3 production. More importantly, A@ production increases under oxidative stress induced in different ways. Both H 2 0 2 and ultraviolet irradiation elevate the production of A(3 peptides in monkey eye lenses (Frederikse et al., 1996) and neuroblastoma cells (Zhang et al., 1997; Olivieri et al., 2001). H 2 0 2 upregulates both the secretion of ApJ in the cell medium (Olivieri et al., 2001) and levels of A|3 in the cell (Misonou et al., 2000). The antioxidants Trolox and dimethyl sulfoxide are able to block this effect (Misonou et al., 2000). Increased production of A(3 in the presence of H 2 0 2 is not related to increased synthesis of A(3PP, but rather to increased generation of A(3 from A(3PP (Misonou et al., 2000). The upregulation of ApJ production from ApSPP is likely to occur through the activation of A(3-l transcription factor (Frederikse et al., 1996). Other sources of oxidative stress, though less common than H 2 0 2 , similarly lead to increased A(3 production in cell culture. Inorganic mercury decreases cellular glutathione and increases the release of Af5 from neuroblastoma cells (Olivieri et al., 2000). Paired helical filaments from AD patients generate superoxide radicals and increase the release of A(3 from neurons (Yan et al., 1995). Interestingly, secretion of A|3 is also increased when oxidative stress is induced by micromolar concentrations of ApJ itself (Olivieri et al., 2001). This provides a feedback loop mechanism that allows A(3 to increase its own production, which can be considered a vicious circle (Zhang et al., 1997). A(3 generation can also be increased when cells are subjected to a more general metabolic stress. For example, serum deprivation increases
Transition Metals, Oxidation, Lipoproteins, and Amyloid- ji
195
A(3 production by human neurons (LeBlanc, 1995) and inhibition of energy metabolism results in increased amyloidogenic ApiPP processing by (3-secretase (Gabuzda et al., 1994). Finally, AfS production increases in vivo after brain injury. In patients with head injury, both A(340 and, especially, A(342 increase in CSF during the first week following the trauma (Raby et al., 1998). Fatal head injury results in the formation of diffuse parenchymal deposits of A(3 in the brain, all of which contain A(342 as a major component (Gentleman et al., 1997). Notably, the post-traumatic deposits of A(3 do not arise as a result of passive leakage from damaged cerebral blood vessels, but are similar to the early AJ342 deposits observed in AD and DS. In addition, Ap accumulates in the brain as a response to ischemic/hypoxic injury localized to the cerebral cortex (Jendroska et al., 1995). Taken together, these data strongly suggest that A(3 behaves as a stressrelated protein whose synthesis is increased under stress conditions. The antioxidant metal-chelating properties of A(3 may form a rationale for this phenomenon. Indeed, an increase in A(3 production may be aimed at chelating potentially harmful transition metal ions which can be released, such as from metal-binding proteins, during abnormal cellular metabolism and otherwise catalyze adverse oxidation of biomolecules. This mechanism was proposed recently (Berthon, 2000). It is supported by the fact that increased levels of oxidative damage (measured as neuronal 80HG immunoreactivity) occur prior to the onset of A(3 deposition in the brains of patients with DS (Nunomura et al., 1999). The increase in A3 production may be a regulatory response which helps cells to cope with abnormal metabolism of transition metals (Smith et al., 2000b). Since A3 binds Cu stronger than Fe and other transition metals (Atwood et al, 2000), and Cu is a more efficient catalyst of oxidation than other transition metals (Sayre et al., 2000), chelation of Cu by Afi can be viewed as the most important part of this ApJ-Cu (A(3C) model. Processing of A(3PP to A3 has been suggested more than a decade ago to represent the release of an active peptide ligand and to constitute a part of the reactive plasticity response to neuronal loss (Whitson et al., 1989). Now, when A3 production is known to occur by a fundamental mechanism of regulated intramembrane proteolysis (Brown et al., 2000), its obligatory physiologic significance is even more prominent. Assuming that oxidative stress causes the increase in A(3 generation in AD, its source becomes central in explaining this pathology. Oxidative damage to neurons
196
Kontush A
is one of the earliest pathological events in AD (Smith et al., 2000c). Mitochondria have long been known to be the major source of ROS in actively metabolic cells (Cadenas and Davies, 2000). This is especially true of neurons, since the brain accounts for 20% to 25% of the total body oxygen consumption, but for less than 2% of the total body weight. Superoxide is a major ROS produced by the mitochondrial respiratory chain as a result of direct "electron leakage" to oxygen. Superoxide can be further metabolized to H 2 0 2 by catalase. Steady-state concentrations of superoxide and H 2 0 2 in the mitochondrial matrix are about 10~10M and 10~8M, respectively (Cadenas and Davies, 2000). H 2 0 2 may diffuse from the mitochondrial matrix into the cytosol and extracellular space, where it can react with redox-active transition metal ions to produce highly reactive hydroxyl radicals. More importantly, superoxide leakage from the mitochondrial respiratory chain increases sharply in aging due to accumulated damage to the mitochondrial DNA and respiratory chain enzymes (Shigenaga et al., 1994). It is worth mentioning that AD most strongly affects brain regions with the highest metabolic rate and expression of mitochondrial enzymes. Thus, mitochondria may represent an important source of ROS in aging and AD. Increased ROS production may lead to increased generation of A(3 as a compensatory response, similar to increased synthesis of antioxidant enzymes well-documented in AD (Markesbery, 1997). This mechanism implies that transition metal ions become abnormally sequestered and need to be chelated in a redox-inactive form by A(3. It is noteworthy that Ap aggregation by transition metals is accelerated at acidic pH (Atwood et al., 1998). Since it is well-known that inflammation decreases pH in the vicinity of the inflammation site, it can facilitate the formation of amyloid plaques. In addition, inflammation leads to increased secretion of CR a Cu-transporting protein, from the liver and accelerated transfer of Cu to the inflammation site (Berthon, 1993). This cascade may represent an important source for redox-active Cu in AD, since microglial activation and inflammation typically accompany this disease (McRae et al., 1997) and CP is increased in the AD brain (Loeffler et al., 1996). While free Cu does not exist in the cytosol (Rae et al., 1999), extracellular Cu may be more readily exchangeable and increased levels of CP-bound Cu may facilitate Cu interaction with A(3. In addition, transition metals released into extracellular space from synapses
Transition Metals, Oxidation, Lipoproteins, and Amyloid-/3
197
upon depolarization (Kardos et al., 1989), as well as Fe produced from mitochondrial heme upon its degradation in the cells (Smith et al., 2000b), may serve as other potential sources for metals in A(3-metal complexes. The A(3-metal complexes formed must be efficiently removed, which may occur through lipoprotein receptors known to be abundant in the CNS (Danik et al., 1999). The balance between synthesis and degradation is very fine, since in most early-onset FAD cases A|3 accumulation is caused by only about a 50% increase in A3 anabolism (Iwata et al., 2000). Degradation is likely to be effective in young age and, in the absence of genetically linked increase in A(3 production is observed in FAD. In contrast, increased oxidative stress in the aged brain can lead to increased production of redox-active transition metals which can, in turn, lead to increased production of A^-metal complexes. At one stage, the efficient removal of A(3-metal complexes can be overtaken by their disproportionately high generation. This can result in their accumulation in a form of A(3 oligomers and/or early (diffuse) senile plaques. Transition metal ions are indeed highly enriched in the plaques (Lovell et al., 1998). Diffuse plaques do not contain fibrillated A(B and are not toxic (Yankner, 1996). Their accumulation can, thus, be considered as a final nonpathological stage of this protective pathway and should, inversely, correlate with oxidative damage, as has recently been reported (Nunomura et al., 2001). In contrast, A(3 oligomers have a fibrillated structure, are highly toxic, and may represent the toxin responsible for neurodegeneration in AD (Klein et al., 2001). It is interesting to speculate that diffuse plaques may represent a form of detoxification of ApJ oligomers, such as deactivation by Zn, as has recently been suggested (Cuajungco et al., 2000). Late (compact) amyloid plaques can be another toxic form of aggregated A(3. They contain fibrillated A(3 and can lead to the formation of pathological structures, such as NFTs, in neurons (Mann and Esiri, 1989). Remarkably, compact plaques contain redox-active transition metal ions that can catalyze H202-dependent oxidation in vitro, and may thereby exert pro-oxidant activity in vivo (Sayre et al., 2000). This finding suggests that compact amyloid plaques may represent a pathological stage of the Ap production pathway, when metal sequestration in the redox-inactive form becomes ineffective. However, a negative correlation between the accumulation of compact plaques and 80HG (Nunomura et al., 2000) contradicts this assumption.
198
Kontush A
Whatever the nature of the toxic form of Af3, the antioxidant activity of A(3 evolves into pro-oxidant activity, representing a typical gain-offunction transformation which can further stimulate A(3 production and prove a feedback loop mechanism to accelerate plaque growth via a "seeding" mechanism (Irizarry et al., 1997). This can further worsen the situation. Massive accumulation of A(3 in the brain of AD patients might be accordingly considered as a hyper-response to increased oxidative stress in aging. This model is in accordance with the recently proposed three-stage mechanism of neurodegeneration in AD comprising protein aggregation in neural tissue, oxidation of neural tissue mediated by redoxactive metal ion interaction with a target protein, and functional demise (Bush, 2000). It also agrees with the accumulation of early amyloid plaques in cognitively normal individuals, which can be considered as a successful compensation for aging. In contrast, an unsuccessful compensation, that is, when "the primary pathogenic force" (Smith et al., 2000a) is too strong, is accompanied by an uncontrollable growth of plaques and represents AD. Finally, this mechanism allows an explanation of a well-known epidemiological association between aluminum exposure and incidence of AD (Wisniewski and Wen, 1992) by accelerated formation of A(3 aggregates in the presence of aluminum ions, which are well-established initiators of A(3 aggregation (Mantyh et al., 1993). Similarly, increased incidence of AD in subjects having the apoE4 allele (Smith, 2000) can be related to its decreased, compared to apoE3, ability to bind transition metals (Miyata and Smith, 1996), thereby preventing their binding to A|3.
REFERENCES Arlt S, Finckh B, Beisiegel U, Kontush A. Time course of oxidation of lipids in human cerebrospinal fluid in vitro. Free Radic Res 2000; 32:103-114. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush Al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273:12817-12826. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush Al. Characterization of copper interactions with Alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid betal-42. J Neurochem 2000; 75:1219-1233.
Transition Metals, Oxidation, Lipoproteins, and Amyloid-B
199
Bassett CN, Neely MD, Sidell KR, Markesbery WR, Swift LL, Montine TJ. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 1999; 34:1273-1280. Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm ParkDis Dement Sect 1991; 3:231-258. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77:817-827. Berndt C, Kontush A, Beisiegel U. Neuronal cell cultures protect low density lipoprotein from oxidation. Neurobiol Aging 1998; 19:S284. Berthon G. Is copper pro- or anti-inflammatory? A reconciling view and a novel approach for the use of copper in the control of inflammation. Agents Actions 1993; 39:210-217. Berthon G. Does human betaA4 exert a protective function against oxidative stress in Alzheimer's disease? Med Hypotheses 2000; 54:672-677. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA. Mitochondrial involvement in Alzheimer's disease. Biochem Biophys Acta 1999; 1410:171-182. Borghini I, Barja F, Pometta D, James RW. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochem Biophys Acta 1995; 1255:192-200. Brasseur R, Pillot T, Lins L, Vandekerckhove J, Rosseneu M. Peptides in membranes: Tipping the balance of membrane stability. Trends Biochem Sci 1997; 22:167-171. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 2000; 100:391-398. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and non-neuronal cells. Proc Natl Acad Sci USA 1993; 90:2092-2096. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000; 4:184-191. Bush AI, Pettingell WH, Multhaup G, d'Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265:1464-1467. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29:222-230. Connor JR, Menzies SL, St. Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992a; 31:75-83. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992b; 31:327-335. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998; 19:339-345. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. / Biol Chem 2000;275:19439-19442.
200
Kontush A
Danik M, Champagne D, Petit-Turcotte C, Beffert U, Poirier J. Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit Rev Neurobiol 1999; 13:357-407. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996; 143:137-142. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radio Biol Med 2000; 28:1735-1744. Frederikse PH, Garland D, Zigler JS Jr, Piatigorsky J. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 1996; 271:10169-74. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 1994; 269:13623-13628. Gentleman SM, Greenberg BD, Savage MJ, Noori M, Newman SJ, Roberts GW, Griffin WS, Graham DI. A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Neuroreport 1997; 8:1519-1522. Haas C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359:322-325. Han SH, Hulette C, Saunders AM, Einstein G, Pericak-Vance M, Strittmatter WJ, Roses AD, Schmechel DE. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol 1994;128:13-26. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-159. Hershey CO, Hershey LA, Varnes A, Vibhakar SD, Lavin P, Strain WH. Cerebrospinal fluid trace element content in dementia: Clinical, radiologic, and pathologic correlations. Neurology 1983; 33:1350-1353. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999a; 38:7609-7616. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999b; 274:37111-37116. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997; 17:7053-7059.
Transition Metals, Oxidation, Lipoproteins, and Amyloid-p
201
Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS. The toxicity in vitro of beta-amyloid protein. Biochem J 1995; 311:1-16. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, KawashimaMorishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major Abetal-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000; 6:143-150. Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen-Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervos-Navarro J, DeArmond SJ. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (Berl) 1995; 90:461^166. Kardos J, Kovacs I, Hajos F, Kalman M, Simonyi M. Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. NeurosciLett 1989; 103:139-144. Keller JN, Hanni KB, Markesbery WR. Oxidized low-density lipoprotein induces neuronal death: Implications for calcium, reactive oxygen species, and caspases. / Neurochem 1999; 72:2601-2609. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 2001; 24:219-224. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-1151. Kontush A. Amyloid-beta: An antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radio Biol Med 2001; 31:1120-1131. Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schippling S, Beisiegel U. Amyloidbeta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001a; 30:119-128. Kontush A, Donarski N, Beisiegel U. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content. Free Radic Res 2001b; 35:507-517. Koo EH, Park L, Selkoe DJ. Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 1993; 90:4748^1752. Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994; 205:1164-1171. Koudinov AR, Berezov TT, Kumar A, Koudinova NV. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: Association with apolipoprotein and lipids. Clin Chim Acta 1998; 270:75-84. Koudinov AR, Koudinova NV. Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol Int 1997; 21:265-271. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with high density lipoproteins. Biochem Biophys Res Commun 1996; 223:592-597.
202
Kontush A
LeBlanc A. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: Possible involvement of apoptosis. J Neurosci 1995; 15:7837-7846. Liu ST, Howlett G, Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry 1999; 38:9373-9378. Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, Pomara N, LeWitt PA. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 1994; 8:190-197. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ, Dick RD, Troyer MD, Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 1996; 738:265-274. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acidreactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45:1594-1601. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158:47-52. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001; 22:187-194. Lovstad RA. Copper catalyzed oxidation of ascorbate (vitamin C). Inhibitory effect of catalase, superoxide dismutase, serum proteins (ceruloplasmin, albumin, apotransferrin) and amino acids. Int J Biochem 1987; 19:309-313. Lynch SM, Frei B. Physiological thiol compounds exert pro- and antioxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochim Biophys Acta 1997; 1345:215-221. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989; 89:169-179. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993; 61:1171-1174. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19:33-36. McRae A, Dahlstrom A, Ling EA. Microglial in neurodegenerative disorders: Emphasis on Alzheimer's disease. Gerontology 1997; 43:95-108. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 2000; 39:6951-6959. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 2000; 39:7024-7031. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55-61.
Transition Metals, Oxidation, Lipoproteins, and Amyloid-f5
203
Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, Smith JD, Tanzi RE. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 1999; 38:4595^-603. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52:562-565. Neuzil J, Thomas SR, Stacker R. Requirement for, promotion, or inhibition by alphatocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radio Biol Med 1997; 22:57-71. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 2001; 60:759-767. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann NY Acad Sci 1999; 893:362-364. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down's syndrome. J Neuropathol Exp Neurol 2000; 59:1011-1017. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, Brockhaus M, Brack C. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: Effects on beta-amyloid secretion and tau phosphorylation. JNeurochem 2001; 76:224-233. Olivieri G, Brack C, Muller-Spahn F, Stahelin HB, Herrmann M, Renard P, Brockhaus M, Hock C. Mercury induces cell cytotoxicity and oxidative stress and increases betaamyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. JNeurochem 2000; 74:231-236. Perry G, Smith MA. Is oxidative damage central to the pathogenesis of Alzheimer's disease? Acta Neurol Belg 1998; 98:175-179. Pirttila T, Kim KS, Mehta PD, Frey H, Wisniewski HM. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 1994; 127:90-95. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987; 262:14352-14360. Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-1783. Raby CA, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Emmerling MR. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. J Neurochem 1998; 71:2505-2509. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 1999; 284:805-808.
204
Kontush A
Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001;30:447-450. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem 2000; 74:270-279. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 2000; 28:351-360. Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995; 216:702-707. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8:447^153. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994; 91:10771-10778. Smith JD. Apolipoprotein E4: An allele associated with many diseases. Ann Med 2000; 32:118-127. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94:9866-9868. Smith MA, Joseph JA, Perry G. Arson. Tracking the culprit in Alzheimer's disease. Ann NY Acad Sci 2000a; 924:35-38. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer's disease. Antioxid Redox Signal 2000b; 2:413^120. Smith MA, Perry G. What are the facts and artifacts of the pathogenesis and etiology of Alzheimer's disease? J Chem Neuroanat 1998; 16:35^11. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000c; 1502:139-144. Soriani M, Pietraforte D, Minetti M. Antioxidant potential of anaerobic human plasma: Role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 1994; 312:180-188. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 2001; 54:565-568. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid betapeptide-associated free radical oxidative stress and neurotoxicity. / Struct Biol 2000; 130:184-208. Walter MF, Mason PE, Mason RP. Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem Biophys Res Commun 1997; 233:760-764. Whitson JS, Glabe CG, Shintani E, Abcar A, Cotman CW. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett 1990; 110:319-324. Whitson JS, Selkoe DJ, Cotman CW. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 1989; 243:1488-1490.
Transition Metals, Oxidation, Lipoproteins, and Amyloid-fi
205
Wisniewski HM, Wen GY. Aluminum and Alzheimer's disease. Ciba Found Symp 1992; 169:142-164. Wisniewski T, Frangione B. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135:235-238. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, al e. Nonenzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid betapeptide. Nat Med 1995; 1:693-699. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996; 16:921-932. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: Aeversal by tachykinin neuropeptides. Science 1990; 250:279-282. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE. Metallothionein III is reduced in Alzheimer's disease. Brain Res 2001; 894:37^5. Zhang L, Zhao B, Yew DT, Kusiak JW, Roth GS. Processing of Alzheimer's amyloid precursor protein during H 2 0 2 - induced apoptosis in human neuronal cells. Biochem Biophys Res Commun 1997; 235:845-848. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomelic amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002; 22:4833-4841.
This page is intentionally left blank
CHAPTER 8
Molecular Basis of Copper Transport: Cellular and Physiological Functions of Menkes and Wilson Disease Proteins (ATP7A and ATP7B) David R Kramer, Roxana M Llanos, Julian FB Mercer
ABSTRACT Eukaryotic cells prevent copper-induced, free radical damage to cell components by employing copper-binding proteins and transporters that minimize the likelihood of free copper ions existing in the cell. In the cell, copper is actively transported from the cytoplasm during the biosynthesis of secreted coppercontaining proteins and, as a protective measure, when there is an excess of copper. In humans, this is accomplished by two related copper-transporting ATPases (ATP7A and ATP7B), which are the affected genes in two distinct human genetic disorders of copper transport, Menkes disease (copper deficiency) and Wilson disease (copper toxicosis). The study of these ATPases has revealed their molecular mechanisms of copper transport and their roles in physiological copper homeostasis. Both ATP7A and ATP7B are expressed in specific brain regions and neurological abnormalities are important clinical features in Menkes and Wilson disease. Keywords: Copper; Menkes disease; Wilson disease; ATPase.
207
208
Kramer DR et al.
1. INTRODUCTION The ability to accept and donate electrons makes copper (Cu) a useful co-factor for oxido-reductase enzymes and oxidative respiration. However, by exploiting this property of Cu, cells expose themselves to a metal ion that is a potential catalyst of reactive oxygen radicals which can damage cell membranes, proteins, and nucleic acids (Kumar et al., 1978). Eukaryotic cells from yeast to humans express a highly conserved set of Cu-binding proteins and transporters which ensure that the uptake and distribution of Cu is tightly regulated, thereby minimizing the likelihood of free Cu ions existing in the cell (Kumar et al., 1978). Saccharomyces cerevisiae has been the basic model system in which many of the genes regulating Cu uptake and distribution have been discovered. In such unicellular organisms, the metabolic demand of continual cycles of cell division and growth requires a constant supply of Cu. Saccharomyces cerevisiae accomplishes this by transcriptional induction and post-translational negative regulation of the major Cu import protein Ctrl (Dancis et al., 1994; Ooi et al., 1996), ensuring that sufficient, but not excessive, uptake of environmental Cu occurs. In contrast, human cells control intracellular Cu levels by the efflux of excess Cu from the cell. This activity is largely dependant on the activity of two related Cu-transporting ATPases (ATP7A and ATP7B) (Chelly et al., 1993; Mercer et al., 1993; Vulpe et al., 1993; Bull et al., Tanzi et al., 1993; Yamaguchi et al., 1993), which are orthologues of the yeast Cu pump, Ccc2 (Yuan et al., 1995). Like Ccc2, ATP7A and ATP7B transport Cu into the lumen of the transGolgi network (TGN) for incorporation into secreted cuproenzymes (such as lysyl oxidase and ceruloplasmin (CP), respectively). However, what makes ATP7A and ATP7B proteins so important to human Cu homeostasis is their remarkable ability to rapidly shuttle from the TGN to the cell periphery to catalyze the removal of excess intracellular Cu (Petris et al., 1996). Besides protecting cells from potential oxidative damage, the latter function is central to physiological Cu homeostasis, as it is the likely mechanism by which Cu is transferred by ATP7A across the cellular boundaries of the intestine and blood-brain barrier (Qian et al., 1998). It also appears to be the molecular mechanism by which ATP7B orchestrates the excretion of Cu into the bile (Roelofsen et al., 200). Our understanding of these respective physiological roles of ATP7A and ATP7B has been gained from the study of two human genetic
Molecular Basis of Copper Transport
209
disorders of Cu transport, Menkes and Wilson diseases (MD and WD), in which the activity of these pumps is lost. The association of Cu (and other metals) with several neurodegenerative diseases has increased the interest in molecular mechanisms of cellular Cu transport and Cu-binding proteins. Alterations in specific Cu-binding proteins have been suggested to promote some of the pathologies seen in neurodegenerative diseases, such as Alzheimer's disease (AD), Creutzfeld-Jakob disease, and other prion diseases, while mutation in Cu/zinc (Zn) superoxide dismutase (SOD) is linked to familial amyotrophic lateral sclerosis (FALS) (Campbell et al., 2001). Profoud neurological disturbances occur in MD and WD patients, with the former demonstrating the essentiality of Cu for normal brain development and function and, for the latter, the potential for dysregulation of Cu to cause neurological damage (Strausak et al., 2001). While both ATP7A and ATP7B are expressed in the brain, the relative importance of functional ATP7A and ATP7B in brain Cu homeostasis and in neurodegenerative processes remains unresolved.
2. MOLECULAR FEATURES OF ATP7A AND ATP7B The Menkes gene, ATP7A, is located within a 150 kb region of the X chromosome. Its 23 exons encode an mRNA of approximately 8.5 kb comprising a single open reading frame, with the ATG codon in exon 2 and the TAA stop codon in exon 23, followed by a 3.8-kb untranslated region (Dierick et al., 1995; Turner et al., 1995). The sequence of ATP7A predicts a 1,500-amino acid protein with eight transmembrane domains (Vulpe et al., 1993). There is limited information on the promoter region of ATP7A (Levinson et al., 1996), although it is unlikely to contain a metal response element as the expression of the mouse orthologue, Atp7a, appears to be unchanged by Cu exposure (Paynter et al„ 1994). The Wilson gene, ATP7B, is contained within human chromosome 13 (Bull et al., 1993) and has 21 exons that encode an mRNA of 7.5 kb with a 162base pair 5' untranslated region (Petrukhin et al., 1994). Four copies of a metal response element have been discovered in the 1.3 kb promoter region of ATP7B, (Xie et al., 1998; Oh et al., 1999) and the expression of ATP7B has been shown to possibly involve interaction between these elements and the Ku-80 transcription factor (Oh et al., 2002). ATP7B is
210
Kramer DR et al.
predicted to be 1,411 amino acids in length and is very similar to ATP7A with an amino acid identity (Bull et al., 1993) of 57%. The structural features of ATP7A and ATP7B indicate that they belong to a subclass of cation P-type ATPases called CpX-ATPases (Solioz and Vulpe, 1996; Lutsenko and Kaplan, 1995). A composite diagram of ATP7A and ATP7B highlighting the conserved and functional domains of these P-type ATPases is presented in Fig. 1. Confirmation that ATP7A functions as a Cu-specific P-type ATPase was obtained using a vesicle assay for Cu transport (Voskoboinik et al., 1998), which showed that Cu transport was inhibited by orthovanadate, a specific inhibitor of P-type ATPases.
Golgi lumen
Fig. 1. Hypothetical representation of ATP7A and ATP7B. Each possesses six metal binding sites (MBSs) containing the GMTCxxC motif. The eight transmembrane domains (depicted as cylinders traversing the transGolgi membrane) are thought to form a pore through which Cu(I) ion is transported. One of these expresses a CPC motif, thought to be crucial for Cu binding during transit. Also represented within the Golgi lumen are clusters of methionine and histidine residues (M, H), which are speculated to be potential low affinity Cu-binding sites. The reaction cycle in P-type ATPases requires the phosphorylation of an invariant aspartic acid residue (D). Also shown are the ATP binding domain, an endogenous phosphatase domain (P-ase), and a C-terminal di-leucine motif thought to be an endocytic signal in ATP7A.
Molecular Basis of Copper Transport
211
Common to all P-type ATPases are an ATP-binding site and an invariant aspartic acid residue (D) which becomes phosphorylated and dephosphorylated during the reaction cycle (Lutsenko and Kaplan, 1995). Heavy metal ATPases also contain a conserved CPC motif within the channel formed by the transmembrane domains (Forbes and Cox, 1998). The cysteines in the motif are thought to co-ordinate Cu and are essential to enzyme activity (Forbes and Cox, 1998), while the conserved proline is thought to be required for suspected conformational changes that facilitate cation transport (Jencks, 1992). The cytoplasmic amino terminal region of ATP7A and ATP7B possesses six metal-binding sites (MBSs) (Jensen et al., 1999a, 1999b; Lutsenko et al., 1997) and the solution, a three-dimensional structure of MBS4 of ATP7A, has been determined (Gitschier et al, 1998). Each MBS possesses a canonical sequence, GMTCxxC, that is thought to co-ordinate Cu via the cysteine residues (Jensen et al., 1999b; Cobine et al., 2000). Alternative forms of both ATP7 A and ATP7B have been reported, but their functional significance is not understood. An alternative form of ATP7A mRNA lacking exon 10 is present in most tissues of normal individuals (Diereick et al., 1995), but the truncated product lacks two of the transmembrane domains and mislocalizes to the endoplasmic reticulum. Hence, it is presumed to be nonfunctional (Francis et al., 1998). Spliced forms of ATP7B mRNA have also been found. Interestingly, two variants of ATP7B may be produced in the brain by alternative processing of mRNA. One variant cloned from a human brain cDNA library was found to lack exons 6, 7, and 8, which encode the first two transmembrane domains, as well as exon 12, which encodes a portion of cytoplasmic loop between the fourth and fifth transmembrane domains (Yang et al., 1997). The product of this cDNA was found to localize to the cytoplasm of cultured cells. Another curious variant whose expression appears to be regulated by light occurs in the pineal gland and retina. It is known to be active in Cu transport despite a lack of MBS (Borjigin et al., 1999).
2.1. Cellular Uptake and Transfer of Copper to ATP7A and ATP7B The delivery of Cu to ATP7A and ATP7B is thought to require a minimum of two steps: uptake of Cu across the plasma membrane followed by the delivery of Cu to the MBS of ATP7A and ATP7B. The uptake of extracellular Cu is a facilitated process thought to involve the recently
212
Kramer DR et al.
described high-affinity Cu import protein hCTRl (Zhou and Gitschier, 1997; Moller et al., 2000; Lee et al., 2000). Disruption of the murine orthologue mCtrl was found by two groups to result in severe developmental abnormalities and fetal death, suggesting an essential role for CTR1 in Cu uptake by mammalian cells (Kuo et al., 2001; Lee et al., 2001). Consistent with this role is the ubiquitous expression of the mRNA (Zhou and Gitschier, 1997) and the apparent lack of human disorders due to mutation in this gene. The genetic sequence of hCTRl predicts an integral membrane protein with three transmembrane domains and an extracellular N-terminus containing two methionein-rich MxxMxM motifs (Moller et al., 2000). A recent biochemical and genetic study has identified key residues in the MxxMxM motif adjacent to the membrane, as well as two conserved methionines within the second transmembrane domain that are critical to Cu transport (Puig et al., 2002). Plasma membrane expression of hCTRl has been shown in some cell lines (Lee et al., 2002; Klomp et al., 2002), while others have shown predominantly vesicular localization (Klomp et al., 2002). Klomp et al. (2002) have suggested that this pattern of localization may represent a pool that circulates between the plasma membrane and vesicles and, thus, may represent a form of regulated Cu uptake. Lee et al. (2002) showed that incubation of hCTRl expressing HEK239 cells with a crosslinking agent generated higher molecular weight forms of hCTRl, suggesting that hCTRl may be a component of an oligomeric complex at the plasma membrane. The distribution of Cu within the cell is accomplished by an evolutionary conserved set of Cu chaperones that bind the ion and, subsequently, deliver it to specific target proteins. This ensures that adequate Cu is supplied for Cu-dependant processes and, at the same time, limits the ability of Cu(I) ion to oxidize cellular components. Three Cu chaperones have been described in human cells: COX 17 is the chaperone that transports Cu to the mitochondria for incorporation into cytochrome c-oxidase (Amaravadi et al., 1997); CCS is the chaperone that delivers Cu into Cu/ZnSOD in the cytosol (Wong et al., 2000); and ATOX1 is the chaperone that delivers Cu to ATP7A and ATP7B (Komp et al., 1997). The structural and functional similarities to their yeast counterparts and to the Cu-binding domains of the target protein(s), with which they interact, have been reviewed (Pena et al., 1999; Harrison et al., 2000; Huffman and O'Halloran, 2001). The specificity and mechanism of Cu donation to a
213
Molecular Basis of Copper Transport
given target is thought to involve complementary interfaces between the chaperone's and target protein's Cu-binding sites (Huffman and O'Halloran, 2001). The structure of ATOX1 is homologous to a single Cu-binding domain of the Cu ATPases (Huffman and O'Halloran, 2001; Pufahl et al., 1997). Based on studies of the yeast orthologues, it is believed that ATOX1 accepts Cu from hCTRl (Xiao and Wedd, 2002) and transports the ion through the cytoplasm to the MBS of ATP7A and ATP7B (Pufahl et al., 1997) which, under normal conditions, are localized to the TGN (Petris et al., 1996). Other investigators have suggested that Cu may also be delivered to ATP7A by glutathione and/or metallothionein (MT) complexes (Jensen et al., 1999a).
2.2. Mechanism of Copper Transport by ATP7A and ATP7B P-Type ATPases P-type ATPases are termed as such due to the formation of a high-energy phosphoryl-enzyme intermediate during the reaction cycle (Lutsenko and A
T2*1
El
transition
E2
Fig. 2. Model of Cu binding and transport through ATP7A and ATP7B. The reaction cycle in ATP7A and ATP7B is thought to involve sequential conformational changes. The enzyme is thought to exist in an initial state, El, that is capable of binding ATP and to receive Cu from the ATOX1 chaperone at the N-terminal metal-binding sites (MBSs). Cu binding to N-terminal MBS is thought to induce conformational changes that facilitate the transfer of Cu to the CPC site and the phosphorylation of the aspartic acid (D). The phosphorylated state, E2, is thought to adopt a conformation that permits the transfer of the ion across the membrane. The aspartic acid is then dephosphorylated and the enzyme returns to the original El state.
214
Kramer DR et al.
Kaplan, 1995; Kuhlbrandt et al., 1998) (Fig. 2). The reaction cycle is thought to involve a minimum of two conformational states and is modeled on the calcium (Ca) P-ATPase (Jencks, 1992). In the El state, the high-affinity CPC Cu-binding site in the channel is accessible to Cu on the cytoplasmic side of the membrane (Jencks, 1992). The binding of Cu to the cytoplasmic MBSs causes significant conformational changes that are presumably related to the Cu transport cycle (Cobine et al., 2000; DiDonato et al., 2000). In P-type ATPases, the binding of a metal ion to the CPC allows the phosphorylation of the aspartic acid to form the E2 state, and causes further conformational changes which then facilitate the transfer of the ion across the membrane to the lower-affinity binding site (MacLenna et al., 1992). For ATP7A and ATP7B, this low affinity site is not known, but is likely to involve one or more clusters of methionines and histidines on the luminal/extracellular side of the channel. An endogenous phosphatase domain, found in the cytoplasmic loop between transmembrane domains four and five of ATP7A (Fig. 1), completes the cycle by catalyzing the E2 to El transition (Jencks, 1992). In addition to their presumed role in the delivery of Cu to the CPC binding site within the membrane channel, the presence of six MBSs may also serve to defect (2000) the Cu concentrations in the cell (Vulpe et al., 1993; Petris et al., 1996). DiDonato et al. (2000) showed that a 70-kd fragment containing the six Cu-binding domains of ATP7B undergoes both secondary and tertiary structural changes upon Cu binding. Such Cudependent, conformational changes may facilitate intramolecular protein interactions, such as that demonstrated between the N-terminal and the ATP binding regions of ATP7B (Tsivkovskii et al., 2001). This interaction was proposed to be part of the overall conformational changes in the protein that are involved in Cu transport. Functional analyses of the individual MBS through in vitro mutagenesis studies, truncations, and domain swapping experiments support the notion that the specific roles of individual MBS may differ between the two homologues. Altering the MBS to the non-Cu binding GMTSxxS in MBS 1-3 of ATP7A abrogated the ability of the mutated ATP7A to complement a Cu transport defect in yeast (Payne and Gitlin, 1998). In contrast, using truncated proteins and domain swapping, Forbes et al. (1999) found that only MBS6 of ATP7B was essential to Cu transport activity in yeast. Interestingly, a mutated version of ATP7A, in which the Cu binding ability of all six MBSs was
Molecular Basis of Copper Transport
215
abrogated, retained the ability to catalyze the delivery of Cu into a vesicle derived from mammalian cells, although this mutant had lost the ability to traffick in response to elevated Cu (Voskobionik et al., 1999). Further evidence for specialization of the MBS relates to the ability of the MBS to interact with the Cu chaperone ATOX1, which is thought to deliver Cu to the MBSs of ATP7A and ATP7B. ATOX1 has been shown to co-immunoprecipitate with ATP7B. (Hamza et al., 1999) This interaction has also been shown to occur at the first four MBSs of ATP7B (Larin et al., 1999). A model has been proposed involving the stepwise transfer of Cu from ATOX1 to the MBSs, from which Cu is subsequently donated to the CPC site in the channel (Forbes et al., 1999) (dotted lines in Fig. 2). The observation that ATP7A, without functional MBSs, retains Cu transport activity into mammalian vesicles (Voskobionik et al., 1999) suggests that there are other ways for Cu to access the channel. Such mechanisms could include donation of Cu from glutathione or MT complexes that may occur during times of elevated intracellular Cu (Freedman et al., 1989; Hidalgo et al., 2001). Glutathione-Cu complexes are also likely to be increased during times of Cu exposures. However, a direct role for glutathione-mediated delivery of Cu to ATP7B is not likely, given the lack of an effect of glutathione inhibitors on the rate of Cu efflux into the bile (Nederbrag, 1989).
3. BIOLOGICAL FUNCTIONS OF COPPER ATPASES ARE GOVERNED BY CELLULAR LOCATION AND TISSUE EXPRESSION Most mature tissues express predominately one form of Cu ATPase. ATP7A mRNA is normally found in the kidneys, lung, heart, brain, testis, gut mucosa, placenta, skeletal muscle, fibroblasts, lymphoblasts, and mammary gland carcinoma cells (Chelly et al., 1993; Vulpe et al., 1993; Payner et al, 1994; Ackland et al., 1997). Very low levels of ATP7A mRNA have been detected in mature liver, although their expression appears to be higher in the developing liver (Paynter et al., 1994; Kuo et al., 1997). The range of tissues expressing ATP7B is more restricted than those expressing ATP7A. ATP7B expression is highest in the liver and, to a lesser extent, in the kidneys, brain, hypothalamus, placenta, mammary gland and pancreas, intestine, and ovary (Bull et al., 1993; Tanzi et al., 1993; Michalczyk et al., 2000; Lockhart et al., 2000). There
216
Kramer DR et al.
are some differences in the above patterns of expression of ATP7A and ATP7B during the developmental stages of an animal and increased expression in the lactating breast and in the placenta, which are suggestive of some specific functions in the delivery of Cu to the fetus and infant (Kuo et al., 1997). ATP7A and ATP7B are required for the biosynthesis of secreted Cu-containing proteins and this is accomplished by the ATPdependent pumping of cytosolic Cu into the lumen of the TGN (Petris et al., 1996; Yamaguchi et al., 1996; Dierick et al., 1997; Schaefer et al., 1999). ATP7A is required for the biosynthesis of the Cu-dependent enzymes expressed in extra hepatic tissues, while ATP7B is required for the synthesis of secreted Cu-dependent enzymes in the liver, including CP, which catalyzes the conversion of the ferrous ion to the ferric form required for transferrin-mediated iron (Fe) uptake. While ATP7A and ATP7B do not directly take part in the biosynthetic pathways of cytoplasmic or mitochondrial cuproenzymes, such as Cu/ZnSOD and cytochrome c-oxidase, their role in physiological Cu homeostasis enables an adequate Cu supply required for the normal activities of these enzymes.
3.1. Copper-Induced Trafficking of ATP7A and ATP7B Facilitates Copper Export Changes in the levels of Cu alter the steady-state location of the Cu ATPases within the cell and determine whether the pumping of Cu by the ATP7A or ATP7B is a part of a biosynthetic or protective function. The pool of ATP7A molecules within the cell is continuously being recycled, via the vesicles, between the TGN and plasma membrane. During normal (safe) Cu exposures, the rate of retrieval of ATP7A from the plasma membrane and its return to the TGN (Petris et al., 1996) is greater than the movement of TGN to the plasma membrane. Cu exposure alters the dynamics of this process (Petris and Mercer, 1999) (Fig. 3). When Cu levels exceed a putative threshold (shown in vitro by increasing the Cu content in the extracellular culture fluid), the rates of ATP7A trafficking change, favoring a plasma membrane localization of the protein (Petris et al., 1996) where ATP7A functions to efflux excess Cu from the cell. Consistent with this regulation, ATP7A contains protein motifs that are important for determining the cellular location of the protein. A 38-amino acid sequence in the third transmembrane domain of ATP7A was identified
111
Molecular Basis of Copper Transport
High copper
L o w copper
Fig. 3. Steady-state localization of ATP7A. ATP7A continuously recycles, via the vesicles, between the TGN and plasma membrane. Under normal physiological Cu exposures, however, the majority of the ATP7A pool is retained at the TGN, where the protein functions to deliver Cu for the biosynthesis of the Cu containing enzymes in the endoplasmic reticulum. However, when intracellular Cu levels are raised, there is a shift in steady-state localization such that more ATP7A is associated with the plasma membrane, thereby allowing efflux of the ion. The precise mechanism of the Cu-induced trafficking of ATP7 A is not fully understood, but it is thought to involve an increase in the rate of transport from the Golgi, and is possibly due to a loss of a retention signal.
as a Golgi localization signal, and may be involved in the retention of the protein in the TGN during basal or safe Cu levels (Francis et al., 1998). Furthermore, Petris et al. (1998) and Francis et al. (1999) have shown that a di-leucine motif in the C-terminal region of ATP7A is required for retrieval of the protein from the plasma membrane. Mutation of the dileucine to di-alanine resulted in a molecule that was constitutively located on the plasma membrane. ATP7B also undergoes Cu-induced trafficking, but the distribution pattern after Cu exposure differs from ATP7A. In nonpolarized cells, such as Chinese hamster ovary cells, Cu induces ATP7B to traffick to a vesicle compartment that resembles late endosomes (La Fontaine et al., 2001). However, Roelofsen et al. (2000) have provided convincing data that, in polarized cultured hepatocytes, ATP7B trafficks to the apical membrane (which in vivo corresponds to the canalicular membrane) via an intermediary pool of subapical, vesicular structure. Although there have been no reports of specific domains of ATP7B that determine protein localization, a tri-leucine motif is found in the
218
Kramer DR et al.
cytoplasmic region of ATP7B, which may be required for retrieval of ATP7B from the cell periphery (J Mercer, unpublished). The conformational changes that the N-terminal region undergoes upon Cu binding have been suggested to be part of the signaling mechanism that stimulates the Cu-induced trafficking of ATP7A and ATP7B (Cobine et al., 2000; DiDonato et al., 2000; Forbes et al., 1999). However, as was discovered for the catalytic function of the protein, not all the MBSs of the proteins may be essential to the response. Data from Strausak et al. (1999) revealed that ATP7A with intact MBS1-3 and mutated MBS4-6 was incapable of relocalizing in high Cu, while no effect was found when only the first three MBSs were mutated. Furthermore, a truncated version of ATP7A, in which the first four MBSs were deleted and only one functional MBS (that is, MBS5 or MBS6) was present, retained the ability to traffick in response to Cu. Thus, either MBS5 or MBS6 of ATP7A is sufficient for Cu-induced trafficking (Strausak et al., 1999). In contrast, Goodyer et al. (1999) showed that an ATP7A molecule with any one of the six MBSs intact could still undergo Cu-induced trafficking. The reason for this discrepancy is not clear.
3.2. Sequential Roles of ATP7A and ATP7B in Physiological Copper Homeostasis The regulation of the overall Cu status of the body occurs by balancing the amount of dietary Cu absorbed with the amount excreted in the bile. The key roles of ATP7A and ATP7B, respectively, in these processes are evident from the pattern of Cu accumulation in MD and WD patients. Studies in human volunteers fed isotopic Cu under controlled conditions revealed that there is little net absorption of Cu over a range of exposures, suggesting that regulatory mechanisms operative within the intestinal epithelium affect the efficiency of Cu absorption (Turnlund et al., 1989). MD patients accumulate Cu in the absorptive epithelial cells of the small intestine due to a blockade in the transfer of absorbed dietary Cu to the portal venous system (Danks, 1995). The known Cu-induced trafficking of ATP7A to the plasma membrane (Petris et al, 1996) suggests that ATP7A might localize to the basolateral membrane after Cu ingestion to deliver Cu to the portal blood (Fig. 4). The liver is the first organ to receive absorbed nutrients and toxicants, and much of the absorbed
Molecular Basis of Copper Transport c/5
3
^4-<
CD
73 CD
T3
C/)
3
o X X
X
03
S
o 00
•J2 CO
5 o
3 -a 3
U CU
X
S3
u
e <
H
j-<
03 CJ
X 3 C/3
219
9
'53 o
X!
» X
CD
X
Xj
03
T3
3
a? u
CO
JH
o "3 §
-a
o
s "3
_o
03 "ft
'a
3
O U
;-* 2
ft 03
a
"el 03 Xj
3
u
o.
13 X
_c«
c
O
CD
X
«3
CD CD
3
u
3
CD
X
CJ
"S3
c
g
X O
CD
X
CD
>
3
V3
o c
&
o
03
>> c o e3
ft XI
3
03
R ,c
U X
CD
a S O a) o 43 o C/J
T3
c 03 O OS
1
ft 3
2 O
«
X
M
d 3
U
3
^ o c
CD
ft 3 O en
03 c X) o 'S
xj o
13 -a
>
CD
U
X CD CD V)
m t--
o CD V5
CD
3 O ft
b0
3
o
U
3
O 3 T3 3
CD
03
^ o ^ "3^^ T3
m s s
1
03
3 X
X
u ft
o
XI
U
3
a
< g xi
3
"^
o XT'
X
CD
ft
o
'o' g
5 x
T3
n o 03
T3
"33 c/:
'Is
> xg
c
^j
4=1
X
"S
-JJ
>
u
ca •a
ft 3
<4H
< s U a, >> o ft CD
o o
X C 03
a
c
3
> U
T3 c+-
o
3
ft 3
cj
'&
§ £3
2 03
o
f
E
JO
<
O H
03
Xj TS
U
13 3 U "53 x o X 3 u S3 C/3
"a
o «3
o 03
3
U
anich
c3 03 •a ,03U , X3 o 3 CD 13 CD 3 t; ">. j§ •a cr o o "o a o3 (U ex
< ^*
<
r-
o X
a
M
o
03
>
T3
o
o B
f2 o
a
1
epi theliu thi the intes
dis tribution and ATP TP7 I roles o:
Fig.
220
Kramer DR et al.
dietary Cu is taken up by the liver, thereby buffering the exposure of vital organs to large fluxes in the concentration of absorbed Cu. This is an example of the "first-pass effect" (Fig. 4). The liver is the primary regulator of Cu distribution and elimination, and this is achieved by modulation of the rate of biliary excretion mediated by ATP7B versus incorporation of Cu into CP (Harris, 2000). The majority of post-hepatic circulating Cu is contained within CP, but this pool is not thought to be immediately accessible to tissues (Harris, 2000). The role of CP as a Cu carrier has been cast in doubt as patients with aceruloplasminemia have defects in Fe homeostasis without appreciable changes in Cu status or other Cu-dependent processes (Gitlin, 1998). Excess absorbed Cu is apparently defected within the hepatocyte and, in response, ATP7B migrates from the TGN towards the cell periphery (La Fontaine et al., 2001). ATP7B is thought to catalyze the efflux of Cu from the cell by pumping it into vesicles, which may either fuse with lysosomes (Gross et al., 1989) or the canalicular membrane and release the Cu directly into the bile (Ballatori, 1991). These conclusions, based on studies in cultured cells, are supported by the distribution of ATP7B in rat liver. Schaefer et al. (1999) found that in Cudeficient rats, ATP7B was localized in the TGN of hepatocytes. However, when the animals were Cu loaded, the protein was distributed in multiple vesicular structures and The authors did not find any ATP7B on the canalicular membrane. ATP7A and ATP7B have additional roles in physiological Cu homeostasis which are depicted in Fig. 5. For instance, ATP7A is required for the delivery of Cu across the blood-brain barrier and for its reabsorption in the kidney. Adequate Cu is essential to normal human growth and development, and dysregulation of Cu homeostasis has profund effects on development. ATP7A and ATP7B both appear to be important in the delivery of Cu to the fetus and newborn, although the precise roles of the homologues in these processes have not been fully resolved. A recent model of placental Cu transport suggests that it involves the sequential activities of ATP7B and ATP7A (Harris et al, 1998). ATP7B expression was localized to the maternal side of the placenta in Long Evans Cinnamon (LEC) rats, a murine model of WD which accumulates Cu in the placenta (Muramatsu et al., 1998). Affected fetuses in mouse models of MD also exhibit placental accumulation of Cu, implicating a role for the mouse orthologue, Atp7a, in placental Cu transport. Also, expression
Molecular Basis of Copper Transport
221
Fig. 5. The transport of Cu across cellular boundaries requires Cu ATPase activity. Studies on Cu transport defects in MD patients and in mouse models of MD suggest that ATP7A is required for the uptake of dietary Cu across the intestinal epithelium (1), the reabsorption of Cu by the renal tubules (2), the transport of Cu into the brain (3), and the efficient uptake of Cu across the fetal side of the placenta (4). Studies of WD and related animal models suggest primary roles for ATP7B in the transfer of Cu across the maternal side of the placenta (4), the biosynthesis of CP (5), biliary excretion of Cu (6), and the delivery of Cu to the milk (7). Note that the lack of systemic Cu deficiency in WD suggests that some Cu is able to bypass the liver or is released by the liver as Cu complexes, such as Cu-histidine (Cu-His), via mechanisms that may not require a functional ATP7B.
222
Kramer DR et al.
of ATP7A by the human placental cell line, BeWo, was found to correlate with the ability of the cells to efflux Cu. These data support the theory that ATP7A functions to transport Cu absorbed by the fetal-derived cells of the placenta to the fetal blood (Harris et al., 1998). A potential role for ATP7B in the delivery of Cu to the milk was suspected from the findings that milk produced by the "toxic milk" mouse mutant (a mouse model of WD) was Cu-deficient (Rauch, 1983). This is supported by the accumulation of Cu in the mammary gland of Atp7b knockout mice (Buiakova et al., 1999). Both ATP7A and ATP7B are expressed in mammary tissue and are located in the TGN of nonlactating breast tissue, but are redistributed to vesicular-like structures in the lactating tissue (Michalczyk et al., 2000; Ackland et al., 1999). Although the physiological stimulus for the change in the intracellular location of the proteins in the lactating gland has not been determined, these studies suggest that the trafficking of ATP7B (and perhaps ATP7A) is an important part of the delivery of Cu into breast milk.
4. GENETIC DISORDERS OF COPPER TRANSPORT 4.1. Menkes Disease and Animal Models MD is one of three X-linked, human Cu deficiency disorders caused by mutations within the ATP7A gene. The others, occipital horn syndrome (OHS) and mild MD, represent subsets of the phenotypes seen in classical MD (Danks, 1995). MD is a rare disorder with an estimated frequency of between one per 100,000 and 300,000 live births (Tonnesen et al., 1991) and likely often arises within the affected families from spontaneous mutations. Classical MD always results when mutations in ATP7A prevent the formation of any functional protein. Partial or complete deletions of ATP7A are found in about 15% of MD patients (Turner et al., 1999). Many missense mutations causing classical MD and the milder variants have also been identified, (Turner et al., 1997) some of which result in aberrant RNA splicing (Das et al., 1994). Some MD patients and patients with the less severe form of OHS appear to retain some residual activity of the mutant ATP7A, or continue to produce small amounts of normal protein (Moller et al., 2000). The occurrence of variant clinical phenotypes and the variable success rate of Cu therapy in MD patients have been suggested to result from the different effects of particular mutations on the protein (Kaler,
223
Molecular Basis of Copper Transport
1996; Mercer, 2001), such as reduction in Cu transport activity, altered intracellular location, and defective trafficking in response to Cu. Classical MD is a fatal disorder due to severe Cu deficiency that results from the combined effects of an inability to transfer Cu across cell boundaries of the intestine, brain endothelium, and kidney tubules (Danks, 1995). Transfer of Cu to the affected fetus is also diminished (Xu et al., 1994). The brains of patients with MD are severely deficient in Cu and the effects on neurological function in these patients are probably responsible for the fatal outcome. In MD , the affected brain has only 2% of total body Cu, compared with a normal brain which contains 35% of total body Cu (Horn et al., 1978). Brain Cu deficiency results in myelin abnormalities and atrophy of the cerebrum and cerebellum, and is associated with an array of major neurological symptoms including mental retardation, seizures, and hypothermia (Strausak et al., 2001). While patients with OHS generally show only minor neurological impairment (Strausak et al., 2001), there has been at least one report of Menkes-like neuropathology in a mentally retarded and dysmorphic 26-year-old patient with OHS (Palmer and Percy, 2001). A recent hypothesis has linked cerebral Cu imbalances, particularly Cu accumulation in the lentiform nuclei, in some patients with idiopathic adult-onset dystonia (Becker et al., 2001). A reduction in the expression of ATP7A has been reported in both the
Table 1. Reduced activity of Cu-dependent enzymes and resultant phenotypes in MD. Phenotype
Defect
Affected enzyme
Connective tissue defects: abnormalities of bone and weak vascular walls
Impaired crosslinking of collagen and elastin
Lysyl oxidase
Impaired melanin biosynthesis
Tyrosinase
Impaired catecholamine biosynthesis and neuropetide processing Electron transport
Dopamine-p-hydroxylase Peptidylglycine-aamidating mono-oxygenase Cytochrome c-oxidase
Sensitivity to oxidative stress
Free radical defense
Cu/ZnSOD
Weakness, hypothermia
Electron transport
Cytochrome c-oxidase
Hypopigmentation Neurological abnormalities
224
Kramer DR et al.
lentiform nuclei and in leukocytes in a significant number of patients with cervical dystonia (Berg et al., 2000; Kruse et al., 2001). Cu deficiency in MD profoundly affects the formation of connective tissues, as well as the formation and function of the brain, due to the low activity of specific cuproenzymes (see Table 1). ATP7A is required for the biosynthesis of the Cu-dependent enzymes tyrosinase, involved in the melanin biosynthesis pathway (Petris et al., 2000), and lysyl oxidase, required for the crosslinking of elastin and collagen within the extracellular matrix (Kosonen et al., 1997). Hence, MD patients, as indicated in Fig. 6 Kinky hair Defective copper transport
Neurological defects metal retardation hypothermia feeding difficulties
Vascular defects Muscular weakness
Defective copper absorption * Hypopigmentation Fig. 6. Diagram illustrating the defects in Cu transport (left side) and some of the clinical outcomes of the resultant Cu defciency (right side) in affected boys with classical Menkes syndrome. Due to a loss of catayltic activity of ATP7A, the intestinal epithelial cells of Menkes children are unable to transfer absorbed Cu to the blood. The small amount of Cu that is absorbed by ATP7A-independent mechanisms (or by a partially active mutant ATP7A) subsequently becomes trapped within tissues, including the kidney tubules that normally reabsorb Cu from the urine. Cu is also trapped in the endothelial cells of the brain. MD patients have a plethora of clinical symptoms that result from the reduced activities of Cu dependent enzymes and processes (right side of diagram) (see Table 1). Some of the neurological deficits are thought to be related to impaired generation of ATP due to reduced electron transport, while other neurological features may result from imbalances in neurotransmitter biosynthesis and death of neurons in specific brain regions.
Molecular Basis of Copper Transport
225
and Table 1, suffer from hypopigmentation, flaccid muscles, and weakened endothelial walls due to the loss of the activities of tyrosinase and lysyl oxidase (Danks, 1995; Kuivaniemi et al., 1985). (These connective tissue defects found in MD patients become predominant features in OHS (Danks, 1995).) The neurological defects are possibly caused by the low activity of cytochrome c-oxidase, a Cu-dependent enzyme in the electron transport chain (Danks, 1995). The low activity of other Cu-dependent enzymes in the brain may also contribute to brain abnormalities (Kaler, 1994) and to the observed abnormal plasma and cerebrospinal fluid (CSF) neurochemical patterns in MD patients (Kaler et al., 1993). These enzymes include Cu/ZnSOD, peptidylglycine-a- amidating mono-oxygenase, and dopamine- ^-hydroxylase. Interestingly, brains from MD patients may compensate for reduced levels of Cu/ZnSOD with increased expression of MnSOD (Shibata et al., 1995). The animal models closest to MD are the mottled mice: a collection of mutant strains with reduced or null activity of Atp7a, the murine orthologue of Atp7A (Mercer et al., 1999). Of these, the macular and brindled strains are considered to be the most accurate representations of classical MD in humans (Mercer, 1999). The mutation in brindled Atp7a has been shown to be an in-frame deletion of six nucleotides (Grimes et al., 1997). In macular mice, probes to Atp7a hybridize to the hippocampus, denate gyrus, olfactory bulb nuclei, cerebral granule layer, choroid plexus, ependyma, and cerebral Purkinje cells (Iwase et al., 1996). Strong expression of Atp7a in the choroid plexus has also been reported in the developing mottled mouse (Kuo et al., 1997). This pattern of expression of the mutant Atp7a is in overall agreement with the findings from histochemical staining of Cu deposits in the macular mouse brain, demonstrating that Cu accumulates in those regions that express the mutant gene (Kuo et al., 1997; Michalczyk et al., 2000; Iwase et al., 1996). Furthermore, the effects of Cu deficiency may occur during both prenatal and postnatal brain development in mice (Kuo et al., 1997). Brindled mice can be rescued from death by injections of Cu salts, provided the injection regimen is commenced prior to 10 days after birth. This suggests that a critical period of Cu-sensitive brain development takes place around this time in the mouse (Fujii et al., 1990). The precise nature of the critical period is unresolved, although there have been suggestions that it may coincide with the expansion of astrocytes in the developing brain (Kuo et al., 1997). In humans,
226
Kramer DR et al.
Cu-histidine (Kaler, 1994; Sarkar et al., 1993) therapy results in clinical improvements and can prolong survival into adolescence, but treatment must be commenced as soon as possible after birth and appears to be successful in only a subset of patients (Turner et al., 1996; Christodoulou et al., 1998). In responding patients, dopamine and norepinephrine levels can normalize after Cu-histidine therapy (Kaler et al., 1993). A recent report of the post-mortem examination of a Cu-histidine treated 12-year-old MD patient revealed minimal pathology in the central nervous system (CNS) (George and Casey, 2001). Despite the success in alleviating some of the neurological features of MD, the connective tissue abnormalities are not corrected and the Cutreated MD patients display many of the clinical features and pathology normally associated with OHS (Turner et al., 1996; Christodoulou et al., 1998; Geroge and Casey, 2001). In the mouse models of MD, treatment with Cu chloride restored brain cytochrome ooxidase and Cu/ZnSOD activity (Yoshimura et al., 1993). However, despite these improvements, some brain abnormalities persist after therapy, including abnormal innervations, heterotypic sprouting of serotonergic neurons (Martin et al., 1994), and reduced number of Purkinje cells (Kuo et al., 1997; Yamano et al., 1988). Neuronal cell death in macular and brindled mice has been reported to involve both necrosis and, more recently, apoptosis. Apoptosis is particularly evident in the cerebral cortex, thalamus, and pyramidal layer of the hippocampus. It begins around day 10 when the affected mice begin to show overt symptoms of neurodegeneration (Rossi et al., 2001; Ohno et al., 2002). Although the timing of the onset of apoptosis is variable in the mice, the time frame is consistent with the therapeutic window of initiation of Cu therapy in affected male mice. The role of Cu deficiency in triggering off apoptosis is supported by the observation that Cu treatment reduces the level of apoptosis (Danks, 1995). The brain regions undergoing apoptosis were found to be those that normally express low levels of SOD, suggesting that the trigger may not be directly related to oxidative damage associated with reduced SOD activity (Ohno et al., 2002). Apoptosis in the cerebral cortex and hippocampus was recently found to be associated with a dramatic decrease in the anti-apoptotic protein Bcl-2 (Rossi et al., 2001). The authors of this study also found that the brains of the brindled mice had significantly increased levels of cytosolic cytochrome C, a 50% reduction in ATP and a 30% reduction in cytochrome
Molecular Basis of Copper Transport
227
c-oxidase activity. They suggest that damage to the mitochondria, due to a Cu-deficient state, may trigger off apoptosis in the affected neurons (Rossi et al., 2001).
4.2. Wilson Disease and Animal Models WD is an autosomal recessive Cu toxicity disorder affecting both the liver and CNS. In WD, mutations of ATP7B result in reduced biliary excretion of Cu and low incorporation of Cu into CP in the liver (Danks, 1995). However, not all patients have low CP levels. In the liver of WD patients, much of the excess metal becomes associated with MTs (Elmes et al., 1989) and accumulates in lysosomes (Evering et al., 1991). The accumulation of Cu eventually causes severe liver damage, liver failure, and death (Danks, 1995). The progressive damage to hepatocytes is thought to result in release of Cu, which is subsequently taken up by other liver cells and the brain (Fig. 7). Cu also deposits in the cornea, resulting in the formation of Kayser-Fleischer rings, which are a valuable diagnostic indicator of the
Fig. 7. Progression of Cu accumulation and toxicosis in WD. In WD, the impaired biliary excretion results in a net uptake of Cu and its accumulation in hepatocytes (steps 1 and 2). The continual accumulation of Cu in the liver of WD patients is thought to eventually overwhelm the capacity of the hepatocytes to store the metal and to repair associated oxidative damage. This results in the ongoing death of hepatocytes and release of the metal (step 3). Cycles of Cu release and uptake by hepatocytes (step 4) exacerbate the damage to the liver and can progress to fulminant hepatitis. The brain also accumulates Cu (step 5), primarily in the basal ganglia with the onset of neurological symptoms often, but not always, secondary to significant liver damage.
228
Kramer DR et al.
disorder (Danks, 1995; Liu et al., 2002). Cu accumulation in the brain is associated with neurological abnormalities, including Parkinsonian symptoms, dystonia, rigidity, and psychological manifestations ranging from depression to psychotic symptoms that can be misdiagnosed as schizophrenia. (Strausak et al., 2001; Rathbun, 1996). The neuropathology appears to be directly related to Cu accumulation as the neurological symptoms are associated with increased Cu levels in the CSF of WD patients (Kodama et al., 1998). Cu accumulates predominantly in the basal ganglia of WD brains and degeneration in the basal ganglia is a common finding in magnetic resonance images (van Wassenaer-van Hall, 1996). The presence of periodic acid-Schiff positive glial cells are also characteristic of the brain changes in WD (Strausak et al., 2001). Demyelination within the cerebrum occurs late in the disease (van Wassenaer-van Hall, 1996). WD is commonly treated with the Cu chelators penicillamine (Walsh, 1973) or ammonium tetrathiomolybdate (Brewer et al., 1994), which aim to mobilize the accumulated Cu (Brewer et al., 1987b) or to reduce the uptake of Cu in the small intestine with large doses of oral Zn, which is thought to lower Cu absorption through induction of MTs (Brewer et al., 1987b). The successful treatment of WD appears to be related to the stage of the disease (Brewer et al., 1987b). Treatment has demonstrated that some of the neurological symptoms are reversible. However, patients with advanced disease frequently experience an initial worsening of their neurological symptoms (Brewer et al., 1987a). One recent study has suggested that disruptions to the blood-brain barrier due to the therapy may account for this outcome (Stuerenburg, 2000). Liver transplantation is employed to treat WD patients with fulminant hepatitis or cirrhosis, and this has been found to improve the neurological features of WD (Wu et al., 2000; Stracciari et al., 2000). LEC rats are an animal model of WD (Li et al., 1991; Wu et al., 1994). In the parental Long Evans rat, Atp7b was localized by immunochemistry to the neuronal cells of the hippocampus, olfactory bulb, cerebellar Purkinje cells, cerebral cortex, and brainstem (Saito et al., 1999). The distribution in the brain was found to correlate to both the distribution of Cu and the normal pattern of dopamine-(^-hydroxylase in the LEC rat (Saito et al., 1999). Saito et al. (1999) also noted the overlap of Atp7b expression in the rat with the published localization of nitric oxide synthase. The brains of
Molecular Basis of Copper Transport
229
LEC rats also show evidence of oxygen radial damage to DNA (Yamamoto et al., 1993). Cu accumulates predominantly in the basal ganglia, subthalamic nuclei, and gray and white matter of LEC rats (Sato et al., 1994). The effects of altered brain Cu metabolism on nerve fiber densities in the brains of LEC rats have been investigated by Kawano et al. (2001) who found that, despite no differences in Cu levels between control and LEC rat brains at 10 weeks of age, there are likely to be significant reductions in norepinephrine producing neurons based on the reduction in tyrosine hydroxylase (an enzyme in the biosynthetic pathway of norepinephrine) positive neurons. An increase in 5-hydroxytrypamine positive neurons in the cortex, hippocampus, and cerebellum of four- and 10-week-old rats was also found (Kawano et al., 2001). Diagnosis of WD is often difficult due to variations in the age of presentation (from two to more than 40 years) and clinical features at diagnosis. Such variations are thought to arise from the mutations causing different degrees of loss of function in the mutant ATP7B proteins. Over 200 mutations have been described and are catalogued on the Internet (http://www.medgen.med.ualberta.ca/database). This work has revealed a diverse array of mutations, although some, such as the Hisl069Gln mutation, appear more frequently in specific populations. Interestingly, large deletions of ATP7B have not been found in WD patients (Thomas et al., 1995). Similar to MD variants, mutations that cause mislocalization of the protein or changes in Cu-induced trafficking may result in distinct phenotypes, such as WD patients with normal CP (Forbes and Cox, 2000). Patients who are homozygous for severe mutations have an earlier onset of disease and are sometimes not recognized as WD because of this fact (Thomas et al., 1995). Milder mutations may present with later-onset neurological disease (Thomas et al., 1995). However, many WD patients are compound heterozygotes (that is, they carry different ATP7B mutations on each of the two chromosome 13s (Thomas et al., 1995) which complicates the genotype/phenotype correlation). The clinical severity of WD might also be influenced by environmental factors, such as the amount of dietary Cu ingested, or allelic variants of modifying genes, such as MTs. Such factors could explain why the common Hisl069Gln mutations are associated with a range of clinical presentations (Due et al., 1998).
230
Kramer DR et al.
Fig. 8. Proposed role of ATP7A in the stepwise transfer of Cu across the blood-brain barrier. Astrocytes adjacent to the blood vessels are in a position to partially buffer the exposure of neurons to Cu. It is not known if Cu ions are preferentially taken up at the astrocytic endfeet (1), or if the pool of interstitial Cu ions are equally acccessible to both astrocytes and neurons (2). Whether or not astrocytes distribute metal ions to neurons via—controling the rates of storage of metal ions, and subsequent release such as in MTs, is speculative. Nevertheless, the release of Cu from astrocytes is presumed to require ATP7A (3).
Molecular Basis of Copper Transport
231
5. ROLES OF ATP7A AND ATP7B IN COPPER HOMEOSTASIS IN THE CNS 5.1. A Specific Role of ATP7A in Copper Transport in the CNS For Cu to be delivered to the CNS, it must be transported across either the blood-brain barrier or the CSF barrier. Endothelial cells in the mature brain display a low rate of endocytosis and are joined by specialised "high electrical resistance" tight junctions that, together, form the blood-brain barrier (Rubin and Staddon, 1999). Astroglial cells are adjacent to the endothelial cells and make contact with the vessels by membranous processes called "endfeet" (Fig. 8). Cu accumulates within brain capillaries of macular and brindled mice (Yoshimura et al., 1995; Yoshimura, 1994; Kodama et al., 1993) and within cultured astrocytes from macular mice (Kodama et al., 1991). In agreement with this pattern of Cu accumulation, Atp7a mRNA has been detected in primary mouse cell lines from cultured brain endothelial explants (Qian et al., 1998) and is expressed in the rat glial cell line, C6 (Qian et al., 1995, 1997). These observations have been incorporated into a model in which ATP7A catalyzes the stepwise transport of Cu across brain endothelial cells and astrocytes to supply neurons with a regulated supply of Cu (Qian et al., 1998; Tiffany-Castiglioni and Qian, 2001). A corollary of this model suggests that the severe Cu deficiency of neurons in MD patients is due to the combined effects of reduced endothelium to brain Cu transport and the accumulation of the already reduced brain Cu supply within astrocytes (Tiffany-Catiglioni and Qian, 2001). This proposed mechanism of brain uptake of Cu follows the mechanisms proposed for brain Fe metabolism (Bradbury, 1997). Fe uptake occurs across the cerebral vascular endothelium, after which if becomes associated with transferrin and is then taken up by glial cells and neurons. An unresolved issue concerns the role of the choroid plexus in brain Cu transport. Unlike most other brain regions, the choroid plexus is supplied by fenestrated capillaries and venule sinusoids that permit the rapid exchange of water and solutes between the plasma and the extracellular fluid (Segal, 2001). Integrity of the brain-CSF boundary results from the expression of tight junctions in the choroidal epithelium (Segal, 2001). The epithelium of the choroid plexus is the major site of production of CSF and delivers micronutrients to the CSF, as well as remove potentially
232
Kramer DR et al.
toxic xenobiotics and organic anions from the CSF (Segal, 2001). Cu accumulates in the choroid plexus of macular mice and Atp7a is highly expressed in the choroid plexus in both developing mottled embryos and adult mice. Mouse choroid plexus also expresses the Cu transporter mCtrl and Atoxl chaperone (Nishihara et al., 1998). A second model of Cu transport to the brain proposed that the choroid plexus may function as an adjunct to Cu transport mediated by brain endothelium and astroglial cells (Kuo et al., 1997). The choroid plexus expresses CP (Aldred et al., 1987) and probably secretes it into the CSF. ATP7B has not been localized to the choroid plexus It is possible that ATP7A in the choroid plexus delivers Cu to CP, which is then secreted into the CSF. (ATP7A may also be important in delivering Cu to CP in astroglial cells, which express a glycosylphosphatidalinositol-anchored form of CP (Hellman and Gitlin, 2002) and have also not been reported to express ATP7B.) Alternatively, ATP7A may catalyze the apical transport of Cu across the epithelium of the choroid plexus. Both proposed functions are analogous to the role of ATP7B in the liver and, indeed, anatomical and physiological comparisons between hepatocytes and the choroid plexus epithelium have been discussed (Segal, 2001). An alternative hypothesis that the choroid plexus may reabsorb Cu from the CSF, which occurs in some metabolic waste products, cannot be ruled out at this time (Segal, 2001).
5.2. Potential Role of ATP7B in the Brain The development of neurological symptoms and pathology in the majority of WD patients is progressive and can often be prevented by early intervention. Moreover, many established neurological features improve with Cu chelation therapy or after liver transplantation. These data suggest that the neurological features of WD are likely to be linked to persistent exposure to elevated Cu and its accumulation in the brain. The degeneration observed in the basal ganglia in many patients with advanced WD likely results from Cu accumulation in these cells. Neurons within the basal ganglia are presumed to express ATP7B (based on information from rat brains), and the loss of ATP7B activity in these neurons may restrict their ability to efflux Cu. Other neurological features may result from alterations in brain chemistry, rather than permanent neuronal loss. One likely role of ATP7B in the CNS is to deliver Cu into the TGN
Molecular Basis of Copper Transport
233
for incorporation into Cu-dependent enzymes that are involved in neurotransmitter biosynthesis, such as dopamine-(^-hydroxylase and peptidylglycine-a-amidating mono-oxygenase. Studies in the rat have colocalized ATP7B expression in neurons that also express dopamine-phydroxylase (Saito et al, 1999). Reduced activity of ATP7B in these neurons may cause reduced neurotransmitter biosynthesis and affect the observed changes in the frequencies of specific types of nerve cells, such as the changes observed in the monoaminergic neurons in the rat.
6. CONCLUSIONS There have been rapid advancements in the understanding of the molecular mechanisms of Cu transport in recent years. Central roles for the Cu-induced trafficking of ATP7A and ATP7B in regulating cellular Cu levels and Cu status in the body have been recognized. These processes are necessarily dependent on controlling the delivery of Cu to ATP7A and ATP7B by the ATOX1 chaperone, but the mechanisms that regulate the distribution of Cu among the chaperones are not understood. Work on hCTRl suggests that its cellular location may differ within cell types, suggesting that Cu uptake may also be a regulated process in some tissues (Klomp et al., 2002). The role of Cu in a number of neurodegenerative diseases has become apparent (Campbell et al., 2001). Still, our understanding of the molecular mechanisms of Cu transport in the brain is largely modeled on the cellular and physiological control of Cu homeostasis outside the CNS. For instance, the normal cellular location of ATP7A and ATP7B in the neurons in which they are expressed, and the ability of the proteins to undergo Cuinduced trafficking in neurons, has yet to be demonstrated. There is also evidence that some components of cellular Cu homeostasis may have brainspecific functions, including the aforementioned variants of ATP7B. In addition, although the expression of ATOX1 in the brain appears to match the distribution of ATP7A (Naeve et al., 1999), ATOX1 has also been suggested to be important in protecting neurons from oxidative stress (Kelner et al., 2000). Protection from oxidative stress may also be a function of the prion protein which is known to bind, Cu (Brown et al, 1997) and which apparently recycles between the plasma membrane and endosomes (Pauly and Harris, 1998). Where the latter observation fits into the cellular Cu homeostasis story and the potential roles of ATP7A and ATP7B in this
234
Kramer DR et al.
process remain a mystery. Lastly, the mechanisms of Cu elimination from the brain have not been addressed. Based on the Fe model,(Bradbury, 1997) it is likely that excess Cu is removed from the CNS via the CSF, perhaps bound to an unknown brain-specific Cu carrier, and returned to the circulation at the arachnoid villi. Whether or not a disruption to the process of Cu efflux from the brain contributes to the accumulation of Cu in WD or other neurodegenerative diseases is not known. It is anticipated that further research into the mechanisms of brain Cu homeostasis will reveal the links between Cu transporters and neurodegenerative diseases associated with Cu.
REFERENCES Ackland ML, Anikijenko P, Michalczyk A, Mercer JFB. Expression of Menkes coppertransporting ATPase, MNK, in the lactating human breast: Possible role in copper transport into milk. J Histochem Cytochem 1999; 47:1553-1561. Ackland ML, Cornish EJ, Paynter J A, Grimes A, Michalczyk A, Mercer JFB. Expression of Menkes disease gene in mammary carcinoma cells. Biochem J 1997; 328:237-343. Aldred AR, Grimes A, Schreiber G, Mercer JFB. Rat ceruloplasmin—molecular cloning and gene expression in liver, choroid plexus, yolk sac, placenta and testis. J Biol Chem 1987; 262:2875-2878. Amaravadi R, Glerum DM, Tzagoloff A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum Genet 1997; 99:329-333. Ballatori N. Mechanisms of metal transport across liver cell plasma membranes. Drug Metab Rev 1991; 23:83-132. Becker G, Berg D, Francis M, Naumann M. Evidence for disturbances of copper metabolism in dystonia: From the image towards a new concept. Neurology 2001; 57:2290-2294. Berg D, Weishaupt A, Francis MJ, Miura N, Yang XL, Goodyer ID, et al. Changes of copper-transporting proteins and ceruloplasmin in the lentiform nuclei in primary adultonset dystonia. Ann Neurol 2000; 47:827-830. Borjigin J, Payne AS, Deng J, Li X, Wang MM, Ovodenko B, et al. A novel pineal nightspecific ATPase encoded by the Wilson disease gene. J Neuroscience 1999; 19:1018-1026. Bradbury MW. Transport of iron in the blood-brain-cerebrospinal fluid system. JNeurochem 1997; 69:443-454. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. Arch Neurol 1994; 51:545-554. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44:490-493. Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson's disease. Sem Neurol 1987; 7:209-220. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, et al. The cellular prion protein binds copper in vivo. Nature 1997; 390:684-687.
Molecular Basis of Copper Transport
235
Buiakova OI, Xu J, Lutsenko S, Zeitlin S, Das K, Das S, et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and lateonset hepatic nodular transformation. Hum Mol Genet 1999; 8:1665-1671. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DC. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5:327-337. Campbell A, Smith MA, Sayre LM, Bondy SC, Perry G. Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Res Bull 2001; 55:125-132. Chelly J, Turmer Z, Tonnerson T, Petterson A, Ishikawa-Brush Y, Tommerup N, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993; 3:14-19. Christodoulou J, Danks DM, Sarkar B, Baerlocher KE, Casey R, Horn N, et al. Early treatment of Menkes disease with parenteral copper-histidine: Long-term follow-up of four treated patients. Am J Med Genet 1998; 76:154-164. Cobine PA, George GN, Winzor DJ, Harrison MD, Mogahaddas S, Dameron CT. Stoichiometry of complex formation between copper (I) and the N-terminal domain of the Menkes protein. Biochemistry 2000; 39:6857-6863. Dancis A, Yuan DS, Haile D, Askwith C, Elde D, Moehle C, et al. Molecular characterization of a copper transport protein in S. cerevisiae: An unexpected role for copper in iron transport. Cell 1994; 76:393^102. Danks DM. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WM, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease, 7th ed. New York: McGraw-Hill; 1995: 2211-35. Das S, Levinson B, Whitney S, Vulpe C, Packman S, Gitschier J. Diverse mutations in patients with Menkes disease often lead to exon skipping. Am J Hum Genet 1994; 55:883-889. DiDonato M, Hsu H-F, Narindrasorasak S, Que L, Sarkar B. Copper-induced conformational changes in the N-terminal domain of the Wilson disease copper-transporting ATPase. Biochemistry 2000; 39:1890-1896. Dierick HA, Adam AN, Escara-Wilke JF, Glover TW Immunocytochemical localization of the Menkes copper transport protein (ATP7A) to the trans-Golgi network. Hum Mol Genet 1997; 6:409^116. Dierick HA, Ambrosini L, Spencer J, Glover TW, Mercer JFB. Molecular structure of the Menkes disease gene (ATP7A). Genomics 1995; 28:462-469. Due HH, Hefter H, Stremmel W, Castaneda-Guillot C, Hernadez HA, Cox DW, et al. Hisl069Gln and six novel Wilson disease mutations: Analysis of relevance for early diagnosis and phenotype. Eur J Hum Genet 1998; 6:616-623. Elmes ME, Clarkson JP, Mathy NJ, Jasani B. Metallothionein and copper in liver disease with copper retention—a histopathological study. J Path 1989; 158:131-137. Evering Haywood S, Bremner I, Trafford J. The protective role of metallothionein in copper-overload I. Differential distribution of immunoreactive metallothionien in copper-loaded rat liver and kidney. Chem Biol Interactions 1991; 78:283-295. Forbes JR, Cox DW. Copper-Dependent Trafficking of Wilson Disease Mutant ATP7B proteins. Hum Mol Genet 2000; 9:1927-1935.
236
Kramer DR et al.
Forbes JR, Cox DW. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 1998; 63:1663-1674. Forbes JR, Hsi G, Cox DW. Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease. J Biol Chem 1999; 274:12408-12413. Francis MJ, Jones EE, Levy ER, Martin RL, Ponnambalam S, Monaco AP. Identification of di-leucine motif within the C terminus domain of the Menkes disease protein that mediates endocytosis from the plasma membrane. J Cell Sci 1999; 112:1721-1732. Francis MJ, Jones EE, Levy ER, Ponnambalam S, Chelly J, Monaco AP. A Golgi localization signal identified in the Menkes recombinant protein. Hum Mol Genet 1998; 7:1245-1252. Freedman JH, Ciriolo MR, Peisach J. The role of glutathione in copper metabolism and toxicity. J Biol Chem 1989; 264:5598-5605. Fujii T, Ito M, Tsuda H, Mikawa H. Biochemical study on the critical period for treatment of the mottled brindled mouse. J Neurol 1990; 55:885-889. George DH, Casey RE. Menkes disease after copper histidine replacement therapy: Case report. Pediatr Dev Pathol 2001; 4:281-288. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998; 44:271-276. Gitschier J, Moffat B, Reilly D, Wood WI, Fairbrother WJ. Solution structure of the fourth metal-binding domain from the Menkes copper-transporting ATPase. Nature Structural Biol 1998; 5(l):47-53. Goodyer ID, Jones EE, Monaco AP, Francis MJ. Characterization of the Menkes protein copper-binding domains and their role in copper-induced protein relocalization. Hum Mol Genet 1999; 8:1473-1478. Grimes A, Hearn C, Lockhart P, Newgreen D, Mercer JFB. Molecular basis of the brindled mouse mutant (Mobr): A murine model of Menkes disease. Hum Mol Genet 1997; 6:1032-1042. Gross JBJ, Myers BM, Kost LJ, Kuntz SM, LaRusso NF. Biliary copper excretion by hepatocyte lysosomes in the rat. J Clin Invest 1989; 83:30-39. Hamza I, Schaefer M, Klomp LWJ, Gitlin JD. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. PNAS 1999; 96:13363-13368. Harris ED, Qian Y, Tiffany-Castiglioni E, Lacy AR, Reddy MC. Functional analysis of copper homeostasis in cell culture models: A new perspective on internal copper transport. Am J Clin Nutr 1998; 67:S988-S995. Harris ED. Cellular copper transport and metabolism. Annu Rev Nutr 2000; 20:291-310. Harrison MD, Jones CE, Solioz M, Dameron CT. Intracellular copper routing: The role of copper chaperones. TIBS 2000; 25:29-32. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22:439-458. Hidalgo J, Aschner M, Zatta P, Vasak M. Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 2001; 55:133-145. Horn N, Heydorn K, Damsgaard E, Tygstrup I, Vestermark S. Is Menkes syndrome a copper storage disorder? Clin Genet 1978; 14:186-187.
Molecular Basis of Copper Transport
237
Huffman DL, O'Halloran TV. Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 2001; 70:677-701. Hung IH, Suzuki M, Yamaguchi Y, Yuan DS, Klausner RD, Gitlin JD. Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae. J Biol Chem 1997; 272:21461-21466. Iwase T, Nishimura M, Sugimura H, Ozsawa F, Shinmura K, et al. Localization of Menkes gene expression in the mouse brain: Its association with neurolgical manifestations in Menkes and model mice. Acta Neuropathol 1996; 91:482^188. Jencks WP. On the mechanism of ATP-driven Ca21 transport by the calcium ATPase of sarcoplasmic reticulum. In: Scarpa A, Carafoli E, Papa S, editors. Ion-motive ATPases: Structure, Function, and Regulation. New York: The New York Academy of Sciences, 1992: 49-57. Jensen PY, Bonander N, Horn N, Turner Z, Farver O. Expression, purification and copperbinding studies of the first metal-binding domain of Menkes protein. Eur J Biochem 1999a; 264:890-896. Jensen YP, Bonander N, Moller LB, Farver O. Cooperative binding of copper(I) to the metal binding domains in Menkes disease protein. Biochimica Biophysica Acta 1999b; 1434:103-113. Kaler SG, Goldstein DS, Holmes C, Salerno JA, Gahl WA. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol 1993; 33:171-175. Kaler SG. Menkes disease mutations and response to early copper histidine treatment. Nat Genet 1996; 13:21-22. Kaler SG. Menkes Disease. Adv Pediatr 1994; 41:262-303. Kawano H, Takeuchi Y, Yoshimoto K, Matsumoto K, Sugimoto T. Histological changes in monoaminergic neurons of Long-Evans Cinnamon rats. Brain Res Dev Brain Res 2001; 915:25-31. Kelner GS, Lees M, Clark ME, Maciejewski D, McGrath D, Rabizadeh S, et al. The copper transport protein atoxl promotes neuronal survival. J Biol Chem 2000; 275: 580-584. Klomp AE, Tops BB, Van Denberg IE, Berger R, Klomp LW. Biochemical characterization and subcellular localization of human copper transporter 1 (hCTRl). Biochem J 2002; 364:497-505. Klomp LW, Lin S-J, Yuan DS, Klausner RD, Culotta VC, Gitlin JD. Identification and functional expression of HAH1: A novel human gene involved in copper homeostasis. J Biol Chem 1997; 272:9221-9226. Klomp LWJ, Gitlin JD. Expression of the ceruloplasmin gene in the human retina and brain: Implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 1996;5(12). Kodama H, Abe T, Takama M, Takahashi I, Kodama M, Nishimura M. Histochemical localization of copper in the intestine and kidney of macular mice: Light and electron microscopic study. J Histochem Cytochem 1993; 10:1529-1535. Kodama H, Meguro Y, Abe T, Rayner MH, Suzuki KT, Kobayashi S, et al. Genetic expression of Menkes disease in cultured astrocytes of the macular mouse. J Inherit Metab Dis 1991; 14:896-901.
238
Kramer DR et al.
Kodama H, Okabe I, Yanagisawa M, Nomiyama H, Nomiyama K, Nose O, et al. Does CSF copper level in Wilson's disease reflect copper accumulation in the brain? Pediatr Neurol 1988; 4:35-37. Kosonen T, Uriu-Hare JY, Clegg MS, Keen CL, Rucker RB. Incorporation of copper into lysyl oxidase. Biochem J 1997; 327:283-289. Kruse N, Berg D, Francis MJ, Naumann M, Rausch WD, Reiners K, et al. Reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia. Ann Neurol 2001; 49:405-408. Kuhlbrandt W, Auer M, Scarborough GA. Structure of the P-type ATPases. Curr Opin Structural Biol 1998; 8:510-516. Kuivaniemi H, Peltonen L, Kivirikko KI. Type IX Ehlers-Danlos syndrome and Menkes syndrome: The decrease in lysyl oxidase activity is associated with a corresponding deficiency in the enzyme protein. Am J Hum Genet 1985; 37:798-808. Kumar S, Rowse C, Hochstein P. Copper-induced generation of superoxide in human red cell membrane. Biochem Biophys Res Comm 1978; 83:587-593. Kuo Y-M, Gitschier J, Packman S. Developmental expression of the mouse mottled and toxic milk genes suggests distinct functions for the Menkes and Wilson disease copper transporters. Hum Mol Genet 1997; 6:1043-1049. Kuo Y-M, Zhou B, Cosco D, Gitschier J. The copper transporter CTR1 provides an essential function in mammalian embryonic development. PNAS 2001; 98: 6836-6841. La Fontaine S, Theophilos M, Firth SD, Gould R, Parton RG, Mercer JF. Effect of the toxic milk mutation (tx) on the function and intracellular localization of Wnd, the murine homologue of the Wilson copper ATPase. Hum Mol Genet 2001; 10:361-370. Larin D, Mekios C, Das K, Ross B, An-Suei Y, Gilliam TC. Characterization of the interaction between the Wilson and Menkes disease proteins and the cytoplasmic copper chaperone, HAH1P*. J Biol Chem 1999; 274:28497-28504. Lee J, Pena MM, Nose Y, Thiele DJ. Biochemical characterization of the human copper transporter Ctrl. J Biol Chem 2002; 277:4380-4387. Lee J, Prohaska JR, Dagenais SL, Glover TW, Thiele DJ. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 2000; 254:87-96. Lee J, Prohaska JR, Thiele DJ. Essential role for mammalian copper transporter Ctrl in copper homeostasis and embryonic development. Proc Natl Acad Sci 2001; 98:6842-6847. Levinson B, Conant R, Schnur R, Das S, Packman S, Gitschier J. A repeated element in the regulatory region of the MNK gene and its deletion in a patient with occipital horn syndrome. Hum Mol Genet. 1996;1737-1742. Li Y, Togashi Y, Sato S, Emoto T, Kang J-H, Takeichi N, et al. Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. J Clin Invest 1991; 87:1858-1861. Liu M, Cohen EJ, Brewer GJ, Laibson PR. Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol 2002; 133:832-834.
Molecular Basis of Copper Transport
239
Lockhart PJ, Wilcox SA, Dahl HM, Mercer JFB. Cloning, mapping and expression analysis of the sheep Wilson disease gene homologue. Biochimica Biophysica Acta 2000; 1491:229-239. Lutsenko S, Kaplan JH. Organization of P-type ATPases: Significance of structural diversity. Biochemistry 1995; 34:15607-15613. Lutsenko S, Petrukhin K, Cooper MJ, Gilliam CT, Kaplan JH. N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilsons and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat. J Biol Chem 1997; 272:18939-18944. MacLennan DH, Clarke DM, Loo TW, Skerjanc IS. Site-directed mutagenesis of the Ca21 ATPase of sarcoplasmic reticulum. Acta Physiol Scand 1992; 146:141-150. Martin P, Ohno M, Southerland SB, Mailman RB, Suzuki K. Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse. Brain Res Dev Brain Res 1994; 77:215-225. Mercer JF. The molecular basis of copper-transport diseases. Trends Mol Med 2001; 7:64-69. Mercer JFB, Ambrosini L, Horton S, Gazeas S, Grimes A. Animal models of Menkes disease. Adv Exp Biol Med 1999; 448:97-108. Mercer JFB, Livingston J, Hall BK, Paynter JA, Begy C, Chandrasekharappa S, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet 1993; 3:20-25. Michalczyk A, Rieger J, Allen KJ, Mercer JF, Ackland ML. Defective localization of the Wilson disease protein (ATP7B) in the mammary gland of the toxic milk mouse and the effects of copper supplementation. Biochem J 2000; 352:565-571. Moller LB, Petersen C, Lund C, Horn N. Characterization of the hCTRl gene: Genomic organization, functional expression, and identification of a highly homologous processed gene. Gene 2000; 257:13-22. Moller LB, Turner Z, Lund C, Petersen C, Cole T, Hanusch R, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: Classical Menkes disease or occipital horn syndrome. Am J Hum Genet 2000; 66:1211-1220. Muramatsu Y, Yamada T, Moralejo DH, Suzuki Y, Matsumoto K. Fetal copper uptake and a homolog (Atp7b) of the Wilson's disease gene in rats. Res Commun Mol Pathol Pharmacol 1998; 101:225-231. Naeve GS, Vana AM, Eggold JR, Kelner GS, Maki R, Desouza EB, et al. Expression profile of the copper homeostasis gene, rAtoxl, in the rat brain. Neuroscience 1999; 93:1179-1187. Nederbragt H. Effect of the glutathione-depleting agents diethylmaleate, phorone and buthionine sulfoximine on biliary copper excretion in rats. Biochem Pharmacol 1989; 38:3399-3406. Nishihara E, Furuyama T, Yamashita S, Mori N. Expression of copper trafficking genes in the mouse brain. Neuroreport 1998; 9:3259-3263. Oh WJ, Kim EK, Ko JH, Yoo SH, Hahn SH, Yoo O-J. Nuclear proteins that bind to metal response element a (MREa) in the Wilson disease gene promoter are Ku autoantigens
240
Kramer DR et al.
and the Ku-80 subunit is necessary for basal transcription of the WD gene. Eur J Biochem 2002; 269:2151-2161. Oh WJ, Kim EK, Park KD, Hahn SH, Yoo OJ. Cloning and characterization of the promoter region of the Wilson disease gene. Biochem Biophys Res Commun 1999; 259:206-211. Ohno M, Narita T, Abe J, Tsuzuki T, Yagi K, Takikita S, et al. Apoptosis in cerebrum of macular mutant mouse. Acta Neuropathol (Bert) 2002; 103:356-362. Ooi CE, Rabinowich E, Dancis A, Bonifacino JS, Klausner RD. Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctrlp in the apparent absence of endocytosis. EMBO J 1996; 15:3515-3523. Palmer CA, Percy AK. Neuropathology of occipital horn syndrome. J Child Neurol 2001; 16:764-766. Pauly PC, Harris D. Copper stimulates the endocytosis of the prion protein. J Biol Chem 1998;273:33107-33110. Payne AS, Gitlin JD. Functional expression of the Menkes disease protein reveals common biochemical mechanisms among the copper-transporting ATPases. J Biol Chem 1998; in press. Paynter J A, Grimes A, Lockhart P, Mercer JFB. Expression of the Menkes gene homologue in mouse tissues lack of effect of copper on the mRNA levels. FEBS Lett 1994; 351:186-190. Pena MMO, Lee J, Thiele DJ. A delicate balance: Homeostatic control of copper uptake and distribution. J Nutr 1999; 129:1251-1260. Petris MJ, Camakaris J, Greenough M, La Fontaine S, Mercer JFB. A C-terminal dileucine is required for localization of the Menkes protein in the trans-Golgi network. Hum Mol Genet 1998; 7:2063-2071. Petris MJ, Mercer JFB, Culvenor JG, Lockhart P, Gleeson PA, Camakaris J. Ligandregulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: A novel mechanism of regulated trafficking. EMBO J 1996; 15:6084-6095. Petris MJ, Mercer JFB. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet 1999; 8:2107-2715. Petris MJ, Strausak D, Mercer JFB. The Menkes copper transporter is required for the activation of tyrosinase. Hum Mol Genet 2000; 9:2845-2851. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, Gilliam TC. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: Genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994;3:1647-1656. Pufahl RA, Singer CP, Peariso KL, Lin S-L, Schmidt PJ, Fahrni V, et al. Metal ion chaperone function of the soluble Cu(I) receptor Atxl. Science 1997; 278:853-856. Puig SLJ, Lau M, Thiele DJ. Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem 2002; 277:26021-26030.
Molecular Basis of Copper Transport
241
Qian Y, Tiffany-Castiglioni E, Harris ED. A Menkes P-type ATPase involved in copper homeostasis in the central nervous system of the rat. Brain Res Mol Brain Res 1997; 48:60-66. Qian Y, Tiffany-Castiglioni E, Harris ED. Copper transport and kinetics in cultured C6 rat glioma cells. Am J Physiol 1995; 269:C892-C898. Qian Y, Tiffany-Castiglioni E, Welsh J, Harris ED. Copper efflux from murine microvascular cells requires expression of the Menkes disease Cu-ATPase. J Nutr 1998; 128:1276-1282. Rathbun JK. Neuropsychological aspects of Wilson's disease. Int J Neurosci 1996; 85:221-229. Rauch H. Toxic milk, a new mutation affecting copper metabolism in the mouse. J Hered 1983;74:141-144. Roelofsen H, Wolters H, van Luyn MJA, Miura N, Kuipers F, Vonk RJ. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterol 2000; 119:782-793. Rossi L, De Martino A, Marchese E, Piccirilli S, Rotilio G, Ciriolo MR. Neurodegeneration in the animal model of Menkes disease involves Bcl-2-linked apoptosis. Neuroscience 2001; 103:181-188. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28. Saito T, Okabe M, Hosokawa T, Kurasaki M, Hata A, Endo F, et al. Immunohistochemical determination of the Wilson Copper-transporting P-type ATPase in the brain tissues of the rat. Neurosci Lett 1999; 266:13-16. Sarkar B, Lindertat-Walsh K, Clarke JT. Copper-histidine therapy for Menkes disease. JPediatr 1993; 123:828-830. Sato M, Ohtomo K, Daimon T, Sugiyama T, Iijima K. Localization of copper to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in cerebellum. JHistochem Cytochem 1994; 42:1585-1591. Schaefer M, Hopkins RG, Failla ML, Gitlin JD. Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Am J Physiol 1999; 276:G639-G646. Segal MB. Transport of nutrients across the choroid plexus. Microsc Res Tech 2001; 52:38^18. Shibata N, Hirano A, Kobayashi M, Umahara T, Kawanami T, Asayama K. Cerebellar superoxide dismutase expression in Menkes kinky hair disease: An immunohistochemical investigation. Acta Neuropathol (Berl) 1995; 90:198-202. Solioz M, Vulpe C. CPX-type ATPases: A class of P-type ATPases that pump heavy metals. Trends in Biochem Sci 1996; 21:237-241. Stracciari ATA, Borghi A, Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 2000; 57:384—386. Strausak D, La Fontaine S, Hill J, Firth SD, Lockhart PJ, Mercer JFB. The role of GMXCXXC metal binding sites in the copper-induced redistribution of the Menkes protein. J Biol Chem 1999; 274:11170-11177.
242
Kramer DR et al.
Strausak D, Mercer JM, Dieter HH, Stremmel W, Multhaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson's diseases. Brain Res Bull 2001;55:175-185. Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm 2000; 107:321-329. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5:344-350. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: Spectrum of mutations and their consequences. Nat Genet 1995a; 9:210-216. Thomas GR, Gudmundsson G, Thorsteinsson L, Cox DW. Wilson disease in Iceland: A clinical and genetic study. Am J Hum Genet 1995b; 56:1140-1116. Tiffany-Castiglioni E, Qian Y. Astroglia as metal deposits: Molecular mechanisms for metal accumulation, storage and release. Neurotoxicology 2001; 22:577-592. Tonnesen T, Kleijer WJ, Horn N. Incidence of Menkes disease. Hum Genet 1991; 86:408-410. Tsivkovskii R, MacArthur BC, Lutsenko S. The Lys1010-Lys1325 fragment of the Wilson's disease protein binds nucleotides and interacts with the N-terminal domain of this protein in a copper-dependent manner. J Biol Chem 2001; 276:2234-2242. Turner Z, Horn N, Tonnesen T, Christodoulou J, Clarke JTR, Sarkar B. Early copperhistidine treatment for Menkes disease. Nat Genet 1996; 12:11-13. Turner Z, Lund C, Tolshave J, Vural B, T0nnesen T, Horn N. Identification of point mutations in 41 unrelated patients affected with Menkes disease. Am J Hum Genet 1997; 60:63-71. Turner Z, Moller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol 1999; 448:83-95. Turner Z, Vural B, Tonnesen T, Chelly J, Monaco AP, Horn N. Characterization of the exon structure of the Menkes disease gene using vectorette PCR. Genomics 1995; 26:437-442. Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr 1989; 49:870-878. van Wassenaer-van Hall HN. Neuroimaging in Wilson disease. Metab Brain Dis 1996; 12:1-19. Voskobionik I, Strausak D, Greenough M, Brooks H, Petris M, Smith S, et al. Functional analysis of the N-terminal CXXC metal-binding motifs in the human Menkes coppertransporting P-type ATPase expressed in cultured mammalian cells. J Biol Chem 1999; 274:22008-22012. Voskoboinik I, Brooks H, Smith S, Shen P, Camakaris J. ATP-dependent copper transport by the Menkes protein in membrane vesicles isolated from cultured Chinese hamster ovary cells. FEBS Lett 1998; 438:178-182.
Molecular Basis of Copper Transport
243
Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet 1993; 3:7-13. Walsh JM. Copper chelation in patients with Wilson's disease. QJ Med 1973; 42:441^150. Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartinakas TB, Culotta VC, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 2000; 97:2886-2891. Wu J, Forbes JR, Chen HS, Cox DW. The LEC rat has a deletion in the copper transporting ATPase homologous to the Wilson disease gene. Nature Genetics 1994; 7:541-545. Wu JC, Huang CC, Jeng LB, Chu NS. Correlation of neurological manifestations and MR images in a patient with Wilson's disease after liver transplantation. Acta Neurol Scand 2000;102:135-139. Xiao Z, Wedd AG. A C-terminal domain of the membrane copper pump Ctrl exchanges copper(I) with the copper chaperone Atxl. Chem Commun (Camb) 2002; 21:588-589. Xie J, Liu G, Wang M, Huang S, LoWilson HY. Cloning and characterization of a metal responsive element-containing fragment from the Wilson disease gene locus by junction trapping. Chin Med Sci J 1998; 1:9-13. Xu GQ, Yamano T, Shimada M. Copper distribution in fetus and placenta of the macular mutant mouse as a model of Menkes kinky hair disease. Biol Neonate 1994; 66:302-310. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Comm 1993; 197:271-277. Yamaguchi Y, Heiny ME, Suzuki M, Gitlin JD. Biochemical characterization and intracellular localization of the Menkes disease protein. Proc Natl Acad Sci USA 1996; 93:14030-14035. Yamamoto F, Kasai H, Togashi Y, Takeichi N, Hori T, Nishimura S. Elevated level of 8hydroxydeoxyguanosine in DNA of liver, kidneys, and brain of Long-Evans Cinnamon rats. Jpn J Cancer Res 1993; 84:508-511. Yamano T, Shimada M, Onaga A, Kawasaki H, Iwane S, Ono K, et al. Electron microscopic study on brain of macular mutant mouse after copper therapy. Acta Neuropathol (Bed) 1988; 76:574-580. Yang X, Kawardada Y, Terada K, Petrukhin K, Gilliam TC, Sugiyama T. Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. Biochem J 1997; 326:897-902. Yoshimura N, Hatayama I, Sato K, Nishimura M. Complete recovery of cytochrome oxidase and superoxide dismutase activities in the brain of brindled mice receiving copper therapy. J Intellect Disabil Res 1993; 37:561-567. Yoshimura N, Kida K, Usutani S, Nishimura M. Histochemical localization of copper in various organs of brindled mice after copper therapy. Pathol Int 1995; 45:10-18. Yoshimura N. Histochemical localization of copper in various organs of brindled mice. Pathol Int 1994; 44:14-19.
244
Kramer DR et al.
Yuan D, Stearman R, Dancis A, Dunn T, Beeler T, Klausner RD. The Menkes/Wilson disease gene homologue in yeast provides copper to a ceruloplasmin-like oxidase required for iron uptake. Proc Natl Acad Sci USA 1995; 92:2632-2636. Zhou B, Gitschier J. hCTRl: A human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 1997; 94:7481-7486.
CHAPTER 9
Importance of Copper and Zinc in Alzheimer's Disease and the Biology of Amyloid-p Protein and Amyloid-p Protein Precursor Avi L Friedlich, Xudong Huang, Seiichi Nagano, Jack T Rogers, Lee E Goldstein, Ashley I Bush, Gerd Multhaup, Konrad Beyreuther, Wolfgang Stremmel, Thomas Bayer
ABSTRACT Alzheimer's disease is an age-dependent neurodegenerative disorder associated with parenchymal and cerebrovascular deposition of fibrillized amyloid-P protein. Strong genetic evidence implicates the amyloid-p protein and its precursor, the amyloid-p protein precursor in the pathogenesis of Alzheimer's disease. Amyloid-p and amyloid-p protein precursor are both metalloproteins, and significant progress has been made toward understanding their biologic functions. A growing body of evidence links pathophysiologic copper and zinc metabolism to Alzheimer's disease. The role of copper and zinc in Alzheimer's disease, as well as possible physiological and pathophysiological interactions between these metals and amyloid-p and amyloid-P protein precursor, is reviewed here and therapeutic implications are discussed. 245
246
Friedlich AL et al. Keywords: Alzheimer's disease; amyloid-(3 protein; amyloid-^ protein precursor; copper; zinc.
1. INTRODUCTION The ~4kDa amyloid-f} (A(3) protein deposits as amyloid in the neuropil and cerebrovasculature in Alzheimer's disease (AD). Strong genetic evidence links A(3 and its precursor, the amyloid- (3 protein precursor (A(3PP), to AD pathogenesis. Although much progress has been made over the past few years toward understanding the biology and pathobiology of A(3 and A(BPP, consensus on the biologic and pathogenic functions of each protein has not been reached. The proteolytic cleavage of A(3PP is a necessary event in pathogenesis. The generation of A|3 occurs in a regulated cascade of cleavage events in A(3PP. The production of Ap is initiated by the transmembrane aspartyl protease f3-site amyloid precursor protein cleaving enzyme (BACE) that cleaves A(3PP at the N-terminus of A(3. Presenilin-1 is essential to gammasecretase cleavage and is part of the catalytic complex by which the Cterminal end of A(3 is liberated. The AfSPP copper (Cu)- binding domain (CuBD) in the amino terminus of A(3PP plays important roles both in modulating Cu homeostasis and in A(3 production (Borchardt et al., 1999), as described below. Substantial evidence links metal ion homeostasis to AD pathophysiology. This evidence derives mainly from in vitro, ex vivo, and in vivo studies of A(3 and A(3PP, as well as biochemical, pathologic, and therapeutic studies in AD. We review the growing body of evidence linking Cu and zinc (Zn) to AD and to Ap/A^PP function and pathogenicity, and discuss the therapeutic implications for Alzheimer patients.
2. METABOLISM OF COPPER AND ZINC IS ALTERED IN ALZHEIMER'S DISEASE Substantial evidence suggests that microscopic Cu and Zn distribution is altered in AD brain. First, accumulation of these metals in AD amyloid deposits has been demonstrated by microparticle X-ray emission spectroscopy (PIXE; Lovell et al., 1998). Cu was localized predominantly to the senile plaque rim, while Zn was elevated in the senile plaque rim and core. In addition, Zn was elevated in the AD neuropil, compared to
Importance of Copper and Zinc in Alzheimer's Disease
247
age-matched control. Another PIXE study demonstrated increased Zn levels in the Alzheimer hippocampus and amygdala in unstained cryostat sections, though no correlation with plaques was made (Danscher et al., 1997). Synchrotron radiation-induced X-ray fluorescence has been employed to identify Cu and Zn in association with diffuse and mature plaques in untreated, fresh frozen cryostat sections of AD brain (Friedlich et al., manuscript in preparation). Histochemical methods for Cu and Zn detection have also been utilized to demonstrate abnormal distribution of these metals in AD. Rubeanic acid and rhodanine have been used to detect Cu in mature plaques, neurofibrillary tangles, and amyloid angiopathy (Friedlich et al., manuscript in preparation). Histochemically reactive Zn (N-(6-methoxy8-quindinyl-4-methylbenzene sulfonamide) (TSQ) fluorescence) has been localized to amyloid plaques and amyloid angiopathy in AD tissue (Suh et al., 2000) and in APPP2576 transgenic mouse brain (Lee et al., 1999). Gross, abnormalities in cerebral Cu and Zn metabolism in AD are less clear. Numerous studies have quantified metal levels in gross brain specimens or homogenates using instrumental neutron activation analysis (INAA) and inductively coupled plasma mass spectroscopy (ICPMS), with conflicting results. ICPMS studies have demonstrated decreased Zn in the AD hippocampus, thalamus, and gyri (Panayi et al., 2002), as well as in the frontal, occipital, and temporal cortices (Corrigan et al., 1993). An INAA study found decreased Cu and increased Zn in the AD hippocampus and amygdala (Deibel et al., 1996). An INAA subcellular fractionation study found decreased nuclear Zn in the temporal lobe (Wenstrup et al., 1990). Some evidence suggests that systemic Cu or Zn metabolism may be altered in AD. In the nun study, Tully et al. (1995) reported that fasting serum Zn about one year prior to death negatively correlated with plaque density in seven brain regions. A consensus is emerging that serum Cu is elevated in Alzheimer patients compared to age-matched control subjects (Kapaki et al., 1993; Squitti et al., 2002), and elevated serum Cu and Zn in AD has been reported to be associated with the apolipoprotein E-4 (apoE4) allele (Gonzalez et al., 1999). In AD cerebrospinal fluid (CSF), one study has reported an increase in Cu (Basun et al., 1991), two studies have reported an increase in Zn (Hershey et al., 1983; Rulon et al., 2000), and two studies have reported a decrease in Zn (Kapaki et al., 1993;
248
Friedlich AL et al.
Molina et al., 1998). Other reports have found no differences between AD and control CSF, with respect to Cu and Zn (Hershey et al., 1983; Sahu et al., 1988). Cerebral expression and distribution patterns of Cu and Zn transport and sequestration proteins provide additional evidence for disrupted metabolism of these cations in AD. Expression of ceruloplasmin (Castellani et al., 1999), metallothioneins I, II, and III (MT-I, -II, and -III; Yu et al., 2001), matrix metalloproteinases (MMP-1; Leake et al., 2000), MMP-2 (Backstrom et al., 1992), and MMP-9 (Asahina et al., 2001) have all been reported to be altered in the Alzheimer brain. MT-III is deficient in AD brain tissue (Uchida et al., 1988, 1991), which may impair the buffering capacity of the cortical tissue and contribute to the extracellular pooling of Zn and Cu that occurs in AD. Whereas abnormal Cu elevation may drive the toxicity of A@ (Huang et al., 1999b), interstitial Zn elevation may reflect a homeostatic antioxidant response. Mechanistically, this could be due to Zn 2+ release from the MT pool upon glial activation (Penkowa et al., 1999) or MT thiols being oxidized by hydrogen peroxide (H202) (Maret & Vallee, 1998), which could be elevated in AD tissue due to production from Ap (Huang et al., 1999a, 1999b). The hypothesis that Zn2+ elevation forms amyloid is supported by the distribution of chelatable (loosely-bound) Zn 2+ in the brain, which is most highly concentrated in the corticofugal system (Frederickson, 1989) and, therefore, parallels the anatomical sites most prone to amyloid deposition. Other Ap-associated proteins may also modulate the precipitation of A(3 in the presence of Zn 2+ , and so play a role in amyloid formation. The Zn-binding properties of alpha-2-macroglobulin, a genetic risk factor for AD (Blacker et al, 1998), modulate its binding to A(3 (Du et al, 1997). Also, apoE preserves A(3 solubility in the presence of Zn 2+ and the apoE4 isoform, a risk factor for amyloid deposition and AD, is the poorest solubility chaperone under these conditions (Moir et al., 1999). Therefore, in apoE4 carriers, A(3 is more likely to be precipitated by Zn.
3. COPPER AND ZINC BIND AMYLOID PRECURSOR PROTEIN Several fatal neurodegenerative disorders, such as AD, familial amyotrophic lateral sclerosis (FALS), and prion-related diseases (also known
Importance of Copper and Zinc in Alzheimer's Disease
249
as the transmissible spongiform encephalopathies), are associated with the misfolding of a Cu-binding protein that is central to the specific disease (Strausak et al., 2001). We have investigated different aspects of the structure-function relationships of the underlying Cu-binding proteins A(BPP and prion protein (PrP), and have studied their cell biology, physiologic role in Cu transport, and role in human neurodegenerative diseases. The latter aspects are greatly facilitated by a number of transgenic and knockout mouse models.
3.1. Copper Binding Modulates A(3PP Homodimerization and Proteolysis Cu binding and oligomerization of A[3PP are important characteristics with implications for A(3PP function and amyloidogenesis. It has been shown that, in brain, a distinct percentage of A(3PP is present on the cell surface as a membrane protein of type I. This cell surface A^PP may mediate the transduction of extracellular signals into the cell via its C-terminal tail. Involvement of AfSPP in neuronal development, synaptogenesis, and synaptic plasticity indicated that the observed function is not restricted to secreted ApPP, raising the possibility that some aspects of synaptic plasticity are mediated by cell-associated ApPP A(3PP belongs to a multigene family of homologous proteins with different amyloid precursor-like protein lineages, including the ancestral drosophila [3-amyloid precursor like (APPL) and caenorhabditis elegans (3-amyloid precursor like-1 (APL-1) (Bayer et al., 1999). There is increasing evidence that all members of the superfamily have similar functional properties in cell-cell, cell-substrate adhesion, and Cu homeostasis. AfJPP has a CuBD located in the N-terminal cysteine-rich region, which can strongly bind Cu 2+ and reduce it to Cu + in vitro (Hesse et al., 1994; Multhaup et al., 1996). The CuBD sequence is similar among the A(3PPfamily paralogs, amyloid precursor-like proteins (APLP1 and APLP2), and its orthologs (including drosophila melanogaster, xenopus laevis, and caenorhabditis elegans), suggesting an overall conservation in its function or activity (Simons et al., 2002; White et al., 2002). The ApPP CuBD is involved in modulating Cu homeostasis and A(3 production. By three lines of evidence (crosslinking experiments, size exclusion chromatography, and mutational analysis), we could demonstrate that,
250
Friedlich AL et al.
under native conditions, cellular Af3PP and recombinant A(3PP from pichia pastoris are capable of forming noncovalent homodimers and tetramers (Scheuermann et al., 2001). AfJPP dimers appear to assemble in the endoplasmic reticulum shortly after the synthesis, suggesting that the homodimeric state could even be an essential prerequisite for its sorting in the transGolgi network and to secretory vesicles. The N-terminal domain is both necessary and sufficient for homodimerization, since the assembly of oligomers only depends on the N-terminal domain and does not require the C-terminal domain. This interaction does not require additional factors, but may be regulated by A(3PP-specific ligands, such as heparin, Cu 2+ , or Zn 2+ . Two highly conserved regions of AfSPP, the N-terminal AfJPP residues 91-111 and the C-terminal A(3PP residues 448-465 representing the collagen-binding site, are of critical importance for the regulation of homo-oligomerization of full-length A(3PP AfSPP dimerization occurs in a zipper-like mechanism. The interaction mediated between the N- and C-terminal domains of A(3PP behaves in a co-operative manner, with the N-terminal one being a prerequisite for efficient interaction and the C-terminal domain linking two pre-existing N-terminally-bound AfJPP molecules to one another. In accordance with this model, a Cys-mutant K624C of A|3PP695 formed disulfide bridges which rearranged spontaneously, possibly in an extended formation of the proposed linear zipper-like array with a third contact between juxtamembrane and intramembrane a-helices enabling a spatial proximity of the A|3 regions of two A|3PP molecules. A(3PP homodimers are a favored substrate of the A|3PP cleaving enzymes beta- and gamma- secretases, which are involved in the processing pathway that generates Ap. Mutant A(3PP with a single cysteine in the ectodomain juxtamembrane position generates stabilized dimers and produces six- to eightfold more amyloids in neuroblastoma cells than normal ApPP. These constitutively formed ApJPP oligomers, which also play a crucial role in AfJPP function. Such oligomers accumulate at the cell surface in populations of intact cells and enhance cell adhesion functions of A(3PP (Multhaup et al., unpublished observations). Taken together, our current efforts to investigate AfSPP dimerization will reveal its function for cell-cell and cell-matrix interactions of A|3PP and if it is the basic event in amyloid formation in AD. A remaining question is whether other APLPs dimerize like A(3PP The conservation of the cysteine-rich N-terminal domain is consistent
Importance of Copper and Zinc in Alzheimer's Disease
251
with the possibility that all APLPs can dimerize and the variable residues in this region could provide the necessary dimerization specificity. To identify novel risk factors for AD and possible inhibitory compounds, it will obviously be important to determine whether ApJPP and APLPs can heterodimerize, and how A|3PP dimerization and increased A(S production are linked to the signaling function of A(3PP A(3PP also binds Zn 2+ through a binding site in its cysteine-rich amino terminus (residues 181 to 189, Kd»750nM), which is homologous in all members of the ApSPP, APLP1, and APLP2 superfamily, and preserved in caenorhabditis elegans and drosophila (Bush et al., 1993, 1994a). Zn 2+ binding at this site promotes ApSPP binding to heparin, which may be important for the interaction of A(3PP with the extracellular matrix and matrix metalloproteinases. Zn 2+ also increases the ability of the Kunitzprotease inhibitory isoform of A(3PP (AfSPP-KPI) to inhibit coagulation factor XIa (Van Nostrand, 1995), which may play a role in blood coagulation since Zn 2+ and A(3PP are releases during platelet activation (Bush et al., 1990). Zn 2+ also inhibits the oxidative fragmentation of A(3PP by Cu 2+ , indicating that Zn 2+ may serve a protective, antioxidant function in binding ApPP (Multhaup et al., 1998).
3.2. Importance of A|JPP for Copper Homeostasis ApPP expression modulates Cu homeostasis since ApPP / _ mice have elevated Cu levels in the liver and cerebral cortex compared to APPP + / + mice (White et al., 1999). In addition, elevated Cu concentrations decrease A(3 production and increase secretion of A(3PP in a cell line transfected with human A(3PP cDNA. This effect could be influenced by Zn or with Zn and Cu chelators (Borchardt et al., 2000). These studies provide strong evidence that AfSPP has an important role in modulating cellular Cu metabolism in certain tissues, including the brain. In general, alterations to A(3PP and/or Cu metabolism, as found in AD, could potentially result in increased A(3PP-Cu+-mediated oxidative stress and altered A(3PP processing to A(3 (Multhaup et al., 1998). In our cell culture studies, ApPP-Cu toxicity was specifically mediated by the Cu-binding ectodomain between residues 135 and 166 of human A(3PP. Mutagenesis of the ApPP CuBD revealed that ApPP-mediated Cu toxicity was dependent on the central histidine residues H147, H149, and H151. Importantly, A(3PP orthologs with different amino acid residues at the his-
252
Friedlich AL et al.
tidine positions have dramatically altered phenotypes. The caenorhabditis elegans APL-1 peptide (APL-lCuBD), which has tyrosine 147 and lysine 151, is strongly protected against Cu toxicity. The reason is that higher species CuBDs have a decreased affinity for Cu 2+ and high Cu2+-reducing activities; ancestral CuBDs form very tight binding sites for Cu 2+ ions and have low Cu2+-reducing activities. Thus, the ApPP lineage displays a gain in activity towards promoting Cu 2+ reduction and Cu + release. These findings identify a significant evolutionary change in the function of the CuBD. The data also highlight the important role of A[3PP CuBD in A(3PP metabolism. Thus, as AD is a typically common multifactorial disease in that environmental and genetic factors interact, a perturbed Cu homeostasis might result in a disease state and vice versa. Our recent data obtained with a mouse model system for AD indicate that Cu has a positive impact on A(3PP metabolism, and that bioavailable Cu cannot be regarded as a general risk factor in the pathogenesis of AD. Biochemical studies are in progress to verify the data on the molecular level. In a pilot study, we have treated three groups of aged AfSPP transgenic mice (A(3PP23 mice expressing human A(3PP751 with the Swedish mutation) and littermate controls with + sucrose, two with Cu-specific chelators DTPA and BC, and three with Cu sulfate. Whereas AfSPP overexpressing mice have a mean probable duration of life that is shorter than that of the littermate controls, a statistical analysis of our pilot study revealed that this effect is rescued in the group of animals that have been treated with Cu sulfate. The transgenic ApPP23 mice of the Cu group show an extended life duration compared with chelator-treated animals. Only the Cu-treated animals reach the ideal value for life duration of the control group, indicating that supplemented Cu rescued the toxic effect caused by the overexpression of human A(3PP, which is known to induce Cu depletion (Multhaup et al., unpublished observations).
4. COPPER AND ZINC BIND THE BETA AMYLOID PROTEIN AfJ possesses high and low affinity binding sites for Cu and Zn (Bush et al., 1994b; Atwood et al., 1998; Miura et al., 2000). The affinity of the Zn 2+ binding sites on AfJl-40 are 100nM and 5 |xM (Table 1), indicating that they might be occupied under physiological conditions (Atwood
253
Importance of Copper and Zinc in Alzheimer's Disease Table 1. Cu and Zn binding affinities of the residue A(340 and -42 proteins. Data are from Atwood et al. (2000). Kd (M)
High affinity
Low affinity
Apl-40/Zn
IX10" 7
1.3 X10" 6
Apl-42/Zn A(31-40/Cu Api-42/Cu
7
1.3 X 10~6 1.3 X10" 8 5X10" 9
IX 10~ 4.6 X 1 0 _ u 7X10~ 18
et al., 1998, 2000). The highest affinity Cu 2+ binding site on Apl-42 has a measured K a « 10" 18 M, which is much greater than the highest affinity Cu 2+ binding site on Apl-40 (Ka% 10"11 M) (Atwood et al., 1998, 2000). This is important since Api-42 is enriched in cerebral amyloid pathology and its overexpression is linked to familial AD.
4.1. Copper and Zinc Binding to A(3 Mediates H 2 0 2 Production The differential affinity of A(342 and A(340 for Cu 2+ may account for the differential redox behavior and toxicity of these two species (Atwood et al., 2000). The Cu2+-A|31-42 complex has a strong reduction potential (+550mM vs Ag/AgCl) compared to the blue Cu proteins. Ap$ binds Cu 2+ and Zn 2+ to form a superoxide dismutase (SOD)- like structure (Curtain et al., 2001). Hence, the oxidative damage induced by A(3 may be mechanistically related to the oxidative stress induced by mutant SOD1 (Atwood et al., 1998, 2000). H 2 0 2 , implicated in AD pathogenesis, is produced by Cu A0 (Huang et al, 1999a). Among A(3 species, Cu A£42 produces H 2 0 2 at a faster rate than Cu A(340, while mouse Cu Ap produces much less H 2 0 2 (Huang et al., 1999a). The redox activities of these Cu A(3 species correlate with their respective neurotoxicity in culture, which is largely mediated by H 2 0 2 formed by Cu Ap (Huang et al., 1999a). H 2 0 2 formation by Cu A(3 and CuZn AfS can also be inhibited by chelation (Huang et al., 1999a), and the H202-mediated toxicity of A(3 in culture can be exaggerated by Cu 2+ and ameliorated by excess Zn 2+ (Cuajungco et al., 2000). Recently, we have determined that the production of H 2 0 2 by the A|3-Cu complex obeys a catalytic relationship (Km^i9 |xM and Vmax*30 nM for dopamine), where biological
254
Friedlich AL et al.
reducing agents are consumed as the reservoir of electrons for the reduction of dioxygen as the co-substrate (Opazo et al., 2002). Various biological reducing agents could drive the catalytic formation of H2Oz, such as dopamine and cholesterol. The neurotoxicity of AfS (in nanomolar concentrations) in cell culture was shown to be mediated by H 2 0 2 and dependent upon the presence of Cu 2+ and biological reducing agents.
4.2. Copper and Zinc Binding to AfJ Alters Protein Conformation It is now well-established that Af3 is rapidly precipitated by physiological concentrations of Zn 2+ , a physiologically inert cation. Under mildly acidic conditions (pH 6.8 to 7), the redox-active metals Cu 2+ and Fe 3+ induce greater A(3 aggregation than does Zn (Atwood et al., 1998). Significantly, the turbidity of rodent Apl-40 (with substitutions of Arg —> Gly, Tyr —> Phe, and His —> Arg at positions 5, 10, and 13, respectively) is unaffected by Zn 2+ or Cu 2+ at low micromolar concentrations (Atwood et al., 1998), perhaps explaining why rodents do not deposit cerebral amyloid. The molecular risk factor, apoE, modulates the precipitation of A|3 by Cu 2+ and Zn 2+ (Moir et al., 1999). We found that that the apoE4 isoform, which is an associated risk factor for the development of AD, is the poorest solubility chaperone for A(3 when compared to the other forms, apoE2 and apoE3. This finding holds regardless of whether the precipitating stress is Cu 2+ or Zn 2+ . CuZn selective chelators markedly enhance the resolubilization of Afi deposits from post-mortem AD brain samples (Cherny et al., 1999), supporting the possibility that Cu and Zn ions play a significant role in assembling these deposits. The metallochemistry of A(3 links oxidative damage and amyloidosis in AD. In vitro precipitation of Ap by Cu 2+ or Zn 2+ can be completely reversed by chelation (Huang et al., 1997). In the post-mortem AD brain, selective Cu or Zn chelators can induce the resolubilization of A$ from plaques (Cherny et al., 1999). Oxidative damage may be the earliest pathologic event in AD (Nunomura et al., 2001) and a negative correlation exists between amyloid burden and levels of 8-hydroxyguanosine, a marker of hydroxyl radical activity (Cuajungco et al., 2000). This is possibly because Zn suppresses H 2 0 2 formation from Ap. Thus, the mature plaque in AD may form through a compensatory
Importance of Copper and Zinc in Alzheimer's Disease
255
mechanism where Zn 2+ is sequestered into accumulations of A(3. However, the quenching of H 2 0 2 formation by Zn 2+ is inefficient and, therefore, if the mass burden of plaque amyloid becomes sufficient, oxidative damage predominates (Opazo et al., 2002).
5. COPPER AND ZINC METABOLISM IS A PROMISING THERAPEUTIC TARGET IN ALZHEIMER'S DISEASE Preclinical and clinical data now support Cu and Zn metabolism as a valid therapeutic target in AD. Clioquinol (CQ), a retired antibiotic with a 0.5 billion patient-day history, was evaluated by Cherny et al. (2001) for efficacy in 21-month-old A(3PP2576 transgenic mice. Administration by lavage of 30 mg/kg for nine weeks resulted in a 49% decrease in brain A(3 load and a decrease in serum A(3, with no evidence of drug-induced toxicity or systemic loss of metals. General health and body weight parameters were significantly improved in the treated animals after only 16 days of treatment. Treatment of A(3PP2576 mice with CQ induced a «15% increase in brain Cu and Zn, indicating that the therapeutic mechanism of CQ is not simply chelation and clearance. A phase II double-blinded clinical trial of CQ in Alzheimer patients has recently been completed. CQ decreased plasma Ap levels and, in more advanced AD patients, slowed the rate of cognitive decline (Masters et al., personal communication). Continued investigation into Cu and Zn metabolism, the metallobiology of A(3 and A|3PP, and the mechanism of action of CQ seems likely to increase the understanding of AD pathogenesis and lead to new treatments for the millions of patients suffering from the disorder.
REFERENCES Asahina M, Yoshiyama Y, Hattori T. Expression of matrix metalloproteinase-9 and urinarytype plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 2001; 20:60-63. Assaf SY, Chung S-H. Release of endogenous Zn 2+ from brain tissue during activity. Nature 1984; 308:734-736. Atwood CS, Moir RD, Huang X, Bacarra NME, Scarpa RC, Romano DM, Hartshorn MA, Tanzi RE, Bush Al. Dramatic aggregation of Alzheimer Ap by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273:12817-12826.
256
Friedlich AL et al.
Atwood CS, Huang X, Moir RD, Tanzi RE, Bush AI. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst 1999; 36:309-364. Atwood CS, Scarpa, RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI. Characterization of copper interactions with Alzheimer AB peptides—identification of an attomolar affinity copper binding site on AB1-42. JNeurochem 2000; 75:1219-1233. Backstrom JR, Miller CA, Tokes ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: Identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992; 58:983-992. Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1991; 3:231-258. Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G. It all sticks together—the ABPP-related family of proteins and Alzheimer's disease. Mol Psychiatry 1999; 4:524-528. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B Jr, Bassett SS, Mclnnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer' disease. Nat Genet 1998; 19:357-360. Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup G. Copper inhibits B-amyloid production and stimulates the non-amyloidogenic pathway of amyloid precursor protein (ABPP) secretion. Biochem J 1999; 344:461-467. Borchardt T, Schmidt C, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup G. Differential effects of zinc on amyloid precursor protein (ABPP) processing in copperresistant variants of cultured Chinese hamster ovary cells. Cell Mol Biol 2000; 46:785-795. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990; 265:15977-15983. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL. A novel zinc(II) binding site modulates the function of the AB4 amyloid protein precursor of Alzheimer's disease. J Biol Chem 1993; 268:16109-16112. Bush AI, Pettingell WH, de Paradis M, Tanzi RE, Wasco W. The amyloid-B protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem 1994a; 269:26618-26621. Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel JFG, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer AB amyloid formation by zinc. Science 1994b; 265:1464-1467. Bush AI. Metals and neuroscience. Curr Opin Chem Biol 2000; 4:184-191. Castellani RJ, Smith MA, Nunomura A, Harris PL, Perry G. Is increased redox-active iron in Alzheimer's disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 1999; 26:1508-1512. Chelly J, Turner Z, Tonnesen T, Petterson A, Ishikawa-Brush Y, Tommerup N, Horn N, Monaco AP. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993; 3:14-19.
Importance of Copper and Zinc in Alzheimer's Disease
257
Cherny RA, Legg JT, McLean CA, Fairlie D, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer's disease A(3 amyloid deposits by biometal depletion. J Biol Chem 1999; 274:23223-23228. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30:665-676. Corrigan FM, Reynolds GP, Ward NI. Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals 1993; 6:149-154. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275:19439-19442. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. Alzheimer's disease amyloid binds Cu and Zn to generate an allosterically-ordered membrane-penetrating structure containing SOD-like subunits. J Biol Chem 2001; 276:20466-20473. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, Stoltenberg M, Ravid R. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997; 76:53-59. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996; 143:137-142. Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM. Alpha2macroglobulin as AP-amyloid peptide-binding plasma protein. J Neurochem 1997; 69:299-305. Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 1989;31:145-328. Frederickson CJ, Suh SW, Silva D, Thompson RB. Importance of zinc in the central nervous system: The zinc-containing neuron. J Nutr 2000; 130:S1471-S1483. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120:885-890. Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia Berrocal B, Navajo JA, Gonzales Buitrago JM. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Inv 1999; 29:637-642. Hambidge M, Krebs NF. Interrelationship of key variables of human zinc homeostasis: Relevance to dietary zinc requirements. Ann Rev Nutr 2001; 21:429^152. Hartter DE, Barnea A. Brain tissue accumulates 67copper by two ligand-dependent saturable processes. J Biol Chem 1988a; 263:799-805.
258
Friedlich AL et al.
Hartter DE, Bamea A. Evidence for release of copper in the brain: Depolarization-induced release of newly taken-up 67copper. Synapse 1988b; 2:412-415. Hershey CO, Hershey LA, Varnes A, Vibhakar SD, Lavin P, Strain WH. Cerebrospinal fluid trace element content in dementia: Clinical, radiologic, and pathologic correlations. Neurology 1983; 33:1350-1353. Hesse L, Beher D, Masters CL, Multhaup G. The beta A4 amyloid precursor protein binding to copper. FEBS Lett 1994; 349:109-116. Howell GA, Welch MG, Frederickson CJ. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 1984; 308:736-738. Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel J-P, Tanzi RE, Bush AL Zincinduced Alzheimer's AfU-40 aggregation is mediated by conformational factors. J Biol Chem 1997; 272:26464-26470. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush, AL The AB peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999a; 38:7609-7616. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall J, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AL Cu(II) potentiation of Alzheimer AB neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction. / Biol Chem 1999b; 274:37111-37116. Jacob C, Maret W, Vallee BL. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc Natl Acad Sci USA 1998; 95:3489-3494. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325:733-736. Kapaki EN, Zournas CP, Segdistsa IT, Xenos DS, Papageorgiou CT. Cerebrospinal fluid aluminum levels in Alzheimer's disease. Biol Psychiatry 1993; 33:679-681. King JC, Shames DM, Woodhouse LR. Zinc homeostasis in humans. J Nutr 2000; 130:S1360-S1366. Krebs NF. Overview of zinc absorption and excretion in the human gastrointestinal tract. J Nutr 2000; 130:S1374-S1377. Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett 2000; 291:201-203. Lee DY, Prasad AS, Hydrick-Adair C, Brewer G, Johnson PE. Homeostasis of zinc in marginal human zinc deficiency: Role of absorption and endogenous excretion of zinc. J Lab Clin Med 1993; 122:549-556. Lee J-Y, Mook-Jung I, Koh J-Y. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 1999; 19:1-5. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158:47-52. Maret W, Vallee BL. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci USA 1998; 95:3478-3482.
Importance of Copper and Zinc in Alzheimer's Disease
259
Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL, Palmiter RD. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J Neurosci 1994; 14:5844-5857. Mercer JF. The molecular basis of copper-transport diseases. Trends Mol Med 2001; 7:64—69. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid B-peptide in insoluble aggregates and soluble complexes. Biochemistry 2000; 39:7024-7031. Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, Smith JD, Tanzi RE. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of AB using physiological concentrations. Biochemistry 1999; 38:4595-4603. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, GonzalezMunoz MJ, de Bustos F, Porta J, Orti-Pareja M, Zurdo M, Barrios E, Martinez-Para MC. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 1998; 105:479^188. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, Kato M, Yanagisawa N. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family. Ann Neurol 1995; 37:646-656. Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996; 271:1406-1409. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, Masters CL, Beyreuther K. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998; 37:7224—7230. Multhaup G, Scheuermann S, Schlicksupp A, Simons A, Strauss M, Kemmling A, Oehler C, Cappai R, Pipkorn R, Bayer T. Possible mechanisms of ABPP-mediated oxidative stress in Alzheimer's disease. Free Radic Biol Med 2000; 33:45-51. Nunomura A, Perry G, Aliev G, Hirai, K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 2001; 60:759-767. Opazo C, Huang X, Cherny R, Moir R, Roher A, White A, Cappai R, Masters C, Tanzi R, Inestrosa N, Bush AI. Metalloenzyme-like activity of Alzheimer's disease B-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H 2 0 2 . J Biol Chem 2002; 277:40302^10308. Palmiter RD, Findley SD. Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J 1995; 14:639-649. Palmiter RD, Cole TB, Findley SD. ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. EMBO J 1996; 15:1784—1791. Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci USA 1996; 93:14934-14939. Panayi AE, Spyrou NM, Iversen BS, White MA, Part P. Determination of cadmium and zinc in Alzheimer's brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 2002; 195:1-10.
260
Friedlich AL et al.
Penkowa M, Giralt M, Moos T, Thomsen PS, Hernandez J, Hidalgo J. Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice. Exp Neurol 1999; 156:149-164. Pullen RG, Franklin, PA, Hall GH. 65Zinc uptake from blood into brain and other tissues in the rat. Neurochem Res 1990; 15:1003-1008. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesbery WR. Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res 2000; 75:79-85. Sahu RN, Pandey RS, Subhash MN, Arya BY, Padmashree TS, Srinivas KN. CSF zinc in Alzheimer's type dementia. Biol Psychiatry 1988; 24:480-482. Sandstead HH. Causes of iron and zinc deficiencies and their effects on brain. J Nutr 2000; 130:S347-S349. Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, Bayer TA, Beyreuther K, Multhaup G. Homodimerization of A(3PP and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem 2001; 276:33923-33929. Simons A, Ruppert T, Schmidt C, Schlicksupp A, Pipkorn R, Reed J, Masters CL, White AR, Cappai R, Beyreuther K, Bayer TA, Multhaup G. Evidence for a copper-binding superfamily of the amyloid precursor protein. Biochemistry 2002; 41:9310-9320. Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agro A. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002; 2:51-59. Strausak D, Mercer JF, Dieter HH, Stremmel W, Multhaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull 2001;55:175-185 Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000; 852:274-278. Szerdahelyi P, Kasa P. Histochemistry of zinc and copper. Int Rev Cytol 1984; 89:1-29. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, Edelman IS, Soares MB, Scheinberg IH, Gilliam TC. Identification of the Wilson's disease gene; a copper transporting ATPase with homology to the Menkes' disease gene. Nat Genet 1993; 3:344-350. Tully CL, Snowdon DA, Markesbery WR. Serum Zinc, senile plaques, and neurofibrillary tangles: Findings from the Nun study. Neuroreport 1995; 6:2105-2108. Uchida Y, Ihara Y, Tomonaga M. Alzheimer's disease brain extract stimulates the survival of cerebral cortical neurons from neonatal rats. Biochem Biophys Res Commun 1988; 150:1263-1267. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth-inhibitory factor that is deficient in the Alzheimer's disease brain is a 68-amino acid metallothionein-like protein. Neuron 1991; 7:337-347. Vallee BL. The function of metallothionein. Neurochem Int 1995; 27:23-33.
Importance of Copper and Zinc in Alzheimer's Disease
261
Van Nostrand WE. Zinc(II) selectively enhances the inhibition of coagulation factor XIa by protease nexin-2/amyloid-beta-protein precursor. Thromb Res 1995; 78:43-53. Wenstrup D, Ehmann WD, Markesbery WR. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res 1990; 533:125-131. White AR, Multhaup G, Galatis D, McKinstry WJ, Parker MW, Pipkorn R, Beyreuther K, Masters CL, Cappai R. Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein. J Neurosci 2002; 22:365-376. White AR, Reyes R, Mercer JFB, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R. Copper levels are increased in the cerebral cortex and liver of ApPP and APLP2 knockout mice. Brain Res 1999; 842:439-444. Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB, Culotta VC, Price DL, Rothstein J, Gitlin, JD. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 2000; 97:2886-2891. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE. Metallothionein III is reduced in Alzheimer's disease. Brain Res 2001; 894:37-45.
This page is intentionally left blank
CHAPTER 10
Copper-Zinc Superoxide Dismutase and Familial Amyotrophic Lateral Sclerosis Moon B Yim, P Boon Chock, Earl R Stadtman
ABSTRACT More than 90 individual mutations in copper-zinc superoxide dismutase are associated with familial cases of amyotrophic lateral sclerosis and they are mostly fatal within one to five years of the onset of the disease. Results obtained from studies with transgenic mice, transfected cells, and patients suggest that familial amyotrophic lateral sclerosis copper-zinc superoxide dismutase mutants have gains or enhancements in one or more cytotoxic properties, which are not related to the superoxide dismutation activity. The proposed nature of the cytotoxic gain-of-function of the familial amyotrophic lateral sclerosis copperzinc superoxide dismutase mutants under debate includes enhanced free radicalgenerating (peroxidative) activity, enhanced activity of peroxynitrite-mediated tyrosine nitration, and familial amyotrophic lateral sclerosis mutant-associated aggregate formation due to failure of protein folding. We review these proposals and summarize our findings from the studies with purified familial amyotrophic lateral sclerosis copper-zinc superoxide dismutase mutants. Keywords: Copper-zinc superoxide dismutase; familial amyotrophic lateral sclerosis; free radical; protein oxidation; protein aggregation.
1. INTRODUCTION Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is an age-dependent, fatal degenerative disorder of motor neurons in the spinal cord, motor cortex, and brainstem. Up to 10% of all ALS patients 263
264
Yim MB et al.
are familial ALS (FALS) and about 20% of FALS are associated with dominantly inherited missense mutations in the coding regions of superoxide dismutase 1 (SOD1), the gene for copper-zinc SOD (Cu,ZnSOD) (Rosen et al., 1993; Deng et al., 1993), which catalyzes the dismutation of superoxide radical anions (0 2 ") to hydrogen peroxides (H 2 0 2 ) and oxygen molecules (0 2 ). Over 90 individual point mutations in Cu,ZnSOD are known to cause FALS, which is usually fatal within one to five years of onset of the disease, generally at the age of 45 years and older (Gaudette et al., 2000; Cleveland and Rothstein, 2001), when the antioxidant defenses start to deteriorate (Moskovitz et al., 2002). The mutation sites are scattered throughout the structure of the wild-type Cu,ZnSOD protein. Several mutated residues are positioned within the electrostatic active site channel and in the active site (H46R, H48Q, or H80R). Another group of mutations causes truncation of the final 20 to 33 amino acids. The most abundant sites of mutation are located in conserved interaction regions critical to the subunit fold and dimer contact. Initial studies suggested that erythrocytes and brain tissues of FALS patients exhibited a marked reduction in Cu,ZnSOD activity compared to that of normal individuals (Deng et al., 1993). This reduction in SOD activity may induce oxidative damage and cause FALS symptoms. However, several studies with transgenic mice (Gurney et al., 1994; Ripps et al., 1995; Bruijn et al., 1997; Wong et al., 1995), transfected cells (Borchelt et al., 1995; Rabizadeh et al., 1995), and lymphoblasts of patients (Deng et al., 1993; Borchelt et al., 1994) revealed that levels of total Cu,ZnSOD activities remain unchanged or higher than normal. These results imply that the FALS mutants have gained or enhanced one or more cytotoxic properties, which are not related to superoxide dismutation (SOD) activity. Although the nature of the cytotoxic gain-of-function caused by Cu,ZnSOD FALS mutants is debatable, several mechanisms have been proposed. They include enhanced free radical-generating (or peroxidative) activity with H 2 0 2 and small anions as substrates (Yim et al., 1996, 1997; Wiedau-Pazos et al., 1996), enhanced activity of peroxynitritemediated tyrosine nitration, especially with Zn-depleted enzymes (Crow et al., 1997a, 1997b; Estevez et al., 1999), and FALS mutant-associated aggregate formation due to failure of protein folding (Bruijn et al., 1998; Chou et al., 1998). For the first two mechanisms, oxidation reactions catalyzed by Cu ions at the active sites or other bound sites are required. In
265
Copper-Zinc Superoxide Dismutase and Familial ALS
contrast, the aggregate formation for the last mechanism may not require Cu incorporation into Cu,ZnSOD, even though enhanced free radicalgenerating activity would lead to aggregation of macromolecules. We review these proposals and summarize our findings obtained from the studies with purified FALS Cu,ZnSOD mutants.
2. STRUCTURE OF Cu,ZnSOD Cu,ZnSOD is a homodimer with each subunit containing 153 amino acids and an active site that contains one Cu ion at the catalytic site (ligated by the four histidines (His) of 46, 48, 63, and 120) and one Zn ion at the structural site (ligated by the three His of 63, 71, and 80 and one Asp, 83) (Tainer et al., 1982; Getzoff et al., 1983). The Cu and Zn ions are bridged by His-63. The catalytic site can be reached by the substrate through a positively charged channel shaped like a funnel, which leads to the catalytically essential Arg 143 and a narrow hydrophobic access (< 4 A) to the Cu ion (see Fig. 1). One oxygen molecule of the superoxide anion binds to the Cu ion at the active site, while the other oxygen molecule forms a hydrogen bond with the positively charged guanidinum nitrogen on Arg 143, which is located 5 A away from the Cu ion. This positively charged channel, which consists the basic residues Arg 143, Lys 122, and Lys 136, is responsible for the favorable electrostatic guidance of the anionic substrate 0^" to the active site to yield an unusually rapid catalytic rate constant (2 X 109 M _ 1 s _1 ) for superoxide dismutation (Klug et al., 1977; Tainer et al., 1982; Getzoff et al., 1983). Other small anions, such as azide, cyanide, halides, and phosphate, are also known to have easy access to the channel and bind to either the active site or the positively charged guanidinum nitrogen on Arg 143 (Rigo et al., 1977; Mata de ( ^ ^
24A
> J
*Thr5§\
5A |
5A
("
L
10A
Argl43"-\
Glu 133
>J (Thrl37
WA^ Cu
Fig. 1. Shape and dimension of the active site channel. The Lys 136 and Lys 122 located front and back of the paper, respectively, at the top of the channel.
266
Yim MB et al.
Freitas and Valentine, 1984). Thus, these anions, as well as many other small anions, behave as inhibitors in the superoxide dismutation reaction and exert profund effects on the general reactions involving Cu,ZnSOD.
3. PRO-OXIDANT, FREE RADICAL-GENERATING (PEROXIDATIVE) ACTIVITY OF Cu,ZnSOD Besides its superoxide dismutation activity, Cu,ZnSOD also reacts with its own reaction product, H 2 0 2 , which leads to its inactivation (Hodgson and Fridovich, 1975a; Fuchs and Borders, 1983). The inactivation appears to be caused by the oxidation of one or more amino acid residues of the enzyme. This includes His, which is ligated to the Cu ion at the active site of the enzyme. A reaction mechanism has been proposed for the inactivation reaction (Hodgson and Fridovich, 1975a): Enz-Cu(II) + H 2 0 2 -> Enz-Cu(I) + 0 2 * + 2H + , Enz-Cu(I) + H 2 0 2 -> Enz-CuQIKOH + OH", Enz-Cu(II)-"OH + ImH -> Enz-Cu(II) + Im" + H 2 0.
(1) (2) (3)
The intermediate product, Enz-Cu(II)-"OH, is a highly oxidizing species, such as free, caged, or Cu-bound "OH radical. The reactive species can react with the enzyme itself, resulting in damage to amino acid residues, such as the imidazole moiety of a His residue at the active site. Analysis of the stable products of the inactivated SOD revealed that 2-oxohistidine (His-118 for bovine SOD) was produced during the inactivation reaction by H 2 0 2 (Uchida and Kawakishi, 1994). Recent spin-trapping electron paramagnetic resonance (EPR) spectroscopic experiments have shown that 2-oxohistidine was formed by the reaction of 0 2 with the 2-histidinyl radical intermediate. This was confirmed by comparing the EPR spectrum of the authentic histidinyl radical generated by the reaction of the free "OH radical with His (Gunther et al., 2002). Some small anions, such as azide and formate, which have easy access to the active channel, protect the enzyme against inactivation caused by H 2 0 2 by scavenging free or metal-bound "OH radicals generated in reaction 3 (Hodgson and Fridovich, 1975b). During this reaction, the scavenger anions were oxidized. Hence, Cu,ZnSOD exhibits peroxidative activity (Hodgson and Fridovich, 1975b). The scavengers that can be oxidized are not limited to small anions that protect the enzyme
Copper-Zinc Superoxide Dismutase and Familial ALS
267
against inactivation, but also include proteins and relatively large molecules, such as ferrocytochrome-c and bilirubin, or neutral molecules, such as alcohols. These molecules or proteins do not protect the Cu,ZnSOD against inactivation by H 2 0 2 . These results may suggest that reactive species were released from the Cu ion to oxidize larger molecules or proteins. In the initial spin-trapping EPR experiments (Yim et al., 1990, 1993), it was demonstrated that during these reactions "OH radicals and other free radical species originating from scavengers are generated and some stable free radicals may diffuse away from the active site to exert oxidative damage on other macromolecules in the cell. Thus, Cu,Zn-SOD can function as a pro-oxidant to generate free radicals that may initiate harmful chain reactions in vivo (Yim et al., 1990, 1993, 1999).
4. FREE RADICAL SPECIES GENERATED BY Cu,ZnSOD In initial studies (Yim et al., 1990, 1993), two spin traps, 5,5'-dimethyl-1pyrroline-N-oxide (DMPO) and N-tert-butyl-a-phenylnitrone (PBN), were used to convert transient free radicals to stable free radical adducts according to the following reaction: DMPO (or PBN) + R' -» DMPO-R* (or PBN-R').
(4)
The nature of the trapped free radical was identified by EPR spectroscopy. When H 2 0 2 was added to the solution containing active Cu,Zn-SOD and DMPO, EPR resonance lines of the hydroxyl radical adduct of DMPO (DMPO-'OH) were observed (Yim et al., 1990). The formation of this radical adduct was greatly affected by various buffer systems: the signal amplitude of DMPO-'OH obtained in phosphate (25 mM, pH 7.3) or borate (25 mM, pH 8.1) buffers was increased dramatically in the NaHC0 3 (23.5 mM)/C0 2 buffer at pH 7.6 (Yim et al, 1990). A recent study (Sankarapandi and Zweier, 1999a) suggested that bicarbonate may bind to the Arg 141 of bovine Cu,ZnSOD and anchors H 2 0 2 at the active site Cu for easier redox cleavage. In the presence of "OH radical scavengers with anionic characteristics, such as HCO^, N J , or glutathione, DMPO adducts of the scavenger-derived radicals, DMPO-C0 2 \ DMPO-Nj, or DMPO-GS' were observed besides DMPO-'OH (Yim et al., 1990; Kwak et al., 1995). Surprisingly, with neutral 'OH radical scavengers, such as ethanol, DMPO-hydroxyethyl radical adducts were
268
Yim MB et al.
formed, but in very small quantities compared to those of anionic scavengers. However, with a different spin trap, PBN, in place of DMPO, PBN-hydroxyethyl radical adducts were formed in a quantity for a competition reaction for free *OH radicals. These seemingly contradictory results can be explained by differences in the affinities of the spin traps used to bind to the positively charged active channel of Cu,ZnSOD, where the "OH radicals are generated (Yim et al., 1990, 1993). For this purpose, we measured binding constants of the spin traps to the active site/channel using a negatively charged chromogen, 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulfonate) (ABTS) (Yim et al., 1993). The ABTS is known to react with the "OH radical at a diffusion-controled rate (reaction 5) to produce a stable oxidized free radical, ABTS+", which has strong absorption at 415 nm (E415 - 3.6 X 104 JVT' cm - 1 ): ABTS + "OH -> ABTS + " + OH~
k = 1.2 X 1010 M _ 1 s"1.
(5)
Addition of active Cu,ZnSOD also produced ABTS+" in the presence of H 2 0 2 and ABTS. The formation of ABTS+* followed first-order kinetics with respect to Cu,ZnSOD and H 2 0 2 . However, it showed a binding isotherm with ABTS that yielded a dissociation constant for ABTSCu,ZnSOD of Kd = 7.1 ± 0.5. The formation of ABTS+" was inhibited by the presence of DMPO or PBN in the reaction mixture. By performing a competition study, Kd values for DMPO and PBN were obtained as 0.63 mM and 11 mM, respectively. A radical scavenger, formate anion, also inhibits the formation of ABTS+", whereas ethanol does not. These results indicate that DMPO and anionic scavengers have much more accessibility to the cavity of the active channel than PBN and neutral ethanol. Consequently, DMPO or anionic scavengers are in a position to intercept the newly formed "OH radicals and drastically reduce the probability for the reaction of "OH radicals with ethanol. Therefore, the concentrations of DMPO-hydroxyethyl radical adducts observed are much lower than that expected under equally competitive conditions. PBN and ethanol, however, are able to compete in the bulk solution for free "OH radicals released from the active site of Cu,ZnSOD. Thus, both PBN-hydroxyethyl radical and PBN-OH can be detected. Conversely, these results indicate that free 'OH radicals and scavenger-derived radicals can reach the bulk solution and may cause oxidative damage to the biological environments.
Copper-Zinc Superoxide Dismutase and Familial ALS
269
Considering the short half-life of "OH radicals, the majority of the radicals released to biological environments will be secondary cascading radicals formed by scavenging the initial 'OH radicals within a short distance of their formation (Yim et al, 1990, 1993, 1999). The term "bulk solution" should not be misunderstood. It is defined as a few bonding distances away (5 A) from the active Cu ion site due to the unique topography of the channel. As shown in Fig. 1, the Cu ion is located about 5 A inside the narrow channel (<4 A width), such that it can be reached by Br~ (diameter of 3.9 A), but not I" (diameter of 4.32 A) (Rigo et al., 1997). Thus, it is quite possible that, in the absence of the small scavenging anion accessible to the Cu ion, some fraction of the newly synthesized 'OH radicals can be released and trapped by DMPO (or oxidized by other molecules) located about 5 A away, but DMPO (or other oxidizing molecules) cannot protect against self-inactivation of Cu,ZnSOD caused by the damage to the Cu ligands: A—
DMPO
-^ Enz-Cu(II) + 'A > DMPO-'A, (6) Enz-Cu(II)-"OH —> 'Enz-Cu(II) —> Inactivation, oxidized protein, (7) -> Enz-Cu(II) + 'OH > DMPO-'OH, B'. (8) DMPO orBH
Several groups (Sankarapandi and Zweier, 1999b; Singh et al, 1998; Goss et al., 1999; Zhang et al., 2000, 2002) carried out similar experiments and concluded against the release of free "OH radicals from metal ions for various reasons. Singh et al. (1998) and Goss et al. (1999) carried out DMPO spin-trapping experiments using O-17-enriched H 2 17 0 2 and H 2 17 0. Their experimental spectra clearly showed that a significant fraction (—65%) of DMPO-'OH (and also with a different spin trap, DEPMPO-'OH) formed during SOD reaction was derived from oxygen of H 2 0 2 , but DMPO cannot protect the enzyme against inactivation. This result supports the above mechanism, although they reached a different conclusion. A recent report (Zhang et al., 2000) by the same group, however, claimed that 100% of oxygen in DMPO-'17OH originated from H 2 17 0, and not from H 2 17 0 2 . They suggested that the DMPO-'OH adducts observed originated entirely from the hydrolysis of DMPO-carbonate radical adducts, which were formed by
270
Yim MB et al.
the scavenging reaction that occurred in the bicarbonate buffer. However, DMPO-'OH adducts can also be observed in phosphate and borate buffers (Yim et al., 1990). In free radical chemistry, propagating radicals and chain carriers frequently govern the final products, rather than initiating species of free radical reactions. Thus, a variety of secondary free radicals can be produced by the reaction involving Cu,Zn-SOD and H 2 0 2 in vivo, irregardless of the identity of the initiating species, be it free, caged, or metal-bound "OH. These secondary free radical species, including radicals originating from glutathione (Kwak, et al., 1995), formate (Yim et al., 1990, 1993), bicarbonate (Goss et al., 1999), neurotansmitters (Yim et al., 1993), and many other radicals that have yet to be identified, may diffuse away from the active channel. These diffused radicals could initiate damaging reactions to proteins and other macromolecules and/or behave as second messengers to induce apoptosis (Guegan et al., 2001).
5. ENHANCEMENT OF FREE RADICAL GENERATION BY FALS Cu,ZnSOD MUTANTS Yim et al. (1996, 1997) and Wiedau-Pazos et al. (1996) have investigated whether there are any differences in the free radical-generating activity between the wild-type and FALS mutant Cu,ZnSOD. For this purpose, we cloned the wild-type and FALS G93A and A4V cDNA of human Cu,ZnSOD, overexpressed them in insect cells (Sf9), purified proteins, and measured their enzymatic activities. Our results revealed that the G93A, A4V, and wild-type Cu,ZnSOD have similar dismutation activities. However, the free radical-generating function of the G93A and A4V mutants measured by the spin-trapping method is enhanced relative to that of the wild-type enzyme (wild-typeG93A (25 mM)>A4V (13 mM)]. Thus, A4V and G93A have higher affinities for H 2 0 2 than the wild type. This increased affinity for H 2 0 2 could favor its conversion to "OH radicals. This enhancement of free radical-generating activity may provide, in part, an explanation for the association of the FALS Cu,ZnSOD mutants to ALS. We have also investigated whether FALS mutants have enhanced capacity for tyrosine nitration mediated by peroxynitrite (unpublished
Copper-Zinc Superoxide Dismutase and Familial ALS
271
results) by using two substrates, free tyrosine and a synthetic pentadecameric peptide, which correspond to the tyrosine phosphorylation site of p34cdc2 kinase used in our previous work (Kong et al., 1996). The results showed that the nitration activity of the FALS mutants is virtually identical to that of the wild-type enzyme. Several reports, however, suggested that FALS mutants have a lower affinity to Zn ion (Lyons et al., 1996; Crow et al., 1997a) and Zn-deficient enzyme, either wild-type or mutant, shows enhanced capacity for nitration involving peroxynitrite (Estevez et al., 1999). Considerable experimental results support the involvement of free radicals in FALS. Hall et al. (1998) and Andrus et al. (1998) demonstrated that lipid peroxidation and protein carbonyl levels, a marker of protein oxidative damage, in G93A transgenic mice were elevated in comparison to nontransgenic mice, respectively. Liu et al. (1998) carried out spin trapping by using azulenyl nitrone, which produces azulenyl aldehyde through reaction with free radicals. The results obtained from G93A transgenic mice showed significant enhancement of free radical generation in the spinal cord prior to motor neuron degeneration compared to wild-type transgenic control mice. Bogdanov et al. (1998) used a microdialysis method to measure oxidation of 4-hydroxybenzoic acid to 3,4-dihydroxybenzoic acid. They observed elevated hydroxyl radical generation in vivo in G93A transgenic mice, but not in wild-type transgenic mice. Aguirre et al. (1998) demonstrated that the fibroblasts obtained from FALS patients showed an increased sensitivity to H 2 0 2 stress, which was explained by the increased affinity of the mutants to H 2 0 2 . Liu et al. (2002) showed that infection of mouse NSC-34 motor neuron-like cells with the G93Acontaining vector increased cellular oxidative stress, indicating mitochondrial dysfunction. Pretreatment of cells containing the mutant with highly oxidizable polyunsaturated fatty acid elevated lipid peroxidation and enhanced cell death, but not with cells containing wild-type Cu,ZnSOD. Pretreatment with DMPO prevents mutant-mediated mitochondrial dysfunction and cell death. Roe et al. (2002) trapped free radicals generated in the FALS mutants (G93A, G93C, L38V, and A4V) expressed in yeast cells using the a-(pyridyl-4-N-oxide)-N-tert-butylnitrone (POBN) spin trap. They found that mutant Cu,ZnSOD produced a greater concentration of trapped free radical adducts. Zhang et al. (2002) used the spinal cords of homogenized mice to detect the oxidation of dichlorodihydrofluoroscein
272
Yim MB et al.
(DCHF) to dichlorofluoroscein. Their results showed a significant increase in the oxidation of DCHF in spinal cord extracts from G93A transgenic mice (90 days' old) relative to that of wild type. This observation strongly suggests that G93A has enhanced free radical-generating activity, unlike their previous assertion that their EPR data obtained with G93A and wild-type Cu,Zn-SOD showed no difference in free radicalgenerating activity (Singh et al, 1998).
6. AGGREGATION INDUCED BY FALS MUTANTS Bruijn et al. (1998) suggested that poorly or unstably folded mutants mitigate Cu,ZnSOD-containing aggregates that are toxic to motor neurons. They suggested that this process is induced by an as yet unidentified chemical reaction, rather than the involvement of free radicals. Subramaniam et al. (2002) reported results recently obtained from FALS transgenic mice (G93A, G37R, or G85R), in which the gene encoding the Cu chaperone for SOD1 (CCS) has been disrupted. They found that the incorporation of Cu ion into mutants was very much diminished in the absence of CCS. However, it did not modify at all (neither accelerate nor delay) the onset and progression of motor neuron disease in transgenic mice, relative to the mice with intact CCS. They concluded that the CCS-dependent Cu loading to mutant Cu,ZnSOD plays no role in the pathogenesis of disease in these mouse models (Subramaniam et al., 2002). The results, however, are not easily understood by invoking the aggregation hypothesis alone. In general, the apo-forms of metalloproteins are less stable and aggregate more easily than their holo forms (Rodriguez et al., 2002). Thus, if mutant-mediated aggregation is the cause of Cu,ZnSOD-associated FALS disease, the onset and progression of the disease should be accelerated in the CCS-disrupted FALS mouse model. Protein aggregates containing Cu,ZnSOD are commonly observed in FALS patients and transgenic mice expressing human Cu,ZnSOD (Kaytor and Warren, 1999; Julien, 2001; Watanabe et al., 2001). Johnston et al. (2000) have studied the formation of FALS Cu,ZnSOD-associated aggregates and insoluble protein complexes (IPCs) in G93A and G85R transfected human embryonic kidney and G93A transgenic mice. They found that SOD IPCs were present in the spinal cords of transgenic mice expressing mutant, but not wild-type SOD, at least three months before either SOD inclusion bodies or motor neuron dysfunction were first
Copper-Zinc Superoxide Dismutase and Familial ALS
273
manifested. They proposed that the accumulation of SOD IPC could cause neuronal death by disrupting the capacity of the ubiquitin-proteasome pathway (Johnston et al., 2000). Several groups have reported the involvement of glycation in the formation of the aggregates. These include the observation of advanced glycation endproducts in neurofilament-associated conglomeration of motor neurons (Chou et al., 1998), detection of glycated SODl-positive inclusions (Kato et al., 2000), and observation of protein glycoxidation in the spinal cords of sporadic ALS patients (Shibata et al., 2001). Advanced glycation endproducts are heterogeneous products that may include various crosslinked proteins. It has been shown that oxidative conditions enhance glycation reactions. In addition, we have shown previously that protein glycation creates catalytic sites for free radical generation in protein-crosslinked products (Yim et al., 1995, 1998; Lee et al., 1998). Thus, the aggregation hypothesis may not exclude the possibility that the aggregation is mediated by free radicals initially, and these crosslinked proteins will then function as free radical generators to create autocatalytic phenomena for the progression of the disease (Yim et al., 1999).
7. CONCLUSIONS It is clear that the mechanism(s) by which FALS Cu,ZnSOD mutants induce ALS is far from resolved. The available data suggest that the processes caused by FALS mutants will eventually lead to the formation of Cu,ZnSOD-containing aggregates, which are commonly found in FALS patients and are believed to be toxic to motor neurons. The formation of aggregates can be facilitated by free radical reactions, protein misfolding and demetallation, and/or protein glycation. All these processes may be mechanistically linked as causes (enhanced free radical-generating activity and/or protein glycation) and consequences (protein glycation and aggregates). Thus, effects of wild-type and mutant Cu,ZnSOD on the formation of aggregates in vitro and characterization of their associated proteins found in the aggregates of FALS patients deserve further investigation.
REFERENCES Aguirre T, Van Den Bosch L, Goetschalckx K, Tilkin P, Mathijs G, Cassiman J J, Robberecht W. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann Neurol 1998; 43:452-457.
274
Yim MB et al.
Andrus PK, Fleck TJ, Gumey ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1998; 71:2041-2048. Bogdanov MB, Ramos LE, Xu ZS, Beal MR Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998; 71:1321-1324. Borchelt DR, Guarnieri M, Wong PC, Lee MK, Slunt HS, Xu Z-S, Sisodia SS, Price DL, Cleveland DW. Superoxide dismutase-1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function. / Biol Chem 1995; 270:3234-3238. Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu Z-S, Wong PC, Brown RH Jr, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase-1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994; 91:8292-8296. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1containing inclusions. Neuron 1997; 18:327-338. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281:1851-1854. Chou SM, Wang HS, Taniguchi A, Bucala R. Advanced glycation end products in neurofilament conglomeration of motor neurons in familial and sporadic amyotrophic lateral sclerosis. Molecular Medicine 1998; 4:324-332. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2:806-919. Crow JP, Sampson JB, Zhuang YX, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants lead to enhanced catalysis of tyrosine nitration of peroxynitrite. J Neurochem 1997a; 69:1936-1944. Crow JP, Ye YZ, Strong M, Kirk M, Barnes S, Beckman JS. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in rod and head domains of neurofilamentL. J Neurochem 1997b; 69:1945-1953. Deng H-X, Hentati A, Tainer J, Iqbal Z, Cayabyab A, Hung W-Y, Getzoff ED, Hu P, Herzfeldt B, Roos RP, Warner C, Deng G, Soriano E, Smyth C, Parge HE, Ahmed A, Roses AD, Hallewell RE, Pericak-Vance MA, Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993; 261:1047-1051. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999; 286:2498-2500. Fuchs HJR, Borders CL Jr. Affinity inactivation of bovine Cu,Zn superoxide-dismutase by hydroperoxide anion, HO2 • Biochem Biophys Res Commun 1983; 116:1107-1113.
Copper-Zinc Superoxide Dismutase and Familial ALS
275
Gaudette M, Hirano M, Siddique, T. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:83-89. Getzoff ED, Tainer JA, Weiner PK, Kollman PA, Richardson JS, Richardson DC. Electrostatic interaction between superoxide and copper, zinc superoxide dismutase. Nature 1983; 306:287-290. Goss SPA, Singh RJ, Kalyanaraman B. Bicarbonate enhances the peroxidase activity of Cu,Zn-superoxide dismutase. J Biol Chem 1999; 274:28233-28239. Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrialdependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001; 21:6569-6576. Gunther MR, Peters JA, Sivaneri MK. Histidinyl radical formation in the self-peroxidation of bovine copper-zinc superoxide dismutase. J Biol Chem 2002; 277:9160-9166. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng H-X, Chen WC, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264:1772-1775. Hall ED, Andrus PK, Oostveen JK, Fleck TJ, Gurney ME. Relationship of oxygen radicalinduced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998; 53:66-77. Hodgson EK, Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: Interaction of the enzyme. Biochemistry 1975a; 14:5294-5299. Hodgson EK, Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: Chemiluimnescence and peroxidation. Biochemistry 1975b; 14:5299-5303. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97:12571-12576. Julien JP. Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded. Cell 2001; 104:581-591. Kato S, Horiuchi S, Liu J, Cleveland DW, Shibata N, Nakashima K, Nagai R, Hirano A, Takikawa M, Kato M, Nakano I, Ohama E. Advanced glycation end product-modified superoxide dismutase-1 (SODl)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation. Acta Neuropathol (Berl.) 2000; 100:490-505. Kaytor MD, Warren ST. Aberrant protein deposition and neurological disease. J Biol Chem 1999; 274:37507-37510. Klug D, Rabani J, Fridovich I. A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis. J Biol Chem 1977; 247:4839-4842. Kong SK, Yim MB, Stadtman ER, Chock PB. Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism by nitrating the tyrosine residue — tyrosine kinase fails to phosphorylate nitrated tyrosine. Proc Natl Acad Sci USA 1996; 93:3377-3382.
276
Yim MB et al.
Kwak HS, Yim HS, Chock PB, Yim MB. Endogenous intracellular glutathionyl radicals are generated in neuroblastoma cells under hydrogen peroxide oxidative stress. Proc Natl Acad Sci USA 1995; 92:4582-4586. Lee C, Yim MB, Chock PB, Yim H-S, Kang S-O. Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J Biol Chem 1998; 273:25272-25278. Liu R, Althaus JS, Ellerbrock BR, Becker DA, Gurney ME. Enhanced oxygen radical production in transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1998; 44:763-770. Liu R, Li B, Flanagan SW, Oberley LW, Gozal D, Qiu M. Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD-1 mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J Neurochem 2002; 80:488-500. Lyons TJ, Liu H, Goto JL, Nersissian A, Roe JA, Graden JA, Cafe C, Ellerby LM, Bredesen DE, Gralla EB, Valentine JS. Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. Proc Natl Acad Sci USA 1996; 93:12240-12244. Mata de Freitas D, Valentine JS. Phosphate is an inhibitor of copper-zinc superoxide dismutase. Biochemistry 1984; 23:2079-2082. Moskovitz J, Yim MB, Chock PB. Free radicals and disease. Arch Biochem Biophys 2002; 397:354-359. Rabizadeh S, Gralla EB, Borchelt DR, Gwinn R, Valentine JS, Sisodia S, Wong P, Lee M, Hahn H, Bredesen DE. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: Studies in yeast and neural cells. Proc Natl Acad Sci USA 1995; 92:3024-3028. Rigo A, Stevanato R, Viglino P. Competitive inhibition of Cu,Zn superoxide dismutase by monovalent anions. Biochem Biophys Res Commun 1977; 79:776-783. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995; 92:689-693. Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, Brown RH Jr, Hayward JL. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem 2002; 277:15932-15937. Roe JA, Wiedau-Pazos M, Moy VA, Goto JJ, Gralla EB, Valentine JS. in vivo peroxidative activity of FALS-mutant Cu,ZnSODs expressed in yeast. Free Rad Biol Med 2002; 32:169-174. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng H-X, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Vergh R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH. Mutations in Cu,Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
Copper-Zinc Superoxide Dismutase and Familial ALS
277
Sankarapandi S, Zweier JL. Bicarbonate is required for the peroxidase function of Cu,Znsuperoxide dismutase at physiological pH. J Biol Chem 1999a; 274:1226-1232. Sankarapandi S, Zweier JL. Evidence against the generation of free hydroxyl radicals from the interaction of copper,zinc-superoxide dismutase and hydrogen peroxide. J Biol Chem 1999b; 27:34576-34583. Shibata N, Nagai R, Uchida H, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001; 917:97-104. Singh RJ, Karoui H, Gunther MR, Beckman JS, Mason RP, Kalyanaraman B. Re-examination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu,Zn superoxide dismutase mutants and H 2 0 2 . Proc Natl Acad Sci USA 1998; 95:6675-6680. Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL, Cleveland DW, Gitlin JD, Wong PC. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nature Neuroscience 2002; 5:301-307. Tainer JA, Getzoff ED, Beem KM, Richardson JS, Richardson DC. Determination and analysis of the 2A structure of bovine copper, zinc superoxide dismutase. J Mol Biol 1982;160:181-217. Uchida K, Kawakishi S. Identification of oxidized histidine generated at the active site of Cu,Zn-superoxide dismutase exposed to H 2 0 2 . Selective generation of 2-oxohistidine at the histidine 118. J Biol Chem 1994; 269:2405-2410. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001; 8:933-941. Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, Valentine JS, Bredesen DE. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996; 271:515-518. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14:1105-1116. Yim, H-S, Kang J-H, Chock PB, Stadtman ER, Yim MB. A familial amyotrophic lateral sclerosis-associated A4V Cu.Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and Km value. J Biol Chem 1997; 272:8861-8863. Yim H-S, Kang S-O, Hah Y-C, Chock PB, Yim MB. Free radicals generated during the glycation reaction of amino acids by methylglyoxal—a model study of proteincrosslinked free radicals. J Biol Chem 1995; 270:28228-28233. Yim MB, Chock PB, Stadtman ER. Copper, zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide. Proc Natl Acad Sci USA 1990; 87:5006-5010. Yim MB, Chock PB, Stadtman ER. Enzyme function of copper, zinc superoxide dismutase as a free radical generator. J Biol Chem 1993; 268:4099^1105.
278
Yim MB et al.
Yim MB, Kang J-H, Yim H-S, Kwak H-S, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 1996; 93:5709-5714. Yim MB, Kang SO, Chock PB. Enzyme-like activity of glycated crosslinked proteins in free radical generation. Ann NY Acad Sci 1998; 899:168-181. Yim MB, Yim HS, Chock PB, Stadtman ER. Enhanced free radical generation of FALSassociated Cu,ZnSOD mutants. Neurotoxicity Res 1999; 1:91-97. Zhang H, Joseph J, Felix C, Kalyanaraman B. Bicarbonate enhances hydroxylation, nitration, and peroxidation reactions catalyzed by copper,zinc-superoxide dismutase. J Biol Chem 2000; 275:14038-14045. Zhang H, Joseph J, Gurney M, Becker D, Kalyanaraman B. Bicarbonate enhances peroxidase activity of copper, zinc-superoxide dismutase. J Biol Chem 2002; 277:1013-1020.
CHAPTER 1 1
Copper and Prion Disease Judyth Sassoon, David R Brown
ABSTRACT The prion protein, PrP c , is a neuronal cell surface glycoprotein. In an abnormal isoform, termed PrPSc, it is associated with the family of neurodegenerative conditions called prion diseases. PrP c was recently shown to bind copper and there is strong evidence that it has a role in the regulation of brain copper metabolism. Its expression alters copper uptake into cells and enhances copper incorporation into superoxide dismutase enzymes. Also, PrP c has a superoxide dismutase-like function and may, therefore, protect neurons from the onslaught of reactive oxygen species. Furthermore, several lines of evidence have suggested that copper ions play a role in the biology of both PrP c and PrPSc and may influence the conversion of PrP c to PrPSc. This chapter provides an overview of the latest findings in this field and discusses structural and functional aspects of the prion protein. Keywords: Antioxidant; copper; neurodegeneration; prion; PrP.
1. INTRODUCTION Prion diseases are a group of fatal neurodegenerative conditions, such as Creutzfeldt-Jakob disease (CJD) in humans and bovine spongiform encephalopathy and scrapie in ruminant animals (Collinge, 2001). The infectious factors associated with these conditions are proteins, composed of PrPSc a post-translationally modified form of a normal cellular protein, designated PrP c (Prusiner, 1998) (Fig. 1). Spectroscopic studies have revealed that PrP c has a high a-helical content, whereas PrPSc is rich in P-sheets (Caughey et al., 1991; Pan et al., 1993; Liu et al., 1999; Zahn et al., 2000). These two isoforms differ biochemically, with PrPSc displaying reduced solubility in nondenaturing detergents and partial resistance to 279
Sassoon J & Brown DR
#
*
*
%
B Fig. 1. Detection of PrPSc in the brains of mice with experimental mouse scrapie. The histoblot technique was used to examine brain sections of mouse brain infected with the ME7 strain of scrapie at (A) 30 days and (B) 120 days post-inoculation. The sections were treated with proteinase K to destroy protease-sensitive PrR An antibody to PrP then allowed detection of PrPSc. This is detected heavily in the 120-day brain.
protease digestion (Oesch et al, 1985; Meyer et al, 1986). The "proteinonly hypothesis" proposed by Prusiner (Prusiner, 1982, 1991) implies that prpSc a i o n e c a n a c t a s t k e infectious agent. However, experiments with recombinant prion protein converted to the PrPSc-like form failed to induce disease in mice (Hill et al., 1999). It is, therefore, possible that some other element is necessary for infectivity or that PrP interacts with some other factor which catalyzes the conversion of PrP c to PrPSc. Although there is still no evidence for a virus or DNA element in prion diseases, a modified version of the protein-only hypothesis is now clearly required to explain the mechanism of infection. Although much data is available about PrPSc in relation to prion diseases, the physiological function of the normal cellular PrP c is still a matter of contention. There is clear evidence that the expression of PrP c and its conversion to PrPSc is connected in some way with disease-associated
Copper and Prion Disease
281
neurodegeneration. It has been shown that mice lacking expression of PrP c cannot be infected with the disease and suffer no neurodegeneration, or any of the symptoms associated with prion diseases (Biieler et al., 1992, 1993). Furthermore, cultured neurons lacking PrP c expression are resistant to the neurotoxicity of PrPSc or peptide homologs, both in vivo and in vitro (Brown et al., 1994; Brandner et al., 1996). In the course of research directed towards understanding the function of PrP c , several lines of evidence suggested that copper (Cu) might play a key role in prion biology (Brown et al., 1997a). Most importantly, through studies on synthetic peptides and recombinant protein, several laboratories have shown that Cu ions bind to the octapeptide repeat region in the N-terminal portion of the mammalian PrP c (Hornshaw et al., 1995a; Brown et al., 1997a; Stockel et al., 1998; Miura et al., 1999; Viles et al., 1999; Whittal et al., 2000). Binding of Cu is pH-dependent and apparently induces a conformational change in the normally unstructured N-terminus of the molecule. In addition, it was shown that Cu rapidly and reversibly stimulated endocytosis of PrP c from the surface, raising the possibility that PrP c may serve as a receptor for cellular uptake and efflux of Cu (Pauly and Harris, 1998; Brown et al., 1999a). An enzymatic function for PrP c has also been claimed based on the observation that Cu binding confers superoxide dismutase (SOD) activity on the protein (Brown et al., 1999b). Other connections between PrP c and Cu have been proposed, but have remained controversial. PrP c was postulated to be a major Cubinding protein in brain based on the observation that the content of Cu is 5% to 50% of normal in membrane fractions derived from the brains of mice which carry a disrupted PrP gene (Brown et al., 1997; Herms et al., 1999). The activity of SOD-1 was also reported to be 50% of normal in the brains of these mice, and neurons cultured from the animals were found to be more susceptible to oxidative stress, further implying a role for PrP c in protection from oxidative damage (Brown and Besinger, 1998; Brown et al., 1999b). There are also several other results suggesting interactions between Cu and the abnormal prion, PrPSc. A role for Cu in mediating the disease process has been proposed for the following reasons. First, Cu facilitated the restoration of protease resistance and infectivity during refolding of guanidine-denatured PrP Sc (McKenzie et al., 1998). Secondly, the protease cleavage pattern of PrPSc derived from the brains
282
Sassoon J & Brown DR
of patients with CJD was altered by addition or chelation of Cu and another trace metal zinc (Zn), suggesting a role for metal occupancy in determining prion strain properties (Wadsworth et al., 1999). In addition, Cu added at high concentration to the prion protein causes it to refold into a protease-resistant form. (Quaglio et al., 2001). Finally, it was reported almost 25 years ago that administration of the Cu- chelating agent cuprizone to mice caused spongiform degeneration of the brain similar to scrapie (Pattison and Jebbett, 1971a). In view of all this, much current research is now being directed towards defining and characterizing the function of Cu within the prion protein.
2. PRION PROTEIN AND COPPER BINDING A link between prion disease and Cu metabolism was first proposed in the early 1970s. Pattison and Jebbett (1971a) noticed that the histopathology of mouse scrapie resembled that induced by the chemical, cuprizone. Cuprizone (bis-cyclohexanone oxaldihydrazone) is a Cu chelator which interferes with oxidative phosphorylation and induces spongiform encephalopathy and gliosis following chronic exposure. Interestingly, this resembles the well-known phenomenon in Wilson's disease, a human disease related to the loss of activity of a Cu-transporting ATPase, which also demonstrates spongiform degeneration (Tanzi et al., 1993). When cuprizone is injected into animals, it depletes the brain of Cu and modifies the activity levels of Cu-dependent enzymes (Venturini, 1973). This effect is not observed if the chelator is first charged with Cu before injection. Many of the symptoms observed in cuprizone-treated hamsters are similar to the enzymatic changes seen in scrapie-infected hamsters (Kimberlin et al., 1974; Kimberlin et al., 1976). Further studies were made in which scrapie-infected mice were treated with cuprizone to see if this would alter incubation times. Although a number of effects were observed, no clear picture emerged (Kimberlin and Millson, 1976). Research on cuprizone, in relation to prion diseases, was not pursued with any great enthusiasm following the publication of studies on PrPSc in the early 1980s (Prusiner, 1982) and the proposal of the "protein-only hypothesis". At that time, the emphasis turned towards determining the proposed function of PrPSc in infectivity rather than to look at the range of other possible factors involved in the disease.
Copper and Prion
Disease
283
2.1. PrPc Structure There is now a considerable amount of biochemical information on the structure and amino acid sequence of PrP c . Translation of the original DNA sequences of the mouse and hamster prion genes revealed a 254amino acid protein (253 in humans) encoded by a single copy gene, Prnp (Locht et al., 1986) (see Fig. 2), The coding region of the prion protein is preceded by a 22-amino acid signal peptide at the N-terminus and followed by a 23-amino acid region at the C-terminus (Easier et al., 1986). Under normal physiological conditions, these N- and C-terminal signal peptides are proteolytically cleaved, leaving residues 23 to 231 in the mature mammalian protein. A glycosyl phosphatidylinositol (GPI) anchor is attached at serine 231. This marks the protein for expression at the cell surface and makes it conceivable that PrP c may be similar to other GPI-anchored proteins that are commonly associated with cell to cell signaling, adhesion, or cellular defense (Sendo et al., 1998). The C-terminal region of PrP c forms a globular structure comprising three a-helices and two short (3-strands Octamerie repeats (5) N-terminal cleavage
Sugar chain attachment
GPI anchor signal peptide
Signal peptide Hydrophobic core
O 23
II
51
90
—J
\
II ,!
llO
\
231
135
Main Cu binding site (four sites)
MS*. 252
Alternative fifth site Histidineat 186
Proposed fifth site Histidine at 111 Fig. 2. Schematic representation of the human prion protein primary sequence showing the main features. Indicated are the main Cu binding sites and two of the possible sites at which a fifth atom of Cu may bind.
284
Sassoon J & Brown DR
(Riek et al., 1996, 1997; Donne et al., 1997) and, during the process of prion infection, can refold into protease-resistant (3-sheet enriched aggregates (McKinley et al, 1983; Oesch et al, 1985; DeArmond et al., 1985; Caughey et al., 1991; Pan et al., 1993). In contrast, the N-terminal domain is highly flexible and typically includes at least four tandem copies of a conserved octapeptide repeat motif (Riek et al., 1997; Donne et al., 1997; Oesch et al., 1985). Evidence suggests that Cu binding occurs predominantly within this region. The N-terminal domain of human PrP c contains these "octarepeat" sequences (PHGGGWGQ: within residues 60 to 91) and one homologous sequence lacking the histidine residue (PQGGGWGQ: residues 51 to 59) (Kretzschmar et al., 1986) Residues 51 to 91 of mouse PrP c consists of four octarepeat sequences (PHGGSWGQ: residues 60-89) and one homologous sequence lacking histidine (PQGGTWGQ: residues 51 to 59) (Westaway, 1987).
2.2. Copper Binding in the Octameric Repeat Region Although the octarepeat motifs within PrP c have no sequence homology to classical Cu-binding proteins (Bazan et al., 1987), evidence suggests that these motifs bind Cu with a remarkable degree of selectivity; as such, they may comprise the prototype of a new class of Cu binding motif. Recombinant PrP c (rPrPc) can be expressed and purified in large amounts from inclusion bodies in an E.coli expression system (Wong et al., 1999). The protein is denatured in 8 M urea and subsequently refolded by gradual removal of urea. rPrP c can be refolded in the presence of Cu, which binds specifically in the octameric repeat region and was also demonstrated to have increased solubility (Brown et al., 1999a). Cu binding to the N-terminal octarepeat region of human recombinant PrP23-98 has now been demonstrated using equilibrium dialysis (Brown et al., 1997a) and in synthesized peptides using mass spectrometry (Hornshaw et al., 1995a; Whittal et al., 2000), fluorescence Spectroscopy (Whittal et al., 2000), Raman spectroscopy (Miura et al., 1999), circular dichroism, proton nuclear magnetic resonance (NMR) spectroscopy (Viles et al., 1999), electron paramagnetic resonance (EPR), and electron spin-echo envelope modulation spectroscopy (Aronoff-Spencer et al., 2000). Cu binding has also been reported for nearly full-length forms of Syrian hamster (residues 29 to 231) (Stockel et al., 1998) and human PrP
Copper and Prion Disease
285
(residues 91 to 231) (Jackson et al., 2001) and full-length mouse PrP (residues 23 to 231) (Kramer et al., 2001). Affinity chromatography using immobilized Cu ions has been used to purify mature, glycosylated PrP c isolated from hamster brain (Pan et al., 1993). With regard to stoichiometry, the number of Cu(II) binding sites in the N-terminal region of PrP c has been variously reported as between two and 5.6 and pH-dependent (Brown et al., 1997a; Whittal et al., 2000; Viles et al., 1999; AronoffSpencer et al., 2000; Stockel et al., 1998; Hornshaw et al., 1995b). At neutral pH, Cu binding to the N-terminal domain occured in the micromolar range with positive co-operativity. There was a remarkably close correlation of Hill coefficients calculated by different laboratories: 3.4 (PrP23 to 98) (Brown et al., 1997a), 3.3 (PrP58 to 91) (Viles et al., 1999), and 3.6 (PrP23 to 98) (Kramer et al., 2001). More recently, the suggestion was made that there are two independent high affinity Cu binding sites of 10" 14 M and 4 X 10 _14 M deduced from the analysis of PrP58 to 98 and PrP91 to 231, respectively (Jackson et al, 2001). Other authors provided different data regarding the binding of Cu at the octameric repeat region, using a mutant protein lacking this region, PrPA59-91. They found that four Cu atoms were missing from each molecule of the mutant protein compared to full-length rPrP c . This corresponded well with evidence showing that the histidines in the octameric repeat region co-ordinate with the four Cu atoms (Brown, 1999a). Other mutants lacking one, two, or three octarepeats were also studied and showed that the amount of Cu binding is directly proportional to the number of repeats, although affinity values were not calculated (Brown et al., 2000). Several other authors also confirmed that Cu can bind to PrP c along the more structured C-terminal domain of the protein (Cereghetti et al., 2001; van Doorslaer et al., 2001). Continuous wave EPR studies demonstrated that, on binding, Cu first fills the C-terminal binding sites before occupying the octarepeats at the N-terminus (Cereghetti et al., 2001).
2.3. Copper Co-Ordination in PrPc Cu in the form of Cu(II) can adopt a range of co-ordination geometries in proteins and peptides and can interact with nitrogen, oxygen, and sulfur atoms. Electron spin resonance spectra have shown that, in PrP peptides, the complexes co-ordinate with tetragonal symmetry (Aronoff-Spencer
286
Sassoon J & Brown DR
et al., 2000). The first study to determine the co-ordination of Cu in the octameric repeat region of PrP c was performed by Viles et al. (1999). Their model proposed that each Cu atom was co-ordinated by nitrogens of two histidine imidazole rings and a nitrogen from a proline residue, as well as with the oxygen of a water molecule. Aronoff-Spencer et al. (2000), however, disputed this model. Their EPR studies suggested that their spectra are composed of two components. The first apparently arose from three nitrogen atoms, and one oxygen atom, while the second consisted of two nitrogens and two oxygens. The first component came from studies of peptides that are equal to or longer than a single octarepeat, and the sequence HGGGW gave a pure spectrum of this kind. Thus, the fragment probably bound Cu(II) in a way that is nearly equivalent to that of peptides containing multiple repeats and, therefore, comprises the fundamental binding unit. Thus, each of the four metal ions bound to the octameric repeat region probably binds to a single HGGGW region. In the three nitrogen co-ordination component, Aronoff-Spencer et al. (2000) proposed that the first nitrogen is contributed by a histidine imidazole ring and the other two originate from deprotonated backbone amide groups. The idea that each Cu is bound by residues primarily within the octarepeat region is further supported by titration experiments on one, two, and four octarepeat-containing peptides (Aronoff-Spencer et al., 2000; Burns et al., 2002). Thus, the ratio of Cu bound within an octarepeat region is one to one and this conflicts with the findings of Viles et al. (1999), who proposed that the Cu interacted with two imidazole rings. An imidazole bridge between a single pair of Cu(II) ions leads to exchange interactions and the resulting EPR transitions take place solely among the two-spin triplet levels. If, in addition, the exchange interaction is large compared to the kT, the Boltzmann factor will favor the singlet ground state, thereby decreasing the integrated EPR absorption signal relative to that expected from uncoupled spins. The work of Aronoff-Spencer et al. (2000) found no evidence for this, suggesting that the exchange coupling does not occur in the binding of Cu to multirepeat peptides. The finding that one repeat binds one Cu ion also agrees with the findings of Miura et al. (1999), whose work was based on Raman spectroscopy studies. They suggested that HGGG is the fundamental binding unit. For a fully Cu(II) loaded protein, the model of Aronoff-Spencer et al. (2000) implies that the metal ion binding sites in the N-terminal PrP c
Copper and Prion Disease
287
domain are like beads on a string, where each bead is a Cu-HGGGW segment separated by intervening Gly-Gln-Pro links. Interestingly, glycine and proline often participate in p-turns. Thus, the intervening links may provide a mechanism that allows the Cu-binding segments to fold and, perhaps, collapse together. Co-ordination dominated by a single histidine would make a PrP c molecule bound to Cu pH sensitive, supporting the idea that it may function in vivo as a Cu transporter, taking Cu into the acidic environment of lysosomes and releasing it there. Although there is now little doubt that Cu binds in the octameric repeat region, the "fifth Cu binding site" (Brown et al., 1997a; Jackson et al., 2001) is still a matter of controversy. Some authors propose that Cu binds in the form of Cu(II) in the C-terminal domain of PrP c . A mutation in amino acid residue 198 abolishes this binding, suggesting that the histidine involved in binding might be at the amino acid residue 187. Other authors suggest that the site of Cu binding is in the region of the toxic peptide PrP106 to 126. If the latter is true, the histidine within the peptide would be the one involved in binding, with additional co-ordination from the appropriate nitrogen atoms in the vicinity. It would also require two peptides to create this site. Recent work by Qin et al. (2002) used mass spectroscopic-based footprinting techniques to attempt to position the histidine-dependent metal co-ordination sites in Cu bound to PrP c . This technique allowed the total number of histidines involved in metal co-ordination to be determined by measuring the mass differences between apo- and metal co-ordinated proteins or peptides. They confirmed the Cu co-ordination sites at the four octarepeat histidines PHGGG/SWGQ (residues 60,68,76, and 84 of mouse PrPc) and also suggested a second type of site involving histidine 95, in the related sequence GGGTHNQ, possibly in conjunction with histidine 110 (equivalent to histidine 111 in human PrP). (Jackson et al., 2001; Hasnain et al., 2001). They reported that these sites had estimated binding affinities ranging from 2.2 X 10 - 6 M to 10" 14 M for the octarepeats and 5 X 10~6 M to 4 X 10~14 M for the site involving histidine-95 (Qin et al., 2000).
2.4. Crystal Structure of Copper-Bound PrPc Following the work reported by Aronoff-Spencer et al. (2000), the group of Glenn Millhauser made further studies on the ability of the sequence
288
Sassoon J & Brown DR
HGGGW to bind Cu. The first crystal structure of Cu binding to this region of the protein was recently reported (Burns et al., 2002). The binding of Cu to this peptide segment is consistent with EPR and other spectroscopic studies. The HGGGW-Cu complex included six ordered water molecules (Fig. 3). Thus, Cu(II) is found in a penta-co-ordinate environment with equatorial ligation from the dl nitrogen of the imidazole ring and deprotonated amide nitrogens of the next glycine residues. The second glycine residue contributes its amide carbonyl oxygen. Except for the histidine backbone nitrogen and a-carbon, all atoms from the histidine through to the nitrogen of the third glycine lie approximately in the equatorial plane and the Cu lies just above this plane, which is consistent with a pentaco-ordinated complex. The tryptophan indole ring also participates in the co-ordination environment in a rather unusual fashion. The indole nitrogen from the tryptophan side-chain is 3.9 A from the oxygen of water bound axially to the Cu(II), suggesting the presence of hydrogen bond. This arrangement places the plane of the indole ring above the Cu, such that it is nearly parallel to the equatorial plane. Two additional water molecules make hydrogen bonds to the axial water to form a network extending from the backbone carbonyl, preceding the histidine, to the carbonyl of the third glycine. There are no equatorial water molecules involved in this model.
Fig. 3. Model of the crystal structure of Cu(II) binding to a fragment of a single octarepeat based on Burns et al. (2002).
Copper and Prion Disease
289
Examinations of the intermolecular contacts found in the crystal structure reveal a potentially important docking interaction between HGGGW-Cu units that may explain previously observed co-operative binding of Cu to PrP c . However, there is still some controversy about this co-operativity as this was not evident from previous studies (Jackson et al., 2001) and the suggestions remain to be confirmed.
3. FUNCTION OF COPPER-BOUND PrP The in vivo function of the prion protein has been investigated, but remains an enigma. Nevertheless, the interaction of PrP c with Cu may hold clues about its physiological role. Much of the evidence discussed above shows that PrP c sequesters Cu. Possible functions for the Cu-bound prion protein might be either in the distribution of Cu in the cellular environment or, alternatively, the Cu might be essential to a specific physiological activity that the protein displays.
3.1. Copper Transport Experiments designed to look at the possible function of PrP c in Cu transport employed the use of Cu67. The studies involved three strains of mice: those overexpressing PrP c , those deficient in PrP c , and wild-type controls. Transport of unchelated Cu67 by cerebellar cells was recorded in all three strains, but kinetic studies showed that histidine-chelated Cu67 was taken up at a rate proportional to PrP c expression (Brown, 1999a). Kinetic parameters for Cu67 transport were also determined, and the Vmax values increased with higher expression of PrP c while the Km values (in the nM range) were not greatly different. These results suggested that there might be an increase in the number of Cu binding sites within the cerebellar cells, which can be related to PrP c expression. Further experiments in which cytosolic enzyme SOD-1 was immunoprecipitated from cells loaded with Cu67 showed that the Cu could be incorporated into SOD-1 in proportion to the level of PrP c expression in the cells studied. Thus, PrP c may participate in the incorporation of Cu into other cellular proteins (Brown and Besinger, 1998). In the brain, the highest concentrations of PrP c are found at the synapses and synaptosomes of PrP0/0 knockout mice demonstrated a strong reduction in Cu concentration. Also, Cu binding in the synaptic
290
Sassoon J & Brown DR
cleft showed a significant influence on synaptic transmission. Cu is released from the synapse during quantal release and it has been proposed that PrP c may have a function in regulating Cu at levels at neuronal synapses. Several studies have been performed to study this phenomenon. In one set of experiments, neuronal cells were loaded with Cu67 and allowed to release Cu spontaneously. Subsequently, they were treated with the depolarizing agent, veratridine, which blocks Na + channels in neurons. Veratridine released Cu from cells at levels corresponding to the expression of PrP c in those cells. Cells which did not express PrP demonstrated almost no veratridine-induced Cu release, while cells which overexpressed PrP c released higher quantities of Cu compared to wild-type cells (Brown and Besinger, 1998). Furthermore, electrophysiological experiments indicated that Cu applied to cerebellar slices inhibited the amplitude and frequency of inhibitory currents measured on Purkinje cells of PrP c deficient cells, but not wild-type cells, suggesting that some protection against Cu is absent from the synapses lacking PrP c . One proposal has been that PrP c itself performs this protective function (Brown et al., 1997b).
3.2. Copper-Dependent Antioxidant Function of PrP It has been demonstrated that both recombinant and brain-derived PrP c have SOD-like activity when bound to Cu (Brown et al., 1999b, 2001). The depletion of PrP c from cell extracts results in a lower SOD activity in the extract (Wong et al., 2000). Also, when PrP c converts to PrPSc, its SOD function is abolished (Thackray et al., 2002). Thus, it is possible that the normal function of PrP c is to act as a SOD-like enzyme and control oxidative stress. It has, however, been demonstrated that PrP c is different from cellular Cu/ZnSOD, especially in the way that it forms its complex with Cu (van Doorslaer et al., 2001). In addition, a very current question concerns oxidative stress as a factor causing neuronal damage in prion diseases and it is, therefore, of considerable interest to consider the SODlike function of PrP in this context. Recombinant PrP c , purified from E.coli expression systems and refolded with Cu can be used in quantitative assays designed to measure SOD activity. Experiments showed that both chicken and mouse rPrP c could catalyze the dismutation of the superoxide radical at a rate equivalent to one-tenth of SOD-1. SOD-1 is a very potent enzyme which
Copper and Prion
Disease
291
catalyzes the reaction at around 100,000 times the spontaneous rate of superoxide degradation (Fridovich, 1975). It was, therefore, concluded that PrP c had significant SOD activity. This was also confirmed for native protein immunoprecipitated from mouse brain (Brown et al., 1999b). Strict controls were used to ensure that the prion protein SOD activity was a real enzymatic activity, and not simply due to Fenton chemistry arising from Cu ligation within the protein. The deletion of the specific octameric repeats of the N-terminal region abolished the SOD activity, despite there still being Cu bound at the C-terminal domain (Brown et al., 1999b). In addition, a peptide based on the octarepeat region with Cu bound to it had no SOD activity. When rPrP c was refolded without Cu and the Cu subsequently added to the refolded protein, the mixture did not demonstrate SOD activity to the level of the co-ordinated Cu in the protein (Brown et al., 1999b). It is, therefore, clear that regions outside the N-terminal octarepeat domain are required for SOD activity of the PrP c . Further evidence for this comes form amino acid analysis of rPrP c after Cu binding. It was found that methionine residues were oxidized in rPrP c with Cu incorporated during refolding (Wong et al., 1999). This is characteristic of certain antioxidant Cu binding enzymes, such as SOD-1 (Chowdhury et al., 1995). Thus, it could be concluded that the observed catalytic SOD activity was not due to the presence of Cu alone, but was more likely due to a true enzymatic activity. It would appear that the dismutation of superoxide could, indeed, be one of the normal functions of the prion protein. At least two Cu atoms per molecule of PrP c were necessary to endow the protein with SOD activity. Binding of Cu also induced a more ordered •structure on the molecule. On binding of two more Cu atoms, a further increase in SOD activity was observed and an additional molecular ordering was found (Miura, 1996, 1999). There are currently three known SODs in mammals (Fridovich, 1997): the cytosolic Cu/ZnSOD-1, mitochondrial MnSOD or SOD-2, and extracellular SOD or SOD-3. The former two are found in all cells at varying concentrations and often show increased expression under conditions of oxidative stress. Extracellular SOD exists in three different isoforms, binds one atom of Cu per molecule, and is either released into the extracellular matrix or remains bound at the cell surface. In brain tissue, the expression of SOD-3 is very low (Ookawara et al., 1998), although it is elevated in PrP knockout mice (Brown et al., 2001). It is interesting to
292
Sassoon J & Brown DR
correlate these observations with the in vivo expression of PrP c , considering its SOD activity. The expression of PrP c is highest in the brain and particularly abundant at synapses. It is also present at neuromuscular junctions (Gohel et al., 1999). Thus, it has been proposed that PrP c may serve as a synaptic SOD and may be released during transmission at the synapse. Superoxide is known to inhibit synaptic transmission and the presence of SOD activity in these regions of the nervous system may have a protective role. The possible protective role of PrP c against oxidative stress was confirmed in cell culture using PC 12 rat tumor cells, which can be differentiated into neurons using nerve growth factor (NGF). It was also observed that PrP c expression increased in PC 12 cell cultures on exposure to oxidative stress (Brown et al., 1997b).
4. ALTERED METAL BINDING IN THE OCTAREPEAT REGION OF PrPc It was recently demonstrated that recombinant PrP c also had the capacity to bind metal ions other than Cu (Brown et al., 2000). Most significantly, the bivalent anion manganese was found to bind in both the octarepeats and C-terminal sites (Collinge, 2001). In vitro metal ion occupancy experiments showed that when manganese replaced the Cu ion in the prion protein, PrP c altered its structure and took on a more PrPSc-like conformation (Brown et al., 2000). Manganese-bound prion protein also lost its SODlike function (Brown et al., 2000). Several lines of investigation have been taken to see if the metal binding of PrP c is altered in TSEs, if metal imbalances also correlate with the loss of antioxidant function in PrP c , and whether these alterations correlate with the disease phenotype, such as PrPSc and the PrP genotype at codon 129, which influences the manifestation of the disease (Worrall et al., 1999). Investigations on alterations in metal ion concentrations were carried out using mouse scrapie models (Thackray et al., 2002) and in samples from sporadic CJD cases (Wong et al., 2001). Changes in the levels of Cu and manganese were detected in the brains of scrapie-infected mice early in the disease, prior to the onset of clinical symptoms. In addition, a major increase in blood manganese was also noted in the early stages of the disease. Analysis of purified PrP from the brains of scrapie-infected mice also showed a reduction in Cu binding to the protein and a proportional decrease in antioxidant activity between 30 to 60 days post-infection.
Copper and Prion Disease
293
A striking elevation of manganese and, to a lesser extent, Zn accompanied by a significant reduction in Cu binding to purified PrP were found in subtypes of sporadic CJD the most common type of human prion disease. Studies were made using brain tissues and affinity purified PrP preparations (that is, PrP c , PrPSc, and possibly other abnormal PrP species) obtained from four major subtypes of sporadic CJD. These were identified according to the genotype at codon 129 of the PrP gene and the PrPSc type established by Parchi et al. (1999). Both Zn and manganese were undetectable in PrP c preparations from control brain preparations. However, Cu and manganese changes were pronounced in sporadic CJD subjects homozygous for methionine at codon 129 and carrying PrPSc type 1. It was also found that a decrease of up to 50% of Cu and an approximately ten fold increase in manganese occurred in the brain tissues of sporadic CJD subjects. Antioxidant activity of purified PrP was dramatically reduced by up to 85% in the sporadic CJD variants, and correlated with an increase in oxidative stress markers in sporadic CJD brains. These results clearly point to the fact that metal ion occupancy alterations in PrP play a pivotal role in the pathogenesis of prion diseases. Since the metal changes differed in each sporadic CJD variant, they may contribute to the diversity of PrPSc and disease phenotypes in sporadic CJD (Wong et al., 2001). These fascinating and significant results could also have a bearing on potential approaches to the diagnosis of CJD. The increase in brain manganese associated with prion infection is potentially detectable by magnetic resonance imaging, and the binding of manganese by PrP in sporadic CJD might represent a novel diagnostic marker.
5. PLASMINOGEN ACTIVATION BY PrP Pericellular proteolytic activity plays an important role in many physiological situations in various organs, including the brain. This proteolytic activity can act to degrade components of the extracellular matrix or activate bioactive molecules, such as growth factors, making it a key regulator of cellular behavior (Werb, 1997). The broad specificity serine protease plasmin is one of the principal activities involved in these processes. Plasmin is generated from the abundant zymogen plasminogen by a single proteolytic cleavage catalyzed by either of the two plasminogen activators, uPA and tPA. At the functional level, the activity of the plasminogen activation system is largely regulated by mechanisms that enhance the generation of
294
Sassoon J & Brown DR
plasmin (Ellis and Whawell, 1997). Thus, uPA-catalyzed plasminogen activation is stimulated by the binding of uPA to its cell surface receptor, uPR (Ellis et al., 1991), and tPA-catalyzed plasminogen activation juxtaposed to the plasminogen activator, either on the same co-factor molecule (as with fibrin) or to discrete cellular binding sites. Interactions with these molecules are mediated by "lysine-binding sites" in the kringle modules of plasminogen, which can be antagonized by lysine, such as eACA (Marti et al., 1997). These kringle modules preferentially bind C-terminal lysine residues (that is, those with a free carboxylate group), which can either be present in the native proteins or generated by the proteolytic action of plasmin. It was reported that plasminogen, which can act as a pro-protease and is implicated in neuronal excitotoxicity, is bound to PrPSc, but not PrP c (Fischer et al., 2000). Therefore, plasminogen represents the first endogenous factor that can discriminate between normal and pathological prion proteins. Binding was abolished if the conformation of PrPSc was disrupted by 6M urea or guanidine, but the isolated lysine-binding site of plasminogen (kringle modules I to III) retained the binding activity. Ellis et al. (2002) tested the hypothesis that, due to its reported ability to bind plasminogen, PrPSc is a regulator of plasminogen activation. They observed the effect of recombinant PrP, either containing Cu (holo-PrP) or devoid of it (apo-PrP), on plasminogen activation by both uPA and tPA. PrP was found to have no effect on plasminogen activation by uPA, but the activity of tPA was stimulated by up to 280 times. This was observed only with the apo-PrP isoforms. Thus, they demonstrated that PrP can, indeed, regulate plasminogen activation, but that a critical determinant of the interaction between PrP and tPA was related to the absence of Cu in the PrP. Failure of Cu to bind PrP may be an early event in the conversion of PrP c to PrPSc and in the stimulation of plasminogen activation. The similarity in the interaction of PrPSc or Cu-free rPrP with plasminogen or plasminogen activators suggests that PrPSc may be a form of PrP devoid of Cu.
6. METAL ION BINDING AND NEURODEGENERATIVE DISEASES Research has suggested that Cu has an important role to play in the prevention or moderation of a number of neurodegenerative diseases, including
Copper and Prion Disease
295
the polyglutamine diseases such as Friedrich ataxia and Huntington's disease, Parkinson's disease (PD), Wilson's disease, Menkes' diseases, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (AD) (Strausak et al., 2001). Cu is an essential metal that serves as a co-factor for a number of proteins and enzymes. Many proteins associated with neurodegenerative diseases have metal-binding properties and/or metal-responsive expression (Bush, 2000). Besides PrP c , the ectodomain of the Alzheimer precurser protein (Multhaup et al., 1996), amyloid-f} peptide (Atwood etal., 2000), and SOD-1 (Fridovich, 1975) exist in Cu-bound forms. In these examples, metal binding relates to pathogenesis via an impact on aggregation or production of oxidative damage. Cells rely on a number of transition metals to regulate a wide range of metabolic activities and signaling functions. The diversity and efficiency of their physiological functions are derived from the specific atomic properties of transition metals,